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Abstract 
 
Epidemiological and clinical studies indicate that overweight and 
obesity are associated with increased risk for depression, but the 
mechanisms linking dietary components with the development of 
depression phenotype are poorly understood. To investigate this 
relationship, we utilized lipidomic and transcriptomic methods to 
evaluate the effects of diet on the brain. We identified a molecular 
mechanism by which even short exposure to high-fat diet (HFD) 
alters hypothalamic functions leading to depression. Consumption of 
a HFD induced in the hypothalamus accumulation of different 
saturated and unsaturated fatty acids, suppression of the 3’, 5’-
cyclic AMP (cAMP)/protein kinase A (PKA) signaling pathway, and 
increase the RNA levels of the free-fatty acid receptor 1 (FFAR1), a G 
protein-coupled receptor (GPCR). Palmitic acid, but not oleic acid, 
both FFAR1 ligands, suppressed PKA activity in a neuronal cell line 
that expresses high levels of FFAR1. Deficiency of phosphodiesterase 
4A (PDE4A), an enzyme that degrades cAMP and modulates GPCR 
signalling, protected from dietary and genetic induced depression 
phenotype in mice. These findings demonstrate that specific dietary 
fatty acids can enter the brain to disrupt hypothalamic functions by 
suppressing cAMP/PKA signaling possibly via the activation of 
FFAR1/PDE4A. FFAR1 inhibition and increase of cAMP signaling in the 
hypothalamus may offer a novel strategy to counteract the effects of 
diet on depression.  
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1. Introduction 
Depression is a devastating mental disorder which affects more than 340 million 
people globally according to the world health organization (WHO, 2012). By the 
year 2030 major depression is expected to be one of the three leading causes of 
morbidity in developed countries (Hughes et al., 2011; Murray and Lopez, 1997). 
There are several risk factors for depression; one of them is obesity (Roberts et 
al., 2003; Roberts et al., 2000). Obesity is a major public health concern with 
alarmingly increasing rates in the western modern societies. The prevalence of 
obesity has doubled the last 50 years. Given the increasing rates of obesity and 
their positive correlation with depression, even a small increase of obesity might 
lead to threatening levels of mental disorders for the society. Dietary and 
lifestyle changes over the last 3 decades are the major reason for the dramatic 
increase of these two chronic human diseases that are also associated with 
various other health complications (Compton et al., 2006). Given the increase in 
obesity and depression in western societies, identifying the underlying molecular 
links may provide important diagnostic and therapeutic opportunities. 
 
1.1. Obesity 
Obesity is a metabolic disorder reaching epidemic proportions; is a public health 
issue and a growing problem (Taubes, 1998; Popkin and Doak, 1998). Obesity 
develops as the result of energy imbalance when energy intake exceeds energy 
expenditure and characterized by excess of fat deposition in the body. Western 
societies are based on high caloric food consumption characterized by high fat, 
sugars and salt but low in vitamins, minerals and other micronutrients. Excess of 
caloric intake from fat and refined carbohydrates combined with the modern 
sedentary western lifestyle characterized by physical inactivity is the main 
reason for appearance of the epidemic of obesity for millions of people 
worldwide (WHO 2012; Venables and Jeukendrup, 2009). Obesity is measured by 
the body mass index (BMI); it is defined as a person’s weight in kilograms divided 
by the square of his height in meters (kg/m2) BMI of 25 kg/m2 or greater 
describes overweight, while BMI of 30 kg/m2 or greater describes obese in the 
general population. The abnormal or excessive fat accumulation in the 
overweight and obese individuals is mainly responsible for their impair health. 
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There are two main consequences of obesity; metabolic syndrome and increased 
risk for various diseases. Obesity confers a profound association with various 
health complications such as hypertension, dyslipidemia, diabetes mellitus, 
coronary heart disease, atherosclerosis, stroke, as well as cancer and increased 
mortality (ΝΙΗ 1998; Allison et al., 1999a; 2000; Kannel et al., 1967; Poirier et 
al., 2006; Das, 2010). Even though obesity has been linked with various diseases 
not commonly associated with metabolic syndrome, such as stroke it has never 
been shown to be a causative factor for any of them except a study recently 
published revealing that obesity is a causative factor for the development of 
hepatic cancer (Park et al., 2010b). 
 
1.2. Depression 
Depression is one of the most common and a serious affective illness that can 
affect people at any age from early childhood to late life and has a great 
socioeconomic cost (Wittchen, 2012). It is characterized by a state of low mood 
and aversion to activity and can affect a person's thoughts, behaviour, feelings 
and physical well-being. The development and progression of depression is 
influenced by genetic, epigenetic and environmental factors. However, 
depression most commonly occurs during adulthood, which is the most 
productive years of one’s life, and this can exert considerable cost upon the 
society and the individual. Depression is one of the most common psychiatric 
disorders that patients are looking for outpatient care (Kimerling et al., 1999). 
The overall risk of developing psychiatric disorders such as depression typically 
rises during the adolescent years (Brooks et al., 2002; Sorenson et al., 1991) and 
is associated with future depression (Lewinsohn et al., 1999). Depression is 
associated with increased risk of coronary heart disease, stroke, myocardial 
infarction, heart failure, low bone mineral density and increased mortality 
(Keller, 2008). 
 
There are two different ways to assess depression: either the Montgomery-
Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) or the 
17-item Hamilton Depression Rating Scale (HAMD-17) (Hamilton, 1960). The 
symptoms of depression can vary considerably and even within the same group 
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of depressed patients there can be major differences with diverse symptoms. 
However, persistent depressed mood and anhedonia are the two core criteria for 
depression. Depression is a widespread and debilitating disorder whose 
pathophysiology remains enigmatic although abnormalities in monoamine 
signalling have been implicated (Charney, 1998). Indeed, some of the major 
drugs developed for depression target the monoamine signalling (Shelton, 2007). 
 
1.2.1. Physiological pathways altered in depressed 
patients 
Depression has predominantly been linked with altered levels of  brain 
neurotransmitters (Charney, 1998), such as  acetylcholine (enhances memory) 
(Higley and Picciotto, 2014), serotonin (regulates sleep, appetite, mood) (Albert 
et al., 2014), norepinephrine (Shelton, 2007), dopamine (Moraga-Amaro et al., 
2014), glutamate (play a role in schizophrenia and bipolar disorder) (Sanacora et 
al., 2004; Burnouf et al., 2013) and GABA (Sanacora et al., 2004; Luscher et al., 
2011; Fatemi et al., 2011). However, there are many other physiological 
pathways that are affected in depression (Heninger et al., 1996). 
 
Stress is a major vulnerability factor for depression and depressive disorders 
have been well known to associate with stress disorders (Kendler et al., 1999; 
Southwick and Charney, 2012). The main pathway involved in stress response is 
the hypothalamic-pituitary-adrenal (HPA) pathway. Depression is accompanied 
with excessive activity of the HPA axis and dysregulation of glucocorticoid 
release in response to stressful experience that are associated with depression 
(Holsboer and Ising, 2010; McEwen, 2007). 
 
Furthermore, depression is associated with increased inflammatory response and 
cytokine production due to activation of the immune system (Schiepers et al., 
2005). Cytokines are a group of polypeptide mediators that are associated with 
the regulation of immunity and inflammation as well as the regulation of the 
HPA axis (Turnbull and Rivier, 1995). Cytokines such as TNF-α and IL-1β can 
lower the availability of tryptophan, one of the precursors of neurotransmitters, 
alter the neurotransmitter metabolism as well as the mRNA of the 
neurotransporters (Watkins et al., 2014; Logan, 2003). Inhibition of TNF-α, a 
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cytokine that is elevated in the adipose tissue of obese rodents, improves 
glucose tolerance and insulin sensitivity, which are main characteristics of 
obesity (Hotamisligil et al., 1993) as well as reducing the depression phenotype 
in mice (Raison et al., 2006). In agreement to the hypothesis that increased 
cytokine production leads to depression is the fact that systemic and chronic 
inflammation is accompanied by increased cytokine production (Dantzer et al., 
2008). Moreover, obesity is associated with chronic and low grade inflammation 
(Weisberg et al., 2003; Xu et al., 2003; Hotamisligil, 2010). This can activate the 
immune system, which, in turn, can alter brain functioning to induce a 
depression phenotype (Dantzer et al., 2008). 
 
Depression is also associated with a distinct pattern of cognitive impairment, 
including memory deficits, which are a core element of depression (Arendash et 
al., 2001). Impairments in cognitive performance in depressed patients have 
been identified across a number of cognitive domains including executive 
functions (Baudic et al., 2004; Merriam et al., 1999; Nebes et al., 2003), working 
memory (Christopher and MacDonald, 2005), as well as emotional memory 
(Siegle et al., 2007). Moreover, evidence suggests a positive correlation between 
the severity of depression symptoms with cognitive impairments (Austin et al., 
2001; McDermott and Ebmeier, 2009). Different neuronal mechanisms have been 
proposed to recapitulate the cognitive model of depression, however the 
neurobiological underpinnings of cognitive deficits in depression remain poorly 
understood (Disner et al., 2011). In accordance to the human studies, the 
socially defeated mouse model, which is an animal model of depression, exhibits 
cognitive and neuronal impairments that correlate with the depression 
phenotype (Yu et al., 2011). 
 
1.3. Obesity is linked with depression 
Depression is a debilitating mental illness that is often comorbid with metabolic 
abnormalities such as central obesity and impaired glucose tolerance which are 
also associated with obesity (Weber et al., 2000). Many metabolic pathways have 
linked obesity with depression (Hryhorczuk et al., 2013) and there is a clear 
interconnectivity between them. Cytokines such as TNF-α and IL-1β can also 
modulate the HPA axis causing resistance to glucocorticoid hormones that can 
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lead to obesity or depression (Turnbull and Rivier, 1995). Activation of the 
sympathoandrenal system and production of pro-inflammatory cytokines caused 
by depression can induce insulin resistance and contributes to obesity (Makki et 
al., 2013). Moreover, depression is accompanied by deleterious changes in the 
autonomic system, activity levels, reproductive system and lipid metabolism all 
of which have also been associated with the pathophysiology of obesity (Allison 
et al., 1999a; 2000; Kannel et al., 1967; Poirier et al., 2006). Increased levels of 
proinflammatory cytokines observed in obesity may interfere with 
neurotransmitter metabolism, alter neurotransmitter RNA expression levels and 
inhibit brain derived neurotrophin factor (BDNF) expression a major protein 
involved in depression as discussed below (Hayley et al., 2005; Anisman, 2009). 
 
A major challenge in exploring the relationship between obesity and depression 
in human studies is the controlling for dietary, environmental and lifestyle 
factors. Among patients with depression and obesity the heterogeneities in 
lifestyles and diets make it difficult to study a correlation or causative 
relationship as both disorders are highly associated with other lifestyle traces 
such as physical inability or eating disorders. Due to the above reasons, 
identifying the strength of correlation between obesity and depression has 
proven difficult and would require large cohorts of individuals while controlling 
for factors such as exercise or lifestyle. 
 
Epidemiological and clinical studies have been effective for the identification of 
the link between obesity and depression (Zhong et al., 2010; Leonore de Wit  
and Frans Zitman, 2010; Boutelle et al., 2010; Stunkard et al., 2003; Simon et 
al., 2010; McElroy et al., 2004; Faith et al., 2002; Luppino et al., 2010; Palinkas 
et al., 1996; Roberts et al., 2003; Dong et al., 2004; Roberts et al., 2002; 
Stunkard, 1957). Both these disorders incur substantial costs to society (Allison 
et al., 1999b; Druss et al., 2000) and the individual (Wells et al., 1989). 
However, most of these studies typically lack large, representative samples and 
did not employ validated measures of psychopathology. 
 
The positive association between obesity and depression is higher between 
women than men. It is more common for women with high BMI to develop 
depression compare to men (Istvan et al., 1992; Carpenter et al., 2000; Onyike 
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et al., 2003) suggesting sex differences play a role for that link. It has been 
suggested that women not only have a greater biological and psychological 
vulnerability to depression than do men but they are also more likely to 
experience acute and chronic stressors that would activate a predisposition to 
depression (Nolen-Hoeksema and Ahrens, 2002). 
 
Certain studies have shown that obesity, defined as a pathologically elevated 
BMI, can predict the development of major depressive disorder (Roberts et al., 
2003; Roberts et al., 2000; Carpenter et al., 2000). Interestingly, it has been 
shown that a short intervention for 4 weeks of adoption of an obesity provoking 
behaviour decreases the health related quality of life and induced a depression 
phenotype (Ernersson et al., 2010). That effect was temporary when followed up 
for 6 to 12 months after the short intervention and there was no remaining 
influence (Ernersson et al., 2010). On the other hand, it has also been shown 
that depression can promote the development of visceral obesity in humans 
(Needham et al., 2010) and perturbed lipid metabolism, a common pathological 
characteristic in obesity that has also been observed in patients with depression 
(Rudisch and Nemeroff, 2003). Baseline depression significantly increased the 
probability for developing obesity over time (Luppino et al., 2010; Pan et al., 
2012). Major depressive disorder among young children can predict a greater 
body mass index in adult life (Pine et al., 2001). Another interesting point that 
links together the pathways of obesity and depression is that the majority of 
currently prescribed psychotropics, which includes antipsychotics, 
antidepressants, and mood stabilizers, will generate weight gain and ultimately 
obesity in some patients over the course of clinical treatment (Schwartz et al., 
2004). Whether this increase is because of the direct effect of the drug or 
because of the mood change of the individual is unknown. Moreover, this 
suggests that antidepressant treatment might differentially regulate the 
pathways of depression and body weight gain as in the short term it reduces the 
depression phenotype but increases body weight. However, whether this body 
weight gain during antidepressant treatment can increase the chances of the 
development of depression later in life needs further investigation. 
 
Even though a correlation between obesity and depression has been proposed in 
different clinical and epidemiological studies this correlation is stronger 
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between extreme obesity and depression phenotype. The most obese individuals 
are at increased risk for the development of depression (Onyike et al., 2003). 
Being obese but not overweight during adolescence has been shown to be a 
predictor of depression later in life (Boutelle et al., 2010). The extremely obese 
individuals that sought bariatric surgery were found to have higher depression 
scores that the non-extremely obese (Berkowitz and Fabricatore, 2005). Due to 
the worldwide progressive increase of the obese population a rapid increase of 
depression will have a major socioeconomic effect. The extremely obese people 
also have greater impairments in health-related life quality than do their less 
obese peers and this might also be influencing their increased risk for 
depression. However, the precise mechanism underlying the interaction between 
obesity and depression remains to be elucidated. 
 
Interestingly, obesity has also been described with impaired noradrenaline 
signalling in specific organs (Levin and Dunn-Meynell, 2000), a main signalling 
pathway affected in depression. Altered weight gain patterns have been linked 
to changes in the expression of β-adrenergic receptors (Charon et al., 1995; 
Raasmaja and York, 1988) and in patients chronically treated with β-adrenergic 
blockers, one of the major side effects is a prominent weight gain (Sharma et 
al., 2001). Additionally genetically modified mice that lack all β-adrenergic 
receptors become massively obese when fed a HFD (Bachman et al., 2002). 
 
1.4. Current antidepressant treatments for depression 
50 years ago, antidepressants were discovered by serendipity as some 
treatments for tuberculosis, were exerting a beneficial effect in the sense of 
well-being (Selikoff and Robitzek, 1952; Bloch et al., 1954). This observation set 
iproniazid as the first antidepressant drug (Loomer et al., 1957). The range of 
different molecular pathologies that can underpin depression and no doubt 
complex biochemical phenotypes in patients with depression has made it hard to 
find drugs that treat all forms of depression. Therefore it has been very difficult 
to find an antidepressant treatment that will satisfy all patients and minimize 
the occurrence of side effects. Rather we can expect advances to be made when 
biomarkers allow the particular cause of individual patients to be uncovered and 
direct them to the most effective therapies. For that reason different 
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antidepressant treatments have been established for the different forms of 
depression that are discussed below. Invasive and non-invasive antidepressant 
treatments have been developed with very promising data coming from the non-
invasive brain stimulations. 
 
There are two main categories for the antidepressant treatment; the chemical 
and non-chemical treatments. The non-chemical treatments of depression 
include electroconvulsive therapy, vagus nerve stimulation and repetitive 
transcranial magnetic stimulation. The chemical treatments are invariably based 
on the monoamine hypothesis of depression that states that depression is 
characterized by reduced levels of the monoamines, such as noradrenaline and 
serotonin, in the brain (Nestler et al., 2002a). Intense attention has been 
focused on the targeting of monoamines (Hamon and Blier, 2013), particularly 
norepinephrine, epinephrine and dopamine for the treatment of depression over 
the last 40 years due to this theory (Bunney and Davis, 1965; Schildkraut, 1995; 
Coppen, 1967). The neurotransmitter system has been implicated in the actions 
of many antidepressant drugs (Frazer and Conway, 1984; Charney, 1998). Drugs 
that can reverse the reduction of the monoamines or slow down their 
metabolism in synapses in order to block the inactivation of the brain serotonin 
and noradrenaline pathways are proposed to have a potential antidepressant 
action. However, the monoamine hypothesis cannot explain the full aetiology 
and pathogenesis of depression (Heninger et al., 1996; Hyman and Nestler, 1996; 
Nestler, 1998; Nestler et al., 2002b). 
 
1.4.1. Categories of antidepressant drugs 
The neurotransmitter’s elevated concentration in the brain is exerted by 
antidepressants either by acute inhibition of its reuptake or of monoamine 
oxidase activity (Banerjee et al., 1977; Wolfe et al., 1978). Therefore, the two 
major classes of the medicine category of antidepressants are the monoamine 
reuptake inhibitors that prevent the normal recapture of either serotonin or 
noradrenaline by their transport back into the presynaptic nerve-terminal as 
well as the monoamine oxidase inhibitors that both lead to an increase or 
serotonin or noradrenaline in the synapse. Table 1.1. summarizes the main 
antidepressant categories with the main drugs used in each category.  
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The most commonly prescribed class of antidepressants are those that act by 
specifically preventing the uptake from the presynaptic neuronal cell of 
serotonin therefore upregulating the amount of serotonin in the synapse and 
called selective serotonin reuptake inhibitors (SSRIs). This results in the 
postsynaptic cell to be constantly activated by the serotonin in the synapse. 
Serotonin is synthesized in cell bodies of the brain stem raphe nuclei. The 
therapeutic response of SSRIs occurs after 3-4 weeks of treatment (Belmaker and 
Agam, 2008). SSRIs are often the first line of treatment for depression due to 
their general safety and few side effects. Fluoxetine (Prozac) is a well-known 
antidepressant that belongs in the SSRI (Wong et al., 2005). One of the potential 
actions of fluoxetine is speculated to be the increase neuronal cell proliferation 
in the dentate gyrus (Manev et al., 2001). Monoamine oxidase inhibitors (MAOIs) 
is another major class of antidepressants that slows down the normal enzymatic 
degradation of these neurotransmitters (Schwartz, 2013). Monoamine oxidase is 
the major enzyme that breaks down serotonin or noradrenaline therefore when 
it is inhibited there is an increase of the monoamines in the synapse. Iproniazid 
was the first antidepressant (Loomer et al., 1957) and the first member of the 
MAOIs family (Zeller and Barsky, 1952). MAOIs have been shown to impair the 
breakdown of tyramine a substance in food such as aged cheese, wines, most 
nuts and chocolate (Gray and Gray, 1989). High blood concentration of tyramine 
due to consumption and administration of MAOIs can elevate blood pressure 
dangerously. Therefore MAOIs are prescribed only after the failure of other first 
line treatments due to these potentially serious drug and food interactions and 
then only with close dietary supervision. 
 
Tricyclic or tetracyclic antidepressants consist of either three or four chemical 
rings. Their therapeutic action is speculated to occur by increasing the level of 
norepinephrine and serotonin in the synapses, however the exact molecular 
mechanism remains unknown (Feighner, 1999). They are used to treat moderate 
to severe depression. Tricyclic antidepressants have a cardiotoxic potential, and 
if taken overdose they can cause life threatening heart-rhythm aberration 
(Thanacoody and Thomas, 2005) and that’s the reason why they are not the first 
option for antidepressant treatment. 
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Drugs that are effective in treating depression and cannot be classified in one of 
the previous categories are called atypical antidepressants. Their antidepressant 
action happens by increasing the levels of neurotransmitters in synapses. 
 
Mood stabilizers, stimulants and antipsychotic drugs are also used to treat 
depression. Antiphychotic drugs in combination with antidepressants have been 
found to be effective mood stabilizers and are therefore used to treat bipolar 
depression. Stimulants are commonly used in combination with other 
antidepressants or medication for the treatment of depression that is resistant 
to other medications but they are rarely used alone due to their potentially 
addictive nature. 
 
Transcranial direct current stimulation (tDCS) trials for major depressive 
disorder (MDD) have shown positive but mixed results therefore further studies 
should be performed (Brunoni et al., 2013). Combination of the pharmacological 
and non-pharmacological treatments with deep brain stimulation appears to be 
working better than using just a single therapy (Brunoni et al., 2013). 
 
Electroconvulsive therapy (ECT) is a non-chemical therapy that is reserved for 
severely depressed patients or patients that are at high risk for suicide that do 
not respond to conventional drug therapy or other antidepressant treatments do 
not provide a satisfactory relief from the symptoms (Medda et al., 2014). During 
the ECT procedure an electric current is passed through the brain to produce 
controlled convulsions (seizures) which is speculated that it works by a massive 
release of neurotransmitters in the brain (Faedda et al., 2010).  
 
All the previous classes of medications that treat depression (MAOIS, SSRIS, TCAS 
and atypical antidepressants) have shown to have an effect on norepinephrine 
and serotonin as well as other neurotransmitters that are thought to be involved 
in depression (Dell'Osso et al., 2011). Some newer developed antidepressant 
drugs called dual-action appear to have a particular robust effect on both the 
norepinephrine and serotonin systems (Duman and Voleti, 2012). However, the 
various medications affect the different neurotransmitters in varying degrees. 
These medications seem to be very effective for the more severe and chronic 
cases of depression. For example, Effexor is a serotonin reuptake inhibitor that 
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at lower doses, shares many of the safety and low side-effect characteristics of 
the SSRIs (Sansone and Sansone, 2014). At a higher dose though it appears to 
block the reuptake of norepinepthrine as well (Sansone and Sansone, 2014). In 
accordance to that, Cymbalta and Pristiq tend to act as equally powerful 
serotonin and norepinephrine reuptake inhibitors regardless of the dose (Sansone 
and Sansone, 2014). 
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Table 1.1. Main categories of antidepressant treatment and 
their representative drugs. A summary of the main 
antidepressant categories with the main drugs used in each 
category and their commercial names. 
Category Drugs 
 
 
Selective serotonin 
reuptake inhibitors 
(SSRIs) 
fluoxetine (Prozac)                             
paroxetine (Paxil) 
sertraline (Zoloft)                   
citalopram (Celexa)                 
fluvoxamine (Luvox)                
escitalopram (Lexapro) 
Monoamine oxidase 
inhibitors (MOAIs) 
phenelzine (Nardil) 
tranylcypromine (Parnate) 
Isocarboxazid (Marplan) 
 
 
 
 
Tricyclic 
antidepressants (TCAs) 
amitriptyline (Elavil)                           
protriptyline (Vivactil)                
desipramine (Norpramin)                
nortriptyline (Aventyl, Pamelor)            
imipramine (Tofranil)                 
trimipramine (Surmontil)  
perphenazine (Triavil) 
amoxapine (Asendin) 
Clomipramine (Anafranil) 
Doxepin (Sinequan) 
Maprotiline (Ludiomil) 
Tetracyclic 
antidepressants 
maprotiline (Ludiomil)                      
mirtazapine (Remeron) 
 
Atypical antidepressants 
nefazodone (Serzone)                      
trazodone (Desyrel)                
bupropion (Wellbutrin) 
 
 
Mood stabilizers 
Lithium (eskalith, lithobid) 
valproate (depakene, deakote) 
carbamazepine (epitol, tegretol) 
lamotrigine (lamictaal) 
 
 
 
Antipsychotic  drugs 
ziprasidone (Geodon)                      
risperidone (Risperdal)                
quetiapine (Seroquel)                 
aripiprazole (Abilify)                  
asenapine (Saphris)                
paliperidone (Invega) 
amisulpride (Solian) 
Stimulants methylphenidate (Ritalin) 
dextroamphetamine (Dexedrine) 
Dual action 
antidepressants 
venlafaxine (Effexor)                         
duloxetine (Cymbalta)                 
desvenlafaxine (Pristiq) 
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1.4.2. Obesity and resistance to antidepressants 
It is noteworthy that not all patients benefit from antidepressant treatment 
(Nelson, 1999; Nestler et al., 2002a). Greater relative body weight was found to 
place patients with major depression at risk for fluoxetine resistance (Prozac) 
regardless of the severity of depression at baseline (Papakostas et al., 2005). 
Overweight and obese patients showed a significantly slower response to 
antidepressant treatment, less improvement in neuroendocrinology and 
attention and less weight gain than that was showed from patients with normal 
body weight under antidepressant treatment (Kloiber et al., 2007). This suggests 
the involvement of unique pathways in depression for the overweight/obese 
population proposing that new antidepressant drugs targeting these specific 
pathways are urgently needed. However, further studies in overweight and 
obese individuals are necessary to further clarify whether the PK of 
antidepressants is an issue and a reason for the resistance. In this context, 
obesity was defined as a possible risk factor for the resistance to Prozac 
treatment in an outpatient study (Papakostas et al., 2005). Given the increasing 
prevalence of obesity in the general population, studies are needed to better 
define the role of obesity in depression and specifically on treatment response 
with standard antidepressants such as SSRIs. 
 
1.5. The G-protein coupled receptors (GPCRs) 
Most of the receptors targeted by the antidepressants belong to the G-protein 
coupled receptor superfamily (GPCRs) which is a large and versatile family of 
cell-surface receptors that participate to the transmission of extracellular 
signals transduced to the interior of the cell and represents the largest signalling 
family in the human genome (Lefkowitz, 2004). Schematic 1.1 represents the 
main components of the GPCR signalling. GPCRs respond to a remarkable range 
of stimuli, including neurotransmitters, hormones, and sensory stimuli and they 
can regulate cell proliferation, differentiation, survival, migration, metabolism, 
secretory properties, electrical activity, shape, and motility of virtually all 
mammalian cells and most organ functions. These properties are placing this 
superfamily of receptors as a master regulator of the human physiology. 
Phylogenetic analyses show that GPCRs are clustered into five families: 
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glutamate, rhodopsin, adhesion, Frizzled/Taste2 and secretin (Fredriksson et 
al., 2003). With more than 1000 unique members (Costanzi et al., 2008) in the 
human genome, GPCRs represent by far the largest family of cell surface 
molecules involved in signal transmission, accounting for >2% of the total genes 
encoded by the human genome. The GPCR family represent the target directly 
or indirectly of 50-60% of all current therapeutic agents (Rosenbaum et al., 
2009; Pierce et al., 2002) as activation, suppression or mimicking the GPCR 
signaling represents one of the most common themes of currently prescribed 
therapeutics. Rising evidence suggests that GPCRs may be involved in both the 
pathogenesis and treatment of mood disorders (Avissar and Schreiber, 2002; 
Schreiber and Avissar, 2003).  
 
All GPCRs share a characteristic core composed of seven-transmembrane α-
helices that weave in and out of the membrane and interact with a wide range 
of messengers. The N-terminal ends of these receptors are located 
extracellularly, whereas their C-terminal ends are in the cytoplasm. After ligand 
binding, GPCRs are activated and expose the intracellular sites for interaction 
with intracellular molecules. Classically, these receptors stimulate 
heterotrimeric G proteins, which control the generation of diffusible second 
messengers and entry of ions at the plasma membrane (Oldham and Hamm, 
2008). Each GPCR is coupled to either a different class of G-proteins, Gs, Gi, Gq, 
or G12/13, or a combination thereof. The binding of the heterotrimeric G proteins 
to the agonist-occupied receptor catalyses the dissociation of GDP bound to the 
Gα subunit and its replacement with GTP that leads to the dissociation of the α 
subunit from the βγ subunits that in turn they signal to several downstream 
effectors (Pierce et al., 2002). A single GPCR can couple to one or more families 
of G proteins resulting in the activation of several downstream effectors (Neves 
et al., 2002). These include classical second messenger pathways such as cyclic 
adenosine monophosphate (cAMP) controlled by adenylyl cyclases, 
phospholipases and ionic channels, as well as different kinase cascades 
(ERK/MAPK, JNK, p38, ERK5) or the Akt/PI3K route. The coupling of a GPCR with 
a G protein determines the nature and specificity of its downstream signalling 
targets (Neves et al., 2002). This activation of the receptor also results to the 
interaction with other cell proteins that drive the initiation of multiple 
intracellular signalling cascades. Ligands are categorized as full or partial 
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agonists, that activate the receptor or as antagonists that bound to the receptor 
and neutrally block the access of the agonist. Despite the vast and longstanding 
efforts of academic and industrial researchers to pair GPCRs with potential 
ligands, more than 150 nonsensory GPCRs still remain orphan receptors, for 
which the cognate ligands have not been identified (Civelli, 2005). 
 
Figure 1.1. The GPCR signalling pathway. Different ligands use G-protein-
coupled receptors (GPCRs) to stimulate membrane, cytoplasmic and nuclear 
targets. GPCRs interact with heterotrimeric G proteins composed of α, β and γ 
subunits. Typically Gs stimulates adenylyl cyclase and increases levels of cyclic 
AMP (cAMP), whereas Gi inhibits adenylyl cyclase and lowers cAMP levels. The 
members of the Gq family activate phospholipase C (PLC), which cleaves 
phosphatidylinositol bisphosphate (PIP2) into diacylglycerol and inositol 
triphosphate (IP3). GABA, gamma-aminobutyric acid; GRK, G protein receptor 
kinase; PI3K, phophatidylinositol 3-kninase; PKA, protein kinase A; AC, adenylyl 
cyclase; ARB, arrestin; PDE4s, phosphodiesterase4. Figure adapted by (Dorsam 
and Gutkind, 2007). 
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1.5.1. The role of arrestins and GRKs in the GPCR 
signalling 
The switch from activation to deactivation of the receptor is not simple and the 
process of the loss of receptor responsiveness is called desensitization 
(Lefkowitz, 1993). The agonist binding, in addition to promoting the activation 
of G proteins and other molecules it also stimulates their phosphorylation by 
GRKs (G protein-coupled receptor kinases). GRKs is a family of at least 6 GRKs 
which phosphorylate and regulate a wide variety of receptors that couple to 
heterotrimeric G proteins (Freedman et al., 1995; Inglese et al., 1993). The 
physiological relevance and non-redundant role of GRKs has been shown by 
various gene targeting approaches (Wess, 2000). All GRKs share a central 
catalytic domain and they can phosphorylate the Ser or Thr residues within the 
third intracellular loop or cytoplasmic tail of the GPCR which is the region with 
the G protein interaction. The C-terminal domain of the GRKs is of variable 
length and seems to facilitate interactions with lipids and other proteins of the 
membrane. 
 
The membrane recruitment of the GRKs and the phosphorylation of the receptor 
is a fundamental step for the desensitization process of the GPCRs however it is 
not sufficient to promote desensitization. Rather, the phosphorylated receptor 
becomes a substrate for the binding of β-arrestins (Gurevich et al., 1995; 
Palczewski, 1994). β-arrestins not only mediate the desensitization of GPCRs but 
they play pivotal role in the internalization of the GPCRs through clathrin-coated 
vesicles (Laporte et al., 2000) a necessary process for the dephosphorylation, 
recycling, and resensitization of many GPCRs (Pippig et al., 1995; Krueger et al., 
1997; Zhang et al., 1997; Klein et al., 2001; Gaborik and Hunyady, 2004). The 
evidence for the participation of β-arrestin in GPCR internalization comes from 
observations that overexpression of β-arrestin can rescue a β2AR sequestration-
defective mutant (Ferguson et al., 1996b). The roles of β-arrestin-1 and β-
arrestin-2 are very different and distinct between them (Vibhuti et al., 2011). β-
arrestins are cytosolic proteins upon binding to GRK phosphorylated GPCRs 
impair and constrain the communication between the GPCR and its effector G 
protein. Indeed they block G protein - receptor interaction even in the presence 
of a GPCR agonist (Ferguson et al., 1996a; Krupnick and Benovic, 1998; 
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Lefkowitz, 1998; DeWire et al., 2007). There are two isoforms of β-arrestins, (β-
arrestin-1 and β-arrestin-2) that are ubiquitously expressed and each can 
differentially regulate GPCR desensitization and internalization (Oakley et al., 
2000). β-arrestin-1 and β-arrestin-2 are able to both homo- and hetero-dimerize 
(Milano et al., 2006; Storez et al., 2005). 
 
Although arrestins have long been appreciated to play key roles in the 
desensitization of function of GPCRs they can also serve as adaptors, scaffolds 
and/or signal transducers that connect activated receptors with diverse 
signalling pathways. They can direct the recruitment, activation, and scaffolding 
of cytoplasmic signalling complexes on the GPCR and evoke signalling pathways 
different from the action of the G proteins (Shenoy and Lefkowitz, 2005). A 
much wider range of roles for the β-arrestins, including interactions with 
receptors outside of the GPCR family and the generation of district, G protein 
independent signals (DeWire et al., 2007; Gurevich and Gurevich, 2006; 
Lefkowitz et al., 2006). Proteomic analysis of β-arrestin with their interacting 
partners revealed more than 200 distinct polypeptides residing in distinct 
cellular compartments with roles in signal transduction, cellular organization 
and nucleic acid binding (Xiao et al., 2007) reflecting the complex role of 
arrestins in the signalling. The essential role of arrestins for the cell signalling 
and homeostasis has been documented by the phenotypes of β-arrestin null mice 
(Zamah et al., 2002; Conner et al., 1997; Kohout et al., 2001). 
 
1.6. cAMP signalling in depression 
3’,5’-cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger, 
which is involved in a wide variety of intracellular signal transduction cascades 
that usually start with a receptor stimulation and play a key role in major 
biological processes (Beavo and Brunton, 2002; Taylor et al., 2005; Wong and 
Scott, 2004). The cAMP signalling pathway is subject to regulation by cross-talk 
through interactions with a number of other distinct signalling cascades at many 
points that carefully controlled intracellular localization of the signalling 
components which allows cAMP gradients to be produced in the cell in response 
to distinct stimuli and environmental conditions (Baillie et al., 2005; Houslay and 
Adams, 2003; Tasken and Aandahl, 2004; Wong and Scott, 2004; Zaccolo et al., 
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2002). The stimulation of cAMP is usually transient and this spatiotemporal 
control of the cAMP signalling dynamics is achieved by numerous feedback 
regulations that are activated to finely tune the cAMP signal in intensity, time 
and its propagation through the intracellular space (Baillie et al., 2005; Houslay 
and Adams, 2003). cAMP mediated signalling appears to have a key role in the 
pathophysiology and pharmacology of depression (Perez et al., 2001) as it has 
been proposed that the mechanism of action for most of the antidepressant 
treatments involves adaptations at several levels of the cAMP signalling cascade 
and the upregulation of the cAMP levels (Duman et al., 1997; D'Sa and Duman, 
2002). cAMP is generated by adenylyl cyclases (AC) following stimulation of the 
GPCRs. cAMP exerts its effects through the activation of 3 effectors: protein 
kinase A (PKA), the exchange protein directly activated by cAMP (EPAC) and the 
cyclic nucleotide-gated ion channels (Bos, 2006; Dremier et al., 2003) which, in 
turn, trigger downstream signals that lead to the regulation of various cellular 
processes including proliferation, differentiation or apoptosis (Tasken and 
Aandahl, 2004). Chronic electroconvulsive shock and antidepressant drugs have 
shown to lead to increase coupling of stimulatory G proteins with adenylyl 
cyclases (Ozawa and Rasenick, 1991), increased levels of cAMP-dependent 
protein kinases activity (Nestler et al., 1989b; Perez et al., 1989; Perez et al., 
1991) as well as increased expression and function of the cAMP response element 
binding protein (CREB) (Nibuya et al., 1996a). 
 
1.7. Phosphodiesterase gene family 
The sole route of cAMP degradation hence termination of its ubiquitous signalling 
action is achieved via the cyclic-nucleotide hydrolysing phosphodiesterase (PDE) 
superfamily (Beavo, 1995; Conti and Beavo, 2007; Bender and Beavo, 2006; 
Maurice et al., 2003). PDEs serve as major regulators of the cAMP signal 
transduction as they dynamically control its localized pools (Butcher and 
Sutherland, 1962) to underpin specificity of physiological responses (Houslay et 
al., 2007). These responses are triggered by cell surface receptors interacting 
with components of signalling systems or intracellular substrates (Houslay and 
Baillie, 2005; Houslay and Baillie, 2003). PDEs represent a heterogeneous family 
of enzymes that are classified into 11 gene families (PDE1-11) (Soderling and 
Beavo, 2000). Alternative mRNA splicing of these genes generates more than 100 
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PDEs isoforms in various tissues. The high degree of conservation between these 
genes implies their important physiological functions. Each PDE subfamily is 
characterized by a unique sequence homology and primary structure with unique 
sensitivity to modulators (e.g. CA2+, calmodulin and cGMP) and pharmacological 
inhibitors (Bender and Beavo, 2006). Different isoforms of PDEs possess different 
affinities for cAMP and/or cGMP (Stangherlin and Zaccolo, 2012). Three families 
specifically hydrolyse cAMP (PDE4,7,8), three families specifically hydrolyse 
cGMP (PDE5,6,9), and the others hydrolyse both cAMP and cGMP 
(PDE1,2,3,10,11). 
 
They exhibit distinct intracellular distribution with tissue- and cell-specific 
expression (Nishi et al., 2008) in order to control the cAMP levels in different 
subcellular compartments and at different times in response to stimuli (Lugnier, 
2006; Conti and Beavo, 2007). Within each family, PDEs can have several genes 
and each gene gives rise to multiple gene products due to alternative mRNA 
splicing coupled to the use of distinct promoters that all share identical catalytic 
units. 
 
From all the different cAMP specific phosphodiesterases, PDE4 plays a critical 
role for the cAMP regulation in the brain (Conti et al., 2003). Elevation of the 
intracellular levels of cAMP either with rolipram, which is a generic PDE4 
inhibitor or stimulation of β-adrenergic receptors, produces an antidepressant 
effect in animal models (O'Donnell, 1993; O'Donnell et al., 1994; O'Donnell and 
Frith, 1999; Zhang et al., 2001a). This upregulation of the cAMP has been 
proposed to lead to a corresponding increase in phosphodiesterase (PDE4) the 
enzyme that metabolizes the cAMP to AMP and this might be a compensatory 
mechanism in response to increased cAMP tone (Duman et al., 1997). 
 
1.7.1. PDE4 isoforms and structure 
Much attention has been focused on the cAMP phosphodiesterase 4 gene family 
(PDE4) (Conti et al., 2003; Houslay and Adams, 2003). The PDE4 gene family is 
highly evolutionarily conserved and is encoded by four separate genes namely 
PDE4A, PDE4B, PDE4C and PDE4D (Dlaboga et al., 2006) all of which have high 
affinity for rolipram, a PDE4-specific inhibitor (Houslay, 2001). Each one of these 
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genes gives rise to multiple variants due to alternative splicing (Francis et al., 
2001) and the use of multiple different initiation sites resulting in the generation 
of 25 different isoforms (Houslay et al., 2007; Houslay and Adams, 2003; Johnson 
et al., 2010). PDE4 isoforms interact with specific proteins/lipids in cells 
(Houslay and Adams, 2003) and in doing so they play a pivotal role in 
underpinning the compartmentalization of cAMP signalling (Houslay, 2010; 
Mongillo et al., 2004). PDE4 is widely distributed but particularly abundant in 
immune, reproductive and central nervous system. Among the PDEs the PDE4 
subfamily represents 70% to 80% of the PDE activity in neuronal tissue (Jin et al., 
1999). Due to their localization in the brain, PDE4s are important in the 
regulation of the intracellular levels of cAMP and are considered to be a prime 
target for therapeutic intervention for a range of psychiatric disorders such as 
depression (Cherry and Davis, 1999; Iona et al., 1998). PDE4s are critical 
components of the cAMP signalling in the brain and responsible in generating 
microdomains of cAMP leading to spatiotemporal regulation of the cAMP 
signalling (Houslay, 2010; Oliveira et al., 2010; Manganiello, 2002). PDE4s are 
the predominant isoforms responsible for the hydrolysis of cAMP formed after b-
adrenergic receptor stimulation (Manning et al., 1996) and are involved in the 
mediation of antidepressant treatment (Ye and O'Donnell, 1996; Ye et al., 1997). 
Different PDE4 isoforms can associate with agonist bound or unbound GPCRs in 
various ways; either by direct bind to the receptors (Baillie et al., 2003; Perry et 
al., 2002; Richter et al., 2008) or with the help of scaffolding proteins such as 
arrestins that result to the activation of a different signaling cascade (Richter et 
al., 2008; De Arcangelis et al., 2009; Bouvier et al., 1989). 
 
Each of these four genes encodes multiple proteins that share identical catalytic 
and C-terminal domains but differ near their N-terminal region. Although much 
of the sequence of PDE4s is conserved between isoforms, the unique N-terminal 
region of PDE4 confers direct isoform specific targeting to intracellular signalling 
complexes (Shakur et al., 1993) and interaction with anchor/scaffold proteins 
(Conti et al., 2003; Houslay and Adams, 2003; Yarwood et al., 1999; McPhee et 
al., 1999) allowing the fine-tuning of cAMP signalling to discrete subcellular 
locations and specific pathways (Bolger, 1994; Conti and Jin, 1999; Houslay, 
2001; Houslay et al., 2007). The N-terminal domain of the PDE4s is also 
responsible for membrane targeting (Shakur et al., 1993; Scotland and Houslay, 
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1995; Shakur et al., 1995; McPhee et al., 1995). This spatial regulation of the 
PDE4s appears to underpin the non-redundant functional role of each isoform. 
This is certainly true when one considers data from approaches that seek to 
ablate PDE4 activity by siRNA (small interfering RNA) (Lynch et al., 2005; 
Kolosionek et al., 2009) – mediated knockdown, dominant negative and gene 
targeting (Houslay, 2010). Gene knock out in vivo studies agree with the non-
redundant role of the different PDE4s (Jin et al., 1999; Jin and Conti, 2002; Jin 
et al., 2005). This is further proven by the identification of the PDE4/anchoring 
protein/PKA signalling complexes (Bolger et al., 2003a; Dodge et al., 2001; 
Tasken et al., 2001). Other PDE4s become associated with the GPCRS with 
adaptor proteins called arrestins (Baillie et al., 2003; Perry et al., 2002; Richter 
et al., 2008). Except the signalling targeting the N-terminal region, it also exerts 
a regulatory effect on its catalytic activity (Shakur et al., 1995; McPhee et al., 
1995), susceptibility to phosphorylation by PKA (Monaco et al., 1994) and 
sensitivity to inhibition (Sette and Conti, 1996; Conti et al., 1995; Laliberte et 
al., 2002; Itoh et al., 2010). 
 
PDE4 isoforms can be subcategorized into dead-short, super-short, short and 
long as indicated in the Figure 1.2 based upon the presence of regulatory 
upstream conserved region (UCR) domains located between the isoform specific 
extreme N-terminal region and the core catalytic domain. PDE4 isoforms can 
contain up to two upstream conserved regions (UCR1 and UCR2) which are joined 
together by two linker regions (LR1 and LR2), a highly conserved catalytic unit 
common to all PDE4s and a C-terminal region, which is unique to each of the 
four PDE4 subfamilies. The long isoforms possess a full intact UCR and LR regions 
and the short isoforms have an intact UCR2 but lack UCR1. In contrast, the 
super-short isoforms lack UCR1 and LR1 but containing a truncated UCR2. The 
dead-short isoforms do not have the regulatory and linker regions and is both N- 
and C- terminally truncated. Since it is enzymatically inactive and has survived 
through evolution, it is speculated that it may be involved in protein scaffolding 
(Johnston et al., 2004). 
 
Different isoforms of the PDE4 family have been shown to be differentially 
regulated at the post-translational level. Some forms of PDE4 are regulated by 
SUMOylation (Li et al., 2010a), ubiquitination (Li et al., 2009a), phosphorylation 
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(Sette et al., 1994) or via altered expression (Torphy et al., 1992; O'Donnell, 
1993; Ye et al., 1997). The electrostatic interaction between UCR1 and UCR2 
domains on the long isoforms leads to a regulatory module that is disrupted upon 
PKA phosphorylation of the UCR1 (Beard et al., 2000). PKA phosphorylation at 
the UCR1 increases enzymatic activity (Sette and Conti, 1996; Hoffmann et al., 
1998; MacKenzie et al., 2002) and sensitivity to rolipram inhibition in vitro 
(Sette and Conti, 1996; Conti et al., 1995; Laliberte et al., 2002) and in vivo 
(Itoh et al., 2010) and the phosphorylate and non-phosphorylated form of PDE4 
isoforms has been shown to have different binding affinity to rolipram (Fujita et 
al., 2007). Therefore, phosphorylation of PDE4 by PKA is believed to provide part 
of the cellular machinery and forms a negative feedback loop whereby localized 
cAMP levels are further decreased to reduce PKA activity, thereby allowing the 
dephosphorylation of PDE4 to reset the system thereby leading to cAMP 
desensitization (Conti et al., 2003). 
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Figure 1.2. PDE4 isoform diversity: long, short, super-short and dead-short. 
Each isoform is defined by its unique N-terminal targeting region. Long isoforms 
have UCR1 and UCR2 domains; short isoforms lack UCR1; super-short isoforms 
have an N-terminally terminally truncated UCR2; dead-short isoforms lack UCR1 
and UCR2 and have an inactive catalytic unit that is both N- and C-terminally 
truncated. Figure adapted from (Houslay et al., 2007). 
 
1.8. Protein Kinase A as a cAMP signalling effector 
The primary effector of cAMP is protein kinase A (PKA) (Skalhegg and Tasken, 
2000). PKA mediates a wide variety of cellular functions via direct 
phosphorylation of a range of substrates at the Ser/Thr amino acids. PKA is a 
tetrameric enzyme complex, which consists of two regulatory subunits with four 
encoded genes (RIa, Rib, RIIa, RIIb), and two catalytic (C) subunits with three 
encoded genes (Ca, Cb, Cg) (Skalhegg and Tasken, 1997). Differential expression 
patterns of the different PKA subunits can generate a range of holoenzyme 
combinations each one with different physiochemical properties (Skalhegg and 
Tasken, 2000). PKA holoenzymes are classified as type I or type II depending on 
the type of R subunit present (RI or RII) (Scott, 1991). These two PKA types 
exhibit differential sensitivity to cAMP activation and have different subcellular 
and tissue distribution. The binding of the cAMP directly to the regulatory 
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subunits of PKA promotes the dissociation of the active monomeric catalytic 
subunits which can freely phosphorylate a wide range of protein targets (Taylor 
and Stafford, 1978). Spatially restricted activation of PKA is conferred to a 
relevant subset of potential substrates by the binding with AKAPs that they bind 
to the regulatory subunits of the PKA holoenzyme (Carr et al., 1991; Gold et al., 
2006; Kinderman et al., 2006; Huang et al., 1997; Kovanich et al., 2010). AKAPs 
do not only position PKA inside the cell but they also ensure that this kinase is 
coupled to its upstream activators, including membrane receptors and ACs, and 
to signal termination enzymes, such as phosphodiesterases (PDEs) and 
phosphatases (Coghlan et al., 1995; Dodge et al., 2001; Tasken et al., 2001). The 
targeting of the two regulatory subunits of PKA by AKAPs is very different 
suggesting their unique functions (Colledge and Scott, 1999). PKA mediated 
phosphorylation process represent a highly efficient kinetic amplification 
mechanism in neurons (Dell'Acqua et al., 2006). 
 
1.8.1. AKAPs as cAMP signalling effectors 
Although cAMP is a small molecule that potentially equilibrates throughout the 
cell in milliseconds the intracellular cAMP concentrations fluctuate transiently 
within a narrow range upon receptor stimulation (Brooker, 1973). Moreover, 
several studies have shown that cAMP is not unevenly distributed with dynamic 
pools throughout the cell (Zaccolo and Pozzan, 2002; Mongillo et al., 2004; Rich 
et al., 2001; Zhang et al., 2001b; Zhang et al., 2005b; Jurevicius and 
Fischmeister, 1996). Indeed, imaging studies revealed rise of the cAMP levels 
selectively in specific cellular compartments upon stimulus in a specific manner 
that do not diffuse from one compartment to the other, allowing fidelity of the 
response (Di Benedetto et al., 2008). This diffusion is further prevented either 
by physical barriers or rapid decay by phosphodiesterases (Houslay, 2010). 
 
The compartmentalization of cAMP signalling is a critical facet of this signalling 
system and is evident in all cell types. The control of the cAMP flux is governed 
by the concerted action of two enzyme classes: adenylyl cyclases (synthesize 
cAMP) and local pools of phosphodiesterases (PDEs) to terminate the signal 
(hydrolyse cAMP to 5’-AMP). Moreover, this spatial and temporal control of the 
cAMP signal transduction is further achieved by compartmentalization of 
Chapter 1  Introduction 
     
EIRINI VAGENA 26 
 
intracellular effectors through adaptors or anchoring proteins (Perino et al., 
2012; Scott, 2006; Smith et al., 2006; Scott et al., 2000). A key mechanism by 
which a common signalling cascade can result in diverse functions is achieved by 
protein scaffolding complexes. Different ligand binding induces the assembly of 
distinct macromolecular signalling complexes with transducer scaffold proteins 
intracellularly of the receptor. Local targeting of an enzyme to a specific 
subcellular compartment not only ensures that this enzyme is near its relevant 
targets, but it also segregates its activity by preventing indiscriminate activity to 
other substrates. 
 
In particular, a family of diverse and well-studied scaffolding proteins are the A-
kinase anchoring proteins (AKAPs) that form multi-protein complexes and 
integrate cAMP signalling with other pathways and signalling events (Beene and 
Scott, 2007; Murphy and Scott, 1998; Scott, 1991; Scott et al., 2013; Wong and 
Scott, 2004; Colledge and Scott, 1999; Michel and Scott, 2002). 
 
AKAPs play an important role in the targeting and regulation of PKA-mediated 
phosphorylation events to specific subcellular locations (Wong and Scott, 2004; 
Tasken and Aandahl, 2004). In this way, AKAPs help to establish intracellular 
cAMP gradients, generated via activation of a specific GPCR and uniquely 
modulated by different subsets of PDEs, resulting in stimulus-specific activation 
and action of PKA (Di Benedetto et al., 2008; Houslay, 2010; Cooper, 2005; 
Lefkimmiatis and Zaccolo, 2014; Gold et al., 2013; Bauman et al., 2007). AKAPs 
consists of a structurally diverse protein family with more than 50 members and 
with numerous splice variants per gene that are expressed in a cell and tissue 
specific manner in mammals and lower organism (Pidoux and Tasken, 2010; 
Wong and Scott, 2004). AKAPs share three common features: first they all 
contain a PKA-anchoring domain; second they can form scaffold complexes by 
binding to other signalling enzymes and third they target these scaffold 
complexes to specific subcellular environments via various targeting motifs, like 
lipid modifications and protein–protein interaction domains (Wong and Scott, 
2004). The first described AKAP that bind to the regulatory subunit of PKA was 
the microtubule-associated protein MAP2 (Theurkauf and Vallee, 1982). Since 
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then, many others came in light (Lohmann et al., 1984; Nauert et al., 1997; 
Carnegie et al., 2004). 
 
In addition to the biological role of AKAPs to bind kinases such as PKA, it has 
been demonstrated that they can also bind phosphatases (Alto et al., 2002; 
Lester and Scott, 1997; Edwards and Scott, 2000; Scott, 1997; Coghlan et al., 
1995; Schillace and Scott, 1999; Steen et al., 2000). A central mechanism for the 
regulation of enzymatic activity (Krebs, 1985) and protein interactions (Pawson 
and Nash, 2000) is achieved by protein phosphorylation regulated by protein 
kinases and protein phosphatases. This dual-directional process is a versatile 
means of influencing cellular activity and any breakdown in the signal 
transduction may lead to pathophysiological outcomes (Cohen, 1999). Therefore, 
AKAPs can incorporate both kinases and phosphatases in the same signaling 
complex promoting the anchoring together of both the positive and negative 
regulators of a common phosphorylation site on the same signalling complex. 
 
Moreover, many AKAPs cluster PKA with PDEs (Dodge et al., 2001; Baillie et al., 
2005; Tasken et al., 2001) to tether local cAMP gradients in specific subcellular 
sites through various PDE binding proteins (Mongillo et al., 2004; Perry et al., 
2002). AKAPs bring different phosphodiesterases in different compartments in 
order to regulate their spatiotemporal action (Tasken et al., 2001; Asirvatham et 
al., 2004; Willoughby et al., 2006; Yarwood et al., 1999). Scaffold protein like 
arrestins, even though they do not have the structural or sequence homology 
with AKAPs, act as AKAPs and interact with phosphodiesterase in order to bring 
them to specific subcellular compartment (Yarwood et al., 1999; Perry et al., 
2002; Verde et al., 2001; Baillie and Houslay, 2005). The importance of co-
anchoring both PKA and PDE has been shown via mutants that lack PDE anchoring 
and this result in sustained PKA activity rather than brief pulses of PKA activity 
showed under normal conditions (Zhang et al., 2001b). This supports the 
hypothesis that, in addition to spatially restricting PKA phosphorylation, the 
complexes composing by AKAP and phosphodiesterases assure that the PKA 
activity is rapidly quenched by local degradation of cAMP caused by 
phosphodiesterases. 
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Thus, spatial and temporal signalling dynamics of cAMP is achieved by various 
proteins, including PKA, PDEs and facilitated by scaffolding proteins such as A-
kinase-anchoring proteins (AKAPs) that provide the structural integrity for 
multiprotein complexes that often represent hubs for processing of multiple 
signals  (Bauman et al., 2007). These complexes are generated in response to 
upstream signals that originate from GPCR and adenylyl cyclase activation, 
creating a complex and continually changing signalling environment in which 
cAMP levels are distributed unequal in the cell. A further layer of specificity 
proceeds through protein- or lipid-targeting domains on AKAPs that direct AKAP 
signaling complexes to intracellular membranes (Skroblin et al., 2010). 
Therefore, AKAPs complexes contain cAMP-dependent protein kinase, 
phosphatases, phosphodiesterases and other signalling effector proteins to 
optimize cellular responses to extracellular signals that cause cAMP or other 
second messenger alterations (Alto and Scott, 2004; Logue and Scott, 2010). 
Even though most of the proteins that control the cAMP signal transduction 
cascade have been identified, there is still the challenge of elucidating the 
mechanics of their action in real time. 
 
 
1.9. The action of rolipram as an antidepressant 
Rolipram, a small-molecule and a generic PDE4 inhibitor is known for its 
antidepressant action in rodents (Zhang, 2009; Zhang et al., 2006; Przegalinski 
and Bigajska, 1983; Overstreet et al., 1989; Schwabe et al., 1976; Zeller et al., 
1984; Kehr W, 1985 ; Wachtel, 1982; Wachtel, 1983b; Li et al., 2009b) and in 
clinical trials (Griebel et al., 1991; Bobon et al., 1988; Wachtel and Schneider, 
1986; Wachtel, 1983a; Fleischhacker et al., 1992; O'Donnell, 1993; Bertolino et 
al., 1988; Hebenstreit et al., 1989). Fig. 1.3 shows the structure of rolipram. 
Rolipram has also been shown to facilitate the establishment of lasting long term 
potentiation that leads to cognitive improvement which is another deficit to 
people with depression (Barad et al., 1998). Chronic administration of rolipram, 
leads to a sustained elevation of cAMP levels (Schneider, 1984) and increases the 
expression of CREB, BDNF and TrkB, all of which are believed to facilitate the 
action of antidepressants (Li et al., 2009b; Nibuya et al., 1996a). Rolipram 
induced elevation of intracellular cAMP levels is responsible for the increased 
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synthesis and release of norepinephrine which enhance central noradrenergic 
transmission (Schwabe et al., 1976; Wachtel, 1983b). Rolipram is believed to 
increase the neurotransmission of noradrenaline in two ways: 1. presynaptically 
by increasing the synthesis and release of norepinephrine (Kehr W, 1985) and 2. 
postsynaptically by the increase availability of cAMP via the inhibition of PDE4s 
that modulate the action of hormones, neurotransmitters and drugs (Krebs and 
Beavo, 1979; Wachtel and Schneider, 1986). As rolipram exerts its effects both 
pre- and post-synaptically, it induces rapid anti-depressant effects compared to 
other antidepressants (Wachtel, 1983b). Co-administration or rolipram with 
other antidepressant has been shown to shorten the time required for cAMP 
response element-binding protein (CREB) upregulation and BDNF expression both 
indicators for antidepressant action (Nibuya et al., 1996a). Enhancement of the 
cAMP response due to rolipram could be particularly advantageous if the 
serotonin and noradrenergic receptors coupled to cAMP are downregulated in 
response to elevated levels of monoamines, as reported for the beta adrenergic 
receptors (Duman, Heninger et al. 1994) and the 5-HT7 receptor (Sleight, Carolo 
et al. 1995). In addition, rolipram has been shown to be an ideal drug candidate 
for brain disorders as PET imaging revealed the ease with which it crosses the 
blood brain barrier (BBB) (Fujita et al., 2005). This confers a competitive 
advantageous characteristic over other comparable antidepressants. 
 
Figure 1.3. Structure of rolipram. 
Image shows the chemical structure 
of the phosphodiesterase inhibitor 
rolipram. 
 
 
However, despite initial promise, the therapeutic potential of rolipram as an 
antidepressant is limited due to the side effects of nausea and emesis (Scott et 
al., 1991; Zeller et al., 1984; Rock et al., 2009; Robichaud et al., 2001) owing to 
its mechanism of action as a non-isoform-specific PDE4 inhibitor (Dyke and 
Montana, 2002; Robichaud et al., 2002; Hirose et al., 2007; Bertolino et al., 
1988; Hebenstreit et al., 1989). The molecular identification of the isoform that 
mediates the antidepressant action of rolipram and the creation of selective 
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inhibitors of PDE4 isoforms may have therapeutic effects with minimal adverse 
reactions (O'Donnell and Zhang, 2004). Structural analysis of the catalytic 
domains of PDE4A, PDE4B, PPDE4C and PDE4D bound to inhibitors revealed 
significant conformational differences between the different enzymes that can 
shed light for the development of selective inhibitors for the different members 
of the PDE4 family (Wang et al., 2007). Despite the fact that the design of 
specific PDE4 inhibitors has been very slow, it has already been achieved for the 
sub-family of PDE4Ds in order to enhance cognition (Burgin et al., 2010; Houslay 
and Adams, 2010). To date, no PDE4 inhibitor has been brought to market as an 
antidepressant drug due to issues related to tolerability and side effects 
(Giembycz, 2005). 
 
1.10. Brain regions involved in depression 
The neurocircuitry of depression is complex and involves portions of the limbic 
system such as hippocampus, amygdala, thalamus, cortex and other structures of 
the emotional brain to play a role in the pathophysiology of depression (Price 
and Drevets, 2010; Eisch and Petrik, 2012). Increasingly sophisticated methods of 
brain imaging such as positron emission tomography (PET), single photon 
emission computed tomography (SPECT) and functional magnetic resonance 
imaging (fMRI) have allowed the imaging of the brain in vivo while it functions 
over tasks. An fMRI scan tracks the changes in a region of the brain in response 
to various tasks. A PET or SPECT scan maps the brain by measuring the 
distribution and density of neurotransmitter receptors in brain regions. Using 
these powerful techniques studies found that depressed patients exhibit 
structural and functional changes in brain regions important for learning and 
memory such as prefrontal cortex (Dolan et al., 1993; Drevets, 2000), 
hippocampus and amygdala (Sheline et al., 1998; Videbech and Ravnkilde, 2004). 
 
Most of the studies are focusing on hippocampus that is significantly altered in 
depression and known to regulate mood and cognition (Pittenger and Duman, 
2008; Sapolsky, 2003). Hippocampus have received much attention in the recent 
years as human imaging and rodent studies showed that depression is associated 
with decreased hippocampal volume and atrophy of neurons (Pittenger and 
Duman, 2008; Fossati et al., 2004; Bremner et al., 2000; Sheline et al., 1996; 
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Duman and Aghajanian, 2012). The reduction of the hippocampal volume 
observed in patients with depression has been speculated to cause the memory 
impairment in these patients (Czeh and Lucassen, 2007). Interestingly, 
experimental obesity on the brain in mice revealed decreased myelin levels and 
marked alterations to the fatty acid composition of myelin in genetically obese 
mice (Sena et al., 1985) and regression studies associate increased body mass 
index with decreased brain volume (Ward et al., 2005) suggesting another link 
between obesity and depression. 
 
Amygdala, a structure of the limbic system deep in the brain that’s associated 
with emotions such as anger, pleasure and fear (Fernando et al., 2013). 
Amygdala has been shown to be activated when a person recalls emotionally 
charged memories, such as frightening situation (Duvarci and Pare, 2014). 
Clinical studies revealed that the activity in amygdala is higher when a person is 
either sad or clinically depressed. Interestingly, this increased activity continues 
even after recovery from depression (Foland-Ross and Gotlib, 2012). The 
prefrontal cortex (PFC) is implicated in executive tasks and reward and recently 
it has been proposed to be involved in the control of emotions and the 
pathophysiology of depression (Krishnan and Nestler, 2008; Nestler and Carlezon, 
2006). 
 
However even though isolated brain regions have been studied in relation to 
depression (Eisch and Petrik, 2012) the connecticome and how they are 
interconnected between each other and the other the brain regions involved in 
depression and where do they send their signals is totally unknown. 
 
1.10.1. The role of hypothalamus in mood disorders 
Despite a brain preference for glucose as its primary energy source, more recent 
evidence suggests that hypothalamic lipid metabolism and signalling have 
significant roles in regulating energy balance, food intake and the aetiology of 
metabolic diseases (Lam et al., 2005b; Lopez et al., 2005). The central nervous 
system has developed mechanisms in order to sense nutrient availability, 
regulate and connect main physiological homeostatic responses peripherally and 
centrally (Lam et al., 2005b). The hypothalamus, the main regulator of energy 
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homeostasis is a brain region highly vascularized with a lot of communication 
with the periphery that has been involved in both obesity and depression. Many 
hormones or macronutrients in the circulation can bind to specific receptors in 
the hypothalamus in order to regulate different signalling pathways. For 
instance, it has been shown that leptin, a main adipose tissue hormone, can be 
transported across the BBB through a substrate concentration dependent manner 
and signal in the hypothalamus feeding circuits that regulate appetite (Bouret, 
2009). 
 
Considering progress has been made to elucidate the key role of hypothalamus in 
regulating the cellular and molecular processes comprising the circuits 
regulating energy homeostasis (Ryan et al., 2012; Schwartz et al., 2000; Woods 
and D'Alessio, 2008). This homeostatic regulation integrates acute satiation 
signals, arising in the gut and secreted phasically during meals, with more 
tonicaly active adiposity signals to appropriately adjust nutrient intake and 
energy expenditure (Ryan et al., 2012; Schwartz et al., 2000; Woods and 
D'Alessio, 2008). Due to this, many studies have investigated signalling pathways 
in the hypothalamus that are critical in nutrient sensing. Also those that regulate 
the complex network of signals impacting on both energy metabolism and 
feeding behaviour, in order to influence energy homeostasis both centrally and 
peripherally (Cota et al., 2007; Le Foll et al., 2009; Moran, 2010; Lam et al., 
2005b; Woods et al., 1998; Schwartz et al., 2000; Ahima et al., 1996; Wang et 
al., 1998; Obici et al., 2002). The quality of dietary FA during postnatal life 
affects permanently the development of the central regulatory circuits in the 
hypothalamus that control energy balance and may do so through a leptin-
independent mechanism (Schipper et al., 2013). 
 
The specific role of different fatty acids in the hypothalamic area for the 
regulation of energy and appetite has been studied as well (Levin et al., 1999; 
Jo et al., 2009; Huang et al., 2004; Wang et al., 2002; Morgan et al., 2004). 
Interestingly, it has been found that dietary fatty acids differentially affect 
signalling pathways in the hypothalamus and modulate overall energy 
expenditure as polyunsaturated fatty acids (PUFAs) have been shown to increase 
pro-opiomelanocortin (POMC) expression and decrease neuropeptide Y (NPY) 
expression, both peptides with important roles in appetite, compared to diets 
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higher in saturated fats (SFAs) (Dziedzic et al., 2007; Huang et al., 2004) 
suggesting a differential role for the different degrees of saturation of fatty 
acids. 
 
1.11. Mechanisms involved in the action of 
antidepressants 
Extensive biochemical research in mood disorders in order to elucidate the 
action of antidepressants has focused along the cascade of events involved in 
signal transduction, from the level of the monoamine neurotransmitter to the 
level of the neurotransmitter receptors and lately to information transduction 
mechanism beyond receptors involving the coupling of receptors with signal 
transducers. However, the precise mechanism of action of antidepressant drugs 
remains unclear. Several mechanisms have been proposed to explain the action 
of antidepressants with the main focus on the increase of the serotonin and 
norepinephrine in the brain as alterations of these neurotransmitter receptors 
appears to play a major role in the pathogenesis of depression (Mann, 1999; 
Ressler and Nemeroff, 1999). A possible explanation for the action of different 
antidepressant treatments is that they affect a common intracellular signal 
transduction pathway beyond the levels of serotonin and norepinephrine and 
their relative receptors, possibly through cross-talk between different 
neurotransmitter/receptor systems. If that’s the case, the regulation of the 
monoamines and their receptors represent an initial effect that subsequently 
leads to the regulation of postreceptor signalling pathways that mediate the 
therapeutic action of antidepressants (Sulser, 1989; Hudson et al., 1993; Duman 
et al., 1994). 
 
A major candidate for the post-receptor target that could be regulated by both 
serotonin and norepinephrine and thereby mediate the long term adaptations in 
response to diverse antidepressant treatments is the nuclear transcription factor 
cAMP response element binding protein (CREB). CREB mRNA and protein 
phosphorylation is upregulated after chronic but not acute antidepressant 
treatment in the hippocampus (Nibuya et al., 1996b; Thome et al., 2000; 
Tiraboschi et al., 2004) suggesting a chronic effect of the treatment on CREB. 
Chronic agonist exposure due to antidepressant treatment causes desensitization 
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of the receptors which can be manifested clinically as tachyphylaxis often 
involving a decrease in the net number of post synaptic receptors at the cell 
surface including β-adrenergic and serotonin receptors (Sulser et al., 1984; Katz, 
2011). This may involve β-arrestins or may be mediated through other distinct 
processes.  However, even though this reduction has been documented it is 
possible that there is an increase in the functional output of these receptor 
coupled intracellular pathways. Therefore, even though the density and function 
of these receptors is reduced, they are not eliminated by chronic antidepressant 
treatment suggesting that the activation of the remaining receptors is sufficient 
enough to stimulate the intracellular signal transduction pathways (Nibuya et 
al., 1996a). The decreased density in monoamine receptors upon antidepressant 
treatment is also observed in cell culture systems that lack presynaptic input 
(Fishman and Finberg, 1987; Kientsch et al., 2001). Another possible explanation 
for reduction of functional monoamine receptors could represent a 
compensatory response to the high levels of the different neurotransmitters in 
the synapse. 
 
Depression has been described as a neurodegenerative disease as there is a 
commonly observed delay of several weeks between the start of the 
antidepressant treatment (Belmaker and Agam, 2008) or ECT to exert their 
therapeutic response and this might reflect the requirement for serotonergic or 
noradrenergic nerve-terminal regrowth (Mamounas et al., 1995). This hypothesis 
is in agreement with observation that different treatments in order to exhibit a 
beneficial effect and ameliorate the symptoms of depression they need to act 
over the course of weeks or months (Baldessarini, 1989; Wong and Licinio, 2001). 
This delay of their therapeutic effects has led to many studies investigating the 
long term pharmacology effects of antidepressants (Mongeau et al., 1997). 
Chronic antidepressant treatment is accompanied by transcriptional and cellular 
modulation, occurring on a later timescale than the changes in monoamine 
levels which is consistent with the onset of the relief of symptoms (Frazer and 
Benmansour, 2002; Nestler et al., 2002a; Young et al., 2002; Carlezon et al., 
2005; Blendy, 2006). However, the acute effects of antidepressants in the 
synapse although not sufficient by themselves, initiate the cascade of events 
that result in clinical improvements (Miller et al., 1996). Furthermore, the 
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generation of fast-acting and more efficacious class of drugs may be proven 
beneficial for the treatment of severe or depression associated with suicide. 
 
Moreover, antidepressant drugs possess no mood elevation or euphoric feelings 
in healthy individuals but correct the mood disturbances in depressed patients 
(Nelson, 1999) indicating that the action of antidepressant drugs that underlie 
their clinical results uncovers only under pathophysiological conditions sharing 
similar aspect of depression. 
 
1.12. CREB as an intracellular target for the regulation 
of depression  
CREB is a member of the basic region/leucine zipper motif (Bzip) superfamily of 
transcription factors that is being activated by phosphorylation at Ser133 and in 
turn influences the transcription of genes that encode a wide range of functions. 
Although the particular CREB-regulated genes that contribute to depression have 
not been identified there are some plausible targets such as DARPP32 (Cantrup 
et al., 2012; Helms et al., 2006) and BDNF (Pittenger and Duman, 2008). CREB 
activation is increased by the cAMP cascade due to its phosphorylation by the 
cAMP effector, PKA (Nibuya et al., 1996a) and this leads to the transcriptional 
regulation of a large cohort of genes. However, there is huge controversy 
whether phosphorylation of CREB has an anti- or pro- depressive effects 
(Carlezon et al., 2005). Chronic antidepressant treatment increases the 
phosphorylation of CREB in certain brain regions (Thome et al., 2000; Tiraboschi 
et al., 2004; Nibuya et al., 1996a) as well as genes regulated by CREB such as 
BDNF (Nibuya et al., 1995). Virus mediated overexpression of CREB in the 
hippocampus produced antidepressant behaviour in acute behavioural tests 
(Chen et al., 2001). Both these observations suggest that CREB mediates some of 
the gene transcription changes that are being induced by chronic antidepressant 
treatment. However, activation of CREB has also been shown to play an opposing 
role. Chronic antidepressant treatment has been shown to decrease CREB 
phosphorylation in certain brain regions (Kuipers et al., 2006; Manier et al., 
2002) as well as the expression of CRE-containing genes such as tyrosine 
hydroxylase (Nestler et al., 1990), corticotropin-releasing hormone (Brady et al., 
1991) and β-adrenoreceptor (Banerjee et al., 1977; Meyerson et al., 1980). Virus 
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mediated overexpression of CREB in the nucleus accumbens has been shown to 
increase immobility in the forced swim test an indicator for depression 
phenotype (Pliakas et al., 2001). Stress also increases CREB activity and the 
likelihood of depression in transgenic CRE-luciferase reporter mice (Boer et al., 
2007a). Lastly, CRE-deficient (CREBADmutant) mice demonstrate increased 
hippocampal neurogenesis and an antidepressant phenotype in the tail 
suspension and forced swim test (Gur et al., 2007). Therefore, whether 
activation of CREB has an anti or pro depressant effect is still unclear. 
 
Much experimental work has focused on the phosphorylation of CREB on either 
the serine-199 of CREB-327 isoform or serine-133 of CREB-341 isoform in the 
brain following anti-depressant treatment (Kuipers et al., 2006; Tardito et al., 
2006; Thome et al., 2000; Tiraboschi et al., 2004). While this phosphorylation 
event promotes the recruitment of CREB coactivator CBP (Shaywitz and 
Greenberg, 1999) and is required for CREB activation, it is not sufficient for 
CREB transcriptional activity (Boer et al., 2007b; Ravnskjaer et al., 2007; 
Schwaninger et al., 1993). Hence a better understanding of the posttranslational 
regulation of CREB in depression might advance our knowledge on its function in 
depression-related brain signalling. 
 
1.13. Serotonin and noradrenergic molecular 
pathways in depression 
It is speculated that antidepressant drugs regulate CREB either via the activation 
of the cAMP cascade (via 5-HT4,6,7 and α1 adrenergic receptor) or by Ca
2+ 
activated protein kinases (5-HT2 and α1 adrenergic receptors) (Shelton, 2007). 
The serotonin pathway is a key modulatory pathway in a plethora of functions of 
the central nervous system in physiological and disease states (Gingrich and Hen, 
2001; Barnes and Sharp, 1999). The plasma tryptophan is the precursor for the 
synthesis of serotonin in the brain, and it is transported into the brain across the 
blood brain barrier (BBB) (Blomstrand, 2001). Numerous reports implicate the 
serotonin pathway in controlling the neuronal functions and to be responsible for 
the cognition and behaviour (Struder and Weicker, 2001). Serotonin receptors 
are involved in several signalling intracellular transduction pathways one of 
them being the regulation of the cAMP pathway (Raymond et al., 2001) that has 
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been suggested to play a role in depression. The hypofunction of the 
serotonergic system is thought to play a major role in the development of 
depression (Middlemiss et al., 2002) and many other neuropsychiatric disorders 
(Barnes and Sharp, 1999; Gingrich and Hen, 2001; Duman et al., 1997; Manji et 
al., 2001) that is treated predominantly with SSRIs or MAOIs. SSRIs, except their 
role in increasing the amount of serotonin in the synapse it has been speculated 
that they also act via the desensitization of the serotonin autoreceptor. Due to 
the recognition of the role of the serotonin in depression different KO mice were 
generated in the serotonin pathway in order to study the role of the different 
molecules in the serotonin pathway such as serotonin transporter and various 
serotonin receptors (Gardier, 2009). 
 
The pathophysiology of the adrenoreceptor pathway has been involved in 
depression. There is an inverse correlation between the severity of depression 
and β-adrenergic receptor density (Jeanningros et al., 1991) and a negative 
association between β-adrenergic receptor stimulated cAMP activity and 
depressive symptoms (Mazzola-Pomietto et al., 1994). Down-regulation or 
desensitization of β-adrenoreceptor is dependent on the phosphorylation 
mediated by cAMP dependent protein kinase A (PKA) and β-adrenergic receptor 
kinase (GRK). Antidepressants have been shown to modulate the density of the 
functional neurotransmitter receptors such as β-adrenergic receptors in the 
brain (Banerjee et al., 1977; Peroutka and Snyder, 1980) as well as in cultured 
cells (Honegger et al., 1986; Fishman and Finberg, 1987). β-adrenergic receptor 
down regulation is accompanied by decreased receptor-stimulated cAMP 
formation (Vetulani and Sulser, 1975) however the mechanism for this reduction 
is not understood. On the contrary it has also been shown that high densities of 
brain α2 adrenoceptor in the brain of depressed suicides and many 
antidepressants are able to modulate the density and/or function of these 
inhibitory receptors (Gonzalez-Maeso et al., 2002). 
 
Dopaminergic signalling has been involved in the pathophysiology of depression 
(Dunlop and Nemeroff, 2007). Acute antidepressant treatments have no 
consistent effect on dopaminergic function however increased dopaminergic 
function has been observed following chronic antidepressant treatments 
(Willner, 1983). The site of these effects is at present unclear, but appears to be 
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beyond the dopaminergic receptors hypothesizing that these effects happen via 
the decreased sensitivity of pre-synaptic dopaminergic autoreceptors (Willner, 
1983). Figure 1.4 shows the two main pathways involved in depression and their 
downstream effectors.  
 
Figure 1.4. Schematic of the main pathways involved in depression. 
Schematic of the main pathways that are involved in depression. The schematic 
represents the major components of the β-adrenergic and serotonin system both 
of which lead to the activation of PKA that phosphorylates CREB and this results 
in the translocation of CREB in the nuclei in order to regulate the transcription 
of different genes. 
 
 
 
 
1.14. The role of p11 in depression 
p11, also called S100A10, is a member of the S100 EF-hand protein family 
(Donato, 1999) and a small acidic protein that has been involved in depression 
due to its interaction with specific serotonin receptors as it increases their cell 
surface localization and regulate their trafficking and signalling (Svenningsson et 
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al., 2006; Warner-Schmidt et al., 2010; Warner-Schmidt et al., 2009). p11 is a 
member of the S100 family of proteins, and a key regulator of depression and 
antidepressant response to rodents (Svenningsson et al., 2006; Warner-Schmidt 
et al., 2010; Warner-Schmidt et al., 2009) as p11 mRNA and protein levels are 
decreased in brain tissue of depressed patients (Svenningsson et al., 2006; 
Anisman et al., 2008) and in animal models of depression (Svenningsson et al., 
2006). Antidepressant or electroconvulsive therapy increases the levels p11 
(Svenningsson et al., 2006). Overexpression of p11 in a transgenic mouse model 
recapitulates certain behaviours seen after antidepressant treatment in mice 
(Svenningsson et al., 2006). p11 knock out mice showed a depression phenotype 
with reduced responsiveness to serotonin receptor agonists as well as resistance 
to behavioural effects upon antidepressant treatment (Svenningsson et al., 
2006). Therefore a modulation of the serotonin receptor by p11 might be 
involved in molecular adaptations occurring in neuronal networks that 
dysfunction in depression. Interestingly, cytokines can increase the p11 levels 
which in turn leads to an antidepressant effect in mice (Warner-Schmidt et al., 
2011) implying that the brain cytokines might also exert an antidepressant 
action. Non-steroidal anti-inflammatory drugs (NSAIDS) can reduce the levels of 
cytokine secretion (Bacchi et al., 2012). This is in accordance with the fact that 
widely prescribed NSAIDs antagonize both biochemical and behavioural responses 
to SSRIs (Warner-Schmidt et al., 2011) as increased levels of different cytokines 
induced by antidepressant treatment can be inhibited by anti-inflammatory 
agents and this reverses the antidepressant effect (Warner-Schmidt et al., 
2011). 
 
1.15. The role of neurotrophins in depression 
Recently, deficiencies in neurotrophin production have been implicated in the 
pathophysiology of depression and has been suggested that antidepressant 
treatment and ECT might work by boosting their production in the brain. This 
hypothesis suggests a ‘neurotrophinboosting’ pharmacotherapy for depression 
that requires nerve growth for a clinical response. 
 
The role of neurotrophins, a family of growth factor hormones has been 
extensively studied in the regulation, development and maintenance of the 
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peripheral (PNS) and central (CNS) nervous system. Chronic infusions of 
neurotrophins such as brain derived neurotrophin receptor (BDNF) or 
neurotrophin 3 (NT-3) into the rat midbrain increased the turnover rate of 
serotonin and noradrenaline in many brain regions such as neocortex, basal 
ganglia and hippocampus (Martin-Iverson et al., 1994; Altar et al., 1994; Siuciak 
et al., 1996). This in turn, promoted the function, sprouting and regrowth of 5-
HT-containing neurons (Mamounas et al., 1995). This effect of BDNF and NT-3 on 
serotonergic neuronal function, growth and regeneration suggested a potential 
link between neurotrophins and depression as the serotonergic system is altered 
in people with depression. This link was also based on the observations that the 
brain tissue as well as the ventricular fluids of patients with major depression 
have reduced serotonin turnover (Asberg et al., 1976; Mann et al., 1989; Risch 
and Nemeroff, 1992). 
 
One of the neurotrophins that its expression and/or function has been shown to 
be involved in the pathophysiology and pharmacotherapy of depression is the 
BDNF (Pittenger and Duman, 2008; Tardito et al., 2006; Kozisek et al., 2008; 
Chen et al., 2006; Sakata et al., 2010) as well as its receptor tropomyosin-
related kinase B (TrkB). TrkB expression is regulated by PKA activation and CREB 
binding (Deogracias et al., 2004). BDNF is a peptide critical for axonal growth, 
neuronal survival, and synaptic plasticity and function. 
 
BDNF levels have been reported to be reduced in patients with depression, and 
antidepressants as well as physical exercise seem to upregulate BDNF (Karege et 
al., 2005; Dias et al., 2003; Tsankova et al., 2006; Russo-Neustadt et al., 2004). 
Chronic rolipram co-administration with antidepressant has also been shown to 
induce BDNF upregulation in the hippocampus (Fujimaki et al., 2000). It has 
been reported that BDNF administration is sufficient to produce an 
antidepressant effect (Nibuya et al., 1996a; Adachi et al., 2008). Peripheral 
BDNF administration induces an antidepressant effect in mice accompanied by 
increased neurogenesis, increased hippocampal BDNF and p-CREB (Schmidt and 
Duman, 2010). Infusions of BDNF into the brain can accelerate the regrowth of 
serotonergic nerve fibres following their destruction by a serotonergic 
neurotoxin (Mamounas et al., 1995). Therefore, positive modulators of 
BDNF/TrkB signalling might result to a potential antidepressant effect in humans 
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(Martinowich et al., 2007). BDNF signalling in the brain is thought to have a 
potential antidepressant action by involving the hippocampus and HPA axis 
(Castren and Rantamaki, 2010; Wang et al., 2008). BDNF has also been involved 
in obesity as dendritically targeted BDNF transcript in the hypothalamus is 
important for the regulation of food intake in mice (Liao et al., 2012). 
 
However, conflicting findings have been reported for BDNF expression level 
depending on the length of the treatment as well as the time interval following 
administration. Short-term antidepressant treatment decreased BDNF expression 
in rodents whereas long-term increased BDNF levels (Coppell et al., 2003; De 
Foubert et al., 2004; Khundakar and Zetterstrom, 2006). This biphasic induction 
of BDNF of the different transcripts of BDNF was also shown in vitro using a 
human hippocampal cell line suggesting a common feature between rodents and 
humans (Donnici et al., 2008). 
 
The role of TrkB, the receptor of BDNF in depression is not clear. Preventing 
BDNF production in dopaminergic regions or inhibiting BDNF/TrkB signalling in 
the nucleus accumbens induces an antidepressant effect (Eisch et al., 2003). 
Activation of TrkB has a depressant effect as administration of a low molecular 
weight ligand for TrkB (ANA-12) that acts as an antagonist (prevents the 
activation of the receptor) for the TrkB demonstrated an antidepressant effect 
in mice (Cazorla et al., 2011). Therefore, a better characterization of the time 
and dose of BDNF and its role in depression in needed. 
 
1.16. Neurogenesis as a potent antidepressant 
mechanism 
In mammals, cell proliferation and neurogenesis in the hippocampus happens 
throughout the adult mammalian life. A possible mechanism of action of 
antidepressants is via anti-apoptotic and neurotrophic effect of antidepressants 
as people with depression exhibit neuronal loss (Drzyzga et al., 2009). More 
specifically, cell loss, atrophy and decreased neurogenesis in the hippocampus 
has been implicated in the pathophysiology of depression and a direct role of the 
adult neurogenesis in depression has been described (Snyder et al., 2011; Eisch 
and Petrik, 2012). Studies in animal models of depression suggest that reduced 
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neurogenesis in the adult hippocampus might contribute to structural changes 
and to alterations of the behaviour of these animals. Increased expression of 
CREB and induction of BDNF and TrkB in response to chronic antidepressant 
treatments could enhance the survival and/or function of neurons as it has been 
reported for direct application of BDNF (Ghosh et al., 1994; Lindsay et al., 1994; 
Lindvall et al., 1994). Hippocampal neurogenesis can be driven by the 
administration of antidepressants (Malberg et al., 2000; Santarelli et al., 2003; 
Sairanen et al., 2005) or electroconvulsive seizure (Madsen et al., 2000) 
suggesting that correlation of increased neurogenesis with antidepressant 
treatment. Increased hippocampal neurogenesis has been used as an indicator 
for antidepressant behaviour (Newton et al., 2002). 
 
However, behavioural studies suggest that antidepressant treatment exert their 
therapeutic effects via both neurogenesis-dependent and –independent pathways 
(Santarelli et al., 2003; Sahay and Hen, 2007; David et al., 2009; Holick et al., 
2008). 
 
Among the various molecules assigned to contribute to adult neurogenesis and 
cognition, the most important is cAMP response element-binding protein (CREB) 
(Mizuno et al., 2002) CREB is a transcription factor that rapidly responds to 
intracellular signalling effectors originating from neurotransmitters and neuronal 
growth signalling in mature neurons (Lonze and Ginty, 2002). BDNF is regulated 
transcriptionally by CREB and except its role in learning and memory it also 
promotes cell proliferation as intra-hippocampal infusion of BDNF promotes 
adult neurogenesis (Scharfman et al., 2005). 
 
Rolipram, a generic PDE4 inhibitor increases the cAMP and phosphorylation of 
CREB and rolipram’s antidepressant effect depends partially on its neurogenic 
action in the hippocampus (Li et al., 2009b; Schneider, 1984). Chronic, but not 
acute, treatment with rolipram increases hippocampal proliferation and survival 
of newborn neurons in the dentate gyrus and this is mediated by cAMP/CREB 
(Nakagawa et al., 2002a; Nakagawa et al., 2002b; Fujioka et al., 2004; Sasaki et 
al., 2007); this effect is accompanied by the activation of CREB (Fujioka et al., 
2004; Nibuya et al., 1996b; Nakagawa et al., 2002b; Zhu et al., 2004). Rolipram 
is a generic inhibitor for PDE4 isoforms for all four sub-families (A/B/C/D). 
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Indeed targeted gene knock down of PDE4D in mice generates animals that are 
characterized by an increase neurogenesis and phosphorylation of CREB (Li et 
al., 2011). Rolipram has also been associated with memory enhancing effects in 
rodents (Barad et al., 1998; Zhang and O'Donnell, 2000; Zhang et al., 2000; 
Zhang et al., 2004; Zhang et al., 2005a), which are associated with the increased 
phosphorylation of CREB in the hippocampus (Blendy, 2006; Monti et al., 2006; 
Sairanen et al., 2007). 
 
1.17. New strategies and targets for the development 
of antidepressant treatments 
The commonly used antidepressant medicine treatments have been developed 
50 years ago targeting the monoamines. Unfortunately ~50% of individuals with 
depression show full remission in response to these mechanisms. Therefore new 
strategies for the development of antidepressant treatment that do not focus on 
monoamines are urgently needed (Berton and Nestler, 2006). The mechanism of 
action underlying the targets beyond monoamines signalling is now emerging in 
both preclinical and clinical reports in depression (Wong and Licinio, 2004; 
Hunsberger et al., 2007). 
 
Many of these new target molecules have been found in the hypothalamus 
underlying the important role of this brain region in depression. However the 
depression related hypothalamic nuclei or neuronal populations inside the 
hypothalamus critical for the depression phenotype remains to be determined. 
The hypothalamus is a brain region that receives most of the sensory information 
and directs it to the appropriate part of cerebral cortex that regulates higher 
functions such as speech, behaviour and movement. Bipolar disorder has been 
suggested to result from problems in the thalamic area that helps link sensory 
input to pleasant and unpleasant feelings. 
 
More genes in the paraventricular nucleus (PVN) of hypothalamus are starting to 
be recognized in depression such as specific alleles of the galanin which is a 
neuropeptide found in the hypothalamus that has been proposed to link obesity 
and depression (Davidson et al., 2011) and has been shown to interact with the 
serotonin receptors (Kuteeva et al., 2010). 
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Melanin-concentrating hormone (MCH) is a 17 amino acid peptide hormone that 
is found in the cell bodies in the nucleus accumbens of hypothalamus that acts 
via the binding to the MCHR receptors. It was found that acute and sub-chronic 
administration of a selective antagonist for MCHR1 showed an antidepressant 
effect in rats and mice (Gehlert et al., 2009). 
 
Another molecule that has been shown to play a role in the pathophysiology of 
depression is the adipocyte derived hormone adiponectin (Liu et al., 2012) that 
acts by binding to its receptor in the hypothalamus (Kubota et al., 2007). It has 
already been described that the plasma levels of adiponectin are reduced in 
major depression (Leo et al., 2006). Plasma levels of adiponectin are also 
reduced in a mouse model of depression. Administration of adiponectin either on 
normal weight as well as diet induced obese mice produces an antidepressant 
effect suggesting a critical role of adiponectin in depression and point out a 
potential innovative therapeutic approach for depressive disorders (Liu et al., 
2012). 
 
Exercise has been shown to have an antidepressant effect on depressed patients 
(Strawbridge et al., 2002) as well as in animal models of depression (Bjornebekk 
et al., 2006). It is believed that exercise exerts its antidepressant effect by 
upregulating neurotrophic factors as well as inducing cell proliferation and 
neurogenesis in hippocampus (Bjornebekk et al., 2005). Studies with enriched 
environments also induce an antidepressant effect in mice (Hattori et al., 2007) 
and it is believed to happen by increasing the number of new neurons in the 
adult dentate gurus (Kempermann et al., 1997). 
 
Vascular endothelial growth factor (VEGF) signalling has been shown to be 
required for the behavioural actions of antidepressant treatment of monoamine 
reuptake inhibitors in the hippocampus (Greene et al., 2009a). The hippocampus 
has attracted a lot of attention due to its role in depression and its central 
function of the limbic system. Neuritin, an activity dependent gene that 
regulates neuronal plasticity in the hippocampus, is decreased with chronic 
stress and is upregulated after antidepressant treatment (Son et al., 2012). 
Moreover, neuritin overexpression produces an antidepressant effect whereas 
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neuritin knock down produces a depression like behaviour (Son et al., 2012). 
Neuritin has also been involved in the final output of the action of BDNF (Naeve 
et al., 1997; Wibrand et al., 2006). 
 
Recently, it has been described that depressed patients have increased 
expression of the mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-
1) which is a negative regulator for the MAP kinase (Duric et al., 2010) 
suggesting potential targeting of the MAPK signalling might recapitulate an 
antidepressant effect. 
 
 
1.18. Western but not Mediterranean diet correlates with 
depression 
Despite their high caloric contents, western diets are poor in essential nutrients 
for the brain such as ω-3 PUFAs and notorious for their high levels of ω-6 PUFAs, 
saturated fatty acids, trans fat and sugar contents that result in malnutrition. 
Such dietary customs critically contribute to the high prevalence of chronic 
diseases such as obesity and metabolic disorders that plagues westernized 
countries. Adherence to an overall Mediterranean diet has been suggested to 
play a protective role for depression phenotype. A beneficial role of unsaturated 
fatty acids such as PUFAs (Mozaffarian et al., 2010) and olive oil (Fernandez-
Jarne et al., 2002; Kontogianni et al., 2007; Barzi et al., 2003) found in the 
Mediterranean diet concerning depression as they are considered healthy lipids. 
Numerous studies supporting the positive relationship between improved 
nutrition and better mental health (Freeman, 2010; Appleton et al., 2010; 
Skarupski et al., 2010; Gilbody et al., 2007). It is believed PUFAs increase the 
fluidity of the neuronal membrane and this gives easier access of the 
neurotransmitters to their receptors fluidity (Horrocks and Farooqui, 2004). ω-3 
fatty acids are suggested also to be inhibitors for the production of cytokines 
(Endres et al., 1989; Oh et al., 2010; Robinson et al., 1996). Figure 1.5 shows 
the main categories of fatty acids. Fatty acids are divided in two main groups: 
the saturated (SFAs) and unsaturated fatty acids (UFAs). The unsaturated fatty 
acids can be further divided in two main categories the monounsaturated 
(MUFAs) and the polyunsaturated (PUFAs) fatty acids. The PUFAs are further 
Chapter 1  Introduction 
     
EIRINI VAGENA 46 
 
classified into ω-3 (n-3), ω-6 (n-6) and ω-9 (n-9) groups. The parent essential 
fatty acid of ω-3 PUFA is α-linoleic acid (ALA; C18:3n-3), and that of the ω-6 
group is linoleic acid (LA;C18:2n-6). 
 
 
 
Figure1.5. Schematic of the different fatty acid categories. The two main 
categories for the fatty acids are the saturated and unsaturated fatty acids. 
Moreover, the unsaturated fatty acids are divided into monounsaturated and 
polyunsaturated fatty acids. The unsaturated fatty acids are divided into 
monounsaturated and polyunsaturated fatty acids. 
 
 
 
Recent studies have revealed a positive correlation between western diet 
consumption and depression. Studies in humans are in accordance with studies in 
animals, showing that high fat diet consumption was accompanied with a 
depression phenotype and altered serum lipids (Chilton et al., 2011). 
Interestingly, at the same study it was observed a negative correlation between 
BMI and depression as well as only a subgroup of monkeys developed a 
depression phenotype, which implies that a high fat western diet is likely to 
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increase depressive behaviour among subgroups of susceptible individuals rather 
than universally (Chilton et al., 2011). Moreover, HFD exacerbated the 
depressive like behaviour in the FSL (Flinders sensitive line) rats (an inbred 
genetic model of depression) but conversely tended to reduce anxiety levels and 
impair cognition in the FSL rats (Abildgaard et al., 2011). The behavioural and 
neurochemical alterations in FSL rats were found to be normalized after chronic 
treatment with antidepressants (Yadid et al., 2000; Overstreet, 2002). However, 
whether a high fat diet provokes a depression-like behaviour has never been 
shown and if that’s the case via which mechanism. On the contrary, HFD 
consumption has been shown to ameliorate the anxiety and depression symptoms 
upon an adverse early life environment (Maniam and Morris, 2010a; Prasad and 
Prasad, 1996). 
 
Vast variations exist in the prevalence of depression across countries suggesting 
that differences like food habits could account for these differences. It is long 
believed that mental health and diet are intimately interrelated as 
demonstrated by the consumption of specific diets and psychiatric disorders. 
Interestingly, reduced caloric intake from fat and processed food is linked with 
amelioration in mood and reduced risk for the development of depression in 
human studies (Akbaraly et al., 2009; Brinkworth et al., 2009). A possible 
mechanism for the detrimental role of trans fat has been proposed to be that 
trans-fat lead to the displacement of essential fatty acids from membranes (Innis 
and King, 1999). 
 
Different categories of fatty acids have been shown to differentially affect the 
serotonin receptor and transporter binding in the rat brain further suggesting 
that different dietary patterns might affect the serotonergic signalling (du Bois 
et al., 2006). Low levels of folate acid have been linked with the development of 
depression (Gilbody et al., 2007) Folate acid is associated with methylation 
processes and the synthesis of neurotransmitters in the CNS (Gilbody et al., 
2007). 
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1.19. Fatty acids can cross the blood brain barrier 
Lipid molecules are the “building blocks” of the CNS as the mammalian brain is a 
lipid rich organ, where gray matter contains 36%-40% lipid, white matter 49%-
66% and the myelin 78%-81% (O'Brien and Sampson, 1965). However what is the 
exact molecular mechanism of the transfer of fatty acids from the periphery to 
the brain remains to be elucidated. The central nervous system (CNS) is 
protected by the blood-brain-barrier (BBB) composed of brain capillary 
endothelial cells and invested by astrocytes foot processes (Scherrmann, 2002). 
The BBB is characterized by enthelial tight junctions and complete absence of 
pinocytic activity. It regulates the transport of endogenous and exogenous 
compounds by controlling their selective uptake, efflux and metabolism in and 
out of the brain (Pardridge, 2002a). Due to the BBB characteristics many 
therapeutic molecules are precluded the entry in the brain from the blood, thus 
causing enormous difficulty to the treatment of cerebral diseases. In fact more 
than 98% small molecules (Tsuji, 2005) and about 100% large molecules are 
prevented from brain uptake by BBB, including peptides, recombinant proteins, 
antisense drugs, monoclonal antibodies, and gene therapies including RNA 
interferes (RNAi). 
 
The plasma levels of free fatty acids (FFAs) are usually 0.2-1.7mM. Fatty acids 
have been shown to be uptaked and incorporated in the brain (Smith and 
Nagura, 2001). Circulating macronutrients such as fatty acids can cross the BBB 
and gain access to the brain where they equilibrate with neuronal LC-CoAs 
(Miller et al., 1987) (Rapoport, 1996). Several studies have been suggested to 
explain the fatty acid uptake from the blood into the brain via the capillary 
membrane. These include 1) receptor mediated transport of acylated species via 
lipoprotein receptors (Meresse et al., 1989) as well as carrier-mediated uptake 
of intact lysophospholipids (Thies et al., 1992; Alberghina et al., 1994; Bernoud 
et al., 1999). Moreover, fatty acids can be cleaved from the circulating lipids by 
endothelial lipoprotein lipase for direct influx of free fatty acids (Brecher and 
Kuan, 1979). Several studies suggest that a primary contributor to brain fatty 
acid influx is uptake of free fatty acid following dissociation from the plasma 
protein (Pardridge and Mietus, 1980; Robinson et al., 1992). However, the 99.9% 
or more of these FFAs are bound tightly with serum albumin (Spector, 1986) 
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resulting in the concentration of unbound FFAs to range between 0.01-10µM 
(Spector and Hoak, 1975). Short, medium or long chain fatty acids can cross the 
BBB, however the mechanism of the transport for the saturated and unsaturated 
fatty acids has been suggested to be different (Spector, 1988; Avellini et al., 
1994). It has already been documented that palmitic acid can cross the BBB 
(Pardridge and Mietus, 1980). Moreover, palmitic and lignoceric acid can enter 
the brain from the blood circulation more efficiently than stearic acid does 
(Morand et al., 1981). The ABC transporters have been shown to play an 
important role in lipid transport in the brain and their targeting shows beneficial 
effects for various neurologic diseases (Kim et al., 2008). Under normal 
physiological conditions the free fraction is estimated to be less than 0.1% in 
serum (Wosilait and Soler-Argilaga, 1975; Richieri et al., 1993). 
 
Once in the brain the fatty acids can further be metabolized in the mitochondria 
via β-oxidation, incorporated into phospholipids or affect molecular pathways 
such as the central control of food intake and energy expenditure (Lopez et al., 
2005). 
 
Even though fatty acids are highly hydrophobic and can cross the BBB only two 
studies focused on the role of fatty acids in crossing the BBB. Myristic acid 
combined with polyarginine peptide was able to mediate in vivo brain targeted 
delivery for myristoylated polyarginine in neurons (Pham et al., 2005). In 
agreement to that, another study showed that molecules conjugated with 
myristic acid were able to accumulate specifically in the brain after i.v. 
injections (Meng et al., 2010) suggesting that myristic acid is a potent ligand in 
the design of brain targeting drug delivery systems. Interestingly, the 
accumulation of myristic acid in the brain was specific to the hypothalamic area 
as shown by MRI (Meng et al., 2010) supporting the hypothesis that hypothalamus 
is a brain region in close proximity and contact with the vasculature. It has been 
suggested that myristic acid due to the high hydrophobicity is able to 
incorporate in the phospholipid bilayer of the eukaryotic plasma membrane of 
the cell is thus capable of acting as a lipid anchor to biomembranes and 
increasing cellular uptake (Pham et al., 2004; Pham et al., 2005). 
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1.20. Main lipids in the CNS 
In contrast to other tissues, the neuronal cell membranes in the CNS are 
enriched in two main PUFAs: arachidonic acid (20:4n-6) and docosahexaenoic 
acid (DHA, 22:6n-3) (Sastry, 1985; Diau et al., 2005). Linoleic acid (18:2n-6, the 
precursor of arachidonic acid) and α-linolenic acid (18:3n-3, the precursor of 
DHA) exist in plants and are digested and absorbed in the small intestine where 
they incorporated into the plasma through lacteals. In mammals, they are then 
being metabolized by elongation and desaturation into arachidonic acid and DHA 
(Rapoport et al., 2007). The conversion of these precursors into long-chain 
PUFAs is mostly hepatic although other organs such as the brain possess the 
necessary enzymes for this conversion (Rapoport et al., 2007). As the synthesis 
of DHA and arachidonic acid is extremely low in the human body, dietary PUFA 
are readily incorporated into lipids of the developing brain before and after birth 
(Innis, 2007) by several types of pathways including the fatty acid translocation 
system (Coburn et al., 2001), fatty acid binding proteins (Hanhoff et al., 2002; 
Glatz et al., 2002; Huang et al., 2002), long chain fatty acyl-coA synthetases 
(Chiu et al., 2001), acyl-coA binding proteins (Knudsen, 1990) and fatty acid 
transport proteins (Stahl, 2004). The effect of different psychiatric disorders on 
the function of these enzymes has not been described but any changes in the 
activity of these enzymes caused under psychiatric disorders might affect their 
normal translocation and incorporation in the brain. 
 
Long chain PUFAs (LC-PUFAs) are critical components for the neuronal and 
immune cell membranes and necessary for the normal development, structure 
and function of the CNS and the prevention of various neurological diseases 
(Bourre, 2005; Innis, 2003; Salem et al., 2001a; Salem et al., 2001b; Innis, 2007; 
Su, 2010) and different biological mechanism have been proposed to explain this 
effect (Bourre, 2006a; Gomez-Pinilla, 2008; Pawels and Volterrani, 2008). 
Mammals are limited in synthesizing PUFA de novo so they can only obtain them 
from a balanced diet containing appropriate amounts of these precursors in 
order to maintain sufficient brain levels of LC-PUFAs in the CNS (Lauritzen et al., 
2001; Burdge et al., 2003). Besides their roles as sources for membrane synthesis 
and energy production, PUFA is believed to be also involved in cell signalling, 
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gene transcription and neuronal plasticity (Nunez, 1997b; Duplus et al., 2000; 
Chen and Bazan, 2005). 
 
Aberrations in PUFA composition in cell membranes can alter membrane 
microstructure, cause abnormal signal transduction and immunologic 
dysregulation, resulting in increased risk for the development of depression 
(Horrobin and Bennett, 1999; Logan, 2003). In accordance to that, it has been 
noted that alterations can occur in the PUFA composition of the neuronal 
membranes of people with various psychiatric disorders (Su et al., 2000). 
 
DHA is the most abundant ω-3 fatty acid in the mammalian brain and enriched in 
brain phospholipids (Sastry, 1985) constituting of 30-50% of the weight of a 
neuron’s plasma membrane. It has been shown to increase during development 
and to decrease with aging (Youdim et al., 2000; Horrocks and Farooqui, 2004; 
Innis, 2008). Fish is the main source of DHA. Arachidic acid (AA) is found in the 
brain and its metabolic products are crucial to orchestrating immunity and 
inflammation (Calder, 2001). 
 
PUFAs can stimulate the proliferation and differentiation of neuronal progenitors 
that have been shown to improve neurogenesis and cognitive impairments such 
as learning and memory or mood disorders as well as the prevention of different 
neurological diseases. Indeed, PUFA deficiency was related to cognitive 
impairment (Conquer et al., 2000) and mental disorders such as depression and 
schizophrenia (Freeman, 2000; Ruxton et al., 2004). More specifically, decreased 
levels of brain DHA due to nutritional deficiency is associated with reduced 
cognitive ability, increased emotional behaviour and decreased vision (Rapoport 
et al., 2007). Severe brain DHA depletion by multigenerational ω-3 PUFA 
deprivation in rats has been reported to reduce neuronal size in the 
hypothalamus (Ahmad et al., 2004). In accordance with that, single generational 
deprivation of dietary ω-3 PUFA results in defective serotonergic and 
dopaminergic signalling, the main signalling pathways involved in depression 
(Kodas et al., 2004; Kodas et al., 2002). In accordance, ω-3 PUFAs deprivation 
postweaning, leads to a reduction in the levels of DHA and increased depression 
(DeMar et al., 2006). On the contrary, enrichment in endogenous levels of DHA 
improves spatial learning in the fat-1 transgenic mouse, and this is associated 
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with increased hippocampal neurogenesis (He et al., 2009). Furthermore 
supplementation of DHA and ARA in patients with memory impairments, due to 
stroke or head injuries, results in remarkable improvement in learning and 
memory (Kotani et al., 2006; Yamashima, 2008). In accordance to the previous 
studies in the brain, a correlation between specific erythrocyte phospholipid 
fatty acid composition have given rise to the “phospholipid hypothesis” of 
depression in the periphery (Hibbeln and Salem, 1995). 
 
Even though there is a relationship between brain PUFA composition affected by 
dietary modifications and monoaminergic neurotransmission (Delion et al., 1996; 
Zimmer et al., 2000; Kodas et al., 2004) the exact signalling pathway by which 
PUFAs conduct their effects on the adult brain still remains poorly understood. 
However, it has been speculated that the transcription factor, CREB may play 
and important role because of the increase in its phosphorylation that occurs in 
rats fed on DHA-enriched diets, which also leads to an improvement in cognitive 
function (Wu et al., 2008). In contrast to this, rats with PUFA-deprivation exhibit 
decreased levels of CREB phosphorylation and exhibit a depression phenotype 
(Rao et al., 2007). 
 
1.21. Mechanisms controlled by dietary fatty acids in the 
CNS 
As mentioned previously, western diet is poor in essential fatty acids that are 
necessary for the brain development and function and characterized by a high 
ratio of ω-6/ω-3 PUFA (Simopoulos, 2009) and high in trans and saturated fat. 
Fatty acid composition determines the biophysical properties of neuronal 
membranes and influences neurotransmission (Salem et al., 2001a). Several 
biological mechanisms have been suggested to explain the inverse associations 
between LC- ω-3 PUFA consumption as well as disproportion ratio between ω-
3/ω-6 PUFAs as well as the high consumption of trans and saturated fatty acids 
and the risk for mental disorders. Omega-3 PUFAs are essential components of 
the neuronal membranes of the CNS and have been implicated in the dynamic 
structure and changing the membrane fluidity and possibly leading to an 
enhancement or impairment of the structure and/or function of any 
membrane/associated receptor complexes. (Horrocks and Farooqui, 2004) 
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therefore there are many mechanisms by which PUFAs might influence cell 
function (Marszalek and Lodish, 2005). Higher ω-3 PUFA concentrations lead to 
increased membrane fluidity, which sequentially increases serotonin transport, a 
major pathway involved in depression (Hibbeln and Salem, 1995; Mullen and 
Martin, 1992; Fernstrom, 1999). Due to the fact that the brain has high 
concentration of LC-PUFAs, neurons are very likely to be sensitive to the ratio of 
ω-3/ω-6. Therefore, dietary deficiency of ω-3 PUFAs consumption as well as 
disproportion of ω-6/ω-3 PUFA has been suggested to modify the brain lipid 
biochemistry, affecting monoaminergic neurotransmitter and glutamate 
receptors resulting in the impairment of behaviour (Chalon, 2006; Bourre, 2005). 
Thus, PUFAs play a key role in affecting receptor function, neurotransmitter 
reuptake resulting in the alteration of the intracellular and intercellular 
signalling pathways. A possible mechanism that has been suggested to link ω-3 
deficiency and the development of a depression phenotype is via the 
endocannabinoid system (Lafourcade et al., 2011). 
 
1.22. The beneficial role of ω-3 fatty acid intake in 
depression 
Polyunsaturated ω-3 fatty acids (ω-3 PUFA) intake is believed to confer 
beneficial effects on human health. Food guidelines recommend regular fish 
consumption in general population to provide a main source of ω-3 PUFAs. A 
large number of retrospective and prospective studies, as well as clinical trials, 
revealed that consumption of fish and fish oils rich in ω-3 LC-PUFAs has a lower 
prevalence of depression (Appleton et al., 2010; Ruxton et al., 2004; Su et al., 
2000). This suggests a link between ω-3 PUFAs and the pathogenesis of 
depression. The SUN cohort, a cohort in Spain characterized by Mediterranean 
diet showed a potential beneficial effect of omega-3 PUFA intake of total mental 
disorders (Sanchez-Villegas et al., 2007).There is a 60-fold variation across 
countries in annual fish consumption and a strong inverse relationship between 
national consumption of fish per capita and the prevalence of depression 
(Hibbeln, 2009; Hibbeln, 1998; Samieri et al., 2008). Several epidemiological and 
clinical data link ω-3 deficiency with neuropsychiatric, mood and 
neurodegenerative disorders such as depression (Parker et al., 2006a; Hibbeln, 
2002; Otto et al., 2003; Llorente et al., 2003; Makrides et al., 2003). Low levels 
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of PUFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
have been detected in the serum and red blood cell membranes of people with 
depression and this negatively correlated with the severity of depression 
(Edwards et al., 1998; Adams et al., 1996; Peet et al., 1998). The ratio of ω-6 to 
ω-3 in erythrocytes and plasma of depressive patients correlated positively with 
the severity of depression (Adams et al., 1996). 
 
A negative correlation was found between fish consumption and worldwide 
depression prevalence (Hibbeln, 1998) and, similarly, an inverse association 
between DHA concentration in human milk and post-partum depression 
prevalence (Hibbeln, 2002). Association between higher severity of depression 
symptoms and lower ω-3 fatty acids levels have been found in several studies 
(Maes et al., 1999; Maes et al., 1996; Parker et al., 2006b). 
 
The beneficial role of ω-3 PUFA on the function of nervous system (Fontani et 
al., 2005) and on neuropsychiatric alterations treatment (Logan, 2003; Logan, 
2004) has been underlined. Clinical trials designed to assess the effectiveness 
and beneficial effect of ω-3 PUFA supplementation on depression have delivered 
remarkably favourable results (Nemets et al., 2006; Nemets et al., 2002; Peet 
and Horrobin, 2002) and to increase the brain serotonin levels (Li et al., 2000). 
Therefore the effectiveness of antipsychotic drugs when combined with changes 
in the diet has been suggested to have a faster effect in ameliorating the 
symptoms of depression. These effects, however, were not the same across all 
the patient group populations (Hallahan et al., 2007; Peet and Stokes, 2005; 
Rogers et al., 2008; Freeman et al., 2008). Thus a meta-analytic review of 
double-blind placebo-controlled trials uncovered the antidepressant effect of ω-
3 PUFAs exemplified by a significant improvement in the symptoms of depressed 
subjects (Lin and Su, 2007; Stahl et al., 2008). 
 
Different trials using fish oils for the treatment of depression showed a 
significant improvement in the depression scores for both the group that 
consumed fish oil as well as the control group that received olive oil (Silvers et 
al., 2005). A possible explanation of the antidepressant effect of both fish and 
olive oil might be the result of a simple increase in fat intake, as low fat diets 
can adversely affect mood (Bourre, 2006b; Logan, 2005). 
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In addition to their beneficial role in mood disorders and depression, diets rich in 
ω-3 fatty acids have been shown to promote weight loss with unaltered energy 
intake (Hill et al., 2007; Wang et al., 2002). This event has been suggested to be 
promoted via increased energy expenditure, increased fatty acid oxidation and 
suppression of the lipogenic pathways (Roche and Gibney, 1999; Sampath and 
Ntambi, 2005). 
 
1.23. Imbalance intake of ω-3 and ω-6 leads to depression 
In contrast to the main human diet in the past, which was focused on hunting 
and gathering of food rich in ω-3 PUFAs, western diet is notoriously poor in these 
nutrients. Modern diets are accompanied by a large increase in the consumption 
of vegetable oils, containing ω-6 PUFAs, at the expense of ω-3 PUFAs (Hallahan 
and Garland, 2005). The lack of the ω essential fatty acids has been linked with 
many psychiatric disorders such as depression (Perica and Delas, 2011). 
Particularly, since the dawn of the industrial revolution, which led to an 
increased intake in processed, high caloric food, the ratio of ω-6/ω-3 PUFAs in 
the diet has increased from 1 to almost 15 in industrialized countries, leading to 
a significant deficiency in ω-3 PUFAs (Simopoulos, 2002; Simopoulos, 2009). 
Interestingly the relationship between depression and diet was not caused as a 
secondary effect due to inflammation, atherosclerosis suggesting the direct 
effect of fatty acid composition on mood (Tiemeier et al., 2003). 
 
Even though both ω-3 and ω-6 PUFAs are important for the brain function and 
development, the lack of ω-3 LC-PUFAs or an imbalance between ω-3 and ω-6 
fatty acids resulted from diet rich in linoleic acid has been associated with 
neurological and psychiatric disorders such as depression in both children and 
adults (Tiemeier et al., 2003; Wolfe et al., 2009) as well as in mice (Lafourcade 
et al., 2011). There are many clinical and epidemiological studies that show 
associations between ω-3/ω-6 imbalance and mood disorders (Parker et al., 
2006a). Patients with clinical depression have either an elevated ratio of 
circulating long chain ω-6/ω-3 PUFAs (Calder, 2001; Peet et al., 1998; Hibbeln, 
2009) or just low circulating long chain ω-3 PUFAs (Lin et al., 2010). Greater 
consumption of linoleic acid correlated with higher rates of homicide mortality 
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with over a 20-fold change across different countries (Hibbeln et al., 2004). 
Dietary intake of seed oils, which are rich in linoleic acid, has been associated 
with depressive symptoms in an elderly (Kyrozis et al., 2009). The elevated 
levels of linoleic and dihomo-gamma-linoleic acid are the key factors that result 
in the change of the ω-6/ω-3 ratio (Chilton et al., 2011). Therefore the dietary 
ω-6/ω-3 ratio is of fundamental importance due to their distinct physiological 
properties and the fact that they compete for their biosynthetic enzymes and 
any imbalance can lead to mood disorders such as depression. Olive oil which is 
a main component of the Mediterranean diet, even though it is a vegetable oil, 
it is rich in oleic acid which is a polyunsaturated ω-9 fatty acid. 
 
 
1.24. The free fatty acid receptor family  
Fatty acids have been shown to act via two major pathways: they can either 
signal directly by binding to their free fatty acid receptors (Kostenis, 2004) or 
they can exert a regulatory role via their diffusion in the cell and activate a 
variety of proteins (Sidhu et al., 2000). There, they can act as substrates to be 
metabolised and incorporated into intracellular lipid signalling pathways 
(Warnotte et al., 1994). The free fatty acids act via the binding on their free 
fatty acid receptors in order to regulate intracellular molecular pathways. High 
throughput screening (HTS) and ligand fishing deorphanizing strategy successfully 
identified and assigned three receptors with unknown ligands as receptors for 
free fatty acids (Hirasawa et al., 2008). These receptors that belong to the 
rhodopsin family of the GPCRs were previously characterized as a cluster of 
orphan GPCRs comprising FFAR1 (GPR40), FFAR2 (GPR43) and FFAR3 (GPR41) and 
are activated by FFAs within physiological concentration ranges (Brown et al., 
2005) and with varying degrees of specificity (Briscoe et al., 2003) (Itoh et al., 
2003) (Kotarsky et al., 2003) (Hirasawa et al., 2005). The free fatty acid 
receptor family plays critical roles in a variety of physiological and 
pathophysiological processes especially in metabolic disorders (Hara et al., 
2011). GPR40-43 are located on the human chromosomal locus 19q13.1 
(Sawzdargo et al., 1997). GPR40–43 are thought to have evolved relatively 
recently and they contain several gene duplications, of which GPR41 and GPR42 
are examples (Brown et al., 2003). This family of receptors that belong to the 
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subfamily of nucleotide and lipid receptors shares an overall sequence homology 
of 30-50% (Brown et al., 2005; Tikhonova et al., 2007) with higher homology 
within their putative transmembrane domains (Surgand et al., 2006). 
 
GPR41 and GPR43 have been shown to be stimulated by short-chain fatty acids 
(C1- C6:0), sharply becoming far less responsive to fatty acids of seven or more 
carbons (Brown et al., 2003; Le Poul et al., 2003). On the contrary, GPR40 
prefers fatty acids of medium to long chain length (Briscoe et al., 2003; Itoh et 
al., 2003) even though it has been documented that higher concentrations of 
short chain fatty acids can activate GPR40 (Stewart et al., 2006). GPR41 and 
GPR43 even though they are very similar and bind the same ligands selective 
orthosteric agonist for GPR43 have been developed suggesting the posiblity of 
the specific targeting of these receptors (Schmidt et al., 2011). 
 
GPR40 is only 30% identical to GPR41 and GPR43 suggesting that its function has 
clearly diverged from its related receptors (Brown et al., 2003). The putative 
transmembrane domains of the three receptors share ~39% sequence identity 
whereas GPR40 is the most dissimilar receptor of the cluster, sharing 35% 
transmembrane sequence identity with the other members. This sequence 
differences might confer the chain length specificity of each receptor as GPR40 
is the only receptor of the cluster to be selectively activated by medium to long 
chain fatty acids, whereas GPR41 and GPR43 are activated by short chain fatty 
acids. 
 
The different pattern of expression of each receptor reflects the different role 
that has been assigned for the molecular signalling. GPR41 has been shown to 
play a role in leptin production from adipocytes (Xiong et al., 2004), whereas 
GPR43 is implicated in differentiation and immune responses of monocytes and 
granulocytes (Senga et al., 2003). GPR43 has also been shown to be increased in 
the adipose tissue of obese pigs compare to normal weight (Hou and Sun, 2008). 
GPR41 is selective for Gi activation, whereas GPR43 can couple and activate Gi 
and Gq (Brown et al., 2005). Lastly, the absence of selectivity of the different 
receptors for a single fatty acid implies that selectivity may be determined by 
the local tissue specific environment. 
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1.24.1. Other GPCRs that are activated by fatty acids 
GPR120 binds to long-chain unsaturated FFAs and is abundantly expressed in 
lung, intestinal tract, and adipocytes (Hirasawa et al., 2005; Gotoh et al., 2007). 
Although GPR40 and GPR120 are both activated by long chain FFAs, the two 
receptors exhibit only 19% sequence identity. GPR120 is involved in the secretion 
of the glucagon-like peptide-1 from enteroendocrine L-cells (Hirasawa et al., 
2005). GPR120 plays a key role as a lipid sensor in the control of energy balance 
in both rodents and humans (Ichimura et al., 2012). 
 
GPR119 is activated by long chain FFA amids such as oleoylethanolamide and 
lysophosphatidylcholine (Rayasam et al., 2007; Winzell and Ahren, 2007; Overton 
et al., 2006) and has been described to coupled with Gs proteins (Soga et al., 
2005). 
 
Even though GPR119 and GPR120 share a relatively high sequence similarity, 
they have a very diverse tissue distribution. GPR40, GPR119, and GPR120 have 
been described as potential targets for the treatment of diabetes due to their 
role in regulating the secretion of insulin (Itoh et al., 2003; Briscoe et al., 2006; 
Hirasawa et al., 2005; Chu et al., 2007; Rayasam et al., 2007). Figure 1.6 shows 
the distribution of the different fatty acid receptors as well as their main role. 
As it is shown, their role in the brain is totally unknown. 
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Figure 1.6. Schematic of the distribution and main functions of the different 
fatty acid receptors. Figure adapted from the review: Kennedy et al. Free fatty 
acid receptors: emerging targets for treatment of diabetes and its 
complications The Adv Endocr Metab, 2010. 
 
1.24.2. The Free fatty acid receptor 1 (FFAR1) or GPR40 
The free fatty acid receptor 1 (FFAR1) or GPR40 was formally an orphan coupled 
receptor whose endogenous ligands have been identified the natural occurring 
medium to long-chain free fatty acids (FFAs) (Briscoe et al., 2003; Tan et al., 
2008) lengths (Brown et al., 2005; Milligan et al., 2006) as well as short chain 
fatty acids such as butyric in higher concentrations (Stewart et al., 2006) and 
has attracted considerable attention (Gromada, 2006). At the DNA levels, the rat 
and mouse GPR40 sequences are 94% identical to each other and 75 and 76% 
identical to the human GPR40, respectively. At the protein level, rat and mouse 
GPR40 are 95% identical to each other and 82 and 83% identical to the human 
receptor, respectively. This highly conserved receptor sequence between mouse, 
rat, hamster and monkey suggests the important role that plays in the cells as 
any evolutionally change can compromise its action. It is abundantly expressed 
on pancreatic β-cells (Tomita et al., 2006; Bartoov-Shifman et al., 2007) and in 
the intestine and endocrine cells of the gastrointestinal tract (Edfalk et al., 
2008) as well as hepatocytes (Suh et al., 2008; Wu et al., 2012) and enhances 
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free fatty acid glucose-stimulated insulin secretion (GSIS) (Itoh et al., 2003; 
Briscoe et al., 2003; Kotarsky et al., 2003; Salehi et al., 2005; Nolan et al., 
2006). Knock down of GPR40 studies using small interfering RNAs or antisense 
treatment greatly reduces free fatty acid mediated insulin release (Itoh et al., 
2003; Shapiro et al., 2005; Salehi et al., 2005). GPR40 deficient beta cells 
secrete less insulin in response to FFAs, and loss of GPR40 protects mice from 
obesity induced hyperinsulinemia, hepatic steatosis, hypertriglyceridemia, 
increased hepatic glucose output, hyperglycemia and glucose intolerance after 
HFD (Steneberg et al., 2005). The ob/ob mouse exhibits β-cell hyperplasia due 
to the increased demand for insulin (Coleman, 1978) and has been characterized 
by increased pancreatic expression of GPR40 mRNA (Lee et al., 2003; Briscoe et 
al., 2003), whereas polymorphisms so far detected in the human GPR40 gene are 
not associated with abnormal insulin release (Hamid et al., 2005). Due to its role 
in insulin secretion GPR40 has attract considerable attention as a new potential 
target for the treatment of type 2 diabetes. However, it is unclear whether an 
agonist or an antagonist (Kebede et al., 2008; Zhang et al., 2010) represents the 
best therapeutic approach as GPR40 ligand for the treatment of diabetes 
(Brownlie et al., 2008) as it has been shown that GPR40 knockout and in vivo 
overexpression mediates both acute stimulatory and chronic detrimental effects 
of insulin secretion of long-chain free fatty acids on murine insulin secretion 
(Steneberg et al., 2005). Therefore, many ligands for GPR40 have been 
discovered as potential novel therapies for obesity and type two diabetes 
(Christiansen et al., 2012; Tsujihata et al., 2011; Briscoe et al., 2006; Song et 
al., 2007; Humphries et al., 2009) and different mechanisms of action of these 
ligands have been proposed (Ou et al., 2013a). 
 
In addition to the FFAs, GPR40 has been reported to be activated by anti-
diabetic drugs such as thiazolidinediones (TZD) ligands of the peroxisome 
proliferator-activated receptor (PPARγ) (Kotarsky et al., 2003; Briscoe et al., 
2003) and experimental anti-obesity drugs (e.g., MEDICA 16) (Kotarsky et al., 
2003) can activate GPR40. 
 
GPR40 is a Gq-coupled receptor that leads to insulin secretion via the activation 
of the PLC pathway and the hydrolysis of inositol lipids as well as the 
intracellular calcium levels  (Shapiro et al., 2005; Kotarsky et al., 2003; Fujiwara 
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et al., 2005; Salehi et al., 2005; Itoh et al., 2003) with subsequent increases in 
cytoplasmic free calcium (Briscoe et al., 2003; Itoh et al., 2003). Binding of oleic 
acid on GPR40 induces Ca2+ signalling that is mediated by PLC (Fujiwara et al., 
2005). Even though most of the literature has shown that GPR40 is a Gq-coupled 
receptor it has also been reported as a Gi-coupled receptor leading to the 
downregulation of the cAMP signalling (Yonezawa et al., 2004; Itoh et al., 2003). 
It has also been reported to inhibit the activity of potassium channels via a 
cAMP-dependent pathway (Feng et al., 2006). The binding potencies of medium 
to long chain fatty acid range from 2 to 17µM (Briscoe et al., 2003). GW9508 is a 
potent agonist that has been developed for GPR40 (Garrido et al., 2006; Briscoe 
et al., 2006) and the specific residues from GPR40 that interact with GW9508 
have also been identified (Sum et al., 2007). GW1100 is a potent antagonist that 
has been developed for GPR40 (Briscoe et al., 2006). 
 
Real time PCR analysis has revealed high levels of the GPR40 in pancreas and 
even higher in the brain with very high levels of detection in the hypothalamus 
(Briscoe et al., 2003). Due to GPR40’s role in insulin secretion it has been 
extensively studied in the pancreas despite its widely distribution in the CNS (Ma 
et al., 2007; Ma et al., 2010). Therefore, even though the high levels of GPR40 
expression in the brain its functions in the brain still remain unknown.
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GPCR Ligands G protein 
signaling 
Effector Main expression Function Literature 
 
 
GPR41, 
FFAR3 
SCFAs (C3-C7) 
formate, 
acetate 
propionate 
butyrate 
pentanoate 
Gi/o 
β-arrestin2 
Gai/o 
↓ cAMP adipocytes 
enteroendocrine L cells 
DC maturation 
leptin production 
regulation of energy 
balance 
(Samuel et al., 2008) 
(Xiong et al., 2004) 
 
 
GPR43, 
FFAR2 
SCFAs (C2-C7), formate 
acetate, propionate 
butyrate, pentanoate 
Gi/o 
Gq 
β-arrestin2 
Gaq/11 
↓ cAMP 
↑ Ca2+ 
innate immune cells 
enteroendocrine L cells 
gut epithelium 
white adipose tissue 
adipocyte 
immune cells 
gut homeostasis 
tumor suppressor 
insulin-mediated fat 
accumulation 
control of body 
energy 
(Kimura et al., 2013) 
(Maslowski et al., 
2009) 
 
 
GPR109A 
SCFAs (C4-C8) Butyrate, 
nicotinic acid (niacin) 
Gi/o 
β-arrestin2 
↓ cAMP 
↑ Ca2+ 
adipocytes 
neutrophils 
macrophages 
intestinal epithelial cells 
DC trafficking, gut 
homeostasis, tumor 
suppressor, 
intracellular 
trigluceride, lipolysis 
in adipocytes 
(Lukasova et al., 
2011) 
(Singh et al., 2014) 
 
 
GPR120 
(FFAR4) 
long chain fatty acids 
(C14-C18), omega-3 
fatty acids C14 C22, 
EPA, 
DHA, palmitoleic acid  
a-linolenic acid 
Gq/11 
β-arrestin2 
Gaq/11 
↑ Ca2+ enteroendocrine cells in 
the colon 
macrophages 
Entero-endocrine cells 
inhibition of TNF and 
IL-6, regulation of 
insulin secretion by 
GLP-1 
(Hirasawa et al., 
2005) 
(Ichimura et al., 2012) 
(Oh et al., 2010) 
Table1.2. A family of free fatty acid receptors. GPCRs known to bind fatty acids and their properties. 
Chapter 1  Introduction 
     
EIRINI VAGENA 63 
 
 
 
GPR40 
medium to long chain 
fatty acids (C12-C18) 
Thiazolidinedione 
Gq/11 ↑ Ca2+ pancreatic beta cells 
enteroendocrine K cells 
insulin secretion of 
pancreatic beta cells 
(Fujita et al., 2011) 
(Itoh et al., 2003) 
 
GPR84 
medium chain fatty 
acids (C9-C14) 
capric acid, undecanoic 
acid and lauric acid 
Gi/o ↓ cAMP immune cells 
spleen 
monocytes 
macrophages 
 (Suzuki et al., 2013) 
 
 
GPR35 
Kynurenic acid 
kysophosphatidic acid 
pamoic acid 
Gi/o 
G16 
β-arrestin2 
↓ cAMP 
↑ Ca2+ 
monocytes 
neutrophils 
iNKT cells, GI tract 
peripheral nervous tissues, 
mast cells 
GPR35 SNPs implicate 
in human 
inflammatory boel 
disease 
 
 
 
 
GPR91 
succinate Gi/o 
Gq 
↓ cAMP 
↑ Ca2+ 
high levels in adipose 
tissue kidney, nervous 
system, DCs, lower levels 
in liver, spleen 
proinflamamtory, 
migration of 
Langerhans cells, 
hematopoiesis, 
angiogenesis, 
hypertensive effects, 
activation of renin-
agiotensin system 
(Sapieha et al., 2008) 
(Toma et al., 2008) 
 
GPR119 
Oleoylethanolamide, 
lysophosphatidylcholine, 
Oleoylethanolamine and 
N-oleoyldopamine 
Gas  β cell 
entero-endocrine cells 
  
 
GPR132 
9-
hydroxyoctadecadienoic 
acid 
Gaq/11 
Gai/o 
Ga12/13 
 Macrophages   
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1.25. Cellular lipotoxicity due to fatty acid exposure 
Lipotoxicity is a metabolic stress response that has been shown to involve lipid-
induced oxidative stress. It involves a series of pathological cellular responses 
after exposure to elevated levels of fatty acids (Unger, 2003). Lipotoxicity is one 
of the main mechanisms that have been involved with the decline and damage of 
the β-pancreatic islets that leads to diabetes (Robertson et al., 2004). 
Hyperlipidemia which is the excessive delivery of fatty acids to non-adipose 
tissues results in lipid accumulation and is associated with cellular dysfunction 
and cell death through lipotoxicity (Unger, 1995). It has been studied in many 
different organs and cell types but the cellular and molecular mechanisms 
underlying this process are totally unknown. Moreover, very few studies were 
done on neuronal cells to examine the role of lipotoxicity in neurodegeneration. 
 
Different cell systems employing fibroblast, myoblasts, hepatocytes and other 
cell lines have been used in order to characterize the cellular mechanisms 
underlying lipotoxicity. In these models, the growth media is supplemented with 
excess of fatty acids complexed to albumin in order to achieve 
pathophysiological ranges of free fatty acids. These studies demonstrated a time 
and dose dependent induction of cell death that is characterized by features of 
apoptosis (Cacicedo et al., 2005; de Vries et al., 1997; Listenberger et al., 2003; 
Wei et al., 2006). 
 
An important and interesting neurochemical event initiated by traumatic brain 
injury or hypoxic-ischemic insults in the CNS is the degradation of membrane 
phospholipids accompanied by the release of high levels of FFAs (Bazan, 1970; 
Rehncrona et al., 1982; Zhang and Sun, 1995; Dhillon et al., 1997; Homayoun et 
al., 1997). FFAs are liberated from the lipid membrane by intracellular lipases 
(Abe et al., 1987; Faden et al., 1987) and may act as the mediators of the 
secondary damage (White et al., 2000) further contributing to the pathogenesis 
of lipotoxicity (Lee et al., 1994). The elevation of FFAs in these 
pathophysiological conditions consists mainly of palmitic acid, stearic acid, oleic 
acid and smaller amounts of arachidonic acid and docosahexaenoic acid 
(Lukacova et al., 1998). Arachidonic acid has been shown to form toxic 
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metabolites therefore it is suggested to be a possible mediator of FFA mediate 
injury on the CNS. 
 
Interestingly, the pathological effects of the different fatty acids are not the 
same between the different fatty acid categories. The lipotoxicity response is 
relatively specific for the saturated free fatty acids and is increased by 
simultaneous exposure to elevated glucose concentrations (El-Assaad et al., 
2003). Exposure to high levels of palmitic acid exhibits significant lipotoxicity 
and apoptotic cell death of cortical neurons and PC12 cells which is a neuronal 
cell line (Almaguel et al., 2009). Moreover, reports have demonstrated that the 
ability of fatty acids to cause apoptosis in the rat pancreatic cell line and in 
human islets is dependent on the degree of saturation. Even though stearic and 
palmitic acid have been shown to induce a pro-apoptotic and toxic effect the 
oleic and arachidonic acid do not have this effect in vitro in concentrations that 
are similar to the ones after CNS injury (Ulloth et al., 2003). Moreover, oleic, 
palmitoleic and linoleic have been shown to have a protective, non-apoptotic 
role of β-cells when they are being incubated with saturated fatty acids (Eitel et 
al., 2002; Maedler et al., 2003). 
 
The pleiotropic effects of FFAs on the pancreatic β-cell function are well known. 
FFAs bind on GPR40 and stimulate insulin release (Prentki et al., 1992; Warnotte 
et al., 1994). However, FFAs also exert a suppressive or detrimental effect on β-
cells via GPR40 (Steneberg et al., 2005). Lipotoxicity of β−cells due to chronic 
exposure to high FFA levels, results in impairment in their function and a 
resulting diminution in their insulin secretory capacity (Steneberg et al., 2005). 
 
Obesity is a disorder characterized by metabolic abnormalities such as elevated 
levels of circulating free fatty acids due to unrestrained lipolysis with ensuing 
detrimental effect on the  β-cell function both in rodents and humans 
(Carpentier et al., 2000; Sako and Grill, 1990). However, the pathological effect 
of this fatty acid overload in obesity on the brain function is unknown. 
Interestingly, it has been observed that people with surgeries to remove part of 
their adipose tissue claim that their mood improves immediately. This suggests 
that the circulating fatty acids due to the high amounts of adipose tissue can get 
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access in the brain and regulate signalling pathways responsible for the 
depression phenotype rather than the actual body weight. 
 
1.26. Main hypothesis and thesis aims 
Depression is a disorder with high socioeconomic burden for the society and the 
individual. For instance, a link between obesity and depression was first 
suggested by different epidemiological and clinical studies (Zhong et al., 2010; 
Leonore de Wit  and Frans Zitman, 2010; Boutelle et al., 2010; Stunkard et al., 
2003; Simon et al., 2010; McElroy et al., 2004; Faith et al., 2002; Luppino et al., 
2010; Palinkas et al., 1996; Roberts et al., 2003; Dong et al., 2004; Roberts et 
al., 2002). Moreover, the higher the BMI of the individual the stronger the 
relationship with depression (Onyike et al., 2003; Boutelle et al., 2010). Given 
the prevalence of overweight and obesity in the western world and their rapid 
increase in developing countries even a modest increase in depression represents 
a major public health problem. However, even though epidemiological studies 
are particularly effective for the identification of the link between obesity and 
depression but rarely identify causative relationship or elucidate the underlying 
mechanisms. 
 
There are several endogenous pathways that have been involved in depression; 
one of them is the cAMP pathway (Duman et al., 1997). cAMP is an important 
second messenger that can regulate a wide spectrum of physiological processes 
in the cell. It is believed that current antidepressant treatments act via the up-
regulation of different molecules at the cAMP pathway (Duman et al., 1997). 
Obesity and depression are both very multicomponent disorders and cAMP is an 
attractive target as it can orchestrate pathways in both disorders. Among 
patients with depression and obesity the heterogeneities in lifestyles and diets 
make it difficult to make it difficult to design experiments that uncover 
causality or mechanistic links between these complex diseases. During the past 
40 years intense research has been focused on the different neurotransmitters 
for the development of antidepressant drugs (Nestler et al., 2002a). However, 
50% of patients do not response to antidepressants (Berton and Nestler, 2006). In 
some of these studies it was pointed out that being overweight or obese is a risk 
factor for resistant to antidepressant treatment (Papakostas et al., 2005). These 
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observations implicate the involvement of unique pathways for the obese and 
overweight population that lead to the development of depression and are not 
targets of the common antidepressants. 
 
Our main hypothesis proposes that dietary or genetic obesity can be a causative 
factor for the development of depression. Through mRNA array analysis as well 
as in vivo and in vitro experiments we will then try to identify the molecular 
pathway of this phenomenon. The identification of novel molecules involved in 
depression will help the development of new therapeutic targets for depression 
specific for individuals that show a resistant to current antidepressants such as 
the overweight and obese. 
 
First, in order to test this hypothesis we wanted to determine whether either 
genetic or dietary obesity can be a causative factor for the development of 
depression as a causative role has not been fully established from the various 
studies. In order to do this we utilized commonly used behavioural paradigms to 
test for depression. We were able to identify a causative role of obesity either 
genetic or dietary for the development of depression. Interestingly, this effect 
was independent of the increase in the body weight caused by either the genetic 
or dietary obesity. Next, mRNA array comparative analysis which is a powerful 
technique to identify signalling pathways and specific molecules that are 
affected was performed between normal mice and mice that developed 
depression. We were able to implicate the PKA signalling cascade in the 
hypothalamus responsible for the depression phenotype due to the consumption 
of a HFD. 
 
Secondly, we wanted to further investigate the molecular mechanism of the 
dietary obesity induced depression phenotype. PKA activity is regulated by cAMP 
levels and the sole route for the cAMP degradation happens via a large family of 
molecules the PDEs. We were able to identify a specific PDE4 phosphodiesterase 
isoform, namely PDE4A5, to play an important role for the development of 
dietary and genetic obesity-induced depression as the in vivo loss of PDE4A 
rescues the depression phenotype in both types of obesity. Even though many 
studies have shown the protective role of polyunsaturated fatty acids on 
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depression little is known about the negative role of specific dietary components 
in mood. Paradoxically the detrimental role of other fatty acids that can play a 
causative role for the development of depression has not been studied. In this 
study we were able to identify palmitic acid, which is a major fatty acid in the 
HFD to affect the PKA signalling. Our preliminary data suggest a potential direct 
role in inducing a depression phenotype. Finally, we were able to identify a free 
fatty acid receptor (GPR40) as a novel binding partner of PDE4A5 that is 
upregulated in the hypothalamus and is responsible for the depression phenotype 
after the consumption of HFD. By blocking the activation of this receptor in the 
hypothalamus using a specific GPR40 antagonist we were able to partially rescue 
the dietary obesity induced depression phenotype observed. This receptor would 
represent a novel therapeutic target for the treatment of depression that is 
caused by dietary factors. 
 
Therefore the main aims in this thesis are as follows: 
1) To address whether obesity in mice can play a causative role for the 
development of depression phenotype 
2) To determine the molecular pathways in the brain that are altered after the 
dietary induced obesity phenotype 
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2. Materials 
All chemicals used in this study were of analytical grade. All compounds were 
supplied by Sigma-Aldrich, USA and fatty acids were purchased from Nu-Check, 
USA and they were typically dissolved in dimethyl sulfoxide (DMSO) unless 
otherwise stated. All aqueous solutions were prepared using water purification 
system with automatic sanitization (Millipore, USA). 
 
2.1. Animal procedures 
2.1.1. Animals 
WT C57BL/6 mice and leptin deficiency mice (Lepob or ob/ob) were obtained 
from The Jackson Laboratory and bred in the mouse facility at the Gladstone 
Institutes, University of California San Francisco (UCSF). The PDE4A-/- mouse line 
was a gift by Professor Marco Conti that he generated and crossed with a 
C57BL/6 background (11 or 12 crossings). The generation of the PDE4A-/- was 
done and described by Professor Marco Conti (Jin and Conti, 2002; Jin et al., 
2005) (Jin et al., 1999). All mice were bred in house, maintained under constant 
temperature (23 oC) and lighting (lights on from 0700-1900 h) and were allowed 
free access to food pellets and water. Following mating, litters were housed 
with the dam in polypropylene cages (20 cm x 27 cm x 17 cm) with wood 
shavings and a metal lid in groups of 5 mice. All studies were done using male 
mice that had access to food and water ad libitum. All animal study protocols 
and procedures were reviewed and conducted in accordance with the Guide for 
the care and use of laboratory animals (LARC) at UCSF and approved by the 
institutional animal care and use committees of UCSF, and are in compliance 
with standards set by the National Institutes of Health. 
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2.1.2. Genotyping 
 Newborn pups up to 7 days old were toe clipped for identification purposes. A 
small portion of the tail was taken for DNA isolation and genotyping purposes. 
Each tail is digested in 500 µl PCR lysis buffer (100 mM Tris pH 8.5, 5 mM EDTA 
pH8.0, 200mM NaCl and 0.2% SDS) supplemented with 4 µl of recombinant 
protein Proteinase K of 14 – 22 µg/µl (Roche). The digestion was incubated at 
150 rpm overnight at 55 oC. The digestion product was spun down for 10 minutes 
at maximum speed to separate the tail hair from the DNA. The supernatant was 
then transfected to another tube with 500 µl of isoprotenerol to precipitate the 
DNA. DNA is insoluble in isoprotenerol and will fall out of solution fast. The 
precipitated DNA was then transferred with a tip in a new tube with ultrapure 
protease and nuclease free water. Polymerase chain reaction (PCR) was 
performed using the quick load master mix (England Biolabs) to determine the 
genotype of the mouse. In this study two different PCRs were performed for 
genotyping purposes. The sequences of the primers are shown in the Table 2.1. 
 
Table 2.1. Sequences of the primers used for genotyping. 
The first three primer sequences are used for the genotyping of the PDE4A. The 
last two primers are used for the genotyping of leptin. 
Primer name Sequence 
PDEA4(4A-5F) GATTCTCAGACTGTGGCACC 
PDE4A(4A-8R) GCAGGTGCAGGCCTTTACAC 
PDE4A(KO2F) CTAAAGCGCATGCTCCAGACTG 
leptin1151 TGTCCAAGATGGACCAGACTC 
leptin1152 ACTGGTCTGAGGCAGGGAGCA 
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PDE4A PCR program  
  
 denaturation 94 0C 3' 
 repeat next 3 steps for 35 cycles   
denaturation 95 0C 30" 
annealing 59 0C 30" 
elongation 72 0C 1'15" 
final elongation 72 0C 10' 
 
The 3 PCR primers for the PDE4A genotyping shown in Table1 [PDEA4(4A-5F), 
PDE4A(4A-8R) PDE4A(KO2F)] are used in combination in the same PCR in order to 
produce 2 different PCR fragments. The WT produces a fragment of 780 b.p. and 
the PDE4A-/- mouse produces a fragment of 423 b.p.  
Leptin PCR program 
  
 denaturation 94 0C 3' 
 repeat next 3 steps for 35 cycles   
denaturation 94 0C 30" 
annealing 62 0C 1’ 
elongation 72 0C 45" 
final elongation 72 0C 10' 
 
The two PCR primers (leptin1151 and leptin1152) lead to a fragment that is 
further digested with DdeI restriction enzyme (England Biolabs) for 4 hours at 37 
oC. The WT gives a band of 155 b.p. and the mutant a band of 55 b.p. and 100 
b.p. 
 
The analysis of the PCR fragment was performed by agarose gel electrophoresis 
in order to separate DNA by molecular weight. The PCR reaction is already 
loaded with a running dye from the PCR master mix (England Biolabs). Agarose 
gel was prepared with tris-acetate acid-EDTA (TAE) buffer containing 40 mM 
Tris-Cl; pH 8.5, 0.114% (v/v) glacial acetic acid and 2 mM EDTA. The agarose 
solution was allowed to cool slightly before adding 1 µl/100 ml of ethidium 
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bromide. For gel casting, the solution was poured into the Bio-Rad Mini-Sub Cell 
GT agarose gel system with comb inserted to create wells and allowed to solidify 
at room temperature. A 1.5% agarose gel was prepared for the separation of the 
PDE4A PCR and a 2.5% agarose gel for the separation of the leptin PCR. Once the 
gel was polymerized the comb was removed and the gel was placed in a gel tank 
containing 1xTAE buffer. A 1 kb DNA ladder (England Biolabs) was used as a 
molecular size marker. The gel was run at 80 V until the dye has migrated about 
2/3 of the gel. Negatively charged DNA samples will migrate from the cathode 
toward the anode during electrophoresis. The gel was then removed from the 
tank and visualized on an ultraviolet transilluminator (Gel Doc XR+ System, Bio-
Rad). 
 
2.1.3. Diets 
Mice on normal diet (ND) were fed the PicoLab Rodent Diet 20 (catalog # 5053) 
from LabDiet that consists of 13.2% fat, 62.1% carbohydrates and 24.7% proteins. 
Mice on the high fat diet (HFD) were fed a 60% fat content diet from Research 
Diets (catalog # 12492) with 20% carbohydrates and 20% proteins. Experiments in 
this study were performed in mice following either 3 or 8 weeks on the two 
different diets. 3 weeks represents a time point before the development of 
metabolic syndrome and 8 weeks is after the development of metabolic 
syndrome (Hwang et al., 2010). 
 
2.2. Behavioural assays 
Behavioural tests were conducted in order to assess the depression phenotype in 
mice. All behavioural tests were conducted during the light phase (1200-1500 h) 
and measurements commenced 4 h after lights on. Animals were allowed to 
adapt to the experimental room for at least 1 h before testing. The mice were 
tested according to the following sequence of tests: open field, elevated plus 
maze, sucrose preference test, tail suspension test and forced swim test placing 
the most stressful tests in the end. 
  
Chapter 2  Materials & Methods 
     
EIRINI VAGENA 74 
 
2.2.1. Open field test 
 To assess the total locomotor activity, the open field test was used. This test is 
commonly used to quatitative and qualitative measure the general locomotor 
activity as well as the exploratory behaviour of rodents. The test was carried out 
using a Digiscan locomotor activity monitor (Model RXYZCM, Omnitech 
Electronics; Columbus, OH) which consist of an open-top 40cm (L) x 30cm (H) 
clear Plexiglass holding box equipedwith photocell beam sensor bars (16 infrared 
sensors per bar, 2.5cm apart) running horizontally across the walls (50). Each 
mouse was placed in the middle of the box for 15 minutes and a computer 
tabulated its movements automatically. The holding box was cleaned with 70% 
ethanol before receiving another mouse. 
 
2.2.2. Tail suspension test 
This test has been used to assess the effectiveness of antidepressant drugs in 
rodents and generally reduced immobilization time is a indicator of an 
antidepressant effect (Cryan et al., 2005), (Cryan et al., 2002a) (Nestler et al., 
2002b). Mice were subjected to the tail suspension procedure by hanging them 
by their tails in a tail suspension system (35 cm x 30 cm), as has been previously 
described (Cryan et al., 2005). Briefly, mice were hung via a strip of masking 
tape with their nose positioned ≈350 mm from the floor for 6 min. Behaviour was 
monitored and recorded using a camera for the last 4 minutes. Immobility, 
Figure 2.1. Open field test. Mouse is 
placed in the middle and the filed 
and can freely explore the area. 
Picture taken from 
https://www.cidd.unc.edu/research/
default.aspx?id=25 
Figure 2.2. Tail suspension 
test. . Mouse is hung from 
the tail and immobilization 
time represents depression 
phenotype. 
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defined as the summation of time mouse does not struggle to escape was 
quantified 3 times and averaged. Experimenter was present during the video 
capture.  
 
2.2.3. Forced swim test 
To assess helplessness, the Porsolt forced swim test was used to assess for 
depressive-like behaviour in rodents (Porsolt et al., 1977b) (Porsolt et al., 2001; 
Cryan et al., 2002b). This test counts rodent’s response to threat of drowning 
and has been widely used to measure the effectiveness of antidepressants. The 
time spent floating represents the immobilization time. Mice were individually 
placed in an inescapable transparent Plexiglas cylindrical tank (40 cm high x 20 
cm in diameter with a depth of 30 cm) filled to a depth 25 cm with tap water 
(25 ± 2 oC) for 6 minutes, and behaviour was recorded with a camera for the last 
4 minutes. Immobility, considered the absence of mobility other than the 
minimal necessary for the mouse to stay afloat, was scored 3 times and 
averaged. Experimenter was present during video capture.  
 
Figure 2.3. Forced swim test. Mouse is placed in a cylinder with water and 
immobility time is counted. 
 
2.2.4. Sucrose preference test 
Anhedonia was tested using sucrose preference test (SPT). To do this, mice were 
singly housed and habituated with ad libitum food and two bottles – one with 
tap water and one with 2 % sucrose solution, for 3 days prior to experimental 
start. Bottles were reversed every day throughout the time of the habituation to 
avoid side preference. On the day of the test, mice were deprived from both 
water and sucrose for 8 h. At the end of the day, the two bottles were put back 
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for 2 h. Bottles were placed in a different order in every cage to avoid side 
preference. The consumption of water and sucrose solution was estimated 
simultaneously in control and experimental groups by weighing the bottles. The 
preference for sucrose was calculated as a percentage of total liquid 
consumed (Akinfiresoye and Tizabi, 2013). Sucrose preference below 65 % is 
usually taken as the criterion for anhedonia, and is based on the ≥ 65 % sucrose 
preference of control animals (Moreau et al., 1992). 
 
2.2.5. Elevated plus maze (EPZ) 
EPM is a commonly employed behavioural animal anxiety test for the 
measurement of anxiolytic or anxiogenic behaviours in rodents. The model is 
based on rodents' aversion of open spaces (Hogg, 1996) (Rodgers and Dalvi, 
1997). This aversion leads to the behaviour termed thigmotaxis, which involves 
avoidance of open areas by confining movements to enclosed spaces or to the 
edges of a bounded space therefore this translates into the restriction of 
movements to the enclosed arms. Anxiety reduction in the EPM is indicated by 
an increase in the proportion of time spent in the open arms (time in open 
arms/total time in open or closed arms), and an increase in the proportion of 
entries into the open arms (entries into open arms/total entries into open or 
closed arms). Total number of arm entries and number of closed-arm entries 
usually represent the general activity. It was conducted after 3 weeks on HFD  
using a plus shaped maze made of opaque Perspex with two opposite open arms 
(50 cm x 10 cm) and two closed arms (50 cm x 10 cm with 40 cm walls) elevated 
80cm above the ground. The light intensity was 80 lux. In a 10-min trial, the 
time spent in the open and closed arms was measured.  
Figure 2.4. Sucrose preference test. 
Mouse is placed in a cage with two 
bottles; one with water and one with 
sucrose. Picture taken from 
http://neurobehaviour.lunenfeld.ca/D
EFAULT.ASP?page=Depression 
Chapter 2  Materials & Methods 
     
EIRINI VAGENA 77 
 
 
 
2.3. Drug administration 
2.3.1. Acute administration of rolipram 
Rolipram is a generic PDE4 inhibitor that has been shown to have antidepressant 
action in mice (Wachtel, 1982) (Wachtel, 1983b) and humans (Bobon et al., 
1988) (Wachtel and Schneider, 1986) (Fleischhacker et al., 1992). 9 mice were 
divided into two groups. The mice received 3 intraperitoneal (i.p.) injections: 2 
injections were done the day before (one in the morning and one in the evening) 
and 1 injection was performed 1 h prior to the tail suspension test. Rolipram was 
first dissolved in dimethyl sulfoxide (DMSO) and then in saline with the final i.p. 
concentration 10 mg/kg and 3% final DMSO concentration. 
 
2.3.2. Chronic administration of rolipram and fluoxetine 
15 mice were divided into 3 groups and received either 10 mg/kg of fluoxetine 
(Sigma-Aldrich F132, also known by the trade name Prozac), 1.25 mg/kg of 
rolipram (Sigma R6520) or normal saline daily for 3 weeks. Both rolipram and 
fluoxetine were dissolved in DMSO and the same percentage of DMSO was added 
to the saline control. Rolipram at this dose has been described in preclinical 
studies to be sufficient to exert an antidepressant effect in rats (O'Donnell, 
1993) (Przegalinski and Bigajska, 1983). The behavioural effect of chronic 
rolipram or Prozac administration was tested after three weeks. All the 
behavioural tests were performed 1 h after drug injections following the 
treatment schedule. 24 h after the last injection, mice were killed by 
decapitation and their hypothalamus, cortex, hippocampus and amydgala were 
dissected, isolated and immediately frozen in liquid nitrogen. 
 
Figure 2.5. Elevated plus maze. Mouse 
was placed in the middle of the 
apparatus and was left to explore for 10 
minutes.Picture taken from 
http://stockholmbrain.se/sbi-
research/translational-behavioural-
neuroscience-tbn/elevated-plus-maze/ 
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2.3.3. Oral gavage of olive oil and ghee 
Oral gavage was performed in wild-type 10 week old mice. The mice were 
gavaged with 300 µl of olive oil or ghee (clarified butter), two times per day for 
7 weeks. Ghee and olive oil were pre-warned at 37oC for 30 minutes before 
being administrated in mice. Mice were provided food ad libitum at all times. 
After the completion of the 7 weeks, mice were tested on different behavioural 
paradigms. 
 
2.3.4. Intracerebrovascular (i.c.v.) administration of 
GPR40 antagonist via implantation of osmotic 
pumps 
Mice were anesthetized with avertin and placed into a stereotaxic instrument. 
Avertin was used as anesthesia as it has been shown that there is a possible 
interaction between xylazine/ketamine anesthesia and PDE4 (Robichaud et al., 
2002). Ketamine has also been shown to have an antidepressant action 
(Salvadore and Singh, 2013). Mice were kept isothermal with heating pads and 
the surgical site prepared with betadine. Eyes were protected with lubricant. 
Using aseptic techniques, a 7-mm incision was made through the scalp skin. A 
pocket for placement of the osmotic pump was created by undermining the skin 
and the interior of the pocket. Coordinates for the 3rd ventricle were obtained 
using the Paxinos and Watson coordinates relative to bregma: 1.3 mm bregma, 
0.0mm lateral, and 5.0 mm dorsal-ventral. A hole was drilled through the skull 
using a dental drill for the cannula implantation. A sterile 28 gauge stainless 
steel cannula (Alzet, Cupertino, CA) was lowered into the brain to the desired 
depth (5.0 mm) and secured with acrylic dental cement and metabond (C&B-
metabond kit #S380). The i.c.v. cannula was connected to an appropriate Alzet 
osmotic mini-pump containing either 0.1µg/µl or 1 µg/µl GPR40 antagonist (1002 
Alzet, Cupertino, CA) via polyvinylchloride tubing. All intracerebroventricular 
(i.c.v.) solutions were dissolved in artificial cerebral spinal fluid (acsf). The scalp 
incision was closed with sutures and the mouse was kept warm during recovery. 
Animals were individually housed and monitored. Stable daily food intake and 
recovery of pre-operative body weight were used as measures of surgical 
recovery and typically normalized within 2 to 3 days post-surgery. At the end of 
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the 14 days of administration, mice were subjected to the tail suspension test. 
The next day, mice were sacrificed and proper infusion was confirmed in all 
animals by taking out and visually inspecting the fluid inside of the pump. 
 
2.3.5. Single stereotactic injections of palmitic acid 
Mice were anesthetized with avertin and placed into a stereotaxic instrument 
with ear bars and nosepiece. Avertin was used as anesthesia as it has been 
shown that there is a possible interaction between xylazine/ketamine anesthesia 
and PDE4 (Robichaud et al., 2002). Ketamine has also been shown to have an 
antidepressant action (Salvadore and Singh, 2013). Mice were kept isothermal 
with heating pads and the surgical site prepared with betadine. Eyes were 
protected with lubricant. Using aseptic techniques, a 7-mm incision was made 
through the scalp skin. Coordinates for the hypothalamic area are: -1.5 mm 
bregma, ±0.4mm lateral, and -5.8 mm dorsal-ventral (Paxinos and Watson 1998). 
A hole was drilled through the skull using a dental drill for the needle. A sterile 
33 gauge stainless steel needle (Hamilton #7803-05) was lowered into the brain 
to the desired depth (5.8 mm). A 10 µl glass syringe (Hamilton # 7635-01) was 
attached to the needle. A stock of 250 µg/µl of palmitic acid in 100% ethanol 
was prepared and further diluted to 1/50 in PBS prior to the in vivo injection, so 
that the final concentration was 5 µg/µl. Mice received 2 µl per hemisphere, 
which is 10 µg of palmitic acid in total. As a control, aCSF injected mice were 
used as well as 1/50 dilution of ethanol in PBS. The 2 µl injection in the 
hypothalamus was given over a period of 8 minutes (0.25 µl per minute). After 
the termination of the injection, the needle stayed at the injection site for 5 
more min before withdrawing; then the needle was withdrawn slowly to avoid 
backflow of the solution to the surface. The scalp incision was closed with 
sutures and the mouse was kept warm during recovery. Animals were 
individually housed and monitored. Tail suspension test was performed 4 days 
after the single stereotaxic injections. The following day, the mice performed 
the open field test. Six days after the injection, mice were sacrificed and the 
proper injection site was confirmed in all animals by visually checking the hole 
on the brain. 
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2.4. Tissue collection 
At the end of the experiments the mice were placed in a CO2 chamber and 
decapitated post-mortem. The isolation was between 1200-1500h. The 
hypothalamus was removed using brain slicer matrix (Zivic instruments) and was 
extracted within 1 minute, snap frozen in liquid nitrogen, and stored at -80 oC 
until further analysis.  
 
2.5. Preparation of lysates 
2.5.1. Whole brain lysates 
Brain protein extracts were prepared from hypothalamic, amygdala, cortex and 
hippocampal samples of WT and PDE4A-/- mice. Brain extracts were lysed in the 
TNE buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP40) or HKEM 
buffer (50 mM KCl, 50 mM HEPES, KOH Ph7.2, 10 mM EGTA, 1.92 mM MgCl2 ) 
supplemented with protease and phosphatase inhibitors cocktail inhibitor 
(Calbiochem). The brain lysates were homogenized with pellet pestle motor 
(Kontes) and were kept on ice for 15 minutes to further enhance the lysis before 
centrifuging at 16,100 x g for 15 min at 4 oC. The lysate supernatant was then 
ready and used immediately for the quantification of total protein levels. 
Supernatants were collected and assayed for total protein using the Bradford 
method (Biorad, Richmond, California). Samples were stored at -80 oC until 
needed. 
2.5.2. Cell lysates  
Protein extracts were prepared from N2a and HEK293 cells. Briefly, the culture 
media was removed and the cells were washed thrice in ice cold sterile PBS. The 
culture plates were drained thoroughly before adding TNE lysis buffer (10 mM 
Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP40) supplemented with protease 
and phosphatase inhibitors (Calbiochem). The cell lysates were collected using a 
sterile scraper and transferred into 1.5 ml Eppendorf tubes kept on ice. The 
tubes were incubated on ice for 30 min at 4 oC before centrifuging at 16,100 g 
for 10 min at 4 oC in order to remove insoluble cellular components. The lysate 
supernatant was then transferred to a new tube and analysed immediately for 
protein quantification. 
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2.6. Subcellular membrane-cytosol fractionation of brain 
samples 
Brain tissue or cells were lysed in 200 µl of KHEM buffer (50 mM KCl, 50 mM 
HEPES, KOH Ph7.2, 10 mM EGTA, 1.92 mM MgCl2) supplemented with protease 
and phosphatase inhibitors (Calbiochem) and sat on ice for 30 min to enhance 
lysis. Lysates were spun down for 10 minutes at 1000 g at 4 oC (the low speed 
pellet precipitates the  cell debris and nuclei) and the lysate supernatant was 
transferred to a new 1.5ml eppendorf tube. The supernatant was then 
centrifuged at 100000 g for 1h at 4oC in a Beckman ultracentrifuge. The 
supernatant was saved as the cytosol fraction. The pellet (high speed pellet) was 
resuspended in KHEM buffer +1% triton and 150mM NaCl and incubated for 30 
minutes on ice with occasional agitation before the second centrifugation for 
100000 g for 1 h at 4 oC. The supernatant was saved as the membrane fraction.  
To assess the purity of the fractionation, membrane and cytcytoplasmic, 
membrane and nuclear fractions were confirmed by immunoblotting using anti-
GAPDH as cytoplasmic marker and anti-GPR40 as membrane marker. 
 
2.7. Determination of protein concentration  
The protein concentration of the brain lysates was determined according to the 
Bradford dye-binding method (Bradford, 1976) using dye reagent from Bio-Rad 
(Hampstead, U.K.). The Bradford assay is a colorimetric assay based on the 
colour change of Coomassie Blue G-250 when it binds to various concentrations 
of protein. Briefly, Bradford reagent was prepared by diluting 1 part of 
concentrated Bio-Rad dye reagent with 4 parts of sterile water. A range of 
bovine serum albumin (BSA) concentrations (1-36 µg/µl) were prepared as 
protein standards. The protein samples were assayed in duplicates in 96-well 
microtitre plates. The 96-well plate was then analysed at 595 nm using a 
SpectraMax M5 (Molecular Device, USA). A standard curve of absorbance against 
BSA concentration was plotted using least squared regression analysis to provide 
a relative measurement of protein concentration. The concentration of protein 
samples was then adjusted to account for any dilution factor. 
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2.8. Protein analysis 
2.8.1. SDS-PAGE 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel 
electrophoresis was carried out to resolve proteins by their molecular weight 
and charge. Briefly, equal amounts of protein samples (50 µg) were denatured 
and reduced in 5x SDS-PAGE sample buffer Laemmli (10 % SDS, 300 mM Tris-Cl; 
pH 6.8, 0.05 % bromophenol blue, 50 % glycerol, 10% β-mercaptoethanol) 
followed by boiling at 100 oC for  10 min. After brief centrifugation, protein 
samples were resolved on precast polyacrylamide gels (4-12 % NuPAGE® Novex 
Bis-Tris gel, Invitrogen) using Invitrogen X-cell apparatus and NuPage® Novex gel 
system immersed in MOPS SDS running buffer according to nature of the samples 
and different protein separation range. Pre-stained precision plus all blue 
standards protein marker (Bio-Rad, USA) was loaded to the first well of the gel 
to be used as a molecular weight market while the protein samples were loaded 
to the subsequent wells. Gels were subjected to electrophoresis at 40 mM for 
1.5 h to allow for adequate separation.  
 
2.8.2. Western immunoblotting  
For Western blotting, SDS-PAGE gels were electrotransfered onto nitrocellulose 
membranes (0.45 µm pore, Immobilon-P Membrane, PVDF, millipore) using Mini 
Trans-Blot® cell (BioRad) in Nu-PAGE transfer buffer containing 20 % methanol. 
Proteins were transferred for 2 h at 150 mA at 4 oC. Transfer efficacy was 
established through visualisation of the prestained molecular weight markers 
onto the nitrocellulose membrane or Ponceau staining. Following transfer the 
membrane was then blocked in 5 % (w/v) non-fat dry milk (BioRad) or 
PhosphoBLOCKER blocking reagent (Cell Biolabs, Inc.) in 1xTBST (20 mM Tris-Cl; 
pH 7.6, 150 mM NaCl, 0.1 % Tween 20) for 1 h at room temperature under 
agitating conditions to block non-specific antibodies binding to the membrane. 
Membranes were then probed with specific primary antibodies (Table 2.2) 
diluted in 1 % milk/TBST solution and incubated overnight at 4 oC under 
agitation. The membranes were washed 3 times for 10 mins each in 1xTBST 
before adding appropriate horseradish peroxidise (HRP) conjugated anti-
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immunoglobulin G (IgG) secondary antibody (Santacruz) diluted 1:2000 in fresh 
prepared 1% milk/TBST solution for 2h at room temperature (RT) (details of 
antibodies and dilutions given in Table 2.2). After secondary antibody 
incubation, membranes were washed 3 times for 10 minutes with TBST and 
detected by enhance chemiluminescence (ECL) Western Blotting Substrate (GE 
Healthcare). Membranes were incubated in ECL substrate for 1 minute before 
transferring to a light-sensitive cassette. Chemiluminescent images of 
immunodetected bands were recorded on blue-light sensitive autoradiography X-
ray films (Blue Devil Film, Genessee Scientifc, Inc.) which were then developed 
using the Kodak® X-Omat Model 2000 processor. Immunoblots intensities were 
quantitatively and analysed using ImageJ (http://imagej.nih.gov/ij/). 
 
Densities of the protein bands were measured by imageJ software and the 
statistical analysis was done by graphpad prism 7. Results are shown as means ± 
standard error of mean (SEM). The differences between the means were 
evaluated by one-way ANOVA followed by Dunett’s post hoc for comparison 
between the control and tested groups, and the tukey-kramper’s post hoc for 
comparison between the groups. Differences at p< 0.05 were considered 
significant. 
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Table 2.2 List of the primary antibodies used in this study. Application key: 
WB=Western blot; IP=Immunoprecipitation. The PDE4A5 specific antibody that 
was produced is house has been described previously (Huston et al., 2000) as a 
specific pan-PDE4A antiserum. 
Antibody Supplier Catalogue # Host Dilution Applications 
GAPDH Abcam ab9485 rabbit  1/4000 WB 
GRK2 Abcam ab32558 rabbit  1/2000 WB 
phospho-CREB Cell signaling 87G3 rabbit  1/2000 WB 
DARPP-32 Cell signaling 19A3 rabbit  1/2000 WB 
p-DARPP-32 Cell signaling D29E8 rabbit  1/2000 WB 
GPR40 Abcam ab109257 rabbit  1/2000 WB 
GFP Abcam ab290 rabbit  1/2000 WB 
b-arrestin1 Santacruz sc-53780 mouse  1/800 WB 
b-arrestin2 Santacruz sc-13140 mouse  1/800 WB 
CREB Cell signaling 9192 rabbit  1/2000 WB 
PDE4A Abcam ab14607 rabbit  1/2000 WB 
p-PDE4A Abcam ab14610 rabbit  1/2000 WB 
GPR40 Santacruz sc-32905 rabbit  1/50 IP 
Flag Sigma F1804 mouse  1/3000 WB/IP 
GAPDH Millipore MAB374 mouse  1/3000 WB 
phospho-PKA Cell signaling 9624S rabbit 1/1000 WB 
PDE4A5 in-house 
produced 
 rabbit 1/1000 WB/IP 
P-pde4a5 in-house 
produced 
 rabbit 1/1000 WB 
vsv Sigma V4888 mouse  1/4000 WB/IP 
 
 
2.9. Ponceau Staining 
Ponceau staining is a reversible way of visualising proteins on a nitrocellulose 
membrane after their transfer. Membranes are incubated in Ponceau solution 
(Pierce) for minimum 30 minutes with gentle agitation. Blots were either 
scanned or washed in dH2O until staining was removed and then used for 
Western blotting. 
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2.10. PDE4 activity assays 
The PDE4 activity in the brain homogenates was assayed by a modification of the 
two-step radio assay procedure of Thompson and Appleman (1971) and Rutten et 
al. (1973) and has been described previously by Marchmont and Houslay (1980). 
The samples were lysated in KHEM buffer (50 mM KCl, 50 mM HEPES pH 7.2, 10 
mM EGTA, 1.9 mM MgCl2) supplemented with protease (COmplete EDTA-free, 
Roche) and phosphatase (PhosSTOP, Roche) inhibitor cocktail tablets. Pilot 
assays were carried out to verify PDE4 activity and ensure activity fell within the 
linear range of 6000-16000 counts. Each sample was done in triplicate and was 
incubated with and without the phosphodiesterase inhibitor rolipram. Rolipram 
was dissolved in 100 % DMSO as a 10 mM stock solution and diluted in 20 mM 
Tris/HCl, 10 mM MgCl2 buffer (final pH 7.4) to a final concentration of 10uM. The 
difference between the two different measurements represents the specific 
PDE4 activity in each sample.  
 
In the first step, 40 µl of the appropriate amount of µgr of brain lysate dissolved 
in KHEM buffer and supplemented with protease and phosphatase inhibitors was 
added to a 100 µl of a reaction mixture. That was further supplemented with 20 
mM Tris, pH 7.4 to the final volume of 50µl, 10µl of either diluted rolipram or 
DMSO and 50µl of 20 mM Tris, pH 7.4 with 5 mM MgCl2 0.1 µCi tritiated cyclic 
nucleotide and 1µM cyclic AMP. For every 1 ml of 20 mM Tris, pH 7.4, 5 mM 
MgCl2 that was used, 3µl of the tritiated cAMP and 2 µl of the non-tritiated cAMP 
were added. The reaction mixture was vortexed and incubated at 30 oC for 10 
minutes before termination of the protein activity by boiling for 2 min. When the 
protein concentration of the samples was too low, 20 minutes of the incubation 
was performed, but then the final counts for the analysis of the PDE4 activity 
were divided by two. During this step, the PDEs in every sample are hydrolyzing 
the 8-[3H]-labelled cAMP substrate to [3H]-5’-AMP. In the second step, after the 
reaction mixture had cooled to 4 oC for 15 minutes, 25 ul of Crotalus Atrox 
venom (1 µgr/µl) was added, and incubation of this mixture was carried out for 
10 min at 30 oC to attain complete conversion of 5’-AMP to adenosine. After this 
stage, 0.4ml of 1:1:1 (v/v/v) slurry of Dowex 1X8 200–400 MESH CI resin, ethanol 
and water were added to the reaction mixture, vortexed and then incubated on 
ice for at least 15 minutes. Anion exchange resin binds negatively charged, 
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unhydrolysed cAMP, separating it from the adenosine. This mixture was vortex-
mixed several times over a 15 min period before being centrifuged at 13000 g in 
a table microcentrifuge for 3 min at 4 oC to sediment the resin thoroughly. 
Samples (150 ul) Dowex/water/ethanol (1:1:1, by vol.) were used for the 
determination of activities. They were mixed with 1ml Opti Flow SAFE 1 
scintillant and counted on a Wallac 1409 Liquid Scintillation Counter. Corrections 
were made for the cyclic [3H] AMP not removed by the resin by using a blank 
that consists of everything except protein sample. The amount of [3H]-adenosine 
is then calculated by scintillation counting, to determine the rate of cAMP 
hydrolysis.  
 
2.11. Protein-protein interaction assays 
2.11.1. In vitro co-immunoprecipitation assay 
In vitro co-immunoprecipitation (co-IP) was performed for the confirmation of 
protein interactions. Cells either express proteins of interest, or are transfected 
with the plasmids that produce the proteins of interest. Media of cells were 
aspirated gently and cells were washed 3 times with ice cold PBS. Cells were 
scraped in the lysis in TNE buffer (10mm Tris, pH8.0, 150Mm NaCl, 1mm EDTA 
PH8.0, 1% NP40) supplemented with protease (Chymotrypsin 1.5 µg/ml, 
Thermolysin 0.8 µg/ml, Papain 1 mg/ml, Pronase 1.5 µg/ml, Pancreatic extract 
1.5 µg/ml, Trypsin 0.002 µg/ml, Roche) and phosphatase ( Calf alkaline 
phosphatase 140u/10ml, potato acidic phosphatase 2u/10ml, human acidic 
phosphatase 640u/10ml, rabbit PP1 200u/10ml, human PP2A 500u/10ml, human 
PTP 500u/10ml) inhibitors and were collected in an eppendorf tube. Tubes were 
incubated on ice for 30 minutes before being centrifuged for 15 minutes at 
maximum speed at 4 oC. Next the supernatant was transferred to a new tube. 
Protein concentration was determined using BioRad as it has been described 
previously. Next, all the samples were normalized to have the same total 
amount of protein in the same volume. The protein lysate was precleared with 
Protein A Plus agarose (Thermo Scientific) for 2 hours with rotation at 4 oC. After 
preclearing, the tubes were spun down at 1000 g for 1 minute at 4 oC and the 
supernatant was transferred to a new tube. 2-3 µgr/ml of the appropriate 
antibody was used to immunoprecipitate (IP) endogenous and overexpression of 
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the proteins of our interest as well as their binding partners (details of 
antibodies given in Table 2.2) and were incubated overnight rotating. Negative 
controls using isotype-matched IgG (Santa Cruz Biotechnology) from the same 
species as the antibodies were included to screen for non-specific binding. The 
resulting immunocomplexes were captured the next day incubating for 2 hours 
using Protein A beads (Thermo scientific) for 2 hours rotating. The 
immunocomplexes were then collected by centrifugation at 1000 g for 2 min and 
washed five times with TNE lysis buffer supplemented with protease and 
phosphatase inhibtiors. Bound proteins were then eluted in Laemmli (10% SDS, 
300 mM Tris-Cl; pH 6.8, 0.05% bromophenol blue, 50% glycerol, 10% β-
mercaptoethanol), then boiled at 100 oC for  10 min and subjected to SDS-PAGE. 
Western immuno-blotting was performed using various antisera as described 
previously. 
 
2.11.2. Co-immunoprecipitation assay of mouse brain 
lysates 
In vivo co-immunoprecipitation (co-IP) was performed for the confirmation of 
protein interactions in mice. Mice were fasted for 7 hours during the day and 
then food was added for 2 hours. Mice were sacrificed and the hypothalamic 
area was isolated and lysed in TNE buffer (10mm Tris, pH 8.0, 150mM NaCl, 1mm 
EDTA pH 8.0, 1%NP40) supplemented with protease and phosphatase inhibitors. 
The lysates were processed as it has been described in the section above.  
 
2.12. RNA Expression Analysis 
Real-time PCR has been widely used to determine relative gene expression. This 
detection method is based on the changes of fluorescence accumulation during 
thermocycling which can be reflected on a sigmoidal amplification plot and give 
a quantitative result of the amplified product (Kubista et al., 2006). Variability 
in qPCR can be influenced by steps upstream which consist of template 
preparation and reverse transcription. 
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2.12.1. RNA extraction  
Total RNA was extracted using the QIAGEN lipid tissue kit with QIAZOL which 
contained phenol and guanidine thiocyanate in a procedure based on the method 
of Chomczynski and Sacchi (1987). Brain homogenates where first lysed in 600 ul 
of QIAZOL with a pellet pestle motor (Kontes) and tubes were incubated for 5 
min at room temperature. RNA was separated from DNA and proteins by the 
addition of 200 ul of chloroform. After vigorous vortexing for 15 sec, the tubes 
were incubated at room temperature for 2-3 min. The aqueous phase, which 
contains the RNA, was then separated by centrifugation at 12,000 x g for 10 
minutes at 4 oC. The aqueous phase was transferred to a new tube, and the RNA 
was precipitated by adding an equal volume of 70% ethanol and mixing 
thoroughly. The samples were then transferred to an RNeasy mini spin column 
and centrifuged for 15 seconds at 8,000 x g at room temperature. The flow-
through was discarded. Next, the mini spin column was washed with 700 µl of 
the RW1 buffer and the flow-through was discarded. The RNeasy spin column 
was further washed twice with 500ul of RPE buffer and the flow-through was 
discarded. After the washes, the RNeasy spin column was placed in a new 1.5 ml 
collection tube (supplied) and 30 µl of the RNase-free water were added directly 
to the spin column membrane. The spin column was then incubated at room 
temperature for 5 minutes and the RNA was eluted by centrifugation for 5 min at 
8000 x g (10,000 rpm). 
 
2.12.2. Gene expression profiling by microarray analysis 
Microarray analysis was performed on hypothalamic areas of mice fed normal 
diet and either 4 or 8 weeks on a high-fat diet. Hypothalamic area was dissected 
using the brain slicer matrix (Zivic instruments). Total RNA was isolated with 
RNeasy Mini kit/RNeasy Lipid tissue mini kit (QIAGEN) according to the 
manufacturer’s instruction. DNase I treatment of the RNA fraction was carried 
out using an RNase free DNase set (QIAGEN) as a precaution against genomic DNA 
contamination of the RNA. Probes were prepared using NuGEN Ovation Pico WTA 
V2 kit and NuGEN Encore Biotin Module, and hybridized to Rat and Mouse Gene 
1.0 ST GeneChip arrays (Affymetrix). Arrays were scanned using an Affymetrix 
GCS3000 scanner and Affymetrix Command Console software, and data were 
Chapter 2  Materials & Methods 
     
EIRINI VAGENA 89 
 
normalized using the RMA algorithm in Affymetrix Expression Console. 
Microarrays were normalized for array-specific effects using Affymetrix's "Robust 
Multi-Array" (RMA) normalization. Normalized array values were reported on a 
log2 scale. For statistical analyses, we removed all array probe sets in which no 
experimental groups had an average of log2 intensity greater than 3.0. This is a 
standard cutoff, below which expression is indistinguishable from background 
noise. Linear models were fit for each gene using the Bioconductor "limma" 
package in R (Gentleman et al., 2004). Moderated t-statistics, fold-change and 
the associated P-values were calculated for each gene. To account for the fact 
that thousands of genes were tested, we reported false discovery rate (FDR)-
adjusted values, calculated using the Benjamini-Hochberg method (Benjamini 
and Hochberg, 1995). FDR values indicate the expected fraction of falsely 
declared differentially expressed ("DE") genes among the total set of declared DE 
genes (i.e., FDR = 0.15 would indicate that ~15% of the declared DE genes were 
expected to be due to experimental noise instead of actual differential 
expression). 
 
2.12.3. Reverse transcription of PCR  
3 µl of RNA was reverse-transcribed to first strand complementary DNA (cDNA) 
using GeneAmp RNA PCR core kit (Applied Biosystems) according to 
manufacturer’s instructions. A reaction mixture containing 5 mM MgCl2 final 
concentration, 1 mM each dNTP), 1 unit of RNase Block Ribonuclease Inhibitor 
and 2.5 units of reverse transcriptase (RT) MULV was added to the random 
hexamer primer mixture and incubated at 42 oC for 20 minutes. The random 
hexamer primers bind to random places on the RNA so that the reverse 
transcriptase cans polymerase. The reaction was then terminated by heating at 
99 oC for 10 min and subsequently chilled on ice for 10 min to deactivate the 
enzyme. The cDNA was stored at -80 oC until use. 
 
2.12.4. Quantitative real-time PCR with SYBR green  
Specific real time PCR primer sets (Eurofins MWG operon) for each gene were 
from the primer bank or designed assisted by the Primer 3 software 
(http://frodo.wi.mit.edu/primer3/). Table 2.3 shows the sequences of the 
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different real time PCR primers that were used. The primers were designed to 
span an exon-intron-exon boundary to exclude amplification of genomic DNA. 
GAPDH was used as an internal control for normalising relative expression levels 
in the different samples. Real-time PCR was performed from reverse transcribed 
cDNA samples using the SYBR Green PCR master mix (Applied Biosystems, 
Invitrogen) following the manufacturer’s instructions. Briefly, 2 µl of cDNA were 
added to a 96-well MicroAmp® Fast Optical Reaction Plate (applied Biosystems) 
with 12.5 µl of SYBR Green and 1 µl each of the 10 µM primer pair. Thermal 
cycling and fluorescent monitoring were performed using StepOne Plus Real-time 
PCR system (Applied Biosystems). Each PCR amplification was run in duplicates 
using the following conditions: initial denaturation at 95 °C for 10 min, followed 
by a total of 40 cycles (15 sec at 95 °C for denaturation, 1 min at 60 °C for 
extension). Fluorescence data were collected during the extension step of each 
cycle. Negative controls using water instead of cDNA as template were also 
included in all runs. 
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Primer name sequence 
mPDE4D_Fw GTCCCATGTGTGACAAGCAC 
mPDE4D_Rv TCAGTGTCTGACTCGCCATC 
mPDE4A_Fw CGAGCACTACAGTGGTGGAA 
mPDE4A_Rv AAAAGGATCAGGCAGGGTCT 
mPDE4B_Fw GTCCCAGGTTGGTTTCATTG 
mPDE4B_Rv ACACAGGGATGGAATCGAAG 
mGAPDH_Rv GGCCTCACCCCATTTGATGT 
mGAPDH_Fw CAAGGCCGAGAATGGGAAG 
mPDE4A5_Fw TCGCCGCACCGGCCCATAGA 
mPDE4A5_Rv GACGAGGGCCAGGACATGCG 
mTNF-α_Fw CCCTCACACTCAGATCATCTTCT 
mTNF-α_Rv GCTACGACGTGGGCTACAG 
mIL-1β_Fw GCAACTGTTCCTGAACTCAACT 
mIL-1β_Rv ATCTTTTGGGGTCCGTCAACT 
mIFN-γ_Fw CAGAGCCAGATTATCTCTTTCTACCTCACCTCAGAC 
mIFN-γ_Rv CTTTTTCGCCTTGCTGTTGCTGAAG 
mBDNF_Fw AGGCACTGGAACTCGCAATG 
mBDNF_Rv AAGGGCCCGAACATACGATT 
mGPR41_Fw CTTGTATCGACCCCCTGGTTTT 
mGPR41_Rv GCTGAGTCCAAGGCACACAAGT 
mGPR120_Fw TTCATATGGGGTTACTCGGC 
mGPR120_Rv GATTTCTCCTATGCGGTTGG 
mGPR40_Fw AATGCCTCCAATGTGGCTAG 
mGPR40_Rv AGTCCTCGTCACACATATTG 
  
Table 2.3. List of real time PCR primers. List of the pcr primers used 
for real time PCR analysis 
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2.12.5. Quantitative real-time PCR analysis 
Relative changes in gene expression of the target genes in different samples 
were quantified using the comparative Ct method (Ct) as described by Livak 
and Schmittgen (2001). The objective of this method is to compare the PCR 
signal of a target gene in a treatment group to the untreated control after 
normalizing to an endogenous reference gene. Firstly, the point at which the 
PCR was detected above a set threshold in exponential phase, termed threshold 
cycle (Ct), was obtained from the real-time PCR instrumentation. Ct is 
determined from a log-linear curve where PCR signal is plotted against the cycle 
number. The Ct values of each sample were then imported into Microsoft Excel 
and the average Ct of duplicate samples was calculated. The amount detected 
at a certain cycle number is directly related to the initial amount of target in 
the sample. Hence, to determine the quantity of gene-specific transcripts 
present in cDNA, Ct values for each treatment had to be normalized first to 
obtain Ct. This was accomplished by subtracting the mean Ct value of 
endogenous reference gene 18s rRNA of each group from the corresponding 
mean Ct value of gene of interest (GOI) accordingly (Ct = CtGOI - Ct18s rRNA). 
The concentration of gene-specific mRNA in treated cells relative to untreated 
cells was then normalized through subtraction again to obtain Ct values (Ct 
= Ct of treated cells - Ct of untreated cells). Finally, the relative expression 
which is often termed as RQ value was determined by raising 2 to the power of 
the negative value of Ct (2-Ct) for each sample (Amount of target = 2-
Ct). Alteration in mRNA expression of target genes was defined as fold 
difference in the expression level in cells after the treatment relative to that 
before treatment. Samples with poor technical replicate values were excluded 
from analysis. 
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2.13. Fatty acid analysis by gas chromatography–mass 
spectrometr. 
 The total concentrations of palmitic acid (16:0), stearic acid (18:0), myristic 
acid (14:0), behenic  acid (22:0), arachidic acid (20:0), gondoic (20:1), oleic 
(18:1)  and linoleic (18:2) were determined from tissues using gas 
chromatography–mass spectrometry (Brunengraber et al., 2003). A known 
quantity of tissue was hydrolyzed and extracted after adding a known amount of 
heptadecanoic acid (17:0). Fatty acids were analyzed as their trimethylsilyl 
derivatives under electron impact ionization mode using an Agilent 5973N-MSD 
equipped with an Agilent 6890 GC system and a DB17-MS capillary column (30 m 
× 0.25-mm internal diameter × 0.25-µm film thickness).  
 
2.14. cAMP measurement of mouse brain lysates 
Measurements of cAMP in vivo were performed using the CatchPoint Cyclic-AMP 
fluorescent assay kit (Molecular Device, CA). Briefly, whole hypothalamic brain 
samples were lysed in lysis buffer provided by the manufacturer and left on ice 
for 15 minutes. Lysates were spun down for 10 minutes at 1000 g at 4oC (low 
speed pellet, cell debris and nuclei) and the supernatant was transferred in a 
new 1.5ml eppendorf tube and was used for the assay. The kit was performed 
according to manufacturer’s instructions. 
 
2.15. FRET imaging 
Förster Resonance Energy Transfer (FRET) is a well established technique to 
study protein-protein interactions as well as second messenger signalling. This 
phenomenon was first described by Theodor Förster (Förster, 1948) and 
describes the interactions between the electron excitation states of two 
fluorophores. Excitation energy is transferred from the donor fluorophore to the 
acceptor fluorophore without emission of a photon, a process which is non-
radiative. The Förster distance, when FRET efficiency is 50% (R0), correlates with 
the distance between the donor and acceptor fluorophores but an essential 
requirement is that the distance (r) between the fluorophores must be less than 
10nm for energy transfer to occur (Kalab and Soderholm, 2010). FRET imaging 
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experiments were performed 24-48 h after transfection with the PKARI sensor on 
mouse neuroblastoma (N2a) cell line that were seeded onto glass cover slips. 
Cells were maintained at room temperature in DPBS (Invitrogen, UK), with added 
CaCl2 and MgCl2, and imaged on an inverted microscope (Olympus IX71) with a 
PlanApoN, 60X, NA 1.42 oil, 0.17/FN 26.5, objective (Japan). The microscope 
was equipped with a CCD camera (cool SNAP HQ monochrome, Photometrics), 
and a beam-splitter optical device (Dual-channel simultaneous-imaging system, 
DV2 mag biosystem (ET-04-EM)). Imaging acquisition and analysis software used 
was Meta imaging series 7.1, Metafluor, and processed using ImageJ 
(http://rsb.info.nih.gov.ucsf.idm.oclc.org/ij/). FRET changes were measured as 
changes in the background-subtracted 480/545-nm fluorescence emission 
intensity on excitation at 430 nm and expressed as either R/R0, where R is the 
ratio at time t and R0 is the ratio at time = 0 s, or R/R0, where R = R − R0. 
Values are expressed as the mean ± SEM. Cells were pretreated with 100uM of 
either palmitic or oleic before 5uM of forskolin treatment. At the end of every 
experiment, saturated doses of forskolin (25uM) or IBMX (100uM) were used to 
check for the responsiveness of the cells.   
 
2.16. Glucose and insulin tolerance tests 
To determine the relative sensitivity or resistance to glucose or insulin, the 
glucose and insulin tolerance tests were performed on PDE4A+/+ and PDE4A-/- 
mice by measuring blood glucose following either a glucose load or insulin dose. 
Mice that were fasted for 6 hours during the day received an intraperitoneal 
injection of either glucose (1-2 milligram/kilogram body weight; 0.01 
milliliter/kilogram body weight in sterile PBS) or bovine insulin (0.4U/ kilogram 
body weight). Blood samples (one drop) were obtained by tail bleeding at 10, 30, 
60, 90 and 120 minutes after initial injection to measure blood glucose levels 
using an OneTouch Ultra2 sugar glucometer (Lifescan, Inc. Milpitas, CA). 
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2.17. Plasmid DNA 
For the mammalian expression of wild-type PDE4A5-vsv and arrestin-2, 
constructs were provided by Professor George Baillie. Mouse GPR40 construct 
was obtained from Origene. All plasmid work was carried out in sterile 
conditions and all buffers made in-house and were autoclaved prior to use. 
 
2.17.1. Transformation 
For mammalian transfection purposes One Shot® DH5a (Invitrogen, USA) 
chemically competent E. coli cells were used for plasmid production. Chemically 
competent cells were stored at -80 °C and thawed on ice immediately prior to 
use. Approximately 1-10 ng of appropriate plasmid DNA was added to 50 ul of 
competent cell and mixed gently. Cells were then incubated on ice for 30 
minutes then heat-shocked for 30 seconds at 42 °C then returned to ice for 2 
minutes before the addition of 200 µl of super optimal broth with glucose (SOC 
media) (Invitrogen, USA) to the cells. Cells were then incubated at 37 °C for 1 
hour at 300 rpm to allow for recovery of the cells. The transformation mix was 
then spread on 100 mm pre-warmed agar petri dishes made with sterile Luria-
Bertani medium (LB) (1 % tryptone (w/v), 0.5 % yeast extract (w/v), 170mM 
NaCl) supplemented with appropriate antibiotic either kanamycin (50 µg/ml) or 
ampicillin (100 µg/ml). Plates were incubated upside down at 37 °C overnight.  
The growth of bacterial colonies indicated successful cell transformation. 
 
2.17.2. Amplification & isolation of the plasmid DNA 
In order to amplify the plasmid DNA, either single colonies were picked from the 
plate or from frozen glycerol stocks under sterile conditions and grown during 
the day in 5 ml LB media containing either kanamycin or ampicillin in an orbital 
shaker at 37 oC at 220rpm. The 5 ml bacterial culture was added in a 200 ml 
flask supplemented with the appropriate antibiotic and incubated a further 12-
16 h. The next day, the culture was pelleted and plasmid DNA was purified in 
accordance with Midi kit (Qiagen), in accordance with manufacturer’s 
instructions. QIAprep Miniprep Kit (Qiagen) was used to isolate smaller amounts 
of plasmid DNA. The purified DNA was then eluted with sterile H20 and stored at 
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-20 oC. The resulting plasmid DNA was sequenced by the MCLAB services (www 
http://www.mclab.com) in order to verify the correct sequence.  
 
2.17.3. Quantification 
The concentration of the purified plasmid DNA was determined using a Nanodrop 
3300 spectrophotometer (Thermo-Scientific). The ratio of absorbance at 260 nm 
and 280 nm determines the purity of the DNA where a value of 1.8 is indicative 
of highly purified DNA. The DNA concentration was calculated using the Beer-
Lambert law, where an A260 reading of 1.0 optical density (OD) unit is 
equivalent to 50 µg/ml double-stranded DNA (Sambrook et al., 1989); which is 
done automatically by the Nanodrop software. 
 
2.17.4. Plasmid Storage  
For long-term plasmid storage, 750 ul of overnight culture was added to 250 µl 
of 70 % glycerol in a sterile cryovial, snap-frozen on dry ice then stored at -80 °C 
until required. For amplification of the plasmid DNA of the glycerol stocks, 
cryovials were placed on dry-ice to prevent thawing and frozen stocks and were 
scraped using a sterile pipette tip and transferred to LB containing appropriate 
antibiotic. 
 
2.17.5. Cloning of the PDE4A5-VSV into the AAV vector 
The adeno-associated vector (AAV) expressing GFP under the synapsin promoter 
was provided by the vector core of the University of Pennsylvania. Figure 2.6 
shows a schematic of the AAV of the construct.  
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Figure.2.6. Map of the Adeno-associated virus used to express eGFP under 
the synapsin promoter. Construct was obtained by the Gene therapy vector 
core at the University of Pensylvania. 
 
 
At the same vector the substitution of GFP with PDE4A5-vsv was performed in 
order to achieve overexpression of PDE4A5 under the synapsin promoter. The 
GFP was excised using EcoRI and XhoI (England Biolabs). Then the PDE4A5-vsv 
was amplified with a set of primers containing the restriction sequences of EcoRI 
and XhoI. The PCR fragment containing the EcoRI-PDE4A5-vsv-XhoI was ligated 
with the digested vector using the rapid DNA ligation kit (Roche #11635379001). 
Briefly, the digested vector and the insert were mixed together in a ratio of 1:3 
and they were further diluted in the dilution buffer in total volume of 10 µl. The 
10 µl of the ligation mix was incubated with 1 µl of 5 units of ligase at RT for 30 
minutes. Next, the ligation product was used to transform the stbl2 bacteria 
(Invitrogen) that is suitable for unstable DNA. The cloning was confirmed by 
sequencing the vector. Figure 2.7 represents a map of the construct that was 
produced. 
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hSynapsin.rPDE4A5.vsv PDE4A5-vsv 
Figure 2.7. Map of the adeno-associated virus used to express the rat 
PDE4A5-wt under the synapsin promoter. Construct was obtained by the 
Gene therapy vector core at the University of Pensylvania and cloning was 
performed in order to add the PDE4A5-vsv. 
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2.18. In vivo delivery of AAV vector expressing PDE4A5 
and GFP 
To investigate the role of PDE4A5 in depression, adeno-associated virus (AAV) 
encoding the PDE4A5-wt rat isoform tagged with vsv and under the synapsin 
promoter was generated to induce overexpression of the PDE4A5 in neurons 
(Fig.2.2). Synapsin promoter has been used widely to drive neuronal 
overexpression. The pde4a5 was tagged with vsv so that we could distinguish 
between the native and the externally overexpressed pde4a5. As a control was 
used the same construct overexpressing GFP under the synapsin promoter 
(Fig.2.1). The production of the virus was carried out at the core of gene 
therapy at the University of Pennsylvania. As anesthesia for the surgeries, we 
used avertin as it has been shown that there is a possible interaction between 
xylazine/ketamine anesthesia and pde4 (Robichaud et al., 2002). AAV vector 
expressing either PDE4A5-WT-vsv or AAV-Egfp were injected bilaterally into the 
thalamus using the following coordinates measured from the bregma AP -1.5mm, 
ML ±0.4mm, DV -5.8mm from dura (Paxinos and Watson 1998). One microliter of 
the AAV-PDE4A5-vsv (4,99x1013 infectious particles/ml) was infused over a 5 
minute period. AAV control GFP (5,5x1013 infectious particles/ml) was used as a 
control. Following injection, the injector was kept in place for additional 5 
minutes to allow for diffusion and prevention of backflow through the needle 
track before the injector was withdrawn. After surgery, the mice were provided 
with high fat diet for 3 weeks. Upon the completion of the three weeks, 
behavioral assays were performed to assess the depression phenotype. Upon the 
completion of all the behavioral assays, mice rest for 2 days before rapid 
decapitation. The hypothalamic area was extracted and snap frozen in liquid 
nitrogen. The injection site was confirmed by visualizing GFP fluorescence suing 
a fluorescent microscopy. 
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2.19. Mammalian cell culture 
All cell culture procedures were carried out in a Class II hoods using standard 
aseptic techniques and sterile equipment. All culture reagents such as media 
were supplied by Invitrogen while the tissue culture flasks, dishes and pipettes 
were supplied by Corning. All cultures were examined regularly under a phase 
contrast inverted microscope (Leitz Diavert, Germany or the Nikon Eclise TS100) 
to confirm the healthy status of the cells and monitor for contamination. N2a 
and HEK293T cell lines were maintained at in 10 cm2 plates at 37 oC in a 
humidified atmosphere of 5 % CO2 and 95 % air. Culture media was routinely 
replaced every 3-4 days and cells upon reaching 80 % confluency were passaged. 
To passage, growth medium was removed and the cells were gently washed in 
sterile pre-warmed phosphate buffer saline (PBS) to remove traces of serum. 
The PBS was then discarded and the cells were treated with 0.5 ml of trypsin-
EDTA solution per 10 cm2 plate of cells to dissociate cells in the monolayer. 8 ml 
of growth medium was then added to inactivate the trypsin-EDTA solution and 
cells were collected by centrifugation at 12,000 rpm for 3 min at room 
temperature. The supernatant was discarded and the cell pellet was 
resuspended in fresh growth media and added to fresh culture flasks at the 
required dilution. The volume of PBS, trypsin-EDTA and growth media were 
adjusted according to the size of the culture flask. When cells were harvested 
for long term storage, the cells were resuspended in 10% dimethyl sulfoxide 
(DMSO) containing 90 % FBS and stored for 3 days in -80 °C before being 
transferred in liquid nitrogen. For the freeze down, cells were placed in a 
container that reduces the temperature by 1oC/minute. 
 
N2a cell line culture: The mouse neuroblastoma cell line (N2a) were maintained 
in growth media containing Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine, 1% (v/v) 
penicillin-streptomycin and 1% (v/v) non-essential amino acid (NEAA).  
 
HEK293 cells: The human embryonic kidney 293 (HEK293) cells were maintained 
in growth media containing DMEM supplemented with 10% (v/v) fetal bovine 
serum, 1% (v/v) L-glutamine, 1% (v/v) penicillin-streptomycin.  
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2.19.1. Transfection of cells with plasmid DNA  
DNA plasmid constructs used for transfection included PDE4A5-vsv, GPR40, 
arrestin-2 in pcDNA3 vectors. For transient expression, HEK293 or N2a cells were 
plated at a density of 2 x 106 cells per 100 mm dish. Transfections were 
performed at 50–60% confluence with 5 µg of total circular plasmid DNA using 
the linear MW~25000 polyethylenimine (Polysciences Inc). For the HEK293 cells 
2µgr of PDE4A5-vsv, 2µgr of GPR40 and 1µgr of arrestin-2 were used per 100 mm 
plate. For the N2a cell line that already expresses GPR40, 2,5ugr of PDE4A5-vsv 
and 2,5µgr of arrestin-2 were used per 10 mm plate.    
 
Briefly, the plasmid DNA was incubated for 5 minutes with 250 µl of 150 mM 
sterile NaCl. In parallel, 30 µl of 1 µg/µl of polyethylenimine (PEI) was incubated 
with 250 µl of 150 mM sterile NaCl. After the 5 minutes, the two tubes 
containing the DNA complexes and the PEI were mixed together for 30 minutes 
before adding the mixture to the cells. The cell media was changed 15 minutes 
before the addition of the DNA with PEI. After 24 h transfection, the medium 
was replaced with fresh pre-warmed culture medium and was further incubated 
for 24 h prior to experiments. This assay was scaled down for smaller culture 
dishes. For microscopic FRET experiments, cells were plated out onto poly(L-
lysine)-treated glass cover slips at approximate 40 % confluence.  
 
2.19.2. In vitro fatty acid treatment 
Palmitic, oleic and myristic acid were purchased from Nu-check and were used 
in this study. The treatment of cells with the different fatty acids was done by 
reducing the serum before the actual experiment. The day before the in vitro 
experiment, cells were washed twice with pre-warmed DMEM and a medium with 
0.3% serum was added to the cells. The next day in the morning the cells were 
washed twice with pre-warmed DMEM and medium was added without any serum 
for 5 till 8 hours. A stock of 100 mM solution was made for the different fatty 
acids and prepared fresh every time. For the fatty acid treatments a stock 
solution was further diluted in pre-warmed DMEM and then it was added on cells.  
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2.20. Statistical analysis 
Data were expressed as mean value ± standard error of the mean (SEM) and an 
alpha level of 0.05 was used as marker of statistical significance. Statistical 
significances between two groups of data were determined using unpaired, two-
tailed Student’s t-test. Statistical analysis of several groups was carried out 
either by using one way analysis of variance (ANOVA) with different post-test 
comparisons against control experiments using GraphPad Prism 7 or mixed model 
analysis with fixed and random factors using R. A p-value greater than 0.05 was 
not considered significant (NS), p-value < 0.05 was labelled as (*), p-value < 0.01 
was labelled as (**), and p-value < 0.001 was labelled as (***). 
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3. Introduction 
3.1. Introduction 
Obesity is a multicomponent syndrome that results from an imbalance in energy 
homeostasis. Obesity has been linked with various other diseases, one of which is 
depression. Many different epidemiological studies have revealed an association 
between obesity and depression (Zhong et al., 2010; Leonore de Wit  and Frans 
Zitman, 2010; Boutelle et al., 2010; Stunkard et al., 2003; Simon et al., 2010; 
McElroy et al., 2004; Faith et al., 2002; Luppino et al., 2010; Palinkas et al., 
1996). On one hand, being overweight or obese is an indicator for depression 
later in life and conversely, antidepressant treatment has been linked with body 
weight gain; whether this increase is due to euphoria or a side effect of the 
treatment remains unknown. As the prevalence of obesity in our modern 
societies is increasing dramatically, any potential positive correlation with 
depression will have detrimental effects for the society. Studies in mice have 
suggested that diet-induced obesity induces depression (Sharma and Fulton, 
2013). However, the mechanisms that link obesity and depression remain 
unknown. Understanding the link between obesity and depression and whether 
one of the two can play a causative role for the development of the other is of 
clinical and social importance. 
 
3.1.1. Obesity models in rodents 
Several genetic models of obesity in rodents have been described (Robinson et 
al., 2000) with five historically naturally occurring mutations (Friedman and 
Leibel, 1992) that led to major breakthroughs in understanding the mechanism 
of obesity and metabolic syndrome. The discovery of leptin (Zhang et al., 1994), 
an adipose tissue hormone and its receptor in the brain (Chen et al., 1996; Lee 
et al., 1996) was a significant breakthrough as it highlighted the importance of 
the communication between peripheral tissues and the central nervous system 
that controls energy homeostasis (Schwartz et al., 2000). 
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High fat diets (in which 60% of the calories come from fat) are often used to 
induce obesity and metabolic disorders in rodents that are comparable to human 
metabolic syndrome (Buettner et al., 2007). Even though the genetically 
developed obese mouse models have increased our understanding of obesity, 
consumption of a high fat diet (HFD) is conceived to be a common cause of 
obesity in humans (Hill and Peters, 1998). Therefore, the animal models of HFD 
induced obesity better mimic the pathophysiological changes in overweight and 
obese individuals (Stein and Colditz, 2004; Freire et al., 2005; Moreno and 
Rodriguez, 2007). 
 
3.1.1.1. Ob/ob: the genetic mouse model of obesity 
Leptin is an adipocyte-derived hormone that was discovered in the 1950s (Ingalls 
et al., 1950) when a natural mutation occurred in a mouse strain resulting in an 
autosomal recessive morbid obesity syndrome called ob/ob or obese. Parabiosis 
experiments in these ob/ob or obese mice with normal mice produced profound 
weight loss in the obese partner, suggesting that the obese gene was encoded by 
a circulating factor (Coleman, 1973). Positional cloning of the obese gene 
identified the product as a secreted protein of 17kD later named leptin (Zhang 
et al., 1994). Leptin enters the brain via a saturable transport mechanism (Banks 
et al., 1996) and has been described as a pleiotropic hormone as it affects 
multiple physiological processes such as appetite, body weight, neuroendocrine 
function and emotional behaviours (Berthoud and Morrison, 2008; Elmquist et 
al., 2005; Friedman and Halaas, 1998; Lu, 2007; Myers et al., 2009; Licinio et 
al., 2007; Myers et al., 2008). 
 
Leptin exerts its effects by activating the leptin receptors (Lepr or db) in the 
brain (Ahima and Flier, 2000; de Luca et al., 2005). There are at least five 
different leptin receptors (designated Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re) 
which are derived via alternative splicing of the db gene (Lee et al., 1996) and 
are widely expressed in different brain regions (Burguera et al., 2000; Elmquist 
et al., 1998; Smedh et al., 1998; Mercer et al., 1998). Many studies have focused 
on Lepr-containing neurons within the subdivision of hypothalamus and 
suggested that the hypothalamic targets are essential for the regulation of the 
centrally involved action of leptin on food intake, body weight and energy 
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homeostasis  (Balthasar et al., 2004; Cowley et al., 2001; Dhillon et al., 2006) 
(Leinninger et al., 2009; Friedman and Halaas, 1998; Schwartz et al., 2000; 
Cheung et al., 1997). However, even though the effects of leptin on the 
hypothalamic centres is well described, leptin receptors are widely expressed in 
numerous extra hypothalamic regions of the brain including the hippocampus, 
cerebellum, amygdala and brain stem (Elmquist et al., 1998; Tartaglia et al., 
1995; Fei et al., 1997), where leptin’s action remain unclear. A number of 
recent studies documented the role of leptin in cognition in the hippocampus 
(Flier, 1998; Harvey et al., 2005; Shanley et al., 2001; Morrison and Berthoud, 
2007). 
 
Leptin deficiency results in the onset of obesity as early as 3 weeks of age. The 
main characteristics of the ob/ob mice are increased body weight due to 
excessive increase of adipose tissue, hyperphagia and hyperdypsia, 
hyperglycemia, hyperinsulinemia, reduced energy expenditure, dyslipidemia, 
decreased body temperature and defective thermogenesis (Bray and York, 1979; 
Campfield, 2000). Elevation of leptin levels induces an anorectic response 
(Halaas et al., 1997) and it has been shown that leptin administration reduces 
hyperphagia and obesity in leptin-deficient mice and humans (Campfield et al., 
1995; Farooqi et al., 1999; Halaas et al., 1995; Pelleymounter et al., 1995). 
 
Although obese humans and rodents usually have high circulating levels of leptin 
in proportion to their greater body fat mass (Frederich et al., 1995; Maffei et 
al., 1995), the high concentration of leptin neither reduces food intake nor 
increases energy expenditure (Schwartz et al., 1996). This paradoxical situation 
in obesity has been termed “leptin resistance” (Hamann and Matthaei, 1996) and 
is considered to be a central dogma for obesity in humans and diet-induced 
obese rodents (Myers et al., 2008). Leptin resistance has been described in both 
normal and obese animals, and this in turn results in failure to regulate energy 
expenditure and appetite (Frederich et al., 1995). Thus, the primary 
physiological role of decrease leptin concentration is to initiate a feeling of 
starvation and the molecular mechanisms regulating appetite (Ahima et al., 
1996). Due to the absence of leptin antagonists, the obese mouse model 
continues to be an invaluable tool for the study of obesity. 
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3.1.1.2. Dietary induced obesity models in rodents 
Susceptibility of diet induced obesity has been described for the different mouse 
strains used in laboratory research, with significant variability in the data from 
different experimental procedures (West et al., 1992). The C57Bl/6J mouse 
strain is the most commonly used for the study of diet induced obesity in 
rodents. High-fat diet has been shown to cause the development of obesity and 
the metabolic syndrome, characterized by hyperglycemia, hyperinsulinemia, and 
hyperleptinemia, hyperlipidemia, endothelial dysfunction and hypertension, in 
C57Bl/6J mice (Surwit et al., 1988; Kim et al., 2000; Roberts et al., 2001). The 
inbred C57Bl/6J strain has a normal weight (~25 g) on standard chow diet, but 
becomes obese (~42 g) when fed a high-fat diet for longer than 6 weeks (Surwit 
et al., 1988). The increase of glycogen synthase kinase-3 activity in adipose 
tissue observed in C57Bl/6J mice is believed to be one of the potential factors 
that contribute to susceptibility of this mouse strain to diabetes (Eldar-
Finkelman et al., 1999). The C57Bl/6J strain is a useful model for human 
diabetes, as it models the development of obesity and diabetes with high-fat 
diet that is found in humans (Stein and Colditz, 2004; Freire et al., 2005; Moreno 
and Rodriguez, 2007). 
 
3.1.2. Models of depression in rodents 
Depression is characterized by cognitive symptoms (guilt, ruminations and 
suicidality), emotional symptoms (anhedonia), homeostatic or neurovegetative 
(abnormalities in sleep and appetite, weight and energy) and psychomotor 
agitation or retardation, most of which are difficult to mimic in animal models. 
None of these characteristics has been proven sufficiently robust or consistent 
enough to be used for the diagnosis of depression in humans or validate an 
animal model (Krishnan and Nestler, 2008; Holmes, 2003; Berton et al., 2012). 
Only a subset of these characteristics such as anhedonia and psychomotor 
behaviour are relevant to human depression and can be measured in mice 
(Holmes et al., 2003; Nestler and Hyman, 2010). Therefore, the development of 
a mouse model that will fully mirror the human neuropsychiatric disorder of 
depression has proven impossible. However, some behavioural paradigms have 
been developed to assess the antidepressant effect of different drugs. 
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Stress is a predisposing risk factor for depression and a variety of experimental 
models of depression have utilized various stressors to induce depression like 
behaviours in mice (Bourin et al., 2001; McArthur and Borsini, 2006). Some of 
these tests rely on the effects of stress responses such as cognitive or 
attentional impairment and abnormalities in psychomotor activity (Cryan and 
Mombereau, 2004; Nestler et al., 2002a). Unpredictable mild stress can induce a 
depression phenotype that is reversed by chronic antidepressant administration 
(Willner et al., 1987). However, short-term and long-term corticosterone 
administration after stress results in opposite effects on depression phenotype 
(Zhao et al., 2009). Psychosocial stress plays an important role in many cases of 
human depression (Coyne and Downey, 1991; Kessler, 1997) and recently 
published studies in mice have validated chronic social defeat as an animal 
model of depression (Malatynska and Knapp, 2005; Tsankova et al., 2006). 
 
The novelty-induced hypophagia (NIH) paradigm provides a promising new model 
for investigations into the neurobiology underlying the antidepressant response 
(Dulawa and Hen, 2005). Social isolation is enough to induce a depression 
phenotype and environmental enrichment showed an antidepressive and 
anxiolytic effect in animal models of depression and anxiety (Brenes Saenz et 
al., 2006). Even though unpredictable chronic mild stress has been shown to 
induce a depression phenotype, that effect depends on the mouse strain 
(Pothion et al., 2004). 
 
The most common mouse models of depression involve a period to induce 
anxiety behaviour. The anxiety phenotype has been proven sufficient enough for 
the development of a depression phenotype. The widely used behavioural tests 
to induce depression are the forced swim (FST) (Petit-Demouliere et al., 2005; 
Porsolt et al., 1977a) and tail suspension test (TST) (Cryan et al., 2005; Cryan et 
al., 2002a; Nestler et al., 2002b). Even though they are not models of 
depression, they are rapid tests that were developed decades ago for the 
screening of antidepressant drugs. During these tests, rodents are subjected to 
an acute, short-duration (minutes) stress and the time during which they 
respond actively versus passively is measured. A major weakness of these two 
tests is that they involve short-term stress applied to rodents, which is very 
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different from human depression in which an underlying genetic vulnerability 
combines with stochastic and chronic environmental exposures to produce long-
lasting behavioural pathology. Despite this, they have proved useful in numerous 
studies for the screening of antidepressant drugs (Porsolt et al., 1977a; Cryan et 
al., 2002a). 
 
A second major class of depression-related behavioural tests involves measuring 
anhedonia, which is the loss of interest in pleasure-giving activities during day-
to-day life. The most commonly used test to evaluate anhedonia is the sucrose 
preference test (SPT), which examines a preference for a sucrose solution over 
water. Decreased sucrose preference, not resulting from a motor or sensory 
deficit, is interpreted as a demonstration of anhedonia and thus depression like 
behaviour (Nestler and Hyman, 2010). The advantage of the second class of tests 
is that they are based on actual symptoms of depression rather than on the 
different physicochemical properties of antidepressants. The anhedonia 
characteristic is also associated with human depression (Tsankova et al., 2006). 
 
3.1.3. Obesity is linked with depression 
Obesity has been linked with depression in different meta-analyses, clinical and 
epidemiological studies (Zhong et al., 2010; Wit et al., 2010; Boutelle et al., 
2010; Stunkard et al., 2003; Simon et al., 2010; McElroy et al., 2004; Faith et 
al., 2002; Luppino et al., 2010). However a major question in the field is 
whether obesity or depression can play a causative role in the development of 
the other one. On one side, studies have shown that obesity, defined as a BMI, 
could predict the development of depression (Roberts et al., 2003; Roberts et 
al., 2000). In accordance with this observation, chronically obese males have 
significantly higher rates of depression compared to non-obese males (Mustillo et 
al., 2003), and obese versus non-obese adolescent females are at increased risk 
for depression as well (Anderson et al., 2007). 
 
On the contrary, in other studies, initial high BMI was not related to the risk for 
future onset of depression (Stice and Bearman, 2001; Stice et al., 2000). Another 
study in elderly Koreans showed that obese elderly women were less likely to 
develop depression compare to their normal weight counterparts (Kim et al., 
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2010). Depression can promote the development of visceral obesity (Needham et 
al., 2010) and perturbed lipid metabolism (Rudisch and Nemeroff, 2003). In 
support of that, depression in youth positively correlates with the development 
of increased BMI during adulthood (Goodman and Huang, 2002; Pine et al., 1997; 
Pine et al., 2001; Richardson et al., 2003), suggesting a causative role of 
depression for obesity. Therefore, even though there is a link between obesity 
and depression, which of the two plays a causative role for the development of 
the other is still unknown, and understanding the molecular and cellular 
pathways that link obesity and depression is clearly of social and clinical 
importance and deserves further investigation. 
 
3.1.4. Aims 
Investigating diet as a risk factor for depression in humans is difficult because 
diet interacts with other environmental (stress) and biological (genetic) factors 
that can influence the incidence of depression in the population. The interaction 
of diet and depression is easier to study in mice, due to the more homogeneous 
environment in which they are raised/bred. Given the coprevalence of obesity 
and depression in different epidemiological studies, it was hypothesized that 
obesity (either dietary or genetic) has a mechanistic role in the development of 
a depression phenotype in mice. 
The aims of this chapter are as follows: 
1) To assess whether obesity in mice has a causative role in promoting the 
development of a depression phenotype 
2) To investigate which molecular signalling pathways are altered after HFD 
induced obesity 
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3.2. Results 
3.2.1. Dietary obesity induces a depression phenotype in 
mice 
The diet-induced obesity (DIO) model was employed to study the role of dietary 
obesity in the development of depression. Male C57Bl/6J mice were used 
throughout the study as it has been shown that male mice are more vulnerable 
than females to high fat diet-induced obesity, metabolic alterations and deficits 
in learning and synaptic plasticity (Hwang et al., 2010). Moreover, male mice 
were used throughout the study as the menstrual cycle of females can affect 
performance during behavioural assays. Mice were fed either normal diet (ND) or 
a high fat diet (HFD), where 60% of calories are fat derived, to induce obesity. 
Consumption of a 60% fat diet was used as it has already been shown that 
consumption of 60% and not 41% fat impaired the cognitive function in mice and 
was linked with brain inflammation even though both diets lead to increase body 
weight (Pistell et al., 2010). 
 
Exposure to HFD induces weight gain and metabolic syndrome, which develops 
after 6-8 weeks on HFD (Hwang et al., 2010). Table 3.1 shows the fatty acid 
composition of the HFD. 
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Table 3.1. Fatty acid composition of the HFD. Table shows the different fatty 
acid composition of the 60% diet that the mice consumed. 
HFD  
Lard 245 
Soybean oil 25 
C2, Acetic 0 
C4, Butyric 0 
C6, Caproic 0 
C8, Caprylic 0 
C10, Capric 0 
C12, Lauric 0 
C14, Myristic 2.2 
C14:1, Myristoleic 1.2 
C16, Palmitic 58.7 
C16:1, Palmitoleic 9.3 
C18, Stearic 33.5 
C18:1, Oleic 106.8 
C18:2, Linoleic 34.4 
C18:3, Linolenic 4.4 
C18:4 0 
C20, Arachidic 4.4 
C20:1 0 
C20:4, Arachidonic 4.2 
C20:5 0 
C22, Behenic 0 
C22:1, Erucic 0 
C22:4, Clupanodonic 0 
C22:5 0 
C22:6 0 
C24, Lignoceric 0 
Total (g) 254.8 
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Depression related behavioural tests were conducted to assess the development 
of behavioural phenotype. Tail suspension test (TST), forced swim test (FST) and 
sucrose preference test (SPT) were used to assess the depression phenotype in 
mice. The elevated plus maze (EPM) was used in order to assess the anxiety 
phenotype in mice. Mice were tested at 2 different time points on the HFD; 3 
weeks (a point prior to the development of the metabolic syndrome) and 8 
weeks (after which mice have started to develop the metabolic syndrome). Fig. 
3.1 is a schematic representing the experimental plan of the dietary induced 
obesity tests. 
 
Figure 3.1. Schematic of the experimental plan for the dietary induced 
obesity and series of behavioral tests. Adult 10 weeks old male mice were fed 
HFD for either 3 or 8 weeks. At the end of each time point difference 
behavioural tests were performed in a specific order; first the anxiety related 
tests and then the depression related tests. (EPM: Elevated Plus Maze, OF: Open 
Field, TST: Tail Suspension Test, FST: Forced Swim Test, SPT: Sucrose 
Preference Test, d: day, wks: weeks). 
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Surprisingly, induction of depression, as assessed by increased immobilization 
time in the TST and FST, was observed as early as 3 weeks on HFD prior to the 
development of metabolic syndrome (Fig. 3.2). Similar effects of the HFD on 
TST and FST was observed between mice fed HFD for either 3 or 8 weeks 
suggesting that the depression phenotype happens early and remains the same 
over time (Fig. 3.2).  
 
 
Figure 3.2. Dietary obesity induces a depression behaviour in mice. A) Tail 
suspension and B) forced swim test for WT mice that have been 3 and 8 weeks 
on ND, 3 and 8 weeks on HFD (n=10, *P < 0.05, **P < 0.01 by Linear mixed model 
fit by REML, Formula : immobilization ~ diet * time + (1 | ID). No interaction 
detected between diet and time and there was no effect of time on the 
immobilization time. Diet has an effect on the immobilization time). This work 
was carried out with Dr Jae Kyu Ryu.  
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HFD consumption was accompanied with less sucrose solution consumption 
compared to WT aged-matched controls on ND suggesting the occurrence of 
anhedonia and thus depression like behaviour (Fig. 3.3). 
 
Figure 3.3. Dietary obesity induces a depression behaviour in mice. Sucrose 
preference test for WT mice on 3 and 8 weeks on HFD and their control aged 
matched mice on ND (n=5-8, **P < 0.01 by Linear mixed model fit by REML, 
Formula : sucrose ~ diet + (1 | time). Diet has an effect on the sucrose 
consumption). 
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As expected, WT mice on HFD gained significantly more weight compared to 
their aged matched control mice on ND as early as the first week on HFD (Fig. 
3.4).  
 
 
Figure 3.4. Body weight curves of WT mice on either ND or HFD. Comparison 
of the increase in the body weight of WT mice on HFD for 10 weeks and their 
litter mate mice on ND (n=10, **P < 0.01 by Linear mixed model fit by REML, 
Formula: weight ~ time + diet + time:diet + weight0 + (1 | id). An interaction 
was detected between diet and time (***P<0.001). Time (***P<0.001) and diet 
(**P<0.01) have an effect on the body weight. The body weight at time zero was 
used as a covariate and had no effect of the body weight gain).  
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Therefore, due to the body weight gain it is difficult to determine whether 
dietary obesity alone is a depression promoter. Interestingly, correlation graphs 
between immobilization time (TST and FST) and body weight showed that the 
performance of these mice was not affected by the increase in body weight 
either on ND or 3 weeks on HFD (Fig. 3.5). For that experimental design the 
mice were weighted just before they undergo the TST and FST, however a body 
weight change should also be plotted in relation to performance in the 
behavioural assays. 
 
 
 
Figure 3.5. Correlation graphs between immobilization time and body weight. 
Correlation graphs between body weight and performance at the tail suspension 
and forced swim test for WT mice on either ND or 3 weeks on HFD (n=25-29). 
Analysis for carried out with Dr Jae Kyu Ryu. 
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Due to the observed depression effect of the HFD consumption, an earlier time 
point was tested in order to investigate the role of diet in depression after 1 
week on the diet. Interestingly, a pilot study on mice just 1 week into a HFD 
regime showed similar depression phenotype compared to WT mice on ND (Fig. 
3.6). 
 
Figure 3.6. High fat diet induces a depression phenotype in mice. Tail 
suspension test for WT mice on ND and 1 week on HFD (n=9, *P < 0.05 by 
unpaired 2 tail unpaired student’s t-test). 
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3.2.2. Genetic obesity induces a depression phenotype in 
mice 
To confirm these results in a genetic model of obesity, we examined whether 
genetic obesity also induces a depression phenotype. The leptin-deficiency 
mouse (Lepob or ob/ob) was used as a model of genetically induced obesity 
(GIO). The leptin-deficiency mouse has been shown to spontaneously develop 
obesity even when kept on normal diet. Fig. 3.7 shows a schematic for the 
experimental plan for the GIO experiments. 
 
 
 
Figure 3.7. Schematic of the experimental plan for the genetic obesity and 
series of behavioural tests. Adult 8 weeks old ob/ob male mice on ND were 
tested on different behavioural tests in a specific order; first the anxiety related 
tests and then the depression related tests. (EPM: Elevated Plus Maze, OF: Open 
Field, TST: Tail Suspension Test, FST: Forced Swim Test, SPT: Sucrose 
Preference Test, d:day, wks:weeks). 
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8 week old ob/ob mice exhibited an increase in immobilization time in TST and 
FST compared to WT aged-matched mice on ND (Fig. 3.8). 
 
Figure 3.8. Genetic obesity induces a depression behaviour in mice.  
Tail suspension and forced swim test for WT and ob/ob mice on ND (n=8-10, *P < 
0.05, ***P < 0.0001 by unpaired 2 tail student’s t-test). This work was carried out 
with Dr Jae Kyu Ryu 
 
The immobilization values for the 8 week old ob/ob mice on ND were very 
similar to the WT mice that were for 3 weeks on HFD (Fig. 3.2). As expected 
ob/ob mice gained significant more weight even from the third week of life on 
ND compare to WT mice on ND (Fig. 3.9). 
Figure 3.9. Body weight 
curves of WT and ob/ob 
mice. Comparison of the 
increase in the body weight 
of the ob/ob mice compare 
to WT aged matched 
controls (n=6-11, ***P < 
0.001 by Linear mixed 
model fit by REML, 
Formula: weight ~ time + 
genotype + time:genotype 
+ weight0 + (1 | id). An 
interaction was detected 
between genotype and 
time (***P<0.001). 
Genotype (***P<0.001) and time (***P<0.001) have an effect on the body weight. 
The body weight at 3 weeks of age was used as a covariate and had no effect on 
the body weight gain). 
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3.2.3. Dietary obesity does not interfere with the 
locomotor or rearing activity of mice 
The TST and FST tests used in this study to assess depression are based on the 
motor performance of mice. However, consumption of the HFD and the 
subsequent increase in the body weight might affect the performance of mice to 
these tests and contribute to the depression phenotype. Therefore, the total 
locomotor activity of all mice, ND, HFD, ob/ob and WT, was tested at the open 
field test. Neither short nor longer HFD consumption affected locomotor or 
rearing activity of mice in the open field test (Fig.3.10). There was no 
significant difference in the total activity, time spent in the central area and 
rearing activity between ND and the two different time points (3 and 8 weeks) 
on the HFD. Rearing activity, which represents the exploratory activity of mice, 
was also not altered after HFD. This suggests that the development of the 
depression phenotype happened independently of any locomotor activity 
impairment. 
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3.2.4. Genetic obesity induces a reduction in the 
locomotor and rearing activity of mice 
Genetically obese mice, ob/ob showed a reduction in the total locomotor and 
rearing activity in the open field test compare to WT aged matched control mice 
(Fig.3.10). This mouse model of obesity has impaired total levels of activity as 
well as high anxiety levels indicated by the little time it spends in the central 
area. The exploratory activity of this mouse is also impaired as is shown by the 
total rearing activity measured by the open field test (Fig.3.10). 
 
Figure 3.10. Genetic but not dietary obesity affects the locomotor activity. 
Open field test for WT mice on either ND or 3 and 8 weeks on HFD as well as 
ob/ob mice on ND. Measurements for total activity in the entire or central area 
as well as rearing (n=7-10 **P<0.01, ****P<0.0001, 1-WAY ANOVA with Tukey’s 
multiple comparison test). 
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3.2.5. Gene expression changes induced by HFD 
consumption 
To investigate which specific molecular pathways in the brain are affected by a 
high-fat diet, comparative genome-wide microarray analysis was performed on 
samples from the hypothalamus of WT mice fed ND versus either 4 or 8 weeks on 
a HFD. The analysis was done on the hypothalamic region of the brain as it is 
known for its dual role in obesity and depression. Analysis of microarray data 
revealed that there were no significant gene expression differences between ND 
and 4 weeks on HFD. Interestingly, 8 weeks on high fat diet resulted in 
statistically highly significant changes in a number of genes. Table3.2 shows all 
the significant gene expression changes between ND and 8 weeks on HFD as well 
as the values for these genes on 4 weeks on HFD. These are only the genes that 
have an average of log2 intensity greater than 3.0 and an FDR (False Discovery 
Rate) value lower than 0.05. Even though many genes had a log2 intensity 
greater than 3.0 the FDR value was not significant. The values for the WT mice 
on ND, 4 weeks and 8 weeks on HFD at the Table3.2 are the average values for 
three samples per group. These values are the array values which are shown as 
log2 values after normalization. 
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Table3.2. Gene expression changes in the hypothalamus of mice fed ND versus HFD. Table shows all the significant gene expression 
changes between ND and 8 weeks on HFD according to the FDR value as well as the values for these genes on 4 weeks on HFD. Each 
condition was done with 3 mice per group and average values are presented on the table. 
 
Gene Name Description Entrez WT ND 
WT 4wks 
HFD 
WT 8wks 
HFD 
Week8 / 
CTRL 
log2(Week8 
/ CTRL) 
FDR Week8 
vs. CTRL 
Ptpn4 
protein tyrosine 
phosphatase, non-
receptor type 4 19258 8.6588 8.9779 7.5775 0.47 -1.08 0.004 
Serpina3n 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 3N 20716 7.756 8.3121 9.0156 2.39 1.26 0.004 
Nelf 
nasal embryonic LHRH 
factor 56876 9.5734 9.8305 8.9099 0.63 -0.66 0.005 
Ptpn3 
protein tyrosine 
phosphatase, non-
receptor type 3 545622 8.4268 8.8052 6.3356 0.24 -2.09 0.005 
Adcy1 adenylate cyclase 1 432530 7.089 7.3184 6.407 0.62 -0.68 0.005 
Lef1 
lymphoid enhancer 
binding factor 1 16842 7.4231 7.8971 6.0589 0.39 -1.36 0.010 
AI593442 
expressed sequence 
AI593442 330941 8.7486 8.9857 7.9638 0.58 -0.78 0.010 
Igfbp7 
insulin-like growth 
factor binding protein 7 29817 7.7371 7.5418 7.0089 0.60 -0.73 0.010 
Cdkl5 cyclin-dependent 382253 8.2159 8.523 7.4087 0.57 -0.81 0.010 
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kinase-like 5 
Cck cholecystokinin 12424 9.4815 9.623 8.1549 0.40 -1.33 0.010 
Rgs7bp 
regulator of G-protein 
signalling 7 binding 
protein 52882 8.6818 8.95 7.8401 0.56 -0.84 0.010 
Trpc3 
transient receptor 
potential cation 
channel. subfamily C, 
member 3 22065 6.2588 6.6164 5.4719 0.58 -0.79 0.011 
Ptpn3 
protein tyrosine 
phosphatase, non-
receptor type 3 545622 8.0911 8.3779 6.3379 0.30 -1.75 0.013 
Ramp3 
receptor (calcitonin) 
activity modifying 
protein 3 56089 8.0233 8.4527 5.8753 0.23 -2.15 0.019 
Ptpn3 
protein tyrosine 
phosphatase, non-
receptor type 3 545622 8.527 8.8681 6.8168 0.31 -1.71 0.019 
Rgs4 
regulator of G-protein 
signaling 4 19736 8.6249 8.5373 7.9138 0.61 -0.71 0.019 
Ptk2b 
PTK2 protein tyrosine 
kinase 2 beta 19229 7.2338 7.5149 6.5248 0.61 -0.71 0.019 
Prkcd protein kinase C, delta 18753 8.976 9.3264 6.3982 0.17 -2.58 0.019 
Rasgrp1 
RAS guanyl releasing 
protein 1 19419 8.8456 9.163 7.7963 0.48 -1.05 0.019 
Plekhg1 
pleckstrin homology 
domain containing, 
family G (with RhoGef 213783 7.9025 8.5069 6.3751 0.35 -1.53 0.019 
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domain) member 1 
Zdhhc22 
zinc finger, DHHC-type 
containing 22 238331 8.8671 9.0805 8.0556 0.57 -0.81 0.019 
Abhd12b 
abhydrolase domain 
containing 12B 328121 7.7577 8.09 4.6214 0.11 -3.14 0.019 
Synpo2 synaptopodin 2 118449 6.792 7.1189 5.7511 0.49 -1.04 0.019 
Ptpn3 
protein tyrosine 
phosphatase, non-
receptor type 3 545622 7.6968 7.9104 5.7734 0.26 -1.92 0.021 
Car4 carbonic anhydrase 4 12351 7.1491 7.025 6.6387 0.70 -0.51 0.021 
Stk33 
serine/threonine kinase 
33 117229 4.8965 4.8033 5.428 1.45 0.53 0.021 
Hap1 
huntingtin-associated 
protein 1 15114 9.1772 9.0994 9.6798 1.42 0.50 0.022 
Rgs16 
regulator of G-protein 
signaling 16 19734 8.791 9.0575 8.0812 0.61 -0.71 0.023 
Gabra4 
gamma-aminobutyric 
acid (GABA) A receptor, 
subunit alpha 4 14397 8.0564 8.5591 6.957 0.47 -1.10 0.023 
Ntng1 netrin G1 80883 8.9767 9.3502 7.5874 0.38 -1.39 0.023 
Hlf hepatic leukemia factor 217082 8.6562 8.9279 8.009 0.64 -0.65 0.026 
Foxp1 forkhead box P1 108655 7.0444 7.1628 6.4746 0.67 -0.57 0.027 
Fam101b 
family with sequence 
similarity 101, member 
B 76566 7.1983 7.2856 6.5417 0.63 -0.66 0.028 
Trnp1 
TMF1-regulated nuclear 
protein 1 69539 8.2172 8.4099 7.8161 0.76 -0.40 0.028 
Etv1 /// Gm5454 ets variant gene 1 /// 14009 7.7723 8.1306 6.8583 0.53 -0.91 0.028 
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predicted gene 5454 /// 
432800 
Ntng1 netrin G1 80883 7.1457 7.5266 6.3886 0.59 -0.76 0.028 
Kcnc2 
potassium voltage 
gated channel, Shaw-
related subfamily, 
member 2 268345 8.3124 8.623 7.5113 0.57 -0.80 0.028 
Mgst3 
microsomal glutathione 
S-transferase 3 66447 9.4959 9.5819 8.7149 0.58 -0.78 0.028 
Dbil5 
diazepam binding 
inhibitor-like 5 13168 4.8211 4.521 4.146 0.63 -0.68 0.028 
Susd4 
sushi domain containing 
4 96935 8.0456 8.3489 8.4758 1.35 0.43 0.028 
Gm10786 predicted gene 10786 1E+08 9.427 9.5418 8.6817 0.60 -0.75 0.028 
Myl2 
myosin, light 
polypeptide 2, 
regulatory, cardiac, 
slow 17906 6.2798 6.2752 5.1847 0.47 -1.10 0.028 
Shox2 
short stature homeobox 
2 20429 5.6504 6.2998 4.6174 0.49 -1.03 0.029 
Ttr transthyretin 22139 12.007 9.2359 8.616 0.10 -3.39 0.029 
Vat1l 
vesicle amine transport 
protein 1 homolog-like 
(T. californica) 270097 8.6031 8.6187 9.0326 1.35 0.43 0.029 
Pnmal2 PNMA-like 2 434128 8.8656 8.9158 9.4061 1.45 0.54 0.031 
Tcf7l2 
transcription factor 7-
like 2, T-cell specific, 
HMG-box 21416 10.011 10.411 8.5769 0.37 -1.43 0.031 
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Ptpn3 
protein tyrosine 
phosphatase, non-
receptor type 3 545622 8.272 8.5649 5.9073 0.19 -2.36 0.031 
Hspa5 heat shock protein 5 14828 8.9652 9.1028 9.4294 1.38 0.46 0.031 
2310046A06Rik 
RIKEN cDNA 2310046A06 
gene 69642 6.0726 6.3235 5.4609 0.65 -0.61 0.031 
Mt2 metallothionein 2 17750 11.437 11.064 10.796 0.64 -0.64 0.031 
Pnck 
pregnancy upregulated 
non-ubiquitously 
expressed CaM kinase 93843 8.4132 8.3811 8.8309 1.34 0.42 0.032 
Nrip3 
nuclear receptor 
interacting protein 3 78593 8.7044 8.8799 8.0572 0.64 -0.65 0.035 
BC030046 
cDNA sequence 
BC030046 277154 6.3352 6.4508 7.3149 1.97 0.98 0.035 
Sh3d19 SH3 domain protein D19 27059 7.1008 7.1171 6.3024 0.58 -0.80 0.035 
ENSMUST00000093902 --- --- 4.8978 5.2884 5.4895 1.51 0.59 0.042 
Necab1 
N-terminal EF-hand 
calcium binding protein 
1 69352 9.3311 9.8131 8.4198 0.53 -0.91 0.044 
Btg2 
B-cell translocation 
gene 2, anti-
proliferative 12227 7.2628 6.6239 6.818 0.74 -0.44 0.044 
Gabrb2 
gamma-aminobutyric 
acid (GABA) A receptor, 
subunit beta 2 14401 10.938 10.91 10.315 0.65 -0.62 0.044 
Nudt10 
nudix (nucleoside 
diphosphate linked 
moiety X)-type motif 10 102954 7.0902 7.4043 7.5891 1.41 0.50 0.045 
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Nexn nexilin 68810 6.9699 7.1364 5.7508 0.43 -1.22 0.047 
Olfr1121 olfactory receptor 1121 258345 2.6072 2.7304 3.2546 1.57 0.65 0.047 
Pdp1 
pyruvate dehyrogenase 
phosphatase catalytic 
subunit 1 381511 9.6512 9.9996 8.7585 0.54 -0.89 0.047 
Slc17a7 
solute carrier family 17 
(sodium-dependent 
inorganic phosphate 
cotransporter), member 
7 72961 6.662 7.0026 5.9552 0.61 -0.71 0.047 
Sprn shadow of prion protein 212518 6.8486 6.9544 6.3923 0.73 -0.46 0.047 
Creg1 /// Pappa2 
cellular repressor of 
E1A-stimulated genes 1 
/// pappalysin 2 
433375 
/// 
23850 7.8029 7.9623 7.2882 0.70 -0.51 0.049 
Mt1 metallothionein 1 17748 11.321 11.05 10.952 0.77 -0.37 0.049 
Pcp4l1 
Purkinje cell protein 4-
like 1 66425 8.9504 9.0574 8.3238 0.65 -0.63 0.050 
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A biocomputational approach was employed to aggregate genes which were up- 
or down-regulated in functional categories. The pathway analysis was performed 
using the QIAGEN’s Ingenuity® iReport (QIAGEN Redwood City, 
www.qiagen.com/ingenuity). Fig.3.11 shows a heatmap of all the significant 
gene expression changes between ND and 8 weeks on HFD as well as the values 
for the 4 weeks on HFD and the top upregulated and downregulated genes after 
8 weeks on HFD. Heatmap was constructed using the array values which are the 
log2 values after normalization. Each condition was done with 3 samples. 
 
 
 
 
 
 
 
 
 
Figure 3.11. HFD induces gene expression changes in the hypothalamus. 
Affymetrix global gene–expression analysis of hypothalamic samples on ND, 4 
weeks and 8 weeks on HFD. Heat maps of the 68 genes with at least false DR less 
than 0.05 between ND and 8 weeks on HFD. The color range indicates the array 
values represented as log2 after normalization. On the right are the top 
upregulated and downregulated genes that are affected by HFD. 
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Table 3.3 summarizes the 5 main canonical pathways and their p-values that 
were affected after exposure to HFD. Interestingly the most affected pathway 
from consumption of HFD in the hypothalamus was the protein kinase A (PKA) 
signalling pathway (Table 3.2). 
 
Table 3.3. Top 5 main canonical pathways affected by HFD. The table 
summarizes the main canonical pathways and their p-values that were 
affected after exposure to HFD. 
p-value Top canonical pathways 
 
       0,000040   Protein Kinase A signalling 
       0,000263   Factors Promoting Cardiogenesis in Vertebrates 
       0,001820   Gaq signalling 
       0,002000   G-Protein Coupled Receptor signalling 
       0,005070   Cholecystokinin/Gastrin-mediated signalling 
 
Fig.3.12 shows the main molecules at the PKA signalling pathway that were 
downregulated after the consumption of 8 weeks on HFD. The main molecules 
affected in the G protein coupled receptor and the GABA receptor signalling as 
also shown. Heatmap was constructing using the array values which are the log2 
values after normalization. 
Figure 3.12. 
HFD 
suppresses 
the PKA 
signalling in 
hypothalamus
. Affymetrix 
global gene–
expression 
analysis of 
hypothalamic 
samples of WT 
mice on either 
ND or 3 and 8 
weeks on HFD. 
Heat maps of 
the genes 
affected from 
HFD and regulate 3 main signaling pathways. The color range indicates the array 
values in the log2 scale after normalization. 
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Table 3.4. contains information about the main pathways that were affected by HFD with the relative genes and information about 
these genes. Fold change, p-value and false discovery rate analysis was done using the Ingenuity IPA software. In addition to PKA 
signalling, other pathways were also suppressed such as G-protein-coupled receptor or GABA receptor signalling involved in neuronal 
functions (Fig.3.12 and Table 3.4). 
  Symbol Entrez Gene Name Fold Change p-value False Discovery 
Rate (q-value) 
Location Type(s) 
 
 
 
 
 
 
 
 
PKA 
ADCY1 adenylate cyclase 1 (brain) -1.605 9.77E-07 5.09E-03 Plasma 
Membrane 
enzyme 
LEF1 lymphoid enhancer-binding 
factor 1 
-2.577 2.72E-06 9.62E-03 Nucleus transcription 
regulator 
MYL2 
 
myosin, light chain 2, 
regulatory, cardiac, slow 
-2.137 4.51E-05 2.80E-02 Cytoplasm other 
PRKCD 
 
protein kinase C, delta -5.952 1.30E-05 1.89E-02 Cytoplasm kinase 
PTK2B protein tyrosine kinase 2 
beta 
-1.634 1.29E-05 1.89E-02 Cytoplasm kinase 
PTPN3 protein tyrosine 
phosphatase, non-receptor 
type 3 
-5.155 5.65E-05 3.07E-02 Cytoplasm phosphatase 
PTPN4 protein tyrosine 
phosphatase, non-receptor 
type 4 (megakaryocyte) 
-2.114 1.88E-07 4.25E-03 Cytoplasm phosphatase 
TCF7L2 transcription factor 7-like 
2 (T-cell specific, HMG-
box) 
-2.703 5.60E-05 3.07E-02 Nucleus transcription 
regulator 
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Gaq 
signaling 
PRKCD protein kinase C, delta -5.952 1.30E-05 1.89E-02 Cytoplasm kinase 
PTK2B protein tyrosine kinase 2 
beta 
-1.634 1.29E-05 1.89E-02 Cytoplasm kinase 
RGS4 regulator of G-protein 
signaling 4 
-1.637 1.26E-05 1.89E-02 Cytoplasm other 
RGS16 regulator of G-protein 
signaling 16 
-1.637 2.49E-05 2.27E-02 Cytoplasm other 
 
 
 
G protein 
coupled 
receptor 
ADCY1 adenylate cyclase 1 (brain) -1.605 9.77E-07 5.09E-03 Plasma 
Membrane 
enzyme 
PTK2B protein tyrosine kinase 2 
beta 
-1.634 1.29E-05 1.89E-02 Cytoplasm kinase 
RASGRP1 RAS guanyl releasing 
protein 1 (calcium and 
DAG-regulated) 
-2.070 1.54E-05 1.89E-02 Cytoplasm other 
RGS4 regulator of G-protein 
signaling 4 
-1.637 1.26E-05 1.89E-02 Cytoplasm other 
RGS16 regulator of G-protein 
signaling 16 
-1.637 2.49E-05 2.27E-02 Cytoplasm other 
 
 
factor 
promoting 
angiogene
sis in 
vertebrat
es 
LEF1 lymphoid enhancer-binding 
factor 1 
-2.577 2.72E-06 9.62E-03 Nucleus transcription 
regulator 
MYL2 Myosin, light chain 2, 
regulatory, cardiac, slow 
-2.137 4.51E-05 2.80E-02 Cytoplasm other 
PRKCD protein kinase C, delta -5.952 1.30E-05 1.89E-02 Cytoplasm kinase 
TCF7L2 transcription factor 7-like 
2 (T-cell specific, HMG-
box) 
-2.703 5.60E-05 3.07E-02 Nucleus transcription 
regulator 
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Epithelial 
adherens 
junction 
signaling 
LEF1 lymphoid enhancer-binding 
factor 1 
-2.577 2.72E-06 9.62E-03 Nucleus transcription 
regulator 
MYL2 myosin, light chain 2, 
regulatory, cardiac, slow 
-2.137 4.51E-05 2.80E-02 Cytoplasm other 
TCF7L2 transcription factor 7-like 
2 (T-cell specific, HMG-
box) 
-2.703 5.60E-05 3.07E-02 Nucleus transcription 
regulator 
GABA 
receptor 
signaling 
GABRA4 gamma-aminobutyric acid 
(GABA) A receptor, alpha 4 
-2.141 2.59E-05 2.27E-02 Plasma 
Membrane 
ion channel 
GABRB2 gamma-aminobutyric acid 
(GABA) A receptor, beta 2 
-1.541 9.95E-05 4.40E-02 Plasma 
Membrane 
ion channel 
Chapter 3  Obesity Induces Depression 
     
EIRINI VAGENA 135 
 
 
Probing the hypothalamic protein samples of mice with a phospho-PKA substrate 
antibody that recognizes sites on proteins containing classical phosphorylated 
PKA sites (sequence RRXS, where S is phosphorylated) revealed a decrease of the 
total p-PKA immunoreactivity after HFD consumption compare to ND (Fig.3.13). 
 
Figure 3.13. High fat diet downregulates the total p-PKA levels in the 
hypothalamus. Western blot analysis using the phospho-PKA substrate that 
recognizes RRXS*/T* from mice fed ND versus 3 weeks on HFD. GAPDH was used 
as a loading control (n=4, ****P < 0.0001 by 2 tail unpaired student’s t-test). 
 
A major regulator of the PKA signalling is the ubiquitous second messenger 
cAMP. Because of the role of the cAMP signalling in depression (Nestler et al., 
2002a) (Shelton, 2007) (Krishnan and Nestler, 2008) we assessed the effects of 
high fat diet on cAMP levels. cAMP measurements of hypothalamic samples 
derived from mice revealed a significant downregulation of cAMP levels after 
HFD consumption compared to ND (Fig.3.14). 
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Figure 3.14. High fat diet downreglates the cAMP levels in the hypothalamus. 
cAMP measurements of hypothalamic samples of WT mice either on ND or 4 
weeks on HFD (n=9-10, *P < 0.05 by 2 tail unpaired student’s t-test). One mouse 
from the ND group was excluded as it was a significant outlier according to the 
extreme studentized deviate or Grubb’s test. 
 
3.3. Discussion 
Despite the high comorbidity between obesity and depression shown in different 
epidemiological studies (Zhong et al., 2010; Leonore de Wit  and Frans Zitman, 
2010; Kerri N Boutelle, 2010; Boutelle et al., 2010), it has been difficult to 
determine which of the two plays a causative role for the development of the 
other due to the mixed results from the various studies. Moreover, little is 
known about the exact molecular pathways that link obesity with depression. 
Thus, with these gaps in our understanding we investigated whether obesity, 
either dietary or genetic, plays a causative role in the development of 
depression and which cellular signalling cascade underpins this phenomenon. 
Therefore, we specifically evaluated the role of diet in depression using male 
C57Bl/6J mice consuming HFD (diet-induced obesity) and the ob/ob mice 
(genetic obesity). Moreover, mRNA array analysis was performed to shed light on 
the molecular pathways that are influenced in the hypothalamus which is a 
major brain region involved in both obesity and depression after the 
consumption of a HFD. 
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3.3.1. Dietary or genetic obesity is sufficient to induce a 
depression phenotype in mice 
The work in this study was done in vivo using WT mice that were fed either ND 
or HFD as well as ob/ob mice on ND. Using behavioural paradigms, we 
demonstrated that dietary or genetic obesity induces a depression phenotype in 
mice. 
 
Therefore, the clinical data from the different patient studies (Zhong et al., 
2010; Leonore de Wit  and Frans Zitman, 2010; Boutelle et al., 2010; Stunkard et 
al., 2003; Simon et al., 2010; McElroy et al., 2004; Faith et al., 2002; Luppino et 
al., 2010) are in accordance with our current findings and strongly support a 
causative role of the western dietary habits and obesity with depression. 
 
Interestingly, depression occurs independently of increases in body weight (Fig. 
3.5). This observation is in agreement with epidemiological studies where 
normal weight people also develop depression (Kim et al., 2010). It has also 
been noticed that the relationship between immobility at the different 
behavioural tests and body weight in mice is not straight forward and cannot be 
taken as a priori fact (Collin et al., 2000). Moreover, preliminary experiments 
have shown no relationship between body weight and immobility at the 
depression related tests in mice (Collin et al., 2000). In agreement with that, 
high fat diet consumption was accompanied with a depression phenotype and 
altered serum lipids in cynomolgus monkeys with a surprisingly negative 
correlation between body weight gain, BMI and depression (Chilton et al., 2011). 
At the same study they also observed that only a subgroup of the monkeys 
develop a depression phenotype which means that western diet can increase 
depressive behaviour among a subgroup of susceptible individuals (Chilton et al., 
2011). Moreover, several studies in humans found that BMI accompanied with 
impaired quality of life was positively associated with symptoms of depression 
(Dixon et al., 2003; Doll et al., 2000; Kolotkin et al., 2002). However when the 
impairments in health related quality of life were included in multivariate 
models there was no correlation between BMI and depression (Fabricatore et al., 
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2005) further supporting the negative correlation between body weight and 
depression phenotype. 
 
In the past, the role of HFD in mood disorders has been conflicting. In our study 
HFD has been shown to play a causative role in the development of a depression 
phenotype via signalling in the hypothalamus. However, HFD has been described 
to improve the depression behavioural profile and stress responses in male rats 
exposed to early life stress and this effect is mediated via the hippocampus 
(Maniam and Morris, 2010b; Prasad and Prasad, 1996). However Maniam et al 
used a diet comprising 32% originating from fat, as opposed to our study where 
60% was deployed, which could also explain the opposing behavioural 
alterations. Therefore, different % of HFD might have a differential effect on 
different signalling pathways in different brain regions. 
 
A caveat of this study is that the HFD used here consisted of 60% calories from 
fat content. This resulted in a 20% reduction of the carbohydrate content 
compared to the ND (Table 3.5). Interestingly, it has been shown that the effect 
of different fatty acids in the brain is dependent on the extracellular glucose 
levels in the hypothalamus suggesting an interaction between glucose and fatty 
acids (Wang et al., 2006). The apparent detrimental effect of HFD in depression 
phenotype in our study could therefore also be caused by the reduction of the 
carbohydrate in addition to the high fat content. Further studies are needed to 
investigate whether this could be the case. 
 
Table 3.5. Percentage of main components of ND and HFD. Table 
summarizes the percentages of the fat, carbohydrates and protein that 
either the normal and high fat diet consists of. 
  
Normal Diet High Fat Diet 
Fat 13.2% 60% 
Carbohydrates 62.1% 20% 
Protein 24.7% 20% 
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3.3.2. Dietary obesity induces a depression phenotype in 
mice 
In this study mice were placed on a HFD for either chronic or short consumption 
and that was sufficient to induce a depression phenotype (Fig. 3.2). This 
observation is in agreement with a previous study shown that long time 
consumption of a HFD (16 weeks) induces a depression phenotype to mice 
compared to a normal diet (Yamada et al., 2011). However, here we show that 
just 3 weeks on a HFD was sufficient to induce a depression phenotype in vivo 
(Fig. 3.2). Moreover Yamada et al used mice between 12-14 weeks old but we 
used 8 weeks old mice. They further showed that substitution of the HFD with 
ND after the 16 week of HFD consumption ameliorated the depression phenotype 
in mice (Yamada et al., 2011). Whether the substitution of the HFD with ND in 
our study would reverse the depression phenotype remains to be determined. 
Moreover, in a recent study diet-induced obesity promotes depressive phenotype 
in mice and it was suggested to be associated with neural adaptations in brain 
reward circuitry (Sharma and Fulton, 2013). 
 
The FSL rat which is an inbred genetic model of depression has been shown to 
exhibit exacerbation of their depression phenotype after consumption of a HFD 
even though their counterparts were consuming higher caloric intake (Abildgaard 
et al., 2011). Since FSL is an inbred genetic model of depression, these findings 
strongly support an interaction between genetic and environmental factors, 
apparently rendering the depressive rat more easily influenced by dietary 
macronutrient composition. This is in agreement with epidemiological studies 
that there is genetic predisposition in the development of depression. However, 
what has not been shown before was whether a high fat diet can provoke 
depression-like behaviour. This study revealed for the first time that early 
consumption of the HFD can be a causative factor for the development of 
depression. 
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3.3.3. Genetic obesity induces a depression phenotype 
The leptin deficiency ob/ob mouse in this study exhibit a depression phenotype 
(Fig. 3.8) which is in agreement with previous studies (Collin et al., 2000; 
Yamada et al., 2011). Leptin overexpression as well as leptin administration has 
been shown to have an antidepressant effect in mice (Yamada et al., 2011;  Liu 
et al., 2010) suggesting that depression associated with obesity is partially due 
to impaired leptin action in the brain (Yamada et al., 2011). However, these 
studies have focused on the antidepressant role of leptin in the hippocampus 
(Yamada et al., 2011; Lu et al., 2006) as hippocampus is known for its role in 
depression (Sahay and Hen, 2007). Interestingly, selective deletion of the leptin 
receptor in the dopamine neurons did not induce any depression related 
behaviours in mice (Liu et al., 2011) suggesting that dopamine neurons are not 
implicated in the role of leptin in depression. 
 
Leptin has been shown to affect cognition and mood in the cerebral cortex and 
hypothalamus (Harvey, 2007) however the neuronal populations as well as the 
neuronal circuits that mediate mood and are associated with the limbic 
functions of leptin remain to be clarified. 
 
Another interesting point is that recent studies have demonstrated that 
consumption of dietary fats promotes hypothalamic resistance to the main 
anorexigenic hormones, leptin and insulin, leading to the progressive loss of 
balance between food intake and thermogenesis and therefore resulting in body 
mass gain (Milanski et al., 2009; De Souza et al., 2005; Munzberg et al., 2004). 
Moreover, leptin administration for the dietary induced obese mice did not 
induce any antidepressant effect (Yamada et al., 2011) suggesting the existence 
of another pathway different than leptin. Measurements of the anorexigenic and 
orexigenic hormones will be necessary to pinpoint their role in this obesity 
induced depression model. 
 
Depression is characterized by an abnormality in the serotonergic system (Mann 
et al., 1996). Leptin deficient ob/ob mice have been shown to have decreased 5-
HT transporter mRNA in the neurons of the dorsal raphe nucleus compare to WT 
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mice suggesting to play a role for the depression phenotype that they exhibit 
(Collin et al., 2000). 
 
3.3.4. The development of the depression phenotype by 
HFD is independent of anxiety behaviour 
The development of the depression phenotype due to the consumption of the 
HFD was not caused by the onset of anxiety as shown by the open field test data 
(Fig.3.10). However, in this study it was shown that the ob/ob mice exhibit an 
anxiety phenotype at the open field test compared to the WT mice (Fig.3.10). 
This is in agreement with previous literature as it has been shown that ob/ob 
mice exhibit increased anxiety (Finger et al., 2010) which was ameliorated when 
the ob/ob mice were treated with leptin (Asakawa et al., 2003). In accordance, 
it has been shown that acute administration of leptin leads to an anxiolytic 
effect (Liu et al., 2010). 
 
3.3.5. PKA signalling in the hypothalamus was affected 
after dietary induced obesity 
Protein phosphorylation by protein kinases and the dephosphorylation by protein 
phosphatases represent one of the major mechanisms of signal integration in 
eukaryotic cells. A kinase with a major role in cell signalling transduction is the 
protein kinase A (PKA). PKA is a tetrameric enzyme containing both regulatory 
and catalytic subunits (Gibson et al., 1997; Walsh et al., 1968). cAMP is bound by 
the regulatory subunits and this in turn, promotes dissociation of the active 
monomeric catalytic subunits, which are then free to phosphorylate other 
protein targets. PKA carries out its function by binding to its substrate and 
transferring one γ-phosphate group from ATP to its protein substrate. PKA 
activity is specific to the phosphorylation of serine/threonine residues located 
within an RxxS/T motif (Taylor et al., 2004; Daniel et al., 1998).  PKA mediated 
phosphorylation of key signalling proteins represent a highly efficient kinetic 
amplification mechanism in neurons for the regulation of diverse pathways. 
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The mRNA array data in this study revealed the important role of the PKA 
signalling in the hypothalamus after the consumption of a HFD (Fig.3.12). The 
finding that HFD downregulates the cAMP/PKA signalling cascade in the 
hypothalamus is of particular significance. Depression is in many ways a 
“pleiotropic” disorder that involves disturbances in mood, sleep, appetitive, 
immune and many other functions. PKA signalling exerts “pleiotropic” actions by 
means of phosphorylation of a variety of receptors, enzymes and transcription 
factors, proteins that are involved in neurotransmitter synthesis, regulation of 
G-protein coupled neurotransmitter receptors, and transcription factors such as 
cAMP responsive element binding protein (CREB) (Colbran et al., 1992). Many of 
these proteins that are regulated by PKA have known functions in depression. 
 
The link between the PKA signalling cascade and depression has been 
documented (Perez et al., 2001). Chronic administration of antidepressant 
treatment or electroconvulsive seizures regulate PKA signalling in the brain 
(Menkes et al., 1983; Nestler et al., 1989b; Perez et al., 1989; Ozawa and 
Rasenick, 1991). These treatments have been shown to reduce cytosolic PKA 
while increasing PKA in the nucleus of rat frontal cortex samples (Nestler et al., 
1989a). This suggests that antidepressant drugs or electroconvulsive seizures 
may stimulate the translocation of PKA from the cytosol to the nucleus. 
Antidepressant treatment and electroconvulsive seizures are believed to cause 
alterations in gene expression and as PKA regulates many transcription factors 
their action might be mediated via the PKA signalling. However, which genes of 
the PKA signalling cascade are involved has not been shown. In the same 
context, it has been shown that patients with major depression exhibit 
significantly less activity of β-adrenoceptor-linked protein kinase A than normal 
subjects (Shelton et al., 1996). 
 
Here, we have identified genes in the PKA signalling cascade that are affected 
after administration of a HFD (Table 3.4) and these may play an important role 
in the development of depression. As protein phosphorylation by PKA has been 
proposed as a final pathway in the regulation of neuronal function, abnormalities 
in the PKA activity of depressed patients could have a wide range of cellular 
consequences (Shelton et al., 1996). 
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In addition, one of the genes that was downregulated after the consumption of 
the HFD is the protein kinase C delta (PRKCD) (Table 3.2). Using the ingenuity 
analysis software (www.qiagen.com/ingenuity), the ingenol 3-angelate (I3A) 
commonly named PEP005 is a potential drug that can be used in this study to 
reverse the depression phenotype. I3A is one of the active ingredients in 
Euphorbia peplus, which has been used in traditional medicine for its anti-
carcinogenic action. I3A has been shown to have a beneficial effect for the 
treatment of cancer (Ersvaer et al., 2010). A gel formulation of the drug has 
been approved by the U.S. Food and Drug Administration (FDA) and by the 
European Medicines Agency (EMA) for the topical treatment of actinic keratosis 
(Siller et al., 2009; Grue-Sorensen et al., 2014). I3A is a ligand and activator for 
the protein kinase C (PKC) (Kedei et al., 2004; Hampson et al., 2005). 
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This suggests that I3A might be able to reverse the depression phenotype 
observed after the consumption of HFD as HFD acts by reducing PKC signalling. 
Further investigation of the role of I3A in our model of depression is needed to 
investigate whether targeting specifically the PKC which is a downstream 
effector of PKA we can reverse the dietary induced depression phenotype. 
Figure 3.15 is a schematic of the main genes affected at the PKA signalling 
cascade after the consumption of the HFD and how they connect between each 
other.  
 
 
Figure 3.15. The main genes at the PKA signalling pathway affected by HFD. 
Schematic represents the main genes affected by HFD and how they connect 
between each other. Schematic was designed using the Ingenuity analysis 
software. With green color are the genes that were downregulated after HFD 
consumption. 
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3.3.6. The role of hypothalamus in the obesity induced 
depression phenotype 
A 50% reduction of the total neurons in the paraventricular nucleus (PVN) in the 
hypothalamus has been observed in patients with major depression (Manaye et 
al., 2005). This study focused on the investigation of the signalling pathways 
affected after HFD in the hypothalamus (Fig. 3.11). However, other brain 
regions such as the frontal cortex, amygdala and hippocampus that have been 
studied extensively with regard to psychiatric disorders as they have been shown 
to be related to emotions, memory and executive function might play an 
important role as well. The role of the hypothalamus as well as cerebellum has 
been underemphasized and has been thought to play a minor role at best. It is, 
however, now becoming clear that the cerebellum plays a more important role 
than previously thought in major depression (Beauregard et al., 1998; Liotti et 
al., 2002; Smith et al., 2002). Data coming from this study also put emphasis on 
the role of hypothalamus in the development of obesity induced depression 
phenotype. Further studies investigating the other brain regions and their 
involvement in this model are necessary. However, even though in this study we 
were able to determine a role of hypothalamus in depression, the exact 
hypothalamic nuclei that are critical for the depression phenotype in response to 
diet remain to be determined. 
 
3.3.7. The role of the HPA axis in the obesity induced 
depression phenotype 
Dysregulation in many different pathways have linked obesity with depression. 
Impaired function of glucocorticoid receptors (Holsboer, 2000; Ljung et al., 
2002) as well as disturbances in central serotonin, norepinephrine and dopamine 
neurotransmitter systems (Bjorntorp and Rosmond, 2000) have been identified to 
play a pivotal role. Moreover, the dysregulation of the hypothalamus-pituitary-
adrenocortical (HPA) axis have also been involved in depression. Hypothalamus 
plays a pivotal role and regulates main functions of the HPA axis. Cytokines and 
adipokines (Elenkov et al., 2005; Miller et al., 2003) play an important role in 
pathophysiology of obesity and depression (Rajala and Scherer, 2003; Wisse, 
2004) and interact with the HPA axis and the neurotransmitter systems 
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(Besedovsky et al., 1986; Schiepers et al., 2005). Moreover overweight and 
obesity has been shown to impair the HPA-axis in depressed and nondepressed 
individuals (Vicennati and Pasquali, 2000), suggesting that increase in body 
weight can play a role. Moreover, leptin has been shown to suppress the HPA 
axis (Heiman et al., 1997). Therefore, further analysis of the HPA pathway in our 
dietary and genetically obesity induced depression phenotype should be 
investigated in order to shed light on the role of this pathway in depression 
caused by diet. 
 
3.3.8. The role of neurogenesis in depression 
HFD consumption has a major impact on the cellular architecture of the arcuate 
nucleus in the hypothalamus; it affects the structure of the BBB so that the 
POMC and NPY cell bodies and dendrites become less accessible to blood vessels 
(Horvath et al., 2010) and this effect might be irreversible due to reactive gliosis 
(Horvath et al., 2010). Moreover, HFD triggers a loss of synapses on POMC 
neurons in the hypothalamus (Horvath et al., 2010). Therefore, one possible 
route for the induction of depression after HFD is aberrant neuronal death. 
Hippocampal neurogenesis has been shown to have an antidepressant effect in 
mice and humans (Sahay and Hen, 2007). Moreover, various antidepressant 
treatments have been shown to increase hippocampal neurogenesis. Cell 
proliferation and de novo neurogenesis has been described in the hypothalamus 
to act as a compensatory mechanism to regulate energy balance during 
progressive degeneration of hypothalamic neurons (Pierce and Xu, 2010). It has 
already been described that consumption of a HFD for 8 weeks induces apoptosis 
of hypothalamic neurons and this effect is dependent upon diet composition and 
not caloric intake (Moraes et al., 2009). Therefore, further investigation whether 
hypothalamic neurogenesis is affected in this model of depression and 
determination of whether neurogenesis in specific hypothalamic nuclei is 
responsible for the dietary or genetic induced depression behavior is required. 
Nissl staining would reveal any cell loss or abnormalities in cell density and 
cytoarchitecture in the hypothalamus that might suggest the cellular toxicity. 
Brdu positive cells represent the number of survived cells (Schmidt and Duman, 
2007). 
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3.4. Conclusions 
In conclusion, dietary or genetic obesity plays a causative role in the 
development of depression in mice. Importantly, this happens independently of 
the increase in the body weight and at a very early stage of obesity. The 
downregulation of the cAMP/PKA signaling pathway in the hypothalamic area 
after the consumption of the HFD is of significant importance. Moreover, this 
study presents for the first time the identification of specific genes that were 
downregulated in the PKA signaling cascade in the hypothalamus after HFD. To 
our knowledge this is the first time that PKA signaling pathway is the linker 
molecular pathway in the hypothalamus that connects obesity and depression. 
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Chapter 4  
The loss of PDE4A rescues the 
depression phenotype observed 
after dietary or genetic obesity 
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4. Introduction 
4.1. Introduction 
Antidepressant drugs are broadly prescribed for a variety of affective disorders; 
however in many cases the molecular and cellular adaptations that underlie 
their therapeutic action remain unknown. It is also clear that the molecular 
targets for the development of therapeutic agents have remained the same the 
last 40 years (mainly the inhibition of monoamine metabolism and reuptake). 
Resistance to antidepressant treatments observed for overweight and obese 
people suggests that unique depression signalling pathways exist for this 
subpopulation (Papakostas et al., 2005). Identifying these pathways might shed 
light on the precise mechanism that links obesity with depression. This 
knowledge will help developing selective strategies for therapeutic intervention 
to treat depression that target molecular pathways specific for the overweight 
and obese subpopulation. 
 
4.1.1. 3’, 5’ – cyclic adenosine monophosphate signalling 
pathway in depression 
3’, 5’-cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger 
that mediates signal transduction of several neurotransmitters including 
dopamine, norepinephrine, serotonin and adenosine, all of them targets of 
antidepressant treatment (Shelton, 2007). It has been proposed that the 
mechanism of action for most of the antidepressant treatments involve the 
upregulation of the 3’-5’-cyclic adenosine monophosphate (cAMP) cascade 
(Duman et al., 1997). cAMP is synthesized from adenosine 5’-triphosphate (ATP) 
by adenylyl cyclase (AC), and hydrolysed by anchored cAMP degrading cyclic 
nucleotide phosphodiesterases (PDEs). The increase in intracellular levels of 
cAMP at the inner surface of the plasma membrane can then activate 
downstream effectors such as protein kinase A (PKA), which in turn trigger 
downstream signals that lead to the regulation of various cellular processes 
including proliferation, differentiation and apoptosis (Tasken and Aandahl, 
2004). Forskolin, a plant diterpene that directly activates adenylyl cyclase, is 
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reported to have antidepressant actions in depressed patients (Bersudsky et al., 
1996). 
 
Tight control of cAMP signalling is orchestrated by strict temporal regulation of 
the generation and degradation of this second messenger. This spatiotemporal 
control of the cAMP signalling dynamics is achieved by numerous feedback 
regulations that are activated to finely tune the cAMP signal in intensity, time 
and its propagation through the intracellular space. This process is centrally 
achieved by various proteins, including PKA, PDEs and is facilitated by 
scaffolding proteins such as A-kinase-anchoring proteins (AKAPs) (Bauman et al., 
2007; Tasken and Aandahl, 2004; Wong and Scott, 2004). Of all the different 
PDEs, PDE4 has been shown to play a critical role for the cAMP signalling in the 
brain (Conti et al., 2003). 
 
4.1.2. The role of phosphodiesterase inhibitors in 
depression 
The sole route for cAMP degradation occurs via the PDEs. Preclinical studies have 
reported that PDE inhibitors have antidepressant like effects in animal models 
(Wachtel and Schneider, 1986; Griebel et al., 1991). Papaverine, a non-specific 
PDE inhibitor, was also found to have antidepressant action in a case report 
(Malison et al., 1997). Tadalafil, a PDE5 inhibitor has been shown to improve 
depressive symptoms, ameliorate memory impairments, suppress apoptosis and 
enhance cell proliferation of hippocampal cells in a model of depression, all of 
which are characteristics of an antidepressant effect (Baek et al., 2011). 
Resveratrol, a phosphodiesterase inhibitor which occurs naturally in the skin of 
red grapes, has been shown to improve memory performance and hippocampal 
neuronal functional connectivity (Witte et al., 2014), both of which are affected 
in people with depression. 
 
Rolipram, a small-molecule and a generic PDE4 inhibitor, is known for its 
antidepressant action in rodents (Zhang, 2009; Zhang et al., 2006; Przegalinski 
and Bigajska, 1983; Overstreet et al., 1989; Schwabe et al., 1976; Zeller et al., 
1984; Kehr W, 1985; Wachtel, 1982; Wachtel, 1983b) and in clinical trials 
(Griebel et al., 1991; Bobon et al., 1988; Wachtel and Schneider, 1986; Wachtel, 
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1983a; Fleischhacker et al., 1992; O'Donnell, 1993; Bertolino et al., 1988; 
Hebenstreit et al., 1989). However, despite initial promise, the therapeutic 
potential of rolipram as an antidepressant is limited due to the side effects of 
nausea, emesis (Scott et al., 1991; Zeller et al., 1984; Rock et al., 2009; 
Robichaud et al., 2001), owing to its mechanism of action as a non-isoform-
specific PDE4 inhibitor (Dyke and Montana, 2002; Robichaud et al., 2002; Hirose 
et al., 2007; Bertolino et al., 1988; Hebenstreit et al., 1989). The molecular 
identification of the isoform that mediates the antidepressant action of rolipram 
and the creation of selective inhibitors of PDE4 isoforms may have therapeutic 
effects with minimal adverse reactions (O'Donnell and Zhang, 2004). Structural 
analysis of the catalytic domains of PDE4A, PDE4B, PPDE4C and PDE4D bound to 
inhibitors revealed significant conformational differences between the different 
enzymes that can shed light for the development of selective inhibitors for the 
different members of the PDE4 family (Wang et al., 2007). Despite the fact that 
the design of specific PDE4 inhibitors has been very slow, it has already been 
achieved for the sub-family of PDE4Ds in order to enhance cognition (Burgin et 
al., 2010; Houslay and Adams, 2010). However, no PDE4 inhibitor have yet been 
brought to market as an antidepressant because of issues related to tolerability 
and side effects (Giembycz, 2005). 
 
4.1.3. The role of phosphodiesterase in depression 
PDE4 gene family plays a major role in regulating the cAMP signalling in the 
brain (Houslay, 2001; Menniti et al., 2006) and is the primary family of 
phosphodiesterase hydrolysing cAMP associated with the central noradrenergic 
system that is involved in depression (Whalin et al., 1988; Challiss and Nicholson, 
1990; Ye and O'Donnell, 1996). PDE4 isoforms show specific expression patterns 
(Houslay, 2001) suggesting their unique role in signalling. PDE4s have also been 
linked with many psychiatric disorders as these enzymes are localized in certain 
areas of the brain (Iona et al., 1998) that are associated with reinforcement, 
movement and affect ( Cherry and Davis, 1999) all of which are affected in 
people with depression. In light of this data, PDE4 has been regarded as a 
potential therapeutic target for the treatment of various mental diseases 
including depression (Houslay et al., 2005; Millar et al., 2005).  
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Much of the published work has been done using the PDE4D-/- mice investigating 
the role of PDE4D on memory in the hippocampus. PDE4D-/- mice display memory 
enhancement that was mimicked by repeated rolipram treatment in WT mice (Li 
et al., 2011). Memory enhancement was not affected for the PDE4D-/- mice by 
chronic antidepressant treatment, indicating the predominant role of PDE4D in 
the mediation of memory (Li et al., 2011). Using miRNA infusion in the 
hippocampus the long isoforms of the PDE4D were identified as responsible for 
memory enhancement, hippocampal neurogenesis and CREB phosphorylation, 
and appeared not to cause emesis (Li et al., 2011) suggesting their potential as 
memory enhancers without side effects. The PDE4D-/- mice exhibit 
antidepressant behaviour as assessed by TST and FST (Zhang et al., 2002). 
PDE4D-/- mice showed a reduced sensitivity to rolipram but not for other 
antidepressants such as desipramine or fluoxetine, suggesting PDE4D is an 
essential mediator of the antidepressant effect of rolipram (Zhang et al., 2002). 
 
From the different members of the PDE4 family, the expression of PDE4A and 
PDE4B subtypes, but not PDE4D, specifically increases after repeated treatment 
with antidepressant drugs such as desipramine and fluoxetine (Takahashi et al., 
1999; Ye et al., 1997; Ye et al., 2000). Upregulation of the PDE4 gene expression 
in response to sustained activation of the cAMP pathway (Conti et al., 1995; 
Conti and Jin, 1999) is thought to represent a compensatory adaptation in 
response to the antidepressant treatment that would reduce cAMP levels back to 
baseline (Conti et al., 1995; Houslay and Milligan, 1997). This possibility is 
supported by in vitro studies where cAMP stimulation of β-adrenergic receptors 
or direct activation of adenylyl cyclase or cAMP dependent protein kinase 
increases the RNA that leads to PDE4A protein expression (Torphy et al., 1995; 
Manning et al., 1996; Verghese et al., 1995). Moreover, in vivo studies reveal 
that PDE4A mRNA and protein activity in the brain appear to be influenced by β-
adrenergic receptor activation, as treatment with the β-adrenergic receptor 
antagonist decreases expression of this isoform (Ye and O'Donnell, 1996; Ye et 
al., 1997). However, the exact underlying mechanism for the upregulation of 
PDE4A and PDE4B expression in brain is unknown, but it is proposed to involve 
activation of gene expression in response to stimulation of the cAMP pathway 
(Conti et al., 1995; Conti and Jin, 1999). 
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From the different PDE4As, the long isoform of this gene family (PDE4A5) has 
been implicated in the regulation of different pathways. The N-terminal of 
PDE4A5 isoform confers an ability to interact with the SH3 domains of specific 
proteins, such as that of the SRC family tyrosyl kinase LYN (O'Connell et al., 
1996) and this interaction affects its catalytic unit (McPhee et al., 1999). PDE4A5 
has been shown to have a role in the survival of at least certain cells as it is the 
sole PDE4 isoform that is cleaved by caspase-3 during apoptosis causing it to be 
redistributed within the cell (Huston et al., 2000). PKA phosphorylation of 
PDE4A4 in humans, which is the equivalent of PDE4A5 in mice, increases its 
activity as well as the sensitivity to rolipram (Laliberte et al., 2002). PDE4A5 
interacts with immunophilin XAP2 and this interaction reversibly inhibits the 
enzymatic activity, attenuates the ability of PKA to phosphorylate PDE4A5 and 
increases the sensitivity to rolipram (Bolger et al., 2003b). PDE4A5 has also been 
shown to be activated by stimulation of the PI-3 kinase cascade (MacKenzie et 
al., 1997). Very recently, PDE4A5 was shown to be the major isoform in the 
hippocampus responsible for the memory impairment due to sleep deprivation 
(Vecsey et al., 2009). Activation of PDE4A5 inhibits the differentiation of 3T3 
cells to adipocytes (MacKenzie et al., 1998). All these previous studies clearly 
underlined the important role of PDE4A5 in the regulation of different molecular 
pathways. 
 
In summary, a variety of studies have identified the cAMP signalling pathway to 
be involved in the depression phenotype, and have highlighted the importance of 
the different PDE4s as well as specific roles for individual PDE isoforms in 
cAMP/PKA signalling in depression. 
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4.1.4. Aims 
Although there is a well-established link between obesity and depression, critical 
mechanistic insights that underpin the links between obesity and depression are 
still unknown. Given the fact that high fat diet downregulates PKA signalling in 
the hypothalamus it was hypothesized that PDE4, the major regulators of the 
cAMP signalling in the brain, and therefore, PKA modulators, may be involved in 
the regulation of PKA signalling to attenuate the depression phenotype. Hence, 
this chapter will focus on the role of PDE4s in dietary or genetic obesity induced 
depression. 
The aims of this chapter are as follows: 
1) to define whether phosphodiesterases play a role in the depression 
phenotype  induced by dietary or genetic obesity 
2) to identify which specific isoform (s) of  the PDE4 family play a functional 
role in maintaining the link between obesity and depression 
 
4.2. Results 
4.2.1. Chronic but not acute administration of rolipram 
tend to reduce the dietary-induced depression 
phenotype in mice 
As mentioned previously, rolipram is a generic PDE4 inhibitor with reported 
antidepressant action in mice. However, whether rolipram can rescue the 
dietary obesity-induced depression phenotype observed in this model is 
unknown. In mice on 3 weeks of HFD, acute intraperitoneal injection (i.p.) of 
rolipram did not affect the immobilization time of mice compared to saline 
injected mice (Fig. 4.1), suggesting that acute rolipram administration did not 
affect the dietary obesity-induced depression phenotype. 
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Figure 4.1. Acute rolipram injection has no effect on the dietary obesity 
induced depression phenotype. Tail suspension test for WT mice on 3 weeks on 
HFD i.p. injected with either saline or rolipram (n=4-5). 
 
Next, chronic administration of rolipram was assessed for its effect on the 
dietary obesity-induced depression phenotype. Fluoxetine (Prozac) was used as a 
positive control due to its popularity as a widely prescribed antidepressant drug 
with known antidepressant action in mice, though as with rolipram, its ability to 
rescue the depression phenotype observed after HFD consumption had been 
previously untested. Immobilization time in the TST tended to be reduced in 
mice injected with rolipram or Prozac compared to control mice, injected with 
saline (Fig. 4.2). Even though the reduction of the immobilization time was not 
significant, it revealed a potentially effect that should be further investigated 
with bigger cohorts of mice as there were only 5 mice per group in that study. 
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Figure 4.2. Chronic administration of either prozac or rolipram reduces the 
immobilization time at the tail suspension test. Tail suspension test for WT 
mice on 3 weeks on HFD daily i.p. injected with either saline, rolipram or Prozac 
(n=5). 
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Prozac or rolipram administration increased sucrose consumption over water 
indicating the reversal of the anhedonia phenotype (Fig. 4.3), though again, this 
was not a statistically significant effect.  
 
Figure 4.3. Chronic administration of either prozac or rolipram increases the 
sucrose consumption. Sucrose preference test for WT mice on 3 weeks on HFD 
daily i.p. injected with saline, rolipram or Prozac (n=5). 
 
 
The mice that received daily Prozac injections gained significantly more weight 
compared to the saline-injected mice, and this was observed as early as after 
the first injection (Fig. 4.4). Surprisingly, the opposite effect was observed with 
the rolipram-injected mice, as they were resistant to the dietary induced 
obesity phenotype observed for the saline injected mice (Fig. 4.5). 
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Figure 4.4. Daily Prozac injections increase body weight compare to saline 
injected mice. Body weight of WT mice injected daily i.p. with Prozac or normal 
saline for 4 weeks while on HFD (n=5, **P < 0.01 by Linear mixed model fit by 
REML, Formula: weight ~ time + drug + time:drug + weight0 + (1 | id). Time 
(***P<0.001) and drug (**P<0.01) have an effect on the body weight. The body 
weight at day 1 was used as a covariate and had no effect of the body weight 
gain). 
 
Figure 4.5. Daily rolipram injections tend to decrease body weight compare 
to saline injected mice. Body weight of WT mice injected daily i.p. with either 
normal saline or rolipram for 4 weeks while on HFD (n=5, by Linear mixed model 
fit by REML, Formula: weight ~ time + drug + time:drug + weight0 + (1 | id). 
Time (***P<0.001) and the interaction between time and drug (**P<0.01) have an 
effect on the body weight. The body weight at day 1 was used as a covariate and 
had no effect of the body weight gain). 
  
Chapter 4  Loss of PDE4A Rescues Depression 
     
EIRINI VAGENA 159 
 
 
In addition, liver measurements revealed an increase in liver weight of the mice 
daily injected with Prozac compare to either saline or rolipram (Fig. 4.6). 
 
Figure 4.6. Chronic administration of Prozac increases liver size compare to 
either saline or rolipram. Liver weight for WT mice on 3 weeks on HFD daily i.p. 
injected with either saline, rolipram or Prozac (n=5, **P<0.01 by 1-way ANOVA 
following by Dunnett’s multiple comparison test). 
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4.2.2. High fat diet specifically increases 
phosphodiesterase 4 (PDE4) activity in the 
hypothalamus of WT mice 
Since the PKA signalling pathway is down regulated after the consumption of 
HFD (Chapter1, Fig. 3.12&3.13), it was hypothesized that this effect might 
happen via the regulation of phosphodiesterase activity. That was further 
supported by the effect of daily rolipram injections, though again, this was not a 
statistically significant effect (Fig. 4.2&4.3). Phosphodiesterases are major 
regulators of PKA signalling pathways as they play a pivotal role in the temporal 
and spatial regulation of cAMP. In light of this, I tested whether high fat diet 
alters the activity of PDE4 in the brain. Four brain regions have been shown to 
be involved in depression: hypothalamus, amygdala, cortex and hippocampus 
(Price and Drevets, 2010). Interestingly, using biochemical assays, a significant 
increase of PDE4 activity of hypothalamic samples of WT mice fed HFD for 3 
weeks compared to mice fed ND was found (Fig. 4.7). 
 
 
Figure 4.7. HFD increases the levels of phosphodiesterase4 activity in the 
hypothalamus. PDE4 activity for whole lysates of hypothalamic samples of WT 
mice fed either normal diet or 3 weeks on HFD (n=7-10 unpaired two tail 
student’s t-test *P<0.05). This work was carried out by Dr Jonathan Day. 
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This effect was specific for the hypothalamus as HFD did not alter the total PDE4 
activity levels in cortex (Fig. 4.8), tended to decrease but not significantly in 
the hippocampus (Fig. 4.9), did not affect the cerebellum (Fig. 4.10) and 
tended to increase but not significantly in amygdala (Fig. 4.11) further proving 
that the hypothalamic area is the only area where the PDE4 activity is affected 
by HFD.  
 
Figure 4.8. HFD does not alter the levels of phosphodiesterase activity in the 
cortex. PDE4 activity for whole lysates of cortical samples of WT mice fed either 
normal diet or 3 weeks on HFD (n=11) This work was carried out by Dr Apostolos 
Zarros. 
 
Figure 4.9. HFD does not alter the levels of phosphodiesterase activity in the 
hippocampus. PDE4 activity for whole lysates of hippocampal samples of WT 
mice fed either normal diet or 3 weeks on HFD (n=9-10). This work was carried 
out by Dr Apostolos Zarros. 
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Figure 4.10. HFD does not alter the levels of phosphodiesterase activity in 
the cerebellum. PDE4 activity for whole lysates of cerebellum samples of WT 
mice fed either normal diet or 3 weeks on HFD (n=9-11) This work was carried 
out by Dr Apostolos Zarros. 
 
 
Figure 4.11. HFD does not alter the levels of phosphodiesterase activity in 
the amygdala. PDE4 activity for whole lysates of amygdala samples of WT mice 
fed either normal diet or 3 weeks on HFD (n=7-11). This work was carried out by 
Dr Apostolos Zarros. 
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4.2.3. High fat diet alters the RNA and protein levels of 
PDE4A5 in the hypothalamus of WT mice 
In mice and humans, the PDE4 gene family is comprised of the PDE4-A, -B, -C 
and -D genes, each of which gives rise to more than four different protein 
isoforms (Perez-Torres et al., 2000). The further study of the PDE4C sub-family 
was excluded as it has been shown that it is not expressed in the brain (Perez-
Torres et al., 2000; Swinnen et al., 1989; Iona et al., 1998). Real-time PCR 
analysis for total RNA levels of PDE4B in the hypothalamus of mice showed 
undetectable RNA levels (data not shown). There was no significant difference in 
the total RNA levels of PDE4D in mice fed normal versus HFD or the genetically 
obese mice with a trend to be downregulated after the consumption of HFD for 
one week (Fig.4.12). 
 
Figure 4.12. Dietary or genetic obesity does not alter the RNA expression 
levels of PDE4D. Real-time PCR analysis of PDE4D in the hypothalamus of WT 
mice on ND, 1 week and 3 weeks on HFD and ob/ob mice (n=4) 
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Interestingly, there was an upregulation of the RNA levels for the PDE4A 
(Fig.4.13). PDE4A gene produces different transcripts due to alternative 
splicing; one of them is the PDE4A5 that has been shown to be regulated by 
sleep deprivation (Vecsey et al., 2009). Surprisingly, there was a specific RNA 
increase for PDE4A5 in the hypothalamus of mice fed HFD compared to ND 
(Fig.4.13). 
 
 
Figure 4.13. Dietary or genetic obesity increases the RNA expression levels of 
PDE4A and PDE4A5. Real-time PCR analysis for PDE4A and PDE4A5  in the 
hypothalamus of WT mice on ND, 1 week and 3 weeks on HFD and ob/ob mice 
(n=4, *P < 0.05 , **P<0.01, by one-way ANOVA with Dunnett’s multiple 
comparison test). 
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Western blot analysis of tissue from the hypothalamus region of WT mice fed 
either ND or 3 weeks HFD revealed a significant upregulation of the protein 
levels of PDE4A5 in the hypothalamic area (Fig.4.14) that was in agreement with 
the induction of RNA (Fig.4.13).  
 
 
 
Figure 4.14. High fat diet increases specificaly the PDE4A5 protein levels in 
the hypothalamus. Western blot analysis for PDE4A5 from mice fed ND versus 3 
weeks on HFD. GAPDH was used as a loading control (n=4, *P < 0.05 by 2 tail 
unpaired Student’s t test). Experiment was performed twice and representative 
blot with its quantification is shown. 
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4.2.4. High fat diet leads to attenuation of CREB 
phosphorylation in the hypothalamus 
The transcription factor CREB is a well characterized substrate for PKA that has 
been implicated in the mechanism of action of many antidepressant drugs. 
Probing hypothalamic samples of mice fed with HFD for 3 weeks, a decrease 
phosphorylation at Set 133 of CREB was observed (Fig.4.15) suggesting that 
exposure to a HFD results in an attenuation of PKA-mediated CREB 
phosphorylation.  
 
 
 
 
Figure 4.15. High fat diet decreases the levels of CREB phosphorylation in the 
hypothalamus. Western blot analysis for total p-CREB and CREB protein levels 
from hypothalamic samples of mice fed ND versus 3 weeks on HFD. (n=3, **P < 
0.01 by 2 tail unpaired Student’s t test). 
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4.2.5. In vivo loss of PDE4A gene rescues the dietary or 
genetically obesity- induced depression phenotype 
If an upregulation of PDE4A5 activity was orchestrating cAMP dynamics that 
resulted in a decrease in phospho-CREB levels, it was hypothesized that the in 
vivo loss of PDE4A gene might rescue the dietary or genetically obesity-induced 
depression phenotype observed in this model. To test this hypothesis, the  
PDE4A-/- mouse was utilised, (a kind gift from Professor Marco Conti, UCSF). The 
PDE4A-/- and their littermates PDE4A+/+ were placed for 3 weeks on HFD. The 
double knock out ob/ob:PDE4A-/- was also generated by crossing these two 
mouse lines together. This strain was used to test whether the loss of PDE4A can 
rescue the genetic obesity-induced depression phenotype. Loss of PDE4A rescues 
the dietary and genetically obesity induced depression phenotype as shown by 
the tail suspension and forced swim tests (Fig4.16).  
 
Figure 4.16. Loss of PDE4A in vivo rescues the dietary or genetic induced 
depression phenotype. Tail suspension and forced swim test for PDE4A+/+ and 
PDE4A-/- mice on either ND and 3 weeks on HFD, ob/ob and ob/ob:PDE4A-/- mice 
on ND (n=7-10, *P < 0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one way ANOVA 
with Tukey’s multiple comparison test). 
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The PDE4A-/- and their PDE4A+/+ litter mate controls showed the same increase in 
body weight on ND and HFD further proving that the depression phenotype does 
not correlate with the increase in body weight (Fig.4.17 and Fig.4.18). 
Similarly, the genetically obese (ob/ob) mice and the double knock-out 
ob/ob:PDE4A-/-, exhibited comparable  body weights on ND (Fig.4.17). 
 
 
Figure 4.17. The loss of PDE4A does not induce any body weight changes on 
ND. Body weight curves of PDE4A+/+, PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on ND 
(n=7-10). 
 
Figure 4.18. Loss of PDE4A does not alter the increase in body weight after 
HFD consumption. Body weight curves of PDE4A+/+, PDE4A-/- on HFD (n=9-10). 
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4.2.6. Genetic ablation of PDE4A is sufficient to abolish 
the increased PDE4 activity observed in 
hypothalamus 
Previously, it was shown that HFD upregulates the total PDE4 activity levels in 
the hypothalamus compared to ND (Fig. 4.7). Phosphodiesterases regulate the 
spatiotemporal concentration of cAMP (Fig. 1.3). Therefore, further 
investigation was performed in order to elucidate in which subcellular 
compartment the increased PDE4 activity occurs. Using biochemical assays, the 
PDE4 activity was measured at the membrane and cytosol fraction of 
hypothalamic samples from mice fed ND and HFD. A specific increase in PDE4 
activity in the membrane fraction (but not the cytosolic fraction) of 
hypothalamic tissue from mice fed high-fat diet for 3 weeks compared to ND was 
observed (Fig.4.19). That increase was not observed for the PDE4A-/- mice 
(Fig.4.19). As no differences were detected in the PDE4 activity of the cytosol 
fraction from either WT or PDE4A-/- on ND or HFD, I hypothesized that 
compartmentalization of the phosphodiesterase activity within the membrane 
fraction is critical for the fidelity of the cAMP/PKA signals, which underpin onset 
of the depression phenotype. 
 
Figure 4.19. High fat diet increases PDE4 activity at the membrane fraction 
of the hypothalamus that is rescued at the PDE4A-/- mice. PDE4 activity assay 
measurements at the membrane and cytosol fraction of hypothalamus of 
PDE4A+/+ and PDE4A-/- on either ND versus 3 weeks on HFD (n=4-6, ***P < 0.001 by 
one-way ANOVA with Dunnett’s multiple post hoc test). This experiment was 
performed with Dr Apostolos Zarros. 
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No differences were detected in the cytosol or membrane fractions of amygdala 
for the WT or PDE4A-/- on either ND or HFD, further proving the specificity of the 
effect of HFD on the hypothalamic area (Fig.4.20). 
 
 
 
Figure 4.20. High fat diet does not alter the PDE4 activity in amygdala either 
at the cytosol or at the membrane fraction. PDE4 activity assay measurements 
at the membrane and cytosol fraction of amygdala of PDE4A+/+ and PDE4A-/- mice 
on either ND or 3 weeks on HFD (n=4-6). 
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Using a specific antibody that recognizes the PKA phosphorylation within the 
UCR1 of PDE4A5, an increased phosphorylation was observed for the 
hypothalamic samples that were fed HFD for 3 weeks compared to ND 
(Fig.4.21). This phosphorylation is known to activate PDE4A5, so it is possible 
that the increase in PDE4 activity seen in the hypothalamic membrane fractions 
is the result of a combination between increased PDE4A5 protein (Fig.4.14) and 
increased PDE4A5 activation (Fig.4.21). 
 
Figure 4.21. High fat diet increases the levels of phosphorylation of PDE4A5 
in the hypothalamus. Western blot analysis for membrane hypothalamic 
samples of p-PDE4A5 from mice fed ND versus 3 weeks on HFD. GAPDH was used 
as a loading control (n=4, ***P < 0.001 by unpaired 2 tail student’s t test). 
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4.2.7. The loss of PDE4A from the ob/ob mouse results in 
increased PDE4 activity at the membrane fraction 
of amygdala and in the cytosol fraction of 
hypothalamus 
PDE4 activity measurements from amygdala samples revealed a significant 
increase in the membrane of the ob/ob:PDE4A-/- compared to ob/ob mice 
(Fig.4.22), suggesting that the membrane fraction of amygdala and a PDE4 from 
a non-PDE4A subfamily might play role in this model of obesity. 
 
Figure 4.22. Loss of the gene PDE4A-/- from the genetically obese mouse 
alters the levels of PDE4 activity at the membrane fraction of amygdala. PDE4 
activity for the membrane or cytosol fraction of either ob/ob or ob/ob:PDE4A-/- 
mice on ND (n=7-10, **P < 0.01 by unpaired 2 tail student’s t-test) 
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A significant increase in PDE4 activity was also observed in the cytosol fraction 
of hypothalamic samples of the ob/ob:PDE4A-/- compared to ob/ob (Fig.4.23), 
suggesting that the cAMP compartmentalization pathway and PDE4 localization 
of the genetic obesity induced depression phenotype might be slightly different 
than the dietary induced depression phenotype. Therefore further investigation 
on the differences between the two different obesity models is required.  
 
Figure 4.23. Loss of PDE4A-/- from the genetically obese mouse alters the 
levels of PDE4A activity at the cytosol fraction of hypothalamus. PDE4 activity 
for the membrane or cytosol fraction of either ob/ob or ob/ob:PDE4A-/- mice on 
ND (n=8-11, ***P < 0.001 by unpaired 2 tail student’s t-test). 
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4.2.8. The loss of PDE4A gene impairs the rearing 
activity at the open field test 
Open field measurements revealed no major differences in locomotor activity 
between WT and PDE4A-/- on both ND and HFD. Additionally, there were no 
significant differences from a direct comparison between the ob/ob and 
ob/ob:PDE4A-/- (Fig.4.24). The ob/ob and ob/ob:PDE4A-/- mouse showed 
decreased locomotor and rearing activity at the open field test (Fig.4.24) when 
compared with WT and PDE4A-/-. Interestingly, the loss of the PDE4A gene from 
the WT and ob/ob mice resulted in a decrease of the rearing activity measured 
at the open field test (Fig.4.24). The reduced rearing activity that was observed 
after the loss of PDE4A gene was further reduced after the consumption of the 
HFD compared to ND (Fig.4.24). The rearing activity represents the exploratory 
activity of mice. It has been suggested that decreased rearing activity might 
predict an autistic phenotype. Further investigation on the role of PDE4A in 
autistic behaviour is needed. 
 
Figure 4.24. Genetic but not dietary obesity alters the total activity at the 
open field test. Open field test for PDE4A+/+, PDE4A-/- on either ND and 3 weeks 
on HFD and ob/ob and ob/ob:PDE4A-/- on ND (n=6-10, *P<0.05, ***P < 0.001, ****P 
< 0.0001, by 1-WAY ANOVA with Tukey’s multiple comparison test). 
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4.2.9. The loss of PDE4A gene does not induce anxiety in 
the elevated plus maze test 
Due to the causative role of anxiety to induce depression, anxiety related tests 
were performed for the WT, PDE4A-/- on HFD and ob/ob and ob/ob:PDE4A-/- on 
ND to check for stress levels. The loss of PDE4A gene did not affect the anxiety 
behaviour measured in the elevated plus maze (EPM) test. Interestingly, in 
addition to the decreased total distance traversed in the closed arms, the ob/ob 
and the ob/ob:PDE4A-/-  mouse showed decrease entry to the closed arms 
(Fig.4.25), suggesting an increased anxiety phenotype. This behaviour may be 
linked to the loss of leptin as both mice were missing the leptin gene. Therefore 
further tests should be done to explore this link. 
 
Figure 4.25. Genetic but not dietary obesity alters the levels of anxiety at 
the elevated plus maze test. Elevated plus maze test for PDE4A+/+ , PDE4A-/-  on 
3 weeks on HFD and ob/ob and ob/ob:PDE4A-/- on ND (n=3-12*P<0.05, by 1-WAY 
ANOVA with Tukey’s multiple comparison post test). 
  
Chapter 4  Loss of PDE4A Rescues Depression 
     
EIRINI VAGENA 176 
 
4.2.10. Early dietary or genetic obesity does not induce 
gene expression changes for inflammatory genes 
in the hypothalamus 
The role of different cytokines, especially TNF-α has been shown to be involved 
in brain dysfunction and disease (Clark et al., 2010) and it has been shown that 
cytokines can play a role in the development of depression (Raison et al., 2006; 
Schiepers et al., 2005). Clinical depression was suggested to arise due to 
cytokines released from activated macrophages (Smith, 1991). HFD has been 
shown to induce the tissue expression of TNF-α (Borst and Conover, 2005). To 
check whether inflammation is involved in this model of depression, expression 
analysis was performed for the main inflammatory cytokines in the 
hypothalamus. Real time PCR analysis on hypothalamic tissue samples from the 
WT, PDE4A-/- , ob/ob:PDE4A-/- and ob/ob did not show any RNA expression 
differences of TNF-alpha (Fig.4.26) or IL-1beta (Fig.4.27). 
 
 
 
 
 
 
 
 
 
 
Figure 4.26. No changes for the RNA levels of TNF-alpha after dietary or 
genetically induced obesity in the hypothalamus. Real-time PCR analysis of 
TNF-alpha for WT, PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on either ND, 1 and 3 
weeks on HFD (n=4). 
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Figure 4.27. No changes for the RNA levels of IL-1beta after dietary or 
genetically induced obesity in the hypothalamus. Real-time PCR analysis of IL-
1beta for WT, PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on either ND, 1 and 3 weeks 
on HFD (n=4) 
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However from the different cytokines, HFD increased the levels of IFN-γ only 
after the consumption of HFD for 3 weeks (Fig.4.28 and Fig.4.29). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28. No changes for the RNA levels of IFN-gamma after dietary or 
genetically induced obesity. Real-time PCR analysis of IFN-gamma for WT, 
PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on either ND, 1 and 3 weeks on HFD (n=4). 
 
 
Figure 4.29. HFD 
consumption induces an 
increase of IFN-gamma 
in the hypothalamus. 
Real-time PCR analysis of 
IFN-gamma for WT mice 
on ND and 3 weeks on 
HFD (n=4, **P < 0.01 by 2 
tail unpaired Student’s t-
test). 
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4.2.11. Dietary or genetic obesity does not alter BDNF 
RNA expression in the hypothalamus of mice 
Neurotrophins have been shown to be involved in depression and in the 
mechanism of action of antidepressants (Pittenger and Duman, 2008) (Tardito et 
al., 2006) (Kozisek et al., 2008) (Chen et al., 2006) (Sakata et al., 2010). BDNF is 
a neurotrophic factor known for its antidepressant action via regulation of 
neurogenesis in the hippocampus (Schmidt and Duman, 2010). BDNF is also 
known to be regulated by cAMP levels (Conti et al., 2002). However, whether 
BDNF levels are altered in the hypothalamus in this model of depression is 
unknown. Real time PCR analysis on hypothalamic tissue from WT, PDE4A-/-, 
ob/ob:PDE4A-/-  and ob/ob mice revealed no significant differences in the 
expression levels of BDNF (Fig.4.30).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30. No changes for the RNA levels of BDNF in the hypothalamus after 
dietary or genetically induced obesity. Real-time PCR analysis of BDNF for WT, 
PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on either ND, 1 and 3 weeks on HFD (n=4) 
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4.2.12. HFD slightly increases the total phosphorylation 
levels of DARPP32 in the hypothalamus of mice 
DARPP32 is a downstream effector of the cAMP pathway phosphorylated by PKA 
(Helms et al., 2006). DARPP-32 plays an important role in schizophrenia (Cantrup 
et al., 2012). Consumption of HFD for 3 weeks slightly increased the total 
phosphorylation levels of DARPP32 (Fig.4.31), suggesting that other molecular 
targets downstream of the PKA signalling pathway might play a role in obesity-
induced depression phenotype. A phospho-proteomics study would be required 
to identify such targets. 
 
 
Figure 4.31. High fat diet does not affect the total levels of p-DARPP32 in the 
hypothalamus. Western blot analysis for p-DARPP32 from mice fed ND versus 3 
weeks on HFD. GAPDH was used as a loading control (n=4). 
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4.2.13. Loss of PDE4A in vivo does not affect body weight, 
food intake, glucose or insulin tolerance on HFD 
Due to the role of HFD in the development of metabolic syndrome, a possible 
explanation for a lack of susceptibility to the depression phenotype exhibited by 
the PDE4A-/- would be via resistance to the metabolic syndrome. Loss of PDE4A 
does not induce appetite or body weight changes on HFD (Fig.4.32). 
 
 
Figure 4.32. The loss of PDE4A does not induce any body weight changes or 
affect food intake on HFD. Food intake and body weight curves for PDE4A+/+ and 
PDE4A-/- on HFD (n=5, by Linear mixed model fit by REML, Formula: weight ~ 
time + genotype + time:genotype + weight0 + (1 | id). Time (***P<0.001) and the 
interaction between time and drug (***P<0.01) have an effect on the body 
weight. The body weight at day 1 was used as a covariate and had no effect of 
the body weight gain). 
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In accordance, loss of PDE4A did not affect the insulin or glucose tolerance 
levels of mice measured after 9 weeks on HFD (Fig.4.33). Finally, loss of PDE4A 
did not affect the weight of epididymal, inguinal fat, or liver, even after 9 
weeks on HFD (Fig.4.34). 
 
Figure 4.33. The loss of PDE4A does not alter the glucose or insulin tolerance 
tests even after 9 weeks on HFD. Glucose tolerance and insulin tolerance test 
for PDE4A+/+ and PDE4A-/- on 9 weeks on HFD (n=5). This work was performed 
with Dr. Bernat Baeza Raja. 
 
Figure 4.34. The loss of PDE4A does not alter neither the white adipose 
tissue size nor the liver even after 9 weeks on HFD. Total weight of 
epididymal fat (IP), inguinal fat and liver for PDE4A+/+ and PDE4A-/- on 9 weeks 
on HFD (n=5). 
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4.2.14. PDE4A5 overexpression induces an increase in 
body weight 
To investigate the role of PDE4A5 specifically in the hypothalamus, an adeno-
associated virus (AAV) overexpression system was employed. The overexpression 
of PDE4A5 was performed in PDE4A-/- mice, therefore overexpression of the 
PDE4A5 in the hypothalamus will reveal the specific role for this enzyme in this 
brain region. A map of the adeno-associated virus (AAV) construct that 
overexpresses PDE4A5-vsv under the synapsin promoter is shown in Fig.2.2. A 
map of the control AAV used in this study overexpressing eGFP is shown in 
Fig.2.1. As mentioned above, PDE4A-/- mice are resistant to the dietary or 
genetic obesity-induced depression phenotype (Fig.4.16). Therefore, we wanted 
to test whether overexpression of PDE4A5 specifically in the hypothalamic area 
of this KO mouse would induce a depression phenotype. Bilateral stereotactic 
injections of the virus overexpressing PDE4A5 or eGFP in the hypothalamic area 
of PDE4A-/- mice were conducted. Immediately after injection, animals were 
provided a HFD for 21 days. After the completion of the 3 weeks on HFD, 
behavioural tests were performed to assess whether overexpression of PDE4A5 in 
the hypothalamus is sufficient to induce a depression phenotype. 
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Surprisingly, following exposure to HFD, bilateral infection of the hypothalamic 
areas of PDE4A-/- mice with the AAV-PDE4A5wt-VSV induced extreme body 
weight gain compared to the mice that received bilateral injections of the 
control AAV-GFP (Fig.4.35). 
 
Figure4.35. Overexpression of PDE4A5 in the hypothalamic area of PDE4A-/- 
mice results in an increase in body weight. Body weight measurements of 
PDE4A-/- mice that received either AAV-Synapsin-PDE4A5vsv or AAV-Synapsin-
eGFP and where on HFD for 3 weeks (n=4 unpaired two tail student’s t-test 
***P<0.001). 
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The immobilization time for the AAV-PDE4A5wt-VSV was reduced but not 
significantly different to the control injected mice (Fig.4.38). Because of the 
excess body weight gain, no conclusions could be made about the role of PDE4A5 
in development of the depression phenotype as the massive increase in body 
weight can play a role in the development of depression in mice. Even though 
previously it was shown that body weight gain might not affect the performance 
to the different behavioural tests the extreme body weight gain that the mice 
enhibited after the virus injections might have an effect as it can not be 
compared with the previous body weights. 
 
Figure.4.36. Overexpression of PDE4A5 in the hypothalamic area of PDE4A-/- 
mice does not affect the immobility after HFD. Immobilization time of PDE4A-/- 
mice that received either AAV-Synapsin-PDE4A5vsv or AAV-Synapsin-eGFP and 
were on HFD for 3 weeks (n=4) 
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After the completion of behavioural tests, western blot analysis was performed 
in order to confirm the exogenous expression of the virus. Expression analysis 
revealed high levels of the vsv protein in the hypothalamus (Fig.4.39). AAV-
mediated EGFP expression was restricted to the deposition site of the 
hypothalamic area indicating very limited diffusion of AAV vector in the brain as 
there was no detection in amygdala, which is a neighbouring area (Fig.4.39). 
 
Figure4.37. AAV mediated overexpression of PDE4A5 and GFP in the 
hypothalamous and amygdala. Western blot analysis for vsv and GFP for the 
PDE4A-/- mice injected with either the AAV-PDE4A5vsv or AAV-eGFP. 
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4.3. Discussion 
One possible target of antidepressant drug administration is the cAMP signal 
transduction system (Duman et al., 1997). Chronic, but not acute, 
antidepressant treatment up-regulates this intracellular cascade at several 
levels (Nestler et al., 1989b; Ozawa and Rasenick, 1991; Nibuya et al., 1996b; 
Duman et al., 1997; Perez et al., 1989). Major modulators of the cAMP signalling 
cascade are the phosphodiesterase enzymes, which serve to hydrolyse the cAMP 
to 5’AMP and terminate its signal transduction. The driving notion behind this 
present study is that PDEs contribute to the generation of intracellular cAMP 
microdomains, which are critical for the link between obesity and depression. 
Phosphodiesterases are localized in areas of the brain that are associated with 
reinforcement, movement, and affect all of which are impaired in people with 
depression ( Cherry and Davis, 1999). There is a lot of epidemiological evidence 
to support the high prevalence of depression observed in overweight and obese 
individuals (Zhong et al., 2010; Leonore de Wit  and Frans Zitman, 2010; 
Boutelle et al., 2010; Stunkard et al., 2003; Simon et al., 2010; McElroy et al., 
2004; Faith et al., 2002; Luppino et al., 2010; Palinkas et al., 1996; Roberts et 
al., 2003; Simon et al., 2010; Dong et al., 2004; Roberts et al., 2002). It is also 
worth noting that overweight and obese individuals exhibit resistance to 
antidepressant treatment (Papakostas et al., 2005). However, little is known 
about the exact molecular mechanism that link obesity with depression and 
whether phosphodiesterases play a role on this pathway. With these statements 
in mind, I wanted to determine whether phosphodiesterases are involved in the 
pathway that links obesity with depression. I hypothesized that identification of 
the specific phosphodiesterase isoform(s) involved would shed light on the 
signalling mechanisms which underpin this link and may help the development of 
more specific therapeutic strategies to target this specific type of depression. 
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4.3.1. The role of rolipram in the dietary obesity induced 
depression phenotype 
Rolipram is a small molecule with multiple in vivo functions, for example, as an 
antidepressant and an anti-inflammatory (Zhu et al., 2001; O'Donnell and Zhang, 
2004). Its actions stem from its ability to inhibit all isoforms from the PDE4 
family, the major regulators of the cAMP signalling in a wide variety of cells. In 
this study it was found that chronic but not acute rolipram administration can 
partially inhibit the dietary obesity- induced depression phenotype that was 
observed in C57Bl/6J mice. This is in accordance with previous studies that 
proposed that the necessary changes that underlie rolipram’s antidepressant 
effect are chronic and not acute and are required for their beneficial clinical 
efficacy in depressed patients (Tardito et al., 2006; Przegalinski et al., 1985). 
HFD induces obesity, the metabolic syndrome (Hwang et al., 2010), as well as 
high expression levels of TNF-α, a pro-inflammatory cytokine (Borst and 
Conover, 2005). On the other hand, obesity is a disorder that is associated with 
an upregulation of the inflammatory response system (IRS) where the main 
characteristic is the hyperproduction of inflammatory cytokines (Makki et al., 
2013) that associates with the development of brain disease (Makki et al., 2013) 
and depression (Schiepers et al., 2005). Low-grade inflammation is frequently 
present among patients with symptoms of depression (Bremmer et al., 2008; 
Gimeno et al., 2009). Antidepressant treatment also affects the levels of 
different cytokines (Kenis and Maes, 2002). A possible explanation for the 
resistance to depression phenotype after rolipram treatment is the anti-
inflammatory effects of rolipram, which downregulates cytokine expression and 
has been proposed for the treatment of inflammatory diseases (Houslay et al., 
2005). Rolipram suppresses the production of cytokines such as TNF-α, 
lymphotoxin-α and IFN-γ, which lead to the suppression of experimental 
autoimmune encephalomyelitis, an inflammatory disease (Sommer et al., 1995). 
The cytokine TNF-alpha is a necessary element in the chain of pathophysiologic 
events leading to inflammation. The PDE4 isoforms are highly expressed in 
monocytes, which are a main source of TNF production, and rolipram is a 500-
fold more potent inhibitor of TNF synthesis in human mononuclear cells 
compared with the nonspecific PDE inhibitor pentoxifylline (Semmler et al., 
1993). 
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However, real-time PCR analysis in my study (Fig.4.26, 4.27, 4.28) revealed no 
changes in levels of cytokines in the hypothalamus of WT and PDE4A-/- mice fed 
either ND or HFD. Measurements of the circulating cytokines in the periphery or 
in other brain regions, though, are necessary to dissect their exact role in this 
model. Although we were not able to detect changes in cytokines, one cannot 
exclude the possibility that durable modifications were caused by transient, but 
sizable elevations of cytokines at an earlier stage that we did not study. 
 
One can also take into consideration that HFD has been shown to affect the 
binding of rolipram to phosphodiesterase 4 in the hypothalamus (Greene et al., 
2009b). Acute treatment with desipramine increases the norepinethrine release 
as well as the total binding of rolipram in the hypothalamus (Greene et al., 
2009b). By contrast, rats that were fed a HFD did not respond to the acute 
desipramine treatment, and revealed less binding of rolipram in the 
hypothalamus compared to ND fed rats (Greene et al., 2009b). The data in the 
previous study suggests that rolipram injections in our model might be affected 
by the consumption of the HFD, therefore further investigation should be done 
to determine the interaction between rolipram and HFD consumption. 
 
Another possible explanation for the resistance to depression phenotype of the 
mice that received rolipram could be deduced from the role of diabetes in 
depression. Consumption of 60% fat induces diabetic characteristics in mice 
(Hwang et al., 2010). Rolipram has been shown to prevent diabetes in a mouse 
model of insulitis by blocking the production of inflammatory cytokines such as 
IL-12, IFN-γ, TNF-α in macrophages (Liang, Beshay et al. 1998). However the role 
of diabetes in my model can be excluded by the GTT and ITT measurements 
from the PDE4A-/- and their litter mate controls PDE4A+/+ mice (Fig.4.33). Even 9 
weeks on HFD failed to induce differences in glucose or insulin tolerance levels 
suggesting that both groups have risk of diabetes even though the PDE4A-/- 
showed a resistance towards the obesity induced depression phenotype. 
Moreover, in the current study, behavioural assays were performed on animals 
that were on HFD for 3 weeks, which is not enough time for the development of 
the complete characteristics of glucose and insulin resistance shown in diabetes. 
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Another possible explanation for the resistance to depression phenotype 
exhibited by the mice that received rolipram is the role of the hypothalamic 
pituitary axis (HPA). The HPA pathway is an important signalling axis that 
connects cytokine production with hypothalamic activity (Turnbull and Rivier, 
1995). Rolipram has been shown to stimulate the HPA axis by acting at the levels 
of both the hypothalamus and the pituitary gland (Kumari, Cover et al. 1997). 
The activation and the role of the HPA pathway in the dietary-induced 
depression phenotype should be further studied. 
 
4.3.2. The effect of rolipram in the dietary-induced 
obesity phenotype 
In this study, daily injections of rolipram to C57Bl/6J mice resulted in resistance 
to the dietary-induced obesity phenotype that is normally seen in this strain. 
This is in accordance with other recent work that reported rolipram’s anti-
obesity effects (Park et al., 2012; Doseyici et al., 2014; Chung, 2012). In 
accordance, clinical trials with roflumilast, another PDE4 inhibitor that is used 
for the treatment of COPD revealed a weight loss for the patients treated with 
roflumilast compare to placebo (Calverley et al., 2009; Rabe, 2011). Cytokine 
production has been involved in the development of obesity induced by HFD 
consumption (Borst and Conover, 2005). Since rolipram blocks cytokine 
production (Liang, Beshay et al. 1998), it might affect the development of 
dietary-induced obesity as well. The PDE4 isoform responsible for the anti-
obesity effect of rolipram is unknown. However, it has already been published 
that loss of PDE4B suppresses TNF-α mRNA levels and PDE4B-/- mice are leaner 
compare to their litter-mates after the consumption of a HFD (Zhang et al., 
2009). In particular, these mice produce smaller fat pads, an indication that 
suggests resistance to dietary-induced obesity (Zhang et al., 2009). Such a result 
points to the fact that PDE4B is a good candidate to target in order to suppress 
obesity. If this is true, one could extrapolate these findings to the current study 
to propose that rolipram administration inhibited the PDE4B sub-family in fat 
tissue and this mechanism might be responsible for the resistance to the diet-
induced obesity. Specific inhibition of the PDE4B in fat or other tissues might 
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shed light whether PDE4B is the enzyme responsible for the resistance to the 
dietary-induced obesity phenotype. 
 
Finally, even though in this model body weight gain does not affect performance 
in the depression-related tests (Chapter 3, Fig.3.5), there is always a possibility 
that rolipram-injected mice are partially rescued from dietary-induced 
depression phenotype due to the fact that they did not gain weight. However, 
this hypothesis is not supported as both Prozac- and rolipram-injected mice 
showed an antidepressant phenotype compared to the saline-injected mice. 
Prozac-injected mice gained significantly more weight and the rolipram-injected 
did not gain any weight, further supporting the lack of correlation between body 
weight and depression phenotype.  Recently the clinical trials for rionabant (CB1R 
antagonist) as an antiobesity and anorectic drug was suspended because of 
increased risks of serious psychiatric problems, including depression (Samat et 
al., 2008). Therefore, finding the specific isoform of the PDE4 family responsible 
for the antiobesity effect of rolipram can be used as a potential target for 
obesity without the psychiatric side effect of depression. 
 
4.3.3. The role of Prozac in the dietary obesity induced 
depression phenotype 
Prozac is a popular, widely prescribed antidepressant and like most of the other 
SSRIs, it has been linked with body weight gain (Schwartz et al., 2004). 
However, whether this body weight gain is a direct effect of Prozac or a 
secondary effect due to euphoria that the depressed patients experience under 
antidepressant treatment remains unknown. Moreover, even though it has been 
shown to improve depression symptoms, the effects of Prozac in other tissues 
have not been investigated. In this study, I have reported that Prozac-injected 
mice gained significantly more weight compared to the saline-injected mice 
while they were on HFD. This is an early effect occurring directly after the first 
Prozac injection (Fig.4.4), suggesting a direct effect of Prozac in body weight. 
This data should provoke thoughts on whether Prozac should be further 
prescribed due to its side effect on body weight gain. Moreover, this study 
showed that daily Prozac injections led to liver enlargement, compared to 
saline-injected mice. 
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In agreement with my observations, the effect of Prozac in liver induces lipid 
accumulation via both the SREBP1c-related lipogenesis and reduction of lipolysis 
in primary mouse hepatocytes (Feng et al., 2012). Further analysis of the 
molecular action of Prozac in liver after HFD, as well as the role of Prozac on ND 
is necessary to dissect whether this effect is specific for mice on a HFD. Due to 
the side effects of Prozac administration in this study, I consider rolipram to be 
a better antidepressant drug (in comparison to Prozac), as it did not induce body 
weight gain or liver enlargement. 
 
In contrast to the results in this study, it has been described that Prozac, 
suppresses appetite in animals (Feldman and Smith, 1978; Kim and Wurtman, 
1988; Li et al., 1996; Luo and Li, 1990) and promotes weight loss in humans  
(Goldstein et al., 1994; Goldstein et al., 1995; Levine et al., 1987; Levine et al., 
1989). These studies suggest that serotonin has a suppressive effect on food 
intake and body weight and it is implicated in the regulation of feeding 
(Grignaschi and Samanin, 1992). Central  administration of serotonin to ob/ob 
and WT mice induced a reduction in food intake in both groups (Currie and 
Wilson, 1992). The ob/ob mice showed an impaired sensitivity to serotonin in 
relation to food intake compare to control mice and this might be the result 
from impaired satiety mechanism in this mouse model of obesity (Currie and 
Wilson, 1992). However, chronic administration of Prozac failed to induce any 
changes in the body weight or food intake of the ob/ob mice (Dubuc and 
Peterson, 1990). Stimulation of 5-HT1A receptor results in hyperphagia whereas 
5-HT1B receptor stimulation mediate hypophagia in rats (Curzon, 1990; Dourish 
et al., 1986; Hutson et al., 1988; Kennett and Curzon, 1988; Weiss et al., 1986). 
Mice lacking functional 5-HT2C receptors are hyperphagic and become obese 
(Nonogaki et al., 1998) suggesting that different serotonin receptors have a 
different effect. Therefore, it is believed that combination of fluoxetine with 5-
HT1A receptor antagonist could be of clinical utility in the treatment of eating 
disorders and obesity (Li et al., 1998). 
 
According to the previous studies, we would expect that mice that received 
Prozac would not gain as much weight as the saline-injected mice. However, 
they gained significantly more weight even from the first injection. The data in 
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our study suggest that the consumption of HFD interferes with the activity of 
serotonin receptors, as the previous studies were performed on ND. It has 
already been suggested that fatty acids can interfere with the serotonergic 
receptor signalling (Kodas et al., 2004), where fatty acids can have a differential 
effect (du Bois et al., 2006). Therefore, further investigation on the interaction 
between serotonin and the consumption of dietary patterns rich in specific fatty 
acids should be studied. Furthermore, even though serotonin has been shown to 
inhibit appetite (Currie and Wilson, 1992), further investigation in this model 
whether Prozac administration increased appetite of mice on HFD should be 
undertaken, as this could be the underlying cause of increased body weight gain. 
 
In this study, daily i.p. injections of rolipram or Prozac were performed in order 
to investigate their role in the onset of complications caused by HFD. However, 
repeated injections are expected to cause peaks and troughs in plasma 
concentration, which would be more extreme in animals with more rapid 
metabolism. In addition, repeated i.p. injections are clearly stressful to the 
animals and it is possible that the antidepressant effect induced by daily 
rolipram or Prozac injections may only occur in the presence of stress. A better 
way to answer this question would be the implantation of an osmotic pump 
which will produce relatively stable plasma levels. In agreement with this 
notion, it has been reported that PDE4 can interact with different partners in 
the in vivo milieu due to different stimulators such as stress, and this can affect 
the affinity for rolipram for PDE4 enzymes (Houslay and Adams, 2003). 
 
4.3.4. The role of the phosphodiesterase 4A subfamily in 
the diet induced depression phenotype 
cAMP plays a prominent role in cellular signalling pathways in neurons and 
processes of neuroplasticity and possibly has a critical role in brain disease 
(Kandel, 2012). Phosphodiesterase-4A (PDE4A) is one of the four genes encoded 
by the PDE4 family which enzymatically regulate spatial and temporal cAMP 
signalling throughout the mammalian organism (Conti et al., 1992; Houslay 
2001). PDE4 enzymes are known for their lack of modulation of cGMP (is cAMP 
specific) and its sensitivity to the antidepressant drug rolipram (Beavo et al., 
1994; Bolger 1994; Beavo 1995). 
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In this study, I have shown for the first time that HFD results in the isoform 
specific upregulation of RNA and protein levels of the PDE4A5 in the 
hypothalamus of WT mice (Fig.4.13&4.14). Interestingly, the phosphorylation 
state and hence activity of the PDE4A5 is also enhanced by HFD (Fig.4.21). 
 
Antidepressant treatment alters PDE4 activity (Zhao et al., 2003) and the levels 
of PDE4A in the brain (Takahashi et al., 1999; Ye et al., 2000; D'Sa et al., 2005; 
Dlaboga et al., 2006; Fujita et al., 2007; Fatemi et al., 2010). Studies in rats 
have shown an increase in PDE4A expression in frontal cortex (Takahashi et al., 
1999; D'Sa et al., 2005), hippocampus  (Ye Y, 2000; Miro et al., 2002), parietal 
cortex (D'Sa et al., 2005) and cerebral cortex (Ye et al., 1997; Zhang et al., 
1999) as a result of chronic antidepressant treatment. Upregulation of PDE4 is 
not limited to antidepressant drug treatment, as chronic electroconvulsive 
seizure also increases PDE4 activity and enhances PDE4 transcription (Takahashi 
et al., 1999; Suda et al., 1998). On the contrary to previous studies that 
revealed PDE4A upregulation, it has been shown that specific PDE4A isoforms 
were significantly decreased in the cerebellum of patients with bipolar disorder 
(Fatemi et al., 2008) and there was no change in patients with schizophrenia or 
major depression (Fatemi et al., 2008), suggesting the importance of the 
localization for the specific targeting of the cAMP degradation to the different 
psychiatric disorders. This is further proven by the distinct pattern of PDE4A 
gene family expression, suggesting their different functional roles in the brain 
(McPhee et al., 2001). Taking all of these observations together, increased 
PDE4A5 after consumption of the HFD - that is proposed to lead to the 
depression phenotype - is in accordance with the increased PDE4A upregulation 
after antidepressant treatment. This is as a result of a compensatory mechanism 
that can inhibit the antidepressant effect caused by antidepressants (Duman et 
al., 1997). 
 
Although rolipram has been proven to be an effective antidepressant in animal 
studies, it failed in clinical trials due to serious side effects such as nausea and 
emesis that were induced in humans. High levels of PDE4D are found in brain 
regions known to be involved in emesis and nausea ( Cherry and Davis, 1999;  
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Miller and Leslie, 1994; Robichaud et al., 2002). It has been suggested that 
inhibition of PDE4D in these areas induces emesis via shortening of a2-
adrenoceptor-mediated anesthesis, a behaviour that correlates with emesis. 
PDE4A is expressed relatively low in areas of the brain that are involved in 
emesis compare to PDE4D that is highly expressed. As shown in this study, the 
PDE4A5 isoform is responsible for the obesity induced depression phenotype. 
Therefore, it is possible that increased expression and activity of PDE4A5 could 
reduce the maximal response to antidepressant treatment. Hence, specific 
inhibition of this enzyme would be a promising therapeutic target, as it does not 
carry the side effect of emesis. Combination of a specific PDE4A5 inhibitor could 
enhance the response to other classes of antidepressants but without the side 
effects of nonselective inhibitors. An effective PDE4A specific inhibitor has yet 
to be discovered. A pair of conserved histidines on the PDE4A has been shown to 
play important role in the activity of the enzyme (Omburo et al., 1998) that 
might help the discovery of a specific inhibitor. 
 
4.3.5. Post-translational modifications of the PDE4As 
might play a role in the dietary obesity induced 
depression phenotype 
The activity of long PDE4s isoform is regulated by phosphorylation within a PKA 
consensus motif located within the UCR1 region (Conti et al., 1995) and studies 
using recombinant PDE4s showed that the phosphorylation also alters the binding 
affinity of rolipram (Hoffmann et al., 1998; Sette and Conti, 1996). In this study 
we showed increased phosphorylation of PDE4A5 by PKA (Fig.4.21), and this is 
suggested to increase the PDE4 activity observed after HFD (Fig.4.7). 
 
Phosphorylation of PDE4A5 by MK2 (MAPKAPK2) attenuates its activation through 
protein kinase A phosphorylation, and selectively disrupts its ability to be 
sequestered by those partner proteins whose interaction involves UCR2, as it 
induces a structural change (MacKenzie et al., 2011). MK2 is a downstream 
effector of p38 MAPK, which is a signalling cascade and a key signal transduction 
pathway involved in the control of cellular immune, inflammatory and stress 
responses (Cowan and Storey 2003). Therefore, increased inflammation after 
HFD might play a role in the regulation of the PDE4A activity in my model. 
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Further investigation into MK2 kinase activity in the hypothalamus after HFD is 
needed to assess the role of the p38 MAPK pathway. Work using a phospho-
specific antibody to the MK2 site on PDE4A5 (MacKenzie et al., 2011)  is also 
required to substantiate the role of this phospho-site in the link between obesity 
and depression. 
 
4.3.6. Compartmentalization of cAMP signalling 
underpinned by PDE4A activity 
PDE4A is widely expressed throughout the rodent brain, but regional and 
intracellular distribution for each subtype is distinct (McPhee et al., 2001). This 
differential distribution suggests that the PDE4A subtypes may serve different 
functions, as it is known that individual PDE4 isoforms have unique non-
redundant roles conferred by their cellular location. The data in this study lends 
support to this notion, as abolishment of PDE4 activity at the membrane fraction 
of the PDE4A-/- mice (after HFD) rescued the increase of the PDE4 activity 
observed for the WT mice after HFD that is believed to cause depression. This 
further shows that diet specifically affects the localization of enzymatic activity 
from the PDE4A subfamily. It is also noteworthy that there is an absence of any 
compensatory mechanism from other phosphodiesterases. Moreover, HFD 
increases the phosphorylation and therefore activity levels of PDE4A5 (Fig.4.21 
& 4.21). However, HFD was shown to decrease the PKA signalling which should 
result in less PKA phosphorylation of its substrates (Fig.3.11). There are two 
possible explanations for that controversy. The first one is that PKA is localized 
in close proximity with PDE4A5 so that PDE4A5 is rapidly phosphorylated when 
PKA is active. The second explanation might be that PKA has a high affinity for 
PDE4A5 therefore even in low levels it can still phosphorylate and activate 
PDE4A5. Both explanations support the idea of the compartmentalization and 
temporal and special regulation of the cAMP signalling. 
 
There is increasing evidence to indicate that the inhibition of these PDE4As 
activities is associated with depression, as they are activated as a compensatory 
mechanism to downregulate cAMP signalling. In support of the data in this study, 
repeated antidepressant treatment selectively increases the PDE4 activity at the 
membrane fractions of hippocampus and cerebral cortex (Zhao et al., 2003). The 
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increased PDE4 at the membrane fraction may be a compensatory response to 
regulate intracellular cAMP concentrations and may represent another 
component of cAMP mediated signal transduction systems affected by repeated 
administration of antidepressants from different pharmacological classes. That 
increase of the PDE4 activity at the membrane fraction shown in this study can 
happen either by increased protein expression or post-translational modification. 
The interaction of the PDE4s with other cellular proteins has also been suggested 
to be involved. 
 
4.3.7. HFD does not induce an anxiety phenotype in mice 
It is generally accepted that repeated stressful events can induce depression in 
humans and mice (Nestler et al., 2002). Therefore, to exclude stress being the 
triggering factor for depression, we examined the anxiety levels of the mice 
using the EPM. No significant differences were observed after HFD (Fig.4.25), 
which indicates that our depression phenotype was independent of the anxiety 
state of the mice. Therefore, in our model of depression, we were able to 
isolate and measure the depression phenotype independently of the 
development of anxiety phenotype. Moreover, it has been shown that loss of 
PDE4B can be responsible for the anxiogenic effect in mice, further underscoring 
the specific roles of different PDE4 isoforms in brain (Zhang et al., 2008) and 
suggesting that the inhibition of PDE4A will not increase any anxiety behaviour.  
 
4.3.8. PDE4A is responsible for the rearing activity in 
mice 
The loss of PDE4A gene did not induce any anxiety related behaviours as 
measured using the EPM. However, it reduced the rearing activity of mice on ND, 
and this deteriorated after HFD. Rearing activity is a measure of the exploratory 
activity in mice and it has been implicated in autism disorders. In agreement 
with this fact, reduced PDE4A5 levels have been discovered in the cerebella of 
patients with autism (Braun et al., 2007). Further investigation on the link 
between autism and a reduction in PDE4A activity is needed. Although these 
mice have not been characterized, an observation made in this study was the 
extreme grooming of their face, another indication of autism.  
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4.3.9. The role of CREB in obesity-induced depression 
phenotype 
Many signaling pathways involving 2nd messengers such as cAMP and calcium lead 
to the phosphorylation of CREB at serine-119. This event allows the recruitment 
of the essential coactivator CBP to CREB (Shaywitz and Greenberg, 1999). 
However, multiple signalling pathways are known to regulate CREB activity at 
different levels and those that depend on the calcium/calmodulin dependent 
protein phosphatase calcineurin, control the transcriptional activity of CBP after 
its recruitment by phospho-CREB (Oetjen et al., 2005; Oetjen et al., 2006; 
Schwaninger et al., 1995a; Schwaninger et al., 1995b) or govern the nuclear 
translocation and binding to the CREB leucine zipper domain of another essential 
CREB coactivator, TORC  (Conkright et al., 2003; Ravnskjaer et al., 2007). 
 
There is much controversy concerning the role of CREB in depression (Carlezon 
et al., 2005) and the actions of CREB may not be as uniform as to fit into a 
simple pro-depressive/anti-depressive scheme. Rather, the outcome of CREB 
action may depend on the duration of its action, the level of activation, the 
specific brain region, and the particular environmental conditions involved in the 
experiment. Moreover, it is also possible that chronic antidepressant treatment 
regulates the expression or function of other transcription factors in addition to 
CREB (Nibuya et al., 1996a) or that CREB leads to regulation of other target 
genes, which may also play a role in the action of antidepressant treatments. 
Promoter analysis of differentially expressed genes in depression revealed a 
clear enrichment of binding sites for the transcription factor CREB1, which is a 
molecule involved in epigenetic regulation (cAMP response element-binding 
protein induces histone modifications) (Lagus et al., 2010). It is noteworthy that 
CREB1 might also constitute one of the major links between disturbed sleep 
habits and mood (Lagus et al., 2010), both important characteristics impaired in 
depression. 
 
In this study, downregulation of the PKA-mediated phospho-CREB levels was 
observed after the consumption of HFD (Fig.4.15). This is in accordance with 
previous expression data in this study that showed that the PKA signalling 
pathway was significantly suppressed in the hypothalamus after HFD (Chapter 3, 
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Fig.3.12&3.13). CREB is an important transcriptional factor regulating a variety 
of pathways and important genes such as BDNF. Further understanding of the 
exact role of CREB in our model should be facilitated via the use of inducible 
hypothalamus-specific CREB transgenic mouse, which has already been used to 
investigate the role of CREB after treatment with psychostimulants (Sakai et al., 
2002). There are different effects on CREB from antidepressant drugs compared 
with non-antidepressant psychotrophic drugs and it has been shown that only 
chronic antidepressant treatment increases the expression of CREB in rat 
hippocampus (Nibuya et al., 1996a). Increased expression of CREB was observed 
after chronic but not acute antidepressant treatment demonstrating that 
upregulation of CREB is dependent on repeated antidepressant treatment 
(Nibuya et al., 1996a) and this correlated with increased levels of BDNF and TrkB 
in the hippocampus (Nibuya et al., 1995). Taken together, these studies indicate 
that increased expression of CREB and induction of BDNF and TrkB in response to 
chronic antidepressant treatments could increase the survival and/or function of 
neurons as this has been reported for direct application of BDNF (Ghosh et al., 
1994; Lindsay et al., 1994; Lindvall et al., 1994). 
 
Sustained elevation of cAMP via chronic administration of rolipram increases the 
expression and phosphorylation of CREB, as well as BDNF and TrkB, and 
facilitates the action of antidepressants on expression of these proteins (Nibuya 
et al., 1996a). Even though all these effects have been proposed for the function 
of CREB in the hippocampus, a similar model might explain the development of 
depression phenotype in the hypothalamus after the consumption of a HFD. 
Reduced phosphorylation of CREB in the hypothalamus might lead to decreased 
transcriptional activation of genes regulated by CREB and this transcriptional 
regulation might lead to the development of depression. Further investigation on 
the role of CREB in a cell-type and brain region specific in the hypothalamus is 
needed to further characterize its role on this pathway. 
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It has already been shown that coadministration of rolipram with an 
antidepressant drug resulted in a more rapid induction of CREB than with either 
treatment alone (Nibuya et al., 1996a). Therefore the identification of the 
isoform responsible for the obesity induced depression phenotype in this study 
and the creation of a specific inhibitor targeting PDE4A5 might be able to be 
used in combination with current antidepressants and have a faster effect. 
Clinical studies are required to determine whether coadministration of a PDE 
inhibitor is capable of shortening the time required for the therapeutic action of 
antidepressant treatments. This might be most beneficial for people with severe 
forms of depression and antidepressant effect is urgently needed. 
 
4.3.10. Neurotrophins and their role in depression 
Infusions of BDNF into the dorsal raphe nucleus produce an antidepressant 
effect, as evaluated by several ‘learned helplessness’ paradigms (Siuciak et al., 
1997). Chronic but not acute antidepressant treatment of rats elevated the BDNF 
and TrkB RNA in the rat hippocampus (Fujimaki et al., 2000; Nibuya et al., 1995; 
Duman et al., 1997) suggesting that many antidepressants act via the 
upregulation of neurotrophins. Further evidence that BDNF and depression are 
linked together has been gleaned from reports that describe stress acting as an 
inducer of depression that results in downregulation of the RNA levels of BDNF. 
Treatment with pscychoactive drugs such as cocaine did not affect the levels of 
BDNF or TrkB suggesting the specificity of the neurotrophins for the depression 
pathway (Nibuya et al., 1995). Induction of seizures in rats by pilocarpine 
(Schmidt-Kastner et al., 1996) or by electroshock (Nibuya et al., 1995; Smith et 
al., 1997)  which mimics the ECT used to treat severe depression, also elevated 
BDNF RNA in the hippocampus, cortex and other brain regions. It has already 
been shown that BDNF in the hippocampus of mice fed HFD was significantly 
lower than mice on ND mice (Yamada et al., 2011), and leptin administration 
was able to increase hippocampal BDNF in the mice fed normal diet compare to 
HFD (Yamada et al., 2011). A major target of the phosphorylated CREB is BDNF 
transcriptional regulation. However even though we detected a downregulation 
of the phosphorylation of CREB, the present study failed to demonstrate any RNA 
changes of BDNF in the hypothalamus after HFD, suggesting that another 
pathway might be involved in the hypothalamus. 
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4.3.11. Virus mediated overexpression of PDE4A5 in the 
hypothalamus induces hyperphagia and obesity 
The data in this study provide strong evidence that AAV-mediated 
overexpression of PDE4A5 in the hypothalamic area can promote obesity possibly 
via hyperphagia in response to the dietary challenge in the adult mice. This 
implicates the PDE4A5 and cAMP signalling in eating disorders. The strikingly 
body weight increase of the PDE4A-/- mice after the overexpression of PDE4A5-wt 
in the hypothalamic area was an unexpected result. 
 
The hypothalamic melanocortin system is a predominant pathway in appetite 
regulation and energy homeostasis (Adan et al., 2006; Seeley et al., 2004; 
Vergoni and Bertolini, 2000). The melanocortin-4 receptor (MC4R) in the central 
nervous system (CNS) plays a critical role in the control of energy balance. 
Activation of MC4R by α-Melanocyte-stimulating hormone (a-MSH), a derivative 
of proopiomelanocortin (POMC), decreases food intake and increases energy 
expenditure. Conversely, inhibition of MC4R by agouti-related protein (AgRP) 
increases food intake and decreases energy expenditure. MC4R deficiency in 
mice or humans results in hyperphagia and a severe obesity syndrome (Huszar et 
al., 1997; Yeo et al., 1998; Vaisse et al., 2000). MC4R is broadly expressed in 
many brain areas implicated in the regulation of energy balance (Mountjoy et 
al., 1994; Kim et al., 2000; Kishi et al., 2003; Lu et al., 2003; Kas et al., 2004) 
and is highly expressed in the paraventricular nucleus (PVN) of hypothalamus 
(Mountjoy et al., 1994; Kishi et al., 2003; Lu et al., 2003). Studies suggest that 
the PVN is one of the key neuroanatomical regions in the brain in mediating 
MC4R signaling and the regulation of energy homeostasis. Lesions of the PVN 
result in hyperphagia in rats and mice (Weingarten et al., 1985; Sawchenko 
1988; Sawchenko 1998). Microinjection of MC4R agonist (MTII or a-MSH) into the 
PVN inhibits food intake, whereas microinjection of MC4R antagonists AgRP, 
SHU9119 or HS014 in the PVN stimulates food intake (Cowley et al., 1999; Kask 
et al., 2000; Kim et al., 2000; Wirth and Giraudo 2001). It has also been 
demonstrated that overexpression of MC4R antagonist agouti in the PVN using 
AAV causes increased food intake and body weight (Kas et al., 2004). 
Interestingly, adeno-associated virus-mediated knockdown of melanocortin-4 
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receptor in the paraventricular nucleus of the hypothalamus promotes high-fat 
diet-induced hyperphagia and obesity (Garza et al., 2008). These data support 
the importance of MC4R activity in the PVN in the control of appetite and body 
weight. The intracellular downstream pathway of the MC4R is unknown and 
should be investigated. 
 
After consideration of the data resulting from my study, the cAMP signalling 
cascade might play an important role in eating disorders and regulating 
appetite. Further investigation whether PDE4A5 is a major modulator of appetite 
is needed as it could be considered as a novel target for appetite disorders. 
 
A possible caveat in this study is the fact that overexpression of PDE4A5 was 
done in the PDE4A-/- mice, therefore whether the effect is specific for the 
PDE4A-/- mice or happens in the WT mice in unknown. Further investigation of 
whether the major driver of the development of obesity is the hyperphagia or 
whether there is a fatty acid oxidation defect or a defect with dysregulation of 
the fatty tissue is warranted. Another possible explanation is that by only 
introducing the PDE4A5 enzyme in the hypothalamic area of the PDE4A-/- mice 
we disturbed a fine balance of cAMP homeostasis that existed in the PDE4A-/- 
mice, and perhaps that is the reason why we failed to notice this phenotype in 
the PDE4A-/-. Further studies overexpressing other PDE4 isoforms are needed to 
test for the specificity of the PDE4A5 involved in obesity. 
 
AMP-activated protein kinase (AMPK) plays a major role in regulating energy 
homeostasis and feeding in the central nervous system (Ruderman et al., 2003) 
(Andersson et al., 2004), and is activated by metabolic stress such as nutrient 
starvation (da Silva Xavier et al., 2000). AMPK is phosphorylated and activated 
when the energy levels are low. Further investigation of the role of AMPK and a 
possible link with the cAMP pathway should be done. Further studies should also 
count weekly the food intake and the body weight. 
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4.3.12. Different brain regions might be involved in the 
obesity induced depression phenotype 
This study focuses on the role of the hypothalamus in the obesity-induced 
depression phenotype. Hypothalamus is a brain area that has historically been 
known to be involved in both obesity and depression. The hypothalamus is 
regarded as the main centre for regulating appetite and obesity has been linked 
with eating disorders (Ryan et al., 2012; Schwartz et al., 2000; Woods and 
D'Alessio, 2008). Using positron emission tomography, a disruption of neural 
circuits linking the cortex, thalamus and cerebellum (cortico-thalamic-
cerebellar-cortical circuit) has been described in patients with schizophrenia 
(Andreasen et al., 1996). Functional imaging studies of patients with depression 
show reduced cerebellar activation (Beauregard et al., 1998; Liotti et al., 2002) 
which persisted even in patients that had recovered from depression (Smith et 
al., 2002). This effect did not correlate with the changes in β-adrenergic 
receptor densities, suggesting antidepressants alter intracellular signal 
transduction pathways in a similar manner (Ye et al., 2000). Further 
investigation of the other brain regions connected to the hypothalamus is 
needed in order to determine the role of the other brain regions in the obesity 
induced depression phenotype. 
 
Studies using autoradiography that detected changes of PDE4 mRNA expression 
in small areas of the brain, such as subregions of hippocampus and selected 
thalamic nuclei after antidepressant treatment  (D'Sa et al., 2005; Miro et al., 
2002), suggest the specificity of the compartmentalization signalling by PDE4s in 
specific and defined brain regions. This should be supported by the development 
of mouse models exhibiting brain region specific overexpression and deletion of 
individual PDE4 isoforms. The differential distribution of the different PDE4A 
isoforms indicates the distinct roles of individual isoforms in CNS function 
further indicating that the development of isoform-specific inhibitors for the 
PDE4A5 may have important therapeutic and pharmacologic properties (McPhee 
et al., 2001; Cherry and Davis, 1999; Perez-Torres et al., 2000). 
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4.4. Conclusions 
In this study rolipram or Prozac administration showed a trend in reducing 
without statistical significance the obesity-induced depression phenotype. 
Interestingly, rolipram injections resulted in resistance to dietary-induced 
obesity phenotype. On the contrary, Prozac daily injections increased body 
weight and induced liver enlargement compared to saline-injected mice. HFD 
increased PDE4 activity at the membrane fraction specifically in the 
hypothalamus. This increase was abolished in PDE4A-/- mice. However, the 
ob/ob:PDE4A-/- mice showed increased PDE4 activity at the cytosol fraction of 
hypothalamus and at the membrane fraction of amygdala compared to the ob/ob 
mice, suggesting a different pathway might be involved in the obesity induced 
depression phenotype. HFD specifically upregulated the levels of RNA, protein 
and phosphorylation state of PDE4A5 in the hypothalamus and downregulated 
the phosphorylation of CREB, a protein regulated by the cAMP signalling 
pathway. Loss of PDE4A in vivo was able to rescue the dietary or genetic obesity-
induced depression phenotype and this effect was independent of the increase in 
the body weight and anxiety behaviour. Short term exposure to HFD or genetic 
obesity did not induce any upregulation of inflammatory cytokines, such as TNF-
α, IL-1β or IFN-γ. No differences could be measured in the RNA levels of BDNF (a 
major neurotrophin that has been linked with depression), when comparing WT 
and PDE4A-/- mice either on ND or HFD, or ob/ob and ob/ob:PDE4A-/-. 
Phosphorylation of DARPP-32 another protein that has been involved in the 
cAMP/PKA signalling pathway was not affected after consumption of HFD, 
suggesting other molecular targets being affected downstream the cAMP 
signalling cascade. The results in this study identify for the first time PDE4A5 as 
a major molecular player in obesity-induced depression phenotype. The exact 
molecular mechanisms need to be elucidated. These data suggest that specific 
targeting of PDE4A5 in the hypothalamus might represent a novel therapeutic 
target for the treatment of depression in overweight and obese individuals. 
Isoform-specific PDE4A5 inhibitors will be challenging to develop due to the 
identical sequence of PDE4 catalytic units. A novel strategy to target the cellular 
location rather than catalytic activity of PDE4A5 may prove beneficial as a 
specific pool of PDE4A5 located in the hypothalamic membrane seems to be 
important in this regard (Lee et al., 2013). 
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5. 
5.1. Introduction 
The communication between the periphery and the brain is a complex and 
selective process that is strictly regulated by the blood brain barrier (BBB). 
The BBB allows only certain molecules to access the brain either for energy 
supply or the regulation of various signalling pathway processes while 
preventing other molecules from entering, in order to protect the brain from 
the damaging factors. 
 
Free fatty acids (FFAs) are not only essential nutritional components, but they 
can also function as signalling molecules (Cao et al., 2008; Itoh et al., 2003; 
Nunez, 1997a; Haber et al., 2003; Coppack et al., 1994). They can cross the 
BBB (Smith and Nagura, 2001) to regulate different molecular pathways in the 
brain (Cao et al., 2008; Itoh et al., 2003; Nunez, 1997a; Haber et al., 2003; 
Coppack et al., 1994). The mechanisms that underpin signal transduction from 
free fatty acids involve the activation of canonical GPCR receptor and PPAR-γ, 
signal transmission and targeted cell response (Lefkowitz, 2004). 
 
Depression rates vary between different countries (Kessler and Bromet, 2013) 
and cultures, and this variation might reflect the variation of food habits, 
especially the intake of dietary fats. Even though there is a correlation 
between the consumption of different fatty acids and prevalence of 
depression (Sanchez-Villegas et al., 2011), the molecular mechanisms behind 
this phenomenon are unknown. 
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5.1.1. Western diet consumption positively correlates 
with depression phenotype in humans and 
rodents, while Mediterranean diet has a 
protective antidepressant effect 
The rising prevalence of depression has been paralleled by a dramatic change 
in the sources of fat in the diet of the westernized world (Pawels and 
Volterrani, 2008). Western diet, commonly consumed in northern Europe and 
USA, is characterized by high caloric consumption, processed food and by the 
replacement of polyunsaturated (PUFA) or monounsaturated fatty acids 
(MUFA) by saturated fatty acids (SFA) and trans-unsaturated fats (TFA) (Pawels 
and Volterrani, 2008). A positive correlation between the development of 
depression and the consumption of trans fat, as well as an inverse relationship 
for PUFA and MUFA intake and depression has been described (Sanchez-
Villegas et al., 2011). 
 
Epidemiological studies suggest that consumption of the western diet can be a 
risk factor for depression later in life (Jacka et al., 2010). In accordance with 
human studies, using a rat strain prone to depression revealed that 
consumption of a high fat diet, but not a high caloric diet, exacerbated the 
depressive phenotype as shown in depression related paradigms (Abildgaard et 
al., 2011). This suggests that the specific diet, rather than the caloric intake, 
was responsible for the depression phenotype. 
 
While a highly processed food diet can be a risk factor for depression, the 
consumption of a whole food diet appears to have a protective effect 
(Akbaraly et al., 2009). Countries located in the southern Europe differ from 
the northern mainly in the consumption of two major food items: olive oil and 
pulses (Naska et al., 2006). Higher adherence to the Mediterranean diet, 
which is rich in legumes, fruits, vegetables, fish and cereals but low in meat 
and dairy products, was found to be inversely associated with the risk of 
depression (Sanchez-Villegas et al., 2009). 
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5.1.2. Fatty acids as signalling molecules in the 
periphery and the brain 
It is now becoming clear that ‘all fats are not created equal’; different fatty 
acids have distinct roles in the cells and can differentially alter the signalling 
pathways in various ways. Fatty acids can either bind to their free fatty acid 
receptors or activate intracellular proteins such as the peroxisome 
proliferator- activated receptor proteins (PPARγ) (Krey et al., 1997). Figure 
5.1 represents the different organs that dietary fatty acids can alter after 
their entrance in our body. 
 
 
Figure 5.1. Schematic of the different pathways affected by dietary fatty 
acids. Figure adapted from: Lam, Schwartz and Rossetti Hypothalamic sensing 
of fatty acids Nature Neuroscience, 2005 
 
FFAs take part in many peripheral physiological processes, including processes 
in fat (Li et al., 2010b) and in the pancreas (Itoh et al., 2003; Briscoe et al., 
2003; Kotarsky et al., 2003; Salehi et al., 2005; Nolan et al., 2006). Ursolic 
acid has been shown to stimulate lipolysis in primary cultured rat adipocytes 
Chapter 5   Hypothalamic Sensing of Fatty Acids 
  Induces Depression 
     
EIRINI VAGENA 209 
 
via the PKA/HSL pathway (Li et al., 2010b). Saturated fatty acids, such as 
stearic and palmitic acid, stimulate MCP-1 secretion, while palmitoleic leads 
to resistin secretion in differentiated adipocytes (Schaeffler et al., 2009). 
Saturated long chain free fatty acids, such as palmitic and lauric acid, have 
both been shown to trigger inflammatory signalling in cultured macrophages 
(Laine et al., 2007; Aronis et al., 2008), whereas short chain fatty acids can 
alter gastrointestinal mobility by regulating enteric neurons (Soret et al., 
2010). 
 
Although many studies have recently investigated the involvement of FFA in 
the regulation of energy balance, the roles of FFAs on brain signalling remain 
largely unknown. Circulating fatty acids gain rapid access to the brain, where 
they equilibrate with neuronal long chain co-As (Miller et al., 1987; Rapoport, 
1996). Once in the brain they can be further metabolized in mitochondria, via 
β-oxidation, incorporated into membranes as phospholipids (Miller et al., 
1987; Rapoport, 1996), used as energy nutrients, or act as potent signalling 
molecules in various cellular processes (Cao et al., 2008; Itoh et al., 2003; 
Nunez, 1997a; Haber et al., 2003; Coppack et al., 1994). The role of FFAs in 
the brain has mostly been studied in the hypothalamus, as it is the brain 
region responsible for the regulation of energy homeostasis, and it has been 
shown that infusion of different fatty acids in this area produces many effects 
in the periphery including hepatic glucose production (Ross et al., 2010). 
Centrally administrated fatty acids can affect signalling related to energy 
balance and body metabolism (Schwinkendorf et al., 2011; Obici et al., 2002; 
Benoit et al., 2009; Milanski et al., 2009; Velloso et al., 2008). Palmitic acid 
administration causes brain insulin resistance (Posey et al., 2009), whereas 
oleic acid acts as a central insulin mimetic, and has a beneficial role on 
hepatic glucose homeostasis and body weight regulation (Obici et al., 2002). 
Palmitoleic acid, a lipid that belongs to the group of lipokines, can act as a 
hormone, as it has been shown to influence energy metabolism (Cao et al., 
2008). Palmitoleic acid play a pivotal role in orchestrating the communication 
of peripheral organs to regulate systemic metabolic homeostasis with 
hypothalamus and its dysfunction leads to obesity, insulin resistance, diabetes 
and hyperlipidemia (Cao et al., 2008). 
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The direct effect of administration of different fatty acids in the 
hypothalamus has been extensively studied to assess their role in the 
regulation of appetite. Intracerebrovascular (i.c.v.) injections of either oleic 
or DHA reduces food intake and body weight by increasing levels of POMC and 
NPY in the hypothalamus (Schwinkendorf et al., 2011; Obici et al., 2002). In 
accordance with this finding, central i.c.v. administration of oleic acid has 
been shown to increase POMC neuronal excitability (Jo et al., 2009). On the 
other hand, i.c.v. infusion of the saturated fatty acid palmitic acid has been 
shown to have an orexigenic effect and promote weight gain, increased local 
inflammation, and impair hypothalamic leptin and insulin signalling (Benoit et 
al., 2009; Milanski et al., 2009; Velloso et al., 2008). Acetate, following 
intraperitoneal injection (i.p.), is able to cross the BBB and enter the brain 
where it can induce changes in the expression profiles of regulatory 
neuropeptides that favour appetite suppression in the hypothalamus (Frost et 
al., 2014). Furthermore, in addition to their roles in the hypothalamus, 
unsaturated fatty acids, such as oleic, linoleic and linolenic (Ikeuchi et al., 
1996; Nishizaki et al., 1998), as well as saturated fatty acids, such as stearic 
acid (Ohta et al., 2003), can facilitate hippocampal synaptic transmission  via 
the PKC signalling pathway. However, even though it has been shown that 
lipids can have various effects in the brain, the specific molecular pathways, 
as well as the receptors responsible for their actions are unknown. 
 
Fatty acids can have a direct or indirect effect on neurons. Medium from 
palmitic acid treated astrocytes may lead to an upregulation of BACE1, a 
protease important in formation of myelin sheaths, and accumulation of 
amyloid precurson proteins (APP) in cortical neurons (Patil et al., 2006). In 
support of the indirect effect, hypothalamic cell lines exposed to saturated 
fatty acids do not reveal any inflammatory activation or insulin resistance 
even though they exhibit endoplasmic reticulum stress and apoptosis (Choi et 
al., 2010). However, even though fatty acids can act as signalling molecules, 
very little is known about the molecular cascades that they activate to have 
this effect. 
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5.1.3. The role of FFAR1 (GPR40) in the brain 
signalling pathways 
To date, Free Fatty Acid Receptor 1 (FFAR1), also known as GPR40, is mostly 
associated with insulin secretion from pancreatic β-cells (Itoh et al., 2003; 
Briscoe et al., 2003; Kotarsky et al., 2003; Salehi et al., 2005; Nolan et al., 
2006). Very few studies have investigated its role in the brain despite its high 
expression levels (Briscoe et al., 2003; Ma et al., 2007). GPR40 expression in 
the hypothalamus has been shown to be involved in the pain regulatory system 
(Nakamoto et al., 2012). GPR40 was found in the hippocampal neurogenic 
niche and GPR40 levels increased in this area after ischemia, implying a role 
for GPR40 in neurogenesis (Ma et al., 2008b). This effect is speculated to be 
mediated via DHA binding on GPR40, as DHA is a representative high-affinity 
GPR40 ligand that promotes hippocampal neurogenesis (Kawakita et al., 2006; 
Yamashima, 2008). This effect is believed to be facilitated by increased 
phosphorylation of CREB after ischemia, and it was correlated with enhanced 
hippocampal neurogenesis (Boneva and Yamashima, 2012). Furthermore, 
arachidonic acid and DHA was recently found to increase intracellular Ca2+ 
levels through activation of GPR40/PLC/IP3 signalling pathway in PC12 cells 
(Yamashima, 2008) or rat fetal brain neural stem cells that were transfected 
with the GPR40 gene (Ma et al., 2010). These findings implicate GPR40 in 
adult neurogenesis of primates and suggest a key role of GPR40 for the action 
of PUFAs. 
 
5.1.4. HFD consumption induces hypothalamic 
inflammation 
In addition to hormonal signals coming from the periphery, such as leptin and 
insulin, nutrients such as lipids can cross the BBB and affect the central 
control of food intake and energy expenditure. This hypothalamic nutrient 
sensing plays a critical role in the complex network of signals controlling 
energy balance (Le Foll et al., 2009; Moran, 2010; Cota et al., 2007). 
Increased dietary fat engages inflammatory processes in the hypothalamus 
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that undermine the efficacy of central nutrient sensing mechanisms critical 
for negative feedback control (De Souza et al., 2005). Hypothalamic sensing of 
glucose has been proposed to be an important intervention for the treatment 
of diabetes (Lam et al., 2005a). It has been observed that as early as little as 
1 to 3 days on HFD is sufficient to induce hypothalamic inflammation along 
with reactive gliosis which involves recruitment of microglia and astrocytes 
(Thaler et al., 2012). 
 
It has been suggested that central availability of dietary fat per se rather than 
the absolute energetic content of consumed food may promote obesity, 
central insulin insensitivity and hypothalamic inflammation (Posey et al., 
2009). Diets high in fat content and refined carbohydrates are known as risk 
factors for metabolic syndrome and they induce insulin resistance in rodents 
(Storlien et al., 1986; Pagliassotti and Prach, 1995; Oakes et al., 1997). 
Dietary or genetic induced obesity leads to hypothalamic inflammation (De 
Souza et al., 2005; Milanski et al., 2009; Moraes et al., 2009) and addition of 
unsaturated fatty acids in the diet can reverse the hypothalamic dysfunction 
(Cintra et al., 2012). 
 
In summary, a variety of studies has shown a positive correlation between the 
consumption of the western diet and the development of mood disorders such 
as depression. On the other hand, the beneficial and protective role of diets 
rich in PUFAs has been documented in numerous studies. The molecular 
mechanisms that involve the regulation of mood disorders by the consumption 
of different diets with different fatty acid composition are unknown. However 
whether specific dietary fatty acids in the western diet can play a causative 
role in the development of depression has never been investigated. 
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5.1.5. Aims 
Given the epidemiological and clinical data linking western data and 
depression it was hypothesized that specific dietary fatty acids may induce a 
depression phenotype and this effect might happen via the cAMP/PDE4A/PKA 
signalling pathway in the CNS. Hence, this chapter will focus on the role of 
different dietary fatty acids in the development of depression and the 
molecular pathways that are affected. 
The aims of this chapter are as follows: 
1) to assess the role of specific fatty acids in the development of depression 
and on PKA signalling 
2) to identify in the hypothalamic area the molecular mechanism(s) of the 
dietary obesity induced depression phenotype 
 
5.2. Results 
5.2.1. HFD specifically alters the hypothalamic fatty 
acid composition 
To investigate whether diet can alter the fatty acid composition in the brain, 
fatty acid profile analysis was performed in the hypothalamic and cortical 
brain regions of mice fed ND and HFD (short-term and longer-term). 
Hypothalamic samples were compared to cortical samples, as there was no 
difference found in the cortex linking diet with depression in this study. 
Hypothalamic and cortical samples were collected from the same mice and 
analysed by mass spectrometry. Interestingly, there was an accumulation of 
most of the fatty acids that were analysed in the hypothalamic area after the 
consumption of either 4 or 8 weeks (short-term and longe-term, respectively) 
on HFD compare to mice fed ND (Fig. 5.2). This effect was specific for the 
hypothalamus as there were no differences in the fatty acid composition in 
the cortex for mice fed either ND or HFD (Fig. 5.2). This suggests that fatty 
acid composition in the hypothalamus is specifically affected by HFD 
consumption compared to other brain region analysed in the same mice. 
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Figure.5.2. Fatty acid profile analysis for hypothalamic and cortical 
samples of mice fed either ND or HFD. Heatmaps for the different fatty acids 
of hypothalamic and cortical samples of mice fed ND versus either 4 or 8 
weeks on a HFD. The heatmaps were constructed converting the actual values 
(µgr) of the different fatty acids into log2 values. The heatmaps of the fatty 
acids were divided in two groups due to the high or low representation of the 
different fatty acids in the brain (n=3-4, analysed by 2-way ANOVA with 
Bonferroni post-hoc test). The mass spectrometry experiment was carried out 
by Dr Michelle Puchowicz. 
 
5.2.2. Different fatty acids can differentially affect the 
forskolin induced activation of PKA signalling 
As described in Chapter 1 fatty acids can be divided into two major groups: 
saturated and unsaturated fatty acids (Schematic 1.4). The opposing roles of 
the two groups of fatty acids has been shown in many signalling pathways, 
with unsaturated fatty acids having a beneficial role and saturated fatty acids 
having a detrimental role (Almaguel et al., 2009; Posey et al., 2009; Obici et 
al., 2002). Central i.c.v. administration of fatty acids have distinct effects on 
energy metabolism, neuropeptide expression and food intake regulation, with 
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unsaturated fatty acids eliciting a more anorexigenic response compared with 
the saturated fatty acids (Schwinkendorf et al., 2011; Obici et al., 2002; 
Benoit et al., 2009; Milanski et al., 2009; Velloso et al., 2008). However, the 
molecular mechanism of these effects is unknown. To investigate the role of 
different fatty acids on PKA signalling, fluorescence resonance energy transfer 
(FRET) experiments were performed in a mouse neuroblastoma cell line (N2a) 
treated with different fatty acids. N2a cells were transfected with a FRET PKA 
sensor that detects the activation of PKA signalling. Figure 5.3. is a schematic 
representation of the FRET PKA sensor used in this study. This sensor consists 
of the regulatory subunit I of the PKA protein and is cloned between the YFP 
and the CFP protein. N2a cells were co-transfected with PDE4A5 as it was 
shown to play an important role in obesity induced depression phenotype 
along with β-arrestin 2. Arrestins act as scaffolding proteins to facilitate the 
interaction between a GPCRs and intracellular molecules (Shenoy and 
Lefkowitz, 2005). At the end of all FRET experiments, cells were treated with 
high concentration of forskolin (stimulation of cAMP production) and with 3-
isobutyl-1-methylxanthine,IBMX (inhibition of cAMP degradation) in order to 
detect FRET signal and verify that cells are still responsive to different 
treatments. 
 
 
Figure 5.3. Schematic of the PKA FRET sensor. Represents a schematic of 
the FRET PKA sensor used in this study. This sensor consists of the regulatory 
subunit I of the PKA protein and is cloned between the YFP and the CFP 
protein. In the absence of cAMP the PKA FRET sensor has a specific structure 
that allows the CFP and YFP to be in close proximity resulting in high FRET 
signal. In the presence of cAMP, cAMP can bind to the PKA regulatory subunit 
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leading to a structural conformation where CFP and YFP are far from each 
other, leading to low FRET signal. 
Figure 5.4 shows the structure of the different fatty acids used for the 
treatment of the neuroblastoma cell line (N2a). 
 
Figure 5.4. Chemical formulas of the fatty acids. Formulas of palmitic, 
myristic and oleic acid used to treat N2a cells. Palmitic and myristic acid 
belong to the saturated group while oleic acid belongs to the unsaturated 
fatty acid group. 
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Treatment of neuronal cells transfected with the PKA sensor with forskolin led 
to an increase FRET signal due to the activation of PKA (Fig. 5.5). Forskolin is 
a diterpine that directly activates adenylyl cyclase to produce cAMP from ATP 
(Seamon et al., 1981) that in turn binds to the PKA regulatory subunit and 
induces a structural transformation that leads to PKA activation and FRET 
signal. Surprisingly, pretreatment of N2a cells with palmitic acid was able to 
block the forskolin-induced PKA activation observed in the N2a cell line (Fig. 
5.5). On the contrary, pretreatment with either oleic acid or myristic acid did 
not affect the forskolin-induced activation of PKA (Fig. 5.5). The 
quantification of the above FRET experiment in N2a cells treated with either 
palmitic, oleic or myristic acid is shown in Fig. 5.6. 
 
Figure 5.5. Palmitic acid specifically abolishes the forskolin induced 
activation of PKA signaling in neuronal cells. FRET analysis of N2a cell line 
(mouse neuroblastoma cell line). Forskolin induced activation of PKA signaling 
is shown alone (A) or following pretreated with 100µM of either (B) palmitic, 
(C) oleic or (D) myristic acid. Cells were transfected with PDE4A5 and β-
arrestin -2 (ARB2). Palmitic but not oleic or myristic acid was able to block the 
forskolin induced activation of PKA. (n=6-8 per condition). This experiment 
was carried out by Dr Nicola Devine. 
A B 
C D 
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Figure.5.6. Palmitic acid specifically abolishes the forskolin induced 
activation of PKA signalling in neuronal cells. Quantification of the FRET 
experiment done in N2a cell line (mouse neuroblastoma cell line) pretreated 
with either 100uM of either palmitic, oleic or myristic acid. Palmitic but not 
oleic or myristic acid was able to block the forskolin induced activation of 
PKA. (n=6-8 ,***P < 0.001 by 1 way ANOVA with Dunnett’s multiple comparison 
test). This experiment was carried out by Dr Nicola Devine. 
 
5.2.3. Increased consumption of palmitic acid may 
induce a depression phenotype in mice 
Many studies support the beneficial and protective role of unsaturated fatty 
acids in depression (Mozaffarian et al., 2010; Fernandez-Jarne et al., 2002; 
Kontogianni et al., 2007; Barzi et al., 2003). Little is known, however, about 
the detrimental effect of specific dietary fatty acids in depression, and 
whether they can play a causative role in the development of depression. To 
investigate whether high consumption of palmitic acid induces a depression 
phenotype in mice, we decided to administer, via oral gavage, high levels of 
palmitic acid. Ghee, (clarified butter) consists of a very high percentage of 
palmitic acid (Mirghani et al., 2010). As a control we administered olive oil, 
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which consists of high levels of oleic acid (Mirghani et al., 2010). Table 5.1 
shows the different fatty acid composition of both ghee and olive oil. Ghee 
consists of almost 40% of palmitic acid. In contrast, olive oil consists of just 
15% palmitic acid. 
Table5.1. Fatty acid composition of ghee and olive oil. Different 
percentages of the different fatty acids in ghee and olive oil. 
Fatty Acid % Ghee % 
Olive 
oil 
    Saturated Fatty Acid   
C4:0 Butyric Acid 0.70% 
65% 
  
14% 
C6:0 Caproic Acid 2.20%   
C8:0 Caprylic Acid 1.20%   
C10:0 Capric Acid 2.50%   
C12:0 Lauric Acid 2.70%   
C14:0 Myristic Acid 11.80% 0.1-1.2% 
C16:0 Palmitic Acid 
32-
36.70% 
7-16% 
C18:0 Stearic Acid 12.50% 1-3% 
    Monounsaturated Fatty Acid   
C16:1 
Palmitoleic 
Acid 
3.30% 
32% 
  
77% C18:1 Oleic Acid 26.20% 65-80% 
C20:1 Gadoleic Acid 1.20%   
C22:1 Eruciic Acid 0.20%   
Polyunsaturated Fatty Acid 3%   9% 
Total % 100%   100% 
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Thus the consumption of high levels of palmitic acid was tested in vivo in 
order to see whether it can induce a depression phenotype. To test this 
hypothesis, mice were orally gavaged twice per day for either three or seven 
weeks with either ghee or olive oil. Fig. 5.7 shows the experimental design 
for the oral gavage administration of either ghee or olive oil for either 3 or 7 
weeks. Both ghee and olive oil were pre-warmed at 37oC for 30 minutes 
before the administration. 
 
 
 
Figure 5.7. Experimental design for the oral gavage with oils. Schematic of 
the experimental design for the mice that were gavaged with either ghee or 
olive oil. The mice were gavaged with 300ul (0.3g FA≈3kcal) twice per day for 
3 or 7 weeks. 
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Following three weeks of oral gavage, there was no difference in the 
depression phenotype, as assessed with either TST or SPT between mice that 
received ghee (high palmitic acid) and mice that received olive oil (low 
palmitic acid) as shown (Fig. 5.8) and (Fig. 5.9). 
 
Figure.5.8. Ghee consumption does not alter the immobilization time at 
the tail suspension test after 3 weeks on gavage. Immobilization time at the 
tail suspension test for mice that were gavaged for 3 weeks with either olive 
oil or ghee (n=9). 
 
 
 
Figure.5.9. Ghee consumption does not affect the sucrose consumption at 
the sucrose preference test after 3 weeks. Sucrose preference test for mice 
that were gavaged for 3 weeks with either olive oil or ghee (n=8-9). One 
mouse per group was excluded as they both had a measurement of zero 
consumption in one of the two bottles. 
 
Interestingly, a pilot experiment after seven weeks of gavage showed a trend 
towards increasing the immobilization in the tail suspension test in ghee 
gavaged mice compared to olive oil gavaged mice (Fig. 5.10). Following this 
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longer period of gavage, mice gavaged with ghee tended to consume less 
sucrose compare to the olive oil gavaged mice (Fig. 5.11). In Fig. 5.11 as 
shown by the plot there was one mouse from each group that consumed much 
less sucrose than the rest in each group. These mice were outliers according 
to the z score test, Thompson Tau, Grubb's test and mild outlier criteria of the 
IQR test. Further excluding these values reveals a significant (P<0.01) 
decrease of sucrose consumption for the ghee gavaged mice compare to olive 
oil. However, further studies with bigger cohorts should be done in order to 
establish whether ghee induces a depression phenotype in mice compared to 
olive oil. This effect was not related to body weight, as both groups showed 
the same body weight, with a trend that ghee gavaged mice gaining weight 
after the seventh week on the gavage (Fig. 5.12).  
Figure.5.10. Ghee 
consumption tended to 
increase the 
immobilization time at 
the tail suspension 
test. Immobilization 
time during the tail 
suspension test for 
mice that were gavaged 
for 7 weeks with either 
olive oil or ghee (n=9). 
. 
 
 
Figure.5.11. Ghee 
consumption tended 
to decrease the 
sucrose 
consumption at the 
sucrose preference 
test. Sucrose 
consumption for mice 
that were gavaged 
for 7 weeks with 
either olive oil or 
ghee (n=9-10). 
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Figure.5.12. Daily oral gavages of either olive oil or ghee does not affect 
the body weight. Body weight curves of WT mice that were gavaged twice per 
day for 8 weeks with either olive oil or ghee on ND (n=9-10). 
 
5.2.4. Single stereotactic injection of palmitic acid in 
the hypothalamus induces a depression 
phenotype in vivo 
Next, it was hypothesized that palmitic acid can directly signal in the CNS to 
induce a depression phenotype. Therefore, the direct effect of palmitic acid 
in the hypothalamic area was tested. In a pilot study with just 3 mice per 
group bilateral single stereotactic injections of 10µg of palmitic acid in the 
hypothalamic area revealed an increase in the immobilization time of the tail 
suspension test compared to the mice that received either artificial cerebro-
spinal fluid (aCSF) or ethanol injections as control (Fig. 5.13). The single 
bilateral stereotactic injections did not affect the rearing or the total levels of 
activity of the mice at the open field test (Fig. 5.14) suggesting that the 
depression phenotype develops independently of the total levels of activity. 
This pilot experiment needs to be repeated and better solvent of palmitic acid 
should be used as ethanol has been shown to affect depressive behaviours in 
mammals.  
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Figure.5.13. Single injection of palmitic acid induces an increase at the 
immobilization time at the tail suspension test. Immobilization time at the 
tail suspension test of mice that received either 2ul of aCSF, 2ul of 2% ethanol 
or 2µl of 5µg/µl of palmitic acid dissolved in ethanol. (n=3 1-WAY ANOVA 
**P<0.01,*P<0.05) Stereotactic injections and immobilization quantification 
was performed by Dr Jae Kuy Ruy. 
 
Figure.5.14. Single injection of palmitic acid does not alter the total 
activity at the open field test. Open field test for WT mice that received a 
single injection of either aCSF, ethanol of palmitic acid (n=3). 
 
5.2.5. Dietary or genetic obesity induces an 
upregulation of fatty acid receptors  
As it has been mentioned before, fatty acids exert their effect by binding to 
appropriate fatty acid receptors to regulate intracellular processes. 
Therefore, the role of different free fatty acid receptors in the hypothalamus 
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for this model of depression was investigated. To investigate the involvement 
of different fatty acid receptors in the hypothalamic area, their RNA levels 
were measured with RT-PCR. Real time PCR data revealed an increase of the 
GPR41 RNA levels after 3 weeks on HFD (Fig. 5.15).  
 
Figure 5.15. Dietary 
obesity tends to 
increase the RNA 
levels of GPR41 in the 
hypothalamus. Real-
time PCR analysis of 
GPR41 in the 
hypothalamus of WT 
mice on ND, 1 week 
and 3 weeks on HFD 
and ob/ob mice (n=4). 
 
 
 
The RNA levels of the GPR120 receptor were up-regulated in the hypothalamic 
area of the genetically obese (ob/ob) mice (Fig. 5.16). 
 
Figure.5.16. Genetic 
obesity increases the 
RNA levels of GPR120 
in the hypothalamus. 
Real-time PCR analysis 
of GPR120 in the 
hypothalamus of WT 
mice on ND, 1 week 
and 3 weeks on HFD 
and ob/ob mice (n=4, 
*P < 0.05 , by one-way 
ANOVA with Tukey’s 
multiple comparison 
test). 
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Most strikingly though, the levels of GPR40 RNA were upregulated 4-5 fold in 
WT mice after just one week on HFD and for the genetically obese mice (Fig. 
5.17). These data suggest that the diet can change the levels of different free 
fatty acid receptors in the brain of WT and ob/ob mice. However at the 
protein level, HFD did not induce any change in the level of GPR40 (Fig. 
5.18). 
 
Figure 5.17. Dietary 
or genetic obesity 
increases the RNA 
levels of GPR40 in the 
hypothalamus. Real-
time PCR analysis of 
GPR40 in the 
hypothalamus of WT 
mice on ND, 1 week 
and 3 weeks on HFD 
and ob/ob mice (n=4, 
*P < 0.05 , by one-way 
ANOVA with Bonferroni 
multiple comparison 
test). 
 
 
Figure 5.18. High fat diet does not affect the total protein levels of GPR40 
in the hypothalamus. Western blot analysis for total levels of GPR40 in the 
hypothalamus. GAPDH was used as a loading control (n=4). 
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5.2.6. No differences at the RNA levels of arrestins in the 
hypothalamus  
As mentioned above, free fatty acids receptors are all GPCRs (Brown et al., 
2005). β-arrestins can interact with GPCRs in order to regulate various GPCRs 
and intracellular signal pathways (Gurevich et al., 1995) (Palczewski, 1994). 
Real time PCR analysis, however, revealed no differences for transcript levels 
of either β-arrestin 1 (Fig. 5.19) or β-arrestin2 (Fig. 5.20). Moreover, no 
differences in the total levels of β-arrestin2 were detected in the 
hypothalamus of mice fed either ND or HFD (Fig. 5.21). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19. No differences in the RNA levels of β-arrestin1 after dietary or 
genetically induced obesity. Real-time PCR analysis of β-arrestin 1 for WT, 
PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on either ND, 1 and 3 weeks on HFD (n=4) 
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Figure.5.20. No differences in the RNA levels of beta-arrestin 2 after 
dietary or genetically induced obesity. Real-time PCR analysis of beta-
arrestin1 for WT, PDE4A-/- , ob/ob and ob/ob:PDE4A-/- on either ND, 1 and 3 
weeks on HFD (n=4) 
 
 
Figure 5.21. High fat diet does not affect the total protein levels of β-
arrestin2 in the hypothalamus. Western blot analysis for total levels of β-
arrestin 2 in the hypothalamus. GAPDH was used as a loading control (n=4). 
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5.2.7. GPR40 interacts with PDE4A5 in the 
hypothalamus  
Previously it was shown that dietary or genetic obesity induces the 
upregulation of PDE4A5 in the hypothalamus (Fig. 4.13&4.14). Therefore, I 
tested whether GPR40 can interact with PDE4A5 in vivo. Studies have shown 
that members from the PDE4 family can interact with GPCRs (Perry et al., 
2002). To investigate the possible interaction of PDE4A5 and GPR40, co-
Immunoprecipitation analysis was performed using extracts from the 
hypothalamus of mice fed either ND or HFD. Immunoprecipitation against 
GPR40 and western blotting for PDE4A5 revealed a putative interaction of 
PDE4A5 with GPR40 in the hypothalamus of mice fed either ND or HFD (Fig. 
5.22).  
 
Figure 5.22. GPR40 interacts with PDE4A5 in the hypothalamus of mice fed 
either normal or high fat diet. Immunoprecipitation of 700ugr of 
hypothalamic samples from mice (fasted for 7h, and then food was added for 
2h) fed either ND or HFD with the GPR40 rabbit antibody (Santacruz) and 
western blotting with PDE4A5. (n=1) 
 
5.2.8. GPR40 interacts with PDE4A5 in vitro  
Next we wanted to see whether we could recapitulate the effects of the 
dietary fatty acids and confirm this interaction in vitro. Fats can be purchased 
with a methyl, ethyl or acid group but the fatty acid group was used as it has 
been shown that the carboxyl group is indispensable for this function as the 
methyl group of fats does not induce any calcium changes after GPR40 
activation (Itoh et al., 2003). For the in vitro treatments, the mouse 
neuroblastoma cell line (N2a) was employed as it has been shown to express 
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high levels of GPR40. Previous studies have shown that members from the 
PDE4 family can interact with GPCRs in an arrestin dependent or independent 
way (Richter et al., 2008). Co-Immunoprecipitation analysis of transiently 
transfected N2a cells with PDE4A5 and β-arrestin 2 (ARB2) revealed a possible 
interaction between PDE4A5 and GPR40 in basal levels and after 5 minutes of 
palmitic acid treatment (Fig. 5.23). 
 
Figure 5.23. PDE4A5 interacts with GPR40 in neurons in vitro. Co-
immunoprecipitation between GPR40 and PDE4A5 in N2a cell line after 5 
minutes with 500µM of palmitic acid stimulation. Immunoprecipitation was 
performed with 1.3mg of protein and using the PDE4A antibody from abcam. 
Cells well transiently transfected with PDE4A5 and ARB1 and ARB2. (n=1) 
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Next I examined whether the GPR40-PDE4A5 interaction happens in HEK293 
cells. HEK293 cells transiently transfected with PDE4A5-vsv, GPR40-flag and β-
arrestin 2 revealed a possible interaction between PDE4A5 and GPR40 (Fig. 
5.24). HEK293 cells were treated at different time points with 500µM of 
palmitic acid and immunoprecipitation analysis was performed. Interestingly, 
the interaction was time dependent to the palmitic acid treatment (Fig. 
5.24). 
 
 
Figure.5.24. PDE4A5 interacts with GPR40 in vitro in HEK293 cells. Co-
immunoprecipitation of PDE4A5 with GPR40 in HEK293 cells treated in 
different time points with 500uM of palmitic acid. Immunoprecipation was 
performed with 50ugr per condition. HEK293 cells were transiently transfected 
with PDE4A5-vsv, ARB2 and GPR40-flag.(n=2) 
 
Palmitic acid is a fatty acid that exists in abundance in the fetal bovine serum 
in which cells grow. Therefore, we decided to investigate whether this 
interaction would be enhanced after serum deprivation of HEK293 cells. The 
same experiment was performed but this time the cells were deprived for 
either 5h (Fig. 5.25) or 12h (Fig. 5.26) prior to the treatment with palmitic 
acid. Co-immunoprecipitation analysis of HEK293 cells revealed a possible 
interaction between PDE4A5 and GPR40 at basal as well as at different time 
points after treatment with palmitic acid (Fig. 5.25) and (Fig. 5.26). The 
immunoprecipitation with the FLAG antibody was not the same for all the 
different conditions and therefore there was an unequal interaction with 
PDE4A5 for (Fig. 5.25) and (Fig. 5.26). Moreover, either 5 or 12 hours of 
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serum deprivation did not affect the interaction between PDE4A5 and GPR40 
(Fig. 5.25) and (Fig. 5.26). 
 
 
Figure. 5.25. PDE4A5 interacts with GPR40 in vitro in HEK293 cells. Co-
immunoprecipitation of PDE4A5 with GPR40 in HEK293 cells treated in different 
time points with 500uM of palmitic acid. Immunoprecipation was performed with 
750ugr per condition. HEK293 cells were transiently transfected with PDE4A5-
vsv, ARB2 and GPR40-flag. The HEK293 cells were deprived from serum for 5h 
prior to the treatments with palmitic acid. (n=1) 
 
 
Figure 5.26. PDE4A5 interacts with GPR40 in vitro in HEK293 cells. Co-
immunoprecipitation of PDE4A5 with GPR40 in HEK293 cells treated in 
different time points with 500uM of palmitic acid. Immunoprecipation was 
performed with 750ugr per condition. HEK293 cells were transiently 
transfected with PDE4A5-vsv, ARB2 and GPR40-flag. The HEK293 cells were 
deprived from serum for 12h prior to the treatments with palmitic acid. (n=1) 
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5.2.9. Palmitic acid treatment of neuronal cells 
increases the PDE4A5 translocation at the 
membrane fraction  
Previously I showed that the compartmentalization of phosphodiesterase 
activity is important for the dietary obesity induced depression phenotype in 
the hypothalamus (Fig. 4.19). To investigate whether palmitic acid treatment 
changes the compartmentalization of PDE4A5 in this in vitro system, N2a cells 
were treated with different concentrations of palmitic acid for 5 minutes. 
Interestingly, there was a concentration dependent increase of the PDE4A5 
protein accumulation at the membrane fraction of N2a cells treated with 
different concentrations of palmitic acid (Fig. 5.27). 
 
Figure.5.27. Concentration dependent increase of PDE4A5 at the 
membrane fraction of neuronal cells. Membrane fractionation of N2a cells 
transfected with PDE4A5 and ARB2 and have been treated with increasing 
concentrations of palmitic acid for 5 minutes. Concentration dependent 
increase of PDE4A5 at the membrane fraction. WB was run with 10ugr for the 
membrane fraction and 5ugr for the cytosol fraction. (n=1) 
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Next, membrane fractionation of N2a cells treated with palmitic acid in 
different time points revealed an increase of the PDE4A5 and ARB2 at the 
membrane fraction after 2 minutes of palmitic treatment (Fig. 5.28). 
 
Figure 5.28. Palmitic acid 
treatment induces an 
accumulation of PDE4A5 and 
ARB2 at the membrane 
fraction in N2a cells. 
Membrane fractionation of 
N2a cells (mouse 
neuroblastoma) treated in 
different time points with 
500uM of palmitic acid. There 
was an increase of PDE4A5 
and ARB2 after 2 minutes of 
treatment. GPR40 was used as 
an indicator for the membrane 
fraction. (n=2) 
 
A similar effect of palmitic acid on HEK293 cells was observed after 5 minutes 
of treatment with increased phosphorylation as well (Fig. 5.29). 
 
Figure 5.29. 
Palmitic acid 
treatment 
induces an 
increase of 
PDE4A5 
phosphorylatio
n at the 
membrane 
fraction in 
HEK293 cells. 
Membrane 
fractionation of 
HEK293 cells (mouse neuroblastoma) treated in different time points with 
500uM with palmitic acid. There was an increase of PDE4A5 and ARB2 after 3 
minutes of treatment. GPR40 was used as an indicator for the membrane 
fraction. (n=1) 
Chapter 5   Hypothalamic Sensing of Fatty Acids 
  Induces Depression 
     
EIRINI VAGENA 235 
 
5.2.10. Oleic acid treatment of neuronal or HEK293 cells 
does not alter the levels of PDE4A5 at the 
membrane fraction  
GPR40 has been shown to bind both saturated and unsaturated fatty acids. We 
thus set out to investigate whether oleic acid, which is an unsaturated fatty 
acid, has the same affects as palmitic acid. Interestingly, the same 
concentration of oleic treatment in N2a cells did not affect the localization of 
the PDE4A5 (Fig. 5.30). In accordance, treatment of HEK293 cells with oleic 
acid in different time points did not affect the protein levels of PDE4A5 at the 
membrane fraction (Fig. 5.31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.30. Oleic acid treatment does not alter the levels of PDE4A5 and 
ARB2 at the membrane fraction in N2a cells. Membrane fractionation of N2a 
cells treated in different time points with 500uM of oleic acid. (n=1) 
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Figure.5.31. Oleic acid 
treatment does not alter 
the levels of PDE4A5 and 
ARB2 at the membrane 
fraction in HEK293 cells. 
Membrane fractionation of 
HEK293 cells treated in 
different time points with 
500uM of oleic acid. (n=1) 
 
 
 
 
5.2.11. GPR40 agonist treatment does not change the 
protein levels of PDE4A5 at the membrane 
fraction 
Palmitic acid has been shown to be a ligand for GPR40. However it has also 
been shown to stimulate other cell membrane receptors as well as 
intracellular receptors. Therefore a specific GPR40 agonist was used to 
determine whether the specific activation of GPR40 induces the translocation 
of PDE4A5 at the membrane fraction. GW9508 is a novel GPR40/GPR120 
agonist that is 100 fold more selective for GPR40 rather than GPR120 (Briscoe 
et al., 2006). GW9508 has a higher affinity for GPR40 than the other fatty 
acids ligands do (Briscoe et al., 2006). Fig. 5.32 shows the structure of the 
GPR40 agonist used in this study.                 
Figure 5.32. Schematic of the 
specific GPR40 agonist. GW9508 
is a specific agonist for GPR40. It 
is a cell-permeable 
aminophenylpropanoate that 
acts as a potent and selective 
agonist for the G-protein 
coupled receptor (GPCR) GPR40 (EC50 ~50 nM) with much reduced activity 
towards family members GPR120 (EC50 ~3.5 µM), GPR41/GPR43 (EC50 >50 µM), 
as well as a panel of eight other fatty acid and prostaglandin receptors. 
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Treatment with either low (10 µM) or high (100 µM) concentrations of the 
GPR40 agonist did not alter the levels of PDE4A5 at the membrane fraction 
(Fig. 5.33) and (Fig. 5.34). 
 
Figure 5.33. 
GPR40 agonist 
does not induce 
any PDE4A5 
accumulation at 
the membrane 
fraction. Membrane 
fractionation of 
HEK293 cells 
treated with 10uM 
of GW-9508, a 
selective GPR40 
agonist. HEK293 
cells transfected 
with PDE4A5, ARB2 
and GPR40. 10µgr 
of the membrane fraction and 10µgr of the cytosol fraction were used for the 
western blot. 
 
Figure 5.34. GPR40 
agonist does not 
induce any PDE4A5 
accumulation at the 
membrane fraction. 
Membrane 
fractionation of 
HEK293 cells treated 
with 100uM of GW-
9508, a selective 
GPR40 agonist. 
HEK293 cells were 
transiently 
transfected with 
PDE4A5, ARB2 and GPR40. 10µgr of the membrane fraction and 5µgr of the 
cytosol fraction were used for the western blot. 
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5.2.12. 
5.2.13. In vivo administration of the GPR40 antagonist 
rescues the dietary obesity induced depression 
phenotype  
Next we set out to determine whether the selective blocking of GPR40 in vivo 
would rescue the dietary obesity-induced depression phenotype. GW1100, a 
selective antagonist for the GPR40 was identified by others previously using 
high-throughput screening (Zhao et al., 2011). GW1100 is a selective GPR40 
antagonist with the exception of oxytocin receptor that acted as an antagonist 
as well (Briscoe et al., 2006). Fig. 5.35 shows a schematic of this GPR40 
antagonist as well as the experimental design for the continuous pump 
infusion of GPR40 antagonist in the third ventricle of mice fed a HFD. 
 
Figure5.35. Experimental design for the pump implantations for the in vivo 
administration of GPR40 antagonist. Schematic of the experimental design 
for the mice that received GPR40 antagonist in the third ventricle via i.c.v. 
pump implantation. Mice were on HFD for three weeks with the last two 
weeks being administered the GPR40 antagonist. 
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Interestingly, a pilot experiment revealed a dose-dependent reduction of the 
immobilization time of the TST of mice that received two different 
concentrations of GPR40 antagonist compare to the mice that received aCSF 
control infusion (Fig. 5.36). 
 
Figure 5.36. GPR40 antagonist administration in vivo tend to reduce the 
immobilization time at the tail suspension test. Immobilization time during 
the tail suspension test for mice that were administered GPR40 antagonist in 
the third ventricle for 2 weeks while the mice were on a HFD. Mice received 
two different concentrations of GPR40 antagonist either 0,1µgr/µl and 1µgr/µl 
for 2 weeks (n=3). Stereotactic surgeries were performed with Dr Jae Kyu Ryu. 
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Moreover, a pilot experiment that included a sham control showed that GPR40 
antagonist administration tend to reduce the immobilization time during the 
TST test (Fig. 5.37), suggesting that blocking the activation of the GPR40 
might be sufficient to rescue the dietary obesity-induced depression 
phenotype in these mice. 
 
Figure 5.37 GPR40 antagonist administration in vivo tend to reduce the 
immobilization time at the tail suspension test. Immobilization time at the 
tail suspension test for mice that were administered GPR40 antagonist and 
aCSF in the third ventricle for 2 weeks while the mice were on a HFD for three 
weeks. Mice were compared with the sham mice that underwent surgery 
without the implantation of pumps (n=3-11). Stereotactic surgeries were 
performed with Dr Jae Kyu Ryu. 
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5.3. Discussion 
Developed countries predominantly consume relatively inexpensive high-
caloric food that is low in essential nutrients (Pawels and Volterrani, 2008).  
The increased adoption of a western type diet positively correlates with the 
development of depression in developed countries as shown in many 
epidemiological studies (Sanchez-Villegas et al., 2011). The prevalence of 
depression is markedly different across various countries and this correlates 
with the dietary differences in these societies (Kessler and Bromet, 2013). 
 
In spite of the high prevalence of mental disorders in modern societies, little 
etiological research has been conducted to assess the molecular mechanisms 
that exist in the CNS to link components of nutrition with depression (Payne, 
2010). Dietary fatty acids are a major component of the diet. The nutritional 
differences between fatty acids of different lengths and saturation states 
make up a great body of conflicting literature. Historically, saturated fatty 
acids have been seen as detrimental insofar as they induce insulin resistance 
and other facets of the metabolic syndrome (Riserus, 2008). On the other 
hand, polyunsaturated fatty acids have been shown to have the opposite 
effect: several, such as linolenic and conjugated linoleic acid, are protective 
against the harmful effects of obesity (Barre, 2007; Li et al., 2008; Zhou et 
al., 2008). However, the molecular mechanisms that link obesity with 
depression are unknown. The aim of this study was to investigate whether 
there are specific components of the diet that can be a causative factor for 
the development of depression. If that’s the case then can we gain an insight 
into the molecular mechanisms that underlie this phenomenon? 
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5.3.1. HFD consumption induces a fatty acid influx 
specifically in the hypothalamus in mice 
High fat diet consumption causes changes in the fatty acid composition of 
brain lipids (Anding and Hwang, 1986). HFD leads to an increase of two long 
chain acyl-coA species, palmitoyl- and stereoyl-coA in the hypothalamus and 
this accumulation has been implicated in the development of peripheral 
insulin resistance (Posey et al., 2009). Essential polyunsaturated fatty acids 
have been shown to modulate enzymes, the transport and interact with lipid 
biolayers to affect metabolic pathways (Mies et al., 2007; Ferrier et al., 2002; 
Kahn-Kirby et al., 2004; Schonfeld et al., 2004). It is further likely that the 
activity of the different enzymes is altered in pathophysiological conditions 
and the different fatty acid processes such as desaturation and elongation are 
different in disease than physiological conditions. When the levels of DHA are 
low in the brain, its turnover rate is much slower rate than in controls 
suggesting the existence of a compensatory mechanism (DeMar et al., 2004). 
Higher levels of saturated fatty acids in the plasma membrane decrease 
membrane fluidity by reducing the polyunsaturated to saturated fatty acid 
ratio in the membrane and this alters the binding of the agonist on adrenergic 
receptors, one of the pathways impaired in depression (Miyamoto et al., 1990; 
Piletz et al., 1991; Wince and Rutledge, 1981). Mood regulating drugs such as 
lithium and valproate play a role on the turnover of a long chain fatty acid, 
arachidonic acid (Chang et al., 1996; Chang et al., 2001). Furthermore, the 
activity of some brain enzymes has been found to be decreased by mood 
stabilizing drugs (Chang and Jones, 1998; Ghelardoni et al., 2004; Bosetti et 
al., 2002; Bosetti et al., 2003). Moreover, the increased arachidonic acid that 
was observed in the hypothalamus of FSL rats, an animal model of depression, 
suggests that the differences in the brain fatty acid composition might be a 
consequence of the disease itself as both FSL and control rats were fed 
identical diets (Green et al., 2005). Another interesting point is the general 
lack of knowledge concerning the transport, metabolism and signalling of all 
these dietary fatty acids or their downstream metabolites after their entrance 
in the brain. Future studies will be needed to characterize the central 
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metabolism of these fatty acids and it will be necessary to determine and 
identify how different dietary patterns can affect the enzymes related to fatty 
acid oxidation and metabolism. 
 
Interestingly, activation of the cAMP/PKA signalling pathway induces rapid 
phosphorylation and activation of SIRT1 that in turn deacetylates substrates 
that can promote lipid oxidation and energy expenditure in vivo (Gerhart-
Hines et al., 2011). Moreover, central inhibition of lipid oxidation is sufficient 
to restore hypothalamic lipid sensing and normalize feeding behaviour and 
glucose homeostasis (Pocai et al., 2006). In this study I showed a decrease of 
the cAMP/PKA signalling in response to the HFD (Fig. 3.12&3.13&3.14) 
suggesting that this decrease of the cAMP/PKA signalling can affect the lipid 
oxidation in the brain. Moreover, we showed that lipids can affect PKA 
signalling (Fig. 5.5&5.6). Therefore, detailed examination of the lipids in the 
brain, as well as the enzymatic pathways of lipid metabolism, in depression 
can lead to new approaches toward understanding and treating this complex 
human disorder. Technological advances that allow the assessment of subtle 
and rapid physiological variation of different fatty acids in the CSF after the 
consumption of a HFD will no doubt help confirm or refine these observations. 
 
Whether there is a different fatty acid composition in the brain of PDE4A-/- 
mice that consume HFD compare to mice fed ND should be further 
investigated. Interestingly it has been shown that phosphodiesterase inhibition 
can rescue the chronic cognitive deficits produced by traumatic brain injury 
(Titus et al., 2013). Traumatic brain injury has been linked with increase 
release of fatty acids (Bazan, 1970; Rehncrona et al., 1982; Zhang and Sun, 
1995; Dhillon et al., 1997; Homayoun et al., 1997). Therefore, whether 
phosphodiesterases control the fatty acid release and composition in the brain 
is a very interesting topic that deserves further investigation. 
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The increase influx of fatty acids specifically in the hypothalamus compared 
to cortex has never been documented before (Fig. 5.3). The hypothalamus is 
a highly vascularized area with a lot of communication with the periphery. It 
plays a central role in coordinating physiological responses between the 
periphery and the central nervous system. The hypothalamus has been studied 
extensively for its role in appetite regulation as well as regulating energy 
balance (Cota et al., 2007; Le Foll et al., 2009; Moran, 2010; Lam et al., 
2005b; Woods et al., 1998; Schwartz et al., 2000; Ahima et al., 1996; Wang et 
al., 1998; Obici et al., 2002). However, this is the first study that points out 
the important role of hypothalamus in linking dietary fatty acids with the 
development of depression. 
 
The elevation of fatty acids in the hypothalamus, such as palmitic acid, might 
lead to increase apoptotic events in the hypothalamus (Ulloth et al., 2003). In 
contrast to this, however, it has been shown that HFD can increase 
neurogenesis in the hypothalamus (Lee et al., 2012). Further studies 
investigating the neuronal death or survival of hypothalamic neurons after the 
consumption of HFD are needed in order to uncover the details of such 
alterations in neurogenesis. Therefore, determining the consequences of this 
local accumulation of FFAs after HFD and its potential connection with 
depression requires further research. 
 
This study also opens a new concept that the BBB is not equally sealed, as 
some areas of the CNS are more prone to be in contact with the molecules in 
the vasculature compared to others. Some brain regions, like the 
hypothalamus, might be more easily accessible compared to others. Future 
drug development strategies could take advantage of a drug crossing of the 
BBB in a more easily accessible area such as the hypothalamus, and then, once 
in the brain, the drug could directed to a different brain region of interest. 
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5.3.2. Different fatty acids can differentially affect the 
PKA signalling cascade 
Epidemiological and clinical studies support the beneficial and protective role 
of unsaturated fatty acids in depression whereas western diet consisting highly 
of trans and saturated fat positively correlates with the development of 
depression (Sanchez-Villegas et al., 2011), however the molecular pathway of 
this discrimination is unknown. The data in this study supports a differential 
role of different fatty acids in the regulation of the PKA signalling (Fig. 
5.5&5.6). To our knowledge this is the first time that pretreatment of 
different fatty acids has been shown to affect forskolin-induced activation of 
PKA in a neuronal cell line (Fig. 5.5&5.6). 
 
The saturated palmitic acid was able to block the forskolin induced activation 
of PKA, whereas the unsaturated fatty acid oleic did not affect the PKA 
activation in vitro in a neuronal cell line (Fig. 5.5&5.6). Interestingly, this 
blockage of PKA signalling after palmitic treatment is in agreement with the 
downregulation of PKA signalling after the consumption of HFD (Fig. 
3.12&3.13). However, the saturated fatty acid myristic did not affect 
forskolin-induced activation by PKA in vitro (Fig. 5.5&5.6). This suggests 
functional differences between saturated fatty acids, as C14-myristic and C16-
palmitic did not have the same effect on PKA. While a possible explanation for 
this effect may be that higher concentration of myristic acid is needed in 
order to suppress in vitro PKA activation, compared to palmitic, it is also 
possible that this reflects neuronal specificity of the receptor and the 
downstream signalling for these different chain length fatty acids. These 
results suggest that we cannot generalize the two categories and propose that 
saturated fatty acids are able to down-regulate PKA signalling compared to 
the unsaturated fatty acids, which do the opposite therefore further 
understanding on the concentration and specificity of the effect of the 
different fatty acids is necessary. 
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It is also possible that fatty acids are acting on the GPR40 protein expressed 
on the plasma membrane by operating from an intracellular location. Whether 
palmitic acid binds directly on GPR40 and this result in the intracellular effect 
on the PKA signalling should be further studied by blocking the receptor first 
with GPR40 antagonist and then pretreating the cells with palmitic acid. 
 
5.3.3. The beneficial and protective role of olive oil in 
depression 
An inverse association between olive oil consumption and depression has been 
described (Sanchez-Villegas et al., 2011); However the molecular mechanism 
of this effect is unknown. Olive oil contains bioactive polyphenols with known 
anti-inflammatory properties (Waterman and Lockwood, 2007) counting for 
the anti-inflammatory role of olive oil (Estruch et al., 2006; Salas-Salvado et 
al., 2008; Mena et al., 2009). Depression has already been described as a 
disease with high levels of inflammation, suggesting that the trend of the 
antidepressant effect of olive oil compare to ghee shown at the TST and SPT 
in this study might be mediated via the anti-inflammatory effect of olive oil 
(Estruch et al., 2006; Salas-Salvado et al., 2008; Mena et al., 2009). Studies in 
various cell types (macrophages, adipocytes, myocytes, hepatocytes) have 
revealed the pro-inflammatory action of saturated fatty acids (Hwang and 
Rhee, 1999; Nguyen et al., 2005; Yu et al., 2002) and this is mediated at least 
in part through activation of TLR4/2 (Lee et al., 2001; Nguyen et al., 2007; 
Schaeffler et al., 2009; Milanski et al., 2009). However, another study 
suggested that saturated fatty acids do not directly stimulate TLR4 receptors, 
suggesting an alternative mechanism that might link dietary fat intake with 
inflammation and they explained the observed effect of previous studies that 
showed activation due to contamination of fatty acid free BSA with LPS 
(Erridge and Samani, 2009). Further investigation on the role of inflammation 
in mice gavaged for 7 weeks as well as the potential suppression of 
inflammation by olive oil in this model of depression is needed. 
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One of the components of olive oil is tyrosol, which has been shown to play a 
role in the intracellular antioxidant defence mechanism (Di Benedetto et al., 
2007). One of the pathological characteristics of depression is oxidative stress 
(Bilici et al., 2001). As it has been shown that the antioxidant defence is 
decreased among people with depression, maybe olive oil act its 
antidepressant effect by restoring the antioxidant defence of the body. 
 
Olive oil consists of 80% oleic acid (Waterman and Lockwood, 2007), which is 
the most abundant fatty acid of myelin, the protective sheath that covers 
axons. Oleic acid is the precursor of the lipid oleamide that has been shown to 
play important role in mood disorders (Puri and Richardson, 2000). In addition, 
it plays an important role in the maintenance of the physiochemical properties 
of membranes via its ability to increase the δ-9 desaturase enzyme activity 
(Yehuda et al., 2002) and thus improving the binding of serotonin to its 
receptors, which is a major pathway affected in people with depression 
(Logan, 2005). 
 
Diets high in saturated fatty acids, such as palmitic, are considered 
obesogenic and promote systemic resistance to catabolic hormones such as 
insulin and leptin and diet- induced insulin resistance (Riccardi et al., 2004; 
van Dijk et al., 2009; Posey et al., 2009) whereas diets rich in 
monounsaturated fatty acids, such as oleic acid, attenuate weight gain 
through increased fat oxidation and diet-induced thermogenesis (Bergouignan 
et al., 2009; Obici et al., 2002; Morgan et al., 2004). Diets rich in ω-3 fatty 
acids promote weight loss with unaltered energy intake (Hill et al., 2007; 
Wang et al., 2002). This suggests that ω-3 fatty acids promote increased 
energy expenditure, perhaps in part by increasing fatty acid oxidation 
pathways and suppressing lipogenic pathways (Roche and Gibney, 1999; 
Sampath and Ntambi, 2005). Indeed, dysregulation of free fatty acid 
metabolism is responsible for insulin resistance and type 2 diabetes mellitus 
(Wilding, 2007) as it reduces insulin biosynthesis and secretion and induces β-
cell apoptosis. As shown in this study, mice that were gavaged with either 
olive oil or ghee showed similar body weights during the first 6 weeks but 
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ghee-gavaged mice revealed a trend of gaining more weight after the 7th week 
and olive oil did not induce any weight loss (Fig. 5.12). Further investigation 
on the role of longer-term administration of ghee and olive oil on body weight 
should be performed. 
 
A consumption of a high fat, low carbohydrate diet has been widely used for 
weight reduction, however the increased fat consumption has been shown to 
raise the levels of the plasma fatty acids and this leads to impaired cognitive 
functions which are detrimental to the human brain (Holloway et al., 2011). 
According to the data in this study the quality of the dietary fatty acids in this 
diet can interfere with the development of mood disorders such as depression 
and therefore, better understanding will shed light on the best diet that will 
have the antiobesity effects without the negative effects on cognition and 
mood. 
 
5.3.4. Chronic consumption of a diet high in palmitic 
acid tended to induce a depression phenotype in 
mice compare to olive oil 
In rats that were fed isoenergetic diets based either on safflower oil (rich in 
ω-6 PUFAs) or beef tallow (rich in saturated fatty acids) for 8 weeks, the beef 
tallow group compare to the safflower oil diet group showed a significantly 
lower binding affinity of the β-adrenergic receptor in the hypothalamus and 
cortex (Matsuo and Suzuki, 1997). Moreover, the beef tallow diet decreased 
membrane fluidity by altering the fatty acid composition of the plasma 
membranes in the hypothalamus and in the cortex (Matsuo and Suzuki, 1997), 
suggesting that there is a possible link between membrane fluidity and the 
changes in affinity of β-adrenergic receptors. Moreover, dietary fat per se 
rather than the absolute energetic content of consumed food has been shown 
to promote obesity, central insulin insensitivity and hypothalamic 
inflammation (Posey et al., 2009) and a similar effect might happen in 
depression. Furthermore, the type and amount of dietary fatty acids have 
been shown to affect leptin receptor signalling as well as the morphology of 
hypothalamic cell membranes (Heshka and Jones, 2001). 
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Even though a positive correlation between the consumption of the western 
diet, which is high in many saturated fatty acids such as stearic and palmitic, 
and depression has been shown (Sanchez-Villegas et al., 2011), this study 
suggests that high levels of palmitic acid might play a role for the 
development of depression phenotype in mice (Fig. 5.10&5.11). As both 
groups showed the same increase in body weight, this suggests that the actual 
diet could play a direct effect on mood rather than indirectly after the 
development of secondary effects of obesity such as metabolic syndrome. This 
is in agreement with the single i.c.v. stereotactic injections of palmitic acid 
that suggest that we were able to induce a depression phenotype in vivo after 
4 days (Fig. 5.13). 
 
Another interesting result from this study was that the depression phenotype 
did not differ between groups administered with either ghee or olive oil for 3 
weeks (Fig. 5.8&5.9). However, we were able to count differences in the 
depression levels after 7 weeks of gavage administration (Fig. 5.10&5.11). 
This might be due to two reasons: the first one is that the oral gavage is a 
very stressful process that induces high levels of stress in both tested groups 
therefore it was not possible to distinguish for the effect of either ghee or 
olive oil as they would be masked by the high stress levels of the gavage 
administration. Another explanation would be that high and prolonged levels 
of consumption of either ghee or olive oil are needed in order to see a 
depression effect of ghee or an antidepressant effect of olive oil. 
 
Therefore, our data suggest the deleterious effect of palmitic fatty acid in 
depression and further investigation for the potential of other fatty acids that 
might lead to the development of depression should be studied. However, due 
to the fact there is no baseline in this preliminary experiment, a saline control 
needs to be included to check whether gavage administration alone can 
induce a depression phenotype in mice, and whether administration of olive 
oil, but not ghee, can rescue. 
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5.3.5. Dietary or genetic obesity induces an up-
regulation of different free fatty acid receptors 
in the hypothalamus 
The real-time PCR data showing the up-regulation of different free fatty acid 
receptors after dietary or genetic obesity is a very unexpected result 
suggesting that these receptors in the brain are affected after obesity (Fig. 
5.15&5.16&5.17). Even though the role of the different fatty acid receptors 
has been studied extensively in different organs such as gut or pancreas, their 
role in the brain is totally unexplored therefore their involvement in 
depression remains to be clarified. 
 
GPR41, which is a receptor for short chain fatty acids, tended to be up-
regulated after the consumption of HFD and for the genetically obese (ob/ob) 
mice (Fig. 5.15). Acetate, a short chain fatty acid, can cross the BBB and 
regulate the expression profile of neuropeptides in the hypothalamus (Frost et 
al., 2014). Gut microbiota have been shown to produce short chain fatty acids 
such as acetate and release it in the circulation suggesting that it might get 
into the brain and regulate different pathways (Thorburn et al., 2014). The 
fatty acid profile analysis experiment that was performed in this study did not 
measure the levels of short chain fatty acids in the hypothalamus. Therefore, 
further investigation of whether HFD leads to accumulation of short chain 
fatty acids in the hypothalamus as well as investigation of the activation of 
the different molecular pathways under the GPR41, as is the main receptor for 
short chain fatty acids, in the hypothalamus should be further explored. 
 
GPR120 is a receptor that has been linked with inflammation and insulin 
sensitivity (Oh et al., 2010). GPR120 RNA up-regulation was detected in the 
hypothalamus of the genetically obese (ob/ob) mice (Fig. 5.16). GPR120 binds 
mostly long chain unsaturated fatty acids, and has already been shown to act 
via β-arrestins (Oh et al., 2010). The role of GPR120 in the genetic mouse 
model of depression as well as the molecular mechanisms that it regulates in 
the hypothalamus needs to be investigated. 
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5.3.6. Up-regulation and activation of the GPR40 
receptor due to dietary or genetic obesity in 
mice 
The striking RNA up-regulation of GPR40 in the hypothalamus of mice after 
just 1 week on the HFD and in the genetically obese mice was a very 
unexpected result (Fig. 5.17). However, the protein levels of this receptor 
were the same between mice that consume ND and HFD (Fig. 5.18), 
suggesting that the actual localization of this receptor might play a role for 
the signalling induced by this receptor. Further studies investigating the 
compartmentalization of GPR40 as well as the level of activation are needed 
to clarify its role in the hypothalamus. GPR40 is a member of the GPCRs that 
has been shown to be regulated in the levels of post-translational modification 
as well as recycling of the receptor (Pippig et al., 1995; Krueger et al., 1997; 
Zhang et al., 1997; Klein et al., 2001; Gaborik and Hunyady, 2004). 
 
The specific GPR40 agonist in vitro did not have any effect on the PDE4A5 
translocation as the palmitic acid treatment did (Fig. 5.35&5.36) Previously, 
it has been shown that different synthetic agonists for GPR40 interact with the 
receptor differently than free fatty acids do (Tan et al., 2008) as long 
exposure of pancreas to free fatty acids impairs glucose dependent insulin 
stimulation (GDIS) and induce lipotoxicity whereas this effect does not happen 
with treatment with synthetic agonist, indicating a different mechanism of 
action due to binding of different ligands (Tan et al., 2008). This suggests that 
the GW9508 agonist regulates a different intracellular pathway than the 
pathway regulated by the free fatty acids via GPR40. Further investigation of 
the differential activation stages of GPR40 depending on the ligand should be 
investigated in order to determine the differential intracellular effect. 
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5.3.7. GPR40 antagonist administration as a therapeutic 
drug for the obesity induced depression 
phenotype 
Chronic administration of the GPR40 antagonist in the hypothalamus tends to 
reduce the immobilization time at the depression related tests that is usually 
observed in mice after HFD consumption (Fig. 5.36). However, the difference 
was not significant and further studies with bigger cohorts of mice should be 
performed in order to further characterize this effect. GPR40 is a Gq-coupled 
GPCR that, after binding of specific free fatty acids, can induce the signalling 
activation of the MAPK cascade (Itoh et al., 2003), which plays an important 
role in inflammation (Cowan and Storey 2003). Therefore, the GPR40 
antagonist might exert its beneficial effect on depression by blocking the 
binding of FFAs thereby blocking the activation of inflammation from 
contributing to the development of the depression phenotype (Raison et al., 
2006; Schiepers et al., 2005). This suggests a protective role for GPR40 
antagonist in inflammation and proposes that it could be used for 
inflammatory diseases. 
 
Administration of the GPR40 antagonist for severely depressed patients that 
results from diet might present a better treatment option in comparison with 
invasive strategies, such as deep brain stimulations, involving high risk of 
infection, complicated process and high neurosurgical costs. It has already 
been suggested that non-invasive strategies such as receptor mediated 
transport (RMT), appear more attractive, because such approaches can realize 
transport of therapeutic agents across the whole brain without disruption of 
the barrier properties of the brain (Pardridge, 2002a; Pardridge, 2002b). In 
support of that, targeting this receptor with an antagonist might represent a 
good candidate for the development of an antidepressant drug. 
 
GPR40 has been shown to play a role in both acute and chronic effects of FFAs 
in the pancreas (Steneberg et al., 2005), thus it is plausible that GPR40 might 
play a similar role in the depression phenotype of both acute and chronic 
effects of FFAs in the hypothalamus. As such GPR40 could have an important 
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role as a therapeutic target to treat depression associated with HFD. Further 
studies investigating a shorter and a longer time on HFD using the GPR40 
antagonist should be done in order to further elucidate the effect of the 
blocker and obtain certainty on its effects for the treatment of depression and 
inflammation. 
 
5.3.8. The phosphorylation status of GPR40 might be 
different between normal and depressed 
patients and regulated after dietary or genetic 
obesity 
Protein phosphorylation by protein kinases and dephosphorylation by protein 
phosphatases represent one of the major mechanisms of signal integration in 
eukaryotic cells. It has already been shown that the different phosphorylation 
barcode of GPCRs can affect the signalling consequences of ligand-receptor 
interactions (Liggett, 2011; Nobles et al., 2011). This phosphorylation of 
GPCRs evoked by G protein-coupled receptor kinases (GRKs) and read by β-
arrestins can direct different signalling cascades from the same receptor 
(Liggett, 2011; Nobles et al., 2011; Baillie et al., 2003). Therefore, in addition 
to the role of GRKs in blocking the coupling of the GPCRs with G proteins and 
the initiation of the desensitization signal they can also recruit additional 
proteins involved in receptor signalling and trafficking of the receptor (Zamah 
et al., 2002). GRK phosphorylation is involved in many signalling pathways and 
is altered during pathological situations (Penela et al., 2006). GRK 
phosphorylation sites have been mapped on various receptors, such as the four 
serine residues on the third intracellular loop, but a consensus sequence has 
not been established. Moreover, most cells express multiple GRKs suggesting 
many possible arrangements of phosphorylation between serine and threonine 
residues that could be phosphorylated by GRKs (Liggett, 2011; Nobles et al., 
2011). However, even though many studies have examined the role of 
neurotransmitters and their receptors in the brain, very few have studied the 
involvement of different GRKs in depression and in the action of 
antidepressants (Garcia-Sevilla et al., 1999). 
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In the prefrontal cortex of people with depression who had committed suicide, 
the immunodensity of GRK2/3 was found to be increased, and this was 
interpreted as a compensation mechanism of the abnormal higher functioning 
of α2 adrenoreceptor (Garcia-Sevilla et al., 1999). Moreover, acute treatment 
of rats with desipramine (indirectly activation of adrenoreceptor by 
norepinephrine), but not fluoxetine, resulted in increased membrane-
associated GRK2/3 in rat brain in the frontal cortex, suggesting that these 
receptors are regulated in vivo by GRK2/3 (homologous regulation) (Miralles et 
al., 2002). Interestingly, GRK2 upregulation was observed in the membrane 
fraction in the prefrontal cortex of drug-free depressed subjects compared to 
subjects treated with antidepressants (Grange-Midroit et al., 2003). That 
increase was specific for the membrane fraction, as there was no difference in 
the cytosol fraction (Grange-Midroit et al., 2003), suggesting the 
compartmentalization of the phosphorylation is important for the action of 
antidepressants. GRK2 is widely expressed in the brain (Arriza et al., 1992; 
Grange-Midroit et al., 2002) and it translocates from the cytosol to the plasma 
membrane to phosphorylate agonist activated receptor (Krupnick and Benovic, 
1998; Lefkowitz, 1998; Pitcher et al., 1998). GRK2 upregulated 
phosphorylation of β2-adrenoreceptors is responsible for heart failure as it 
leads to increased Gi signalling (Zhu et al., 2012). Whether GRK2 can 
phosphorylate GPR40 and regulate its downstream signalling should be further 
studied. 
 
Another possible mechanism of GPR40 phosphorylation in this model is by PKA. 
It has already been shown that PKA phosphorylates the β-adrenoreceptor and 
that this can affect the translocation of GRK at the membrane fraction (Li et 
al., 2006). This PKA phosphorylation does not affect GRK kinase activity per 
se, but enhances the binding of GRK2 to the membrane and facilities its 
interaction with the activated receptor (Li et al., 2006). 
 
Whether PKA can phosphorylate GPR40 and/or regulate any GRKs and β-
arrestins that might interact with it needs to be evaluated. Therefore, the 
phosphorylation status of GPR40 by GRK2 and PKA and their interaction is 
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needed, as is a better understanding on the mechanisms underlying these 
barcode phosphorylation changes and the profile of the downstream 
alterations that participate in the triggering or progression of depression. 
These signalling consequences may contribute to the design of novel 
diagnostic and therapeutic strategies targeting the phosphorylation status of 
this receptor. The phosphorylation might have implications for drug discovery 
as inhibition of this phosphorylation might rescue the dietary obesity induced 
depression phenotype. Further investigation of the conformational states of 
GPR40 caused by the phosphorylation and the functional responses of this 
change should be done. 
 
5.3.9. Fatty acids can modify the action of 
phosphodiesterases 
In addition to the role of FFAs in the activation of different free fatty acid 
receptors, they can also enter the cell by diffusion and modify proteins in 
different ways such as prenylation, S-acylation, N-myristoylation. These 
protein modifications can affect their signalling and subcellular targeting 
(Sorek et al., 2009). Lipid modifications increase the hydrophobicity of 
proteins, facilitating their integration into intracellular and plasma 
membranes and it is considered a major mechanism for the 
compartmentalization of protein signalling (el-Husseini Ael and Bredt, 2002; 
Resh, 2006). Palmitoylation is a common posttranslational lipid modification 
that refers to the addition of palmitate to a Cys residue. The reversible nature 
of palmitoylation provides a potential mechanism for the shuttling of proteins 
between intracellular compartments (Linder and Deschenes, 2007; Fukata and 
Fukata, 2010). Protein palmitoylation regulates a diverse aspects of neuronal 
protein trafficking and function and might be implicated in various aspects of 
neuronal pathophysiology (Fukata and Fukata, 2010). 
 
PDE4 enzymes can be post-translationally modified by, for example, 
phosphorylation (Sette et al., 1994), ubiquitination (Li et al., 2009a) and 
sumoylation (Li et al., 2010a). PDE4s have been shown to bind to phosphatidic 
acid, implying this modification is responsible for their membrane localization 
(Nemoz et al., 1997). PDE4D3 activation occurs through direct binding of 
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phosphatidic acid (Grange et al., 2000). In this study, high levels of palmitic 
acid were detected in the hypothalamus after the consumption of a HFD, and 
that correlated with the development of the depression phenotype. The 
increased levels of palmitic acid in the milieu could affect the activity and/or 
localization of the phosphodiesterases and lead to phenotypic changes. 
Therefore, a possible mechanism by which palmitic acid might interact with 
PDE4A5 would be via palmitoylation. Interestingly, using the CSS-Palm 
software, it was predicted that either the Cys 817 or Cys 820 might be a 
potential palmitoylaton site on PDE4A5 (Table5.3). The predicted score for 
palmitoylation was similar to the score for proteins that are known to be 
palmitoylated (Table5.2). PDE10A has already been shown to be modified by 
palmitoylation and there is an interplay of palmitoylation and phosphorylation 
in the trafficking and localization of PDE10A (Charych et al., 2010). p75 
neurotrophin receptor was used as it has been shown to be palmitoylated 
(Barker et al., 1994) to compare the prediction scores with PDE4A5. 
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Table 5.2. Prediction of potential palmitoylation sites of PDE4A5. CSS-Palm 
software was used to predict the palmitoylation scores of different cysteines 
on PDE4A5. Moreover, the prediction scores of two proteins known to be 
palmitoylated on these specific cysteines are shown (p75 and PDE10A). 
    
Species Sequence 
Sites 
(Aa) 
Score 
PDE4A4 ENST00000352831 Human QIPC 727 0.774 
PDE4A4 ENST00000352831 Human KRACSA 858 0.5 
PDE4A4 ENST00000352831 Human CSACAGT 861 0.595 
PDE4A5 
ENSMUST000000394
13 
Mouse MRACSAC 817 1.202 
PDE4A5 
ENSMUST000000394
13 
Mouse CSACSGT 820 0.881 
PDE4A5 
ENSRNOT000000611
00 
Rat TRACSAC 817 0.976 
            
p75NTR ENST00000172229 Human NSCKQN 279 0.861 
PDE10A NP_035996  Mouse NASCFRR 11 1.6 
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5.3.10. In vitro fatty acid treatment of neuronal cells 
expressing GPR40 
In this study, the differential effect of palmitic versus oleic acid on the 
translocation of PDE4A5 at the membrane fraction was observed (Fig. 
5.28&5.30). This data is in agreement with another study showed that in the 
hypothalamus palmitic but not oleic acid induces the translocation of PKC-θ at 
the membrane fraction (Benoit et al., 2009). 
 
During the in vitro treatments of the cells with the fatty acids in this study, a 
great deal of variability was observed between experiments concerning the 
stimulation stage of cells. Different fetal bovine serum consists of differential 
amount of fatty acids, and this may contribute to the observed variability. 
More experiments should be performed to identify the exact experimental 
conditions with the correct time and concentration of fatty acids in order to 
see stimulations of GPR40 and the effects on PDE4A5 and arrestin 
translocation. In accordance with these observations, it has been shown 
previously that GPR40 is a receptor that is highly activated under normal 
conditions due to endogenous ligands, and these high levels of activation were 
reversed after addition of BSA free fatty acid in the media that traps the fatty 
acids that exists in the media from the serum (Stoddart et al., 2007). Thus to 
perform in vitro stimulation of GPR40, we need to deprive the medium of 
GPR40 endogenous ligands. 
 
Another caveat to keep in mind during in vitro treatments with fatty acids is 
the fact that long chain fatty acids are relatively insoluble in aqueous solution 
and form micelles at higher concentrations that can bind to plastics and 
glassware. This can greatly reduce the active unbound monomeric 
concentration of the fatty acid, in a manner analogous to the effects of 
albumin. On the contrary, short-chain saturated fatty acids, such as butyric 
acid, as well as long chain unsaturated fatty acids such as oleic acid, are 
water soluble in aqueous solution. It is possible that these differences might 
had an effect in the experimental system used in this study.  
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Lastly, fatty acids have been shown to exert a detergent effect on cell 
membranes, possibly via FFA exposure of GPR40 (Steneberg et al., 2005). 
However, the concentrations used in this study are well below those at which 
fatty acids exert detergent effects on cell membranes (Cistola et al., 1988). 
 
5.3.11. The central role of GPR40 in the regulation of 
neurogenesis is signalled by fatty acids in the 
hypothalamus 
A major characteristic in depressed patients is reduced neurogenesis (Snyder 
et al., 2011) (Eisch and Petrik, 2012). Of the various molecules that contribute 
to adult neurogenesis, as well as depression, the most important is cAMP 
response element-binding protein (CREB), a transcription factor which is a 
rapidly responding intracellular effector of signalling pathways in neurons 
(Carlezon et al., 2005). Reduction in CREB activation leads to a depression 
phenotype, whereas global inhibition of degradation of the cAMP pathway 
results in an antidepressant effect (Nibuya et al., 1996a). The cellular 
localization of pCREB is identical to that of GPR40 in the hippocampal 
neurogenic niche, and both are upregulated after ischemia, which functionally 
links them both in hippocampal neurogenesis (Ma et al., 2008a; Boneva and 
Yamashima, 2012). This is suggested to happen after the binding of PUFAs on 
GPR40, and might trigger the phosphorylation of CREB, which and that might 
result in specific gene activation – intracellular events that are crucial for 
adult neurogenesis, cognition and depression. 
 
The influx of different fatty acids in the hypothalamus after the consumption 
of the HFD observed in this study (Fig. 5.3) might play a central role in the 
signalling of neurogenesis or apoptosis. Palmitic or stearic acid can induce 
apoptosis in neuronal cells (Ulloth et al., 2003) that can be prevented by 
treatment with unsaturated fatty acids (Almaguel et al., 2009; Welters et al., 
2006). Moreover, different fatty acids have been shown to have opposing 
effects on food intake or body weight in the hypothalamus (Schwinkendorf et 
al., 2011), suggesting that mere infusion of fatty acids is not responsible, but 
rather distinct signals involving specific FA are most likely involved.  
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Furthermore, in this study it has been shown that HFD consumption increases 
RNA levels of GPR40 (Fig. 5.17). As a large range of both saturated and 
unsaturated fatty acids are ligands for GPR40, the primary role of the receptor 
may be to distinguish the ligand. Different ligands will lead to the initiation of 
different intracellular pathways and yield different result. This might explain 
how palmitic acid can cause the development of the depression phenotype 
while unsaturated fatty acids have a protective effect (Mozaffarian et al., 
2010). Binding of palmitic acid on GPR40 might lead to apoptosis whereas 
unsaturated fatty acids might play a protective role and induce neurogenesis. 
Moreover it has been shown that short or long exposure of fatty acids to 
GPR40 has a differential effect in the pancreas (Steneberg et al., 2005), 
suggesting that the length of the HFD consumption might play a role in the 
development of depression phenotype. The differential role of the different 
fatty acids, such as oleic or palmitic, should be explored, including their 
different downstream effects of either neurogenesis or apoptosis, which can 
potentiate depression. 
 
The role of nutritional factors in brain cognition and behaviour is a new area 
of research. The direct and differential contribution of dietary fatty acids in 
the context of mental depression, focusing on dietary experimental 
paradigms, deserves further investigation. Although the agonist action on cell 
surface receptors can trigger a variety of intracellular signalling events, the 
ligand-receptor interaction and their downstream responses are very specific. 
The potential protective effects of polyunsaturated fatty acids, antioxidant 
micronutrients, and folates against age-associated cognitive and mood 
disorders due to a diet high in trans and saturated fat are arousing increasing 
interest. In further studies towards the understanding of the mechanism of 
depression due to dietary factors and its therapeutic implications for 
medicine, it will be indispensable to comprehend the molecular interactions 
within this complex process that precede the development of depression. 
  
Chapter 5   Hypothalamic Sensing of Fatty Acids 
  Induces Depression 
     
EIRINI VAGENA 261 
 
 
5.3.12. The potential sequence of the interaction 
between PDE4A5/ARB2/GPR40 
It has been shown that GPCRs can directly or indirectly recruit certain 
phosphodiesterases via the help of scaffolding proteins such as β-arrestins 
(Houslay, 2010; Perry et al., 2002). This interaction has been described clearly 
with peptide arrays and mutagenesis studies (Baillie et al., 2007). This study is 
the first to show an interaction of a free fatty acid receptor with PDE4A5.  
 
Several reports have described the significance of a highly conserved stretch 
of amino acid residues located in the second intracellular loop of various 
GPCRs (Glu/Asp)-Arg-Tyr in G protein activation (Probst et al., 1992; Savarese 
and Fraser, 1992). This domain is generally designated the DRY motif and is 
considered to maintain the receptor conformation (Ballesteros et al., 1998; 
Ballesteros et al., 2001). In particular, the central Arg residue of this motif 
has been reported to be directly responsible for the receptor G protein 
coupling. This motif has also been involved in the binding of β-arrestins. 
Figure 5.38 shows a structural alignment of GPR40 with β-adrenoceptor using 
the T-coffee online algorithm (Chang et al., 2012). GPR40 has the GRY motif 
instead of DRY. The importance of this change and how it affects the binding 
of G proteins or arrestins should be further investigated. 
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Figure 5.38. Structural alignment of human and mouse GPR40 with beta 2 
adrenergic receptor. The multiple sequence alignment result was produced 
by TM-Coffee, Version_9.02.r1228 (2012-02-16 18:15:12 - Revision 1228 -
 Build 336) 
 
 
From the structural analysis, the suggested intracellular loops as well as the 
C-terminal tail of GPR40 are:  
c1: SHAKLRLTP 
c2: LGAAFPFGYQAIRRP 
c3: VGCLRALVRSGLSHKRKL 
c-terminal: GYLGTGPGRGTICVTRTQRGTIQK 
 
Further characterization of the interaction of ARB2 with GPR40 should be 
studied via peptide arrays and mutation analysis. Moreover, the potential 
serines or threonines on the intracellular loops that might be phosphorylated 
by GRK or PKA should be studied. 
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5.4.  Conclusions 
The clinical and epidemiological data point in the same direction as our 
current findings and strongly support a causative role of the western dietary 
habits on depression. We discovered that a diet high in saturated fatty acids 
can markedly increase the influx of different fatty acids in the hypothalamic 
area of mice. The different free fatty acid receptors are in the unique position 
to link food lipids and mood disorders such as depression. Levels of GPR40 are 
markedly increased in the hypothalamus after dietary or genetic obesity, and 
this novel finding was also accompanied by a partial rescue of dietary obesity 
induced depression after GPR40 antagonist administration. These data provide 
a potential mechanism through which dietary or genetic obesity can play a 
causative role for the development of depression phenotype. Moreover, 
administration of the GPR40 antagonist might be a better way of treating 
depression compared to other invasive strategies that involve high risk of 
infection, complicated and high neurosurgical costs. Further studies on this 
topic are needed to assess the potential of GPR40 antagonist as an 
antidepressant. However, even though fatty acids can act as signalling 
molecules, very little is known about the mechanisms of saturated fatty acid 
function in mental disorders. The exact molecular mechanism by which 
saturated fatty acids are induces depression should be further investigated. 
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6. Background 
Depression is a psychiatric disorder associated with excessive sadness and other 
alterations of mood, cognition and neurovegetative functions such as sleep and 
appetite. It is a leading cause for long term disability worldwide and, as such, 
carries a considerable human and economic cost (Moussavi et al., 2007). The 
cAMP signalling cascade provides a central facet in the regulation of signalling 
pathways involved in depression, being a downstream effector of both the 
serotonin and noradrenergic GPCRs (Shelton, 2007). In particular, different 
antidepressant treatments have been shown to alter the levels of protein 
molecules involved in the cAMP signalling cascade (Duman et al., 1997). 
 
The relationship between obesity and depression has also been widely discussed, 
as many epidemiological studies have consistently identified a strong positive 
association between depression and obesity (Faith et al., 2002). However, 
epidemiological and clinical studies are unable to provide insight in the 
causative relation and mechanistic linkages associated with this relationship due 
to other life style factors in humans that can interfere. My PhD project was 
aimed to provide mechanistic insight into the putative link between obesity and 
depression using two different models of obesity. 
 
Within this body of work I have utilised in vivo models to investigate the role of 
obesity in depression in mice as well as in vitro methods in order to elucidate 
the molecular pathway that may link obesity with depression. Several postulates 
were evaluated with regard to establishing the molecular and behavioural link 
between obesity and depression. First of all, I examined whether obesity, either 
dietary or genetic can be a causative factor for the development of depression.  
Secondly, as to what are the signalling cascades that are being affected after 
the consumption of a diet high in saturated fatty acids. Thirdly, I wished to 
establish what is/are the key molecule/s that play/s a pivotal role linking 
obesity with depression and the intracellular molecular mechanism that links 
diet with mood disorders such as depression. While, the fourth and final aim was 
to try and identify a novel therapeutic target for depression that could 
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potentially be used to treat obese and overweight populations that are resistant 
to other antidepressant drugs.  
6.1. Obesity is a causative factor for the depression 
Previous epidemiological studies have revealed a link between obesity and 
depression (Faith et al., 2002). However there has been no causal link identified 
between the two and no indication on the mechanism. A major challenge in 
exploring the relationship between diet and depression is due to the complexity 
of dietary, environmental and lifestyle parameters. Thus there is a need to 
dissociate or control these factors in order to actually detect causality in human 
studies. Moreover, some characteristics, such as paucity of exercise and obesity, 
usually pair together and are difficult to dissociate. Therefore, animal models 
are often employed to control such heterogeneity and the many variables 
inherent to human populations. Animal models provide a more homogeneous 
environment and background and are easier to study and evaluate. Using 
behavioural paradigms I established that obesity, either dietary or genetic, can 
be a causative factor for the development of depression (Fig.3.2&3.3&3.8). 
Such an effect is independent of the increase in body weight caused by diet 
(Fig.3.5). I also demonstrated that dietary obesity does not induce anxiety, 
suggesting that the depression phenotype observed in mice is independent of 
stress inducers (Fig.3.10). 
 
6.2. Dietary obesity down-regulates the cAMP/PKA 
signalling pathway in the hypothalamus  
Chronic antidepressant treatment regulates the levels of adenylyl cyclase and 
PKA in the brain (Menkes et al., 1983; Nestler et al., 1989b; Perez et al., 1989; 
Ozawa and Rasenick, 1991). Fibroblasts from patients with major depression 
exhibit significantly less PKA activity linked with β-adrenoreceptor function than 
do normal subjects, even though cAMP is able to activate PKA similarly in both 
groups (Shelton et al., 1996). Both antidepressant treatment and 
electroconvulsive seizure therapy have been shown to reduce cytosolic PKA 
activity while increasing nuclear PKA localization in rat frontal cortex (Nestler et 
al., 1989a). Therefore, a link between antidepressant drugs, electroconvulsive 
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seizures and PKA functioning has been established. However the molecular 
mechanism as well the gene targets involved in such PKA signalling are unknown. 
 
Depression is in many ways a “pleiotropic” disorder that involves disturbances in 
mood, sleep, autonomic, endocrine, appetite, sexual, immune and other 
functions. Protein kinase A (PKA) exerts “pleiotrophic” actions by linking a 
variety of receptors and affecting, by means of protein phosphorylation, 
enzymes involved in neurotransmitter synthesis, regulation of neurotransmitter 
receptors, ion channels, enzymes involved in the regulation of second 
messengers, transcription factors such as cAMP responsive element modulator 
protein CREB, proteins involved in both DNA transcription and mRNA translation 
as well as the cytoskeleton. Protein phosphorylation by PKA has been proposed 
as a critical pathway in the regulation of different neuronal functions (Kandel, 
2012). Therefore, given the wide range of PKA targets this might be the reason 
of the wide range of abnormal cellular responses that the depressed patients 
exhibit (Shelton et al., 1996). 
 
The mRNA array analysis of hypothalamic samples of mice fed HFD compare to 
ND revealed a decrease in the RNA of many molecules involved in the PKA 
signalling cascade (Fig.3.11&3.12). Gratifyingly, these data were in agreement 
with the western blot data that also highlighted the decrease in levels of PKA 
phosphorylation of hypothalamic proteins in animals fed HFD compare to 
controls (Fig.3.13). However, the mRNA array analysis did not reveal any RNA 
changes of the PDE4A, CREB or GPR40 (Fig.3.11&3.12) that have been examined 
in this study suggesting that the effect of these genes on depression might 
synergically depend on other signalling molecules involved in this phenomenon. 
 
PKA provides a central effector for the cAMP signalling pathway whose activity is 
directly controlled by the levels of cAMP. cAMP binding to the regulatory (R) 
subunit of PKA leads to the activation of the PKA catalytic (C) subunit that is 
now able to phosphorylate associated protein substrate targets. cAMP signalling 
has been shown to be down-regulated in depressed patients (Mazzola-Pomietto 
et al., 1994). Moreover, many antidepressant drugs act via the upregulation of 
molecules at the cAMP signalling which is the major regulator of PKA (Duman et 
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al., 1997). A similar mechanism of action suggesting the upregulation of the 
cAMP signalling pathway has been proposed for rolipram, a specific 
phosphodiesterase4 inhibitor with antidepressant action (Zeller et al., 1984; 
Kehr W, 1985;  Overstreet et al., 1989). In accordance, this study revealed that 
the down-regulation of PKA signalling when analysed by mRNA array after HFD 
consumption (Fig.3.11&3.12&3.13) was accompanied by the down-regulation at 
the total levels of cAMP in the hypothalamus in vivo (Fig.3.14). Taken all 
together these data reveal for the first time that HFD induces a down-regulation 
of the cAMP/PKA signalling cascade in the hypothalamus and this is implicated 
behaviourally for the development of depression in mice. 
 
6.3. The central role of PDE4A5 for the dietary or 
genetic obesity induced depression phenotype 
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that provide the sole 
route for cAMP degradation in cells (Conti and Beavo, 2007; Bender and Beavo, 
2006; Maurice et al., 2003). PDEs are a big family with each member displaying 
distinct roles and intracellular localization (Houslay et al., 2007; Lugnier, 2006; 
Conti and Beavo, 2007). Rolipram, a generic PDE4 inhibitor, has been shown to 
have antidepressant action in mice and humans (Zeller et al., 1984; Kehr W, 
1985; Overstreet et al., 1989). However, despite rolipram’s promising 
antidepressant actions in mice and man, it causes significant side effects owing 
to its mechanism of action as a non-isoform-specific PDE4 inhibitor. This made it 
impossible to develop as a human therapeutic (Dyke and Montana, 2002; 
Robichaud et al., 2002; Hirose et al., 2007; Bertolino et al., 1988; Hebenstreit et 
al., 1989). PDE4 enzymes are major regulators of the cAMP signalling in the brain 
(Jin et al., 1999) and have been shown to localize in brain regions that are 
associated with reinforcement, movement and affect, all of which are affected 
in people with depression (Cherry and Davis, 1999). 
 
Chronic, but not acute, rolipram treatment in mice, has been shown to have an 
antidepressant effect in humans and mice (Tardito et al., 2006; Przegalinski et 
al., 1985). This is in accordance with our study that revealed that only chronic 
administration tends to reduce the depression phenotype due to the 
consumption of the HFD (Fig.4.2&4.3) implicating the role of the PDE4/cAMP 
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pathway. This experiment was accompanied with the unexpected observation 
that when rolipram was injected into mice they did not gain any body weight 
even on HFD. In contrast to this, Prozac injected mice gained significantly more 
body weight even from the first administration (Fig.4.4&4.5). The resistance to 
body weight gain of the mice that were daily injected with rolipram even though 
they were on a HFD might be explained by the fact that rolipram has been 
suggested to alter metabolic processes in adipose tissue (Doseyici et al., 2014) 
whereas the role of the serotonin signalling under HFD conditions should be 
further investigated. 
 
Next, my aim was to investigate the role of PDE4s in depression due to obesity. 
With this in mind the cAMP PDE4 activity in different brain regions was 
investigated after the consumption of HFD. An increased PDE4 activity was 
detected specifically in the hypothalamus of mice fed HFD compare to ND 
(Fig.4.7). Associated with this we observed an increase in total protein and 
phosphorylation state of PDE4A5 in the hypothalamus of mice fed HFD compare 
to ND (Fig.4.14&4.21). Identifying the specific isoform responsible for the 
antidepressant action of rolipram may be of potential therapeutic importance as 
the design of a specific inhibitor will minimize the side effects that a generic 
PDE4 inhibitor poses. Comparative real time PCR analysis revealed a specific 
increase of PDE4A and, specifically, for the PDE4A5 isoform at the RNA levels in 
the hypothalamus of mice fed HFD compare to ND (Fig.4.13) suggesting that the 
specific inhibition of PDE4A5 might lead to the rescue of the depression 
phenotype due to obesity. 
 
The role of the transcription factor CREB in depression is very controversial as 
some studies suggest the increase or the decrease phosphorylation of CREB being 
important component for the action of the antidepressant treatment (Carlezon 
et al., 2005). Moreover, it has been suggested that the regulation of CREB might 
also be cell-type or brain region specific. CREB is directly phosphorylated by PKA 
and can regulate the transcription of a well-defined and substantial cohort of 
genes. As the total phosphorylation levels of PKA were down-regulated after HFD 
(Fig.3.12) the total phosphorylation levels of CREB was tested. Western blot 
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analysis revealed down-regulation of total p-CREB levels of in the hypothalamus 
of mice fed HFD compare to ND (Fig.4.15).  
 
Another target of the cAMP signalling cascade is the neurotrophin factor, BDNF 
that has been extensively studied for its role in depression (Pittenger and 
Duman, 2008). BDNF expression in the hippocampus is down-regulated after HFD 
in rodents (Molteni et al., 2002) and this is associated with major depressive 
disorder (Yulug et al., 2009). However, in our model of depression we did not 
detect any BDNF RNA changes after the dietary or genetic obesity in the 
hypothalamus (Fig.4.30). 
 
Another direct target for PKA phosphorylation is DARPP-32, a protein associated 
with the dopamine receptor (Walaas and Greengard, 1984) that has been 
involved in depression (Svenningsson et al., 2002). Western blot analysis data for 
the total levels of DARPP-32 phosphorylation revealed a trend for an increase 
after the consumption of the HFD (Fig.4.31). Increased phosphorylation of 
DARPP-32 by PKA was observed even though there was a global down-regulation 
of the PKA phosphorylation. This suggests that DARPP-32 lies in a cellular sub-
compartment where PKA is still highly active; indicating perhaps that 
compartmentalized PDE activity in such a localization may not be increased or 
even decreased so as to allow this. 
 
6.4. The loss of PDE4A in vivo was able to rescue the 
dietary and genetic obesity induced depression 
phenotype 
Given the biochemical data supporting an important role of PDE4A5 in 
depression a collaboration was established with Professor Marco Conti, UCSF to 
obtain genetic knockout PDE4A-/- mice in order to investigate the in vivo loss of 
PDE4A gene.  The PDE4A-/- as well as the PDE4A+/+ mice were fed HFD and tested 
with behavioural paradigms. The double knock out ob/ob:PDE4A-/- was also 
generated in order to check the effect of the loss of PDE4A in a genetic mouse 
model of obesity. Interestingly, the loss of PDE4A gene in vivo was able to rescue 
the dietary and genetic obesity induced depression phenotype (Fig.4.16). This 
effect was independent of the body weight gain, as both PDE4A-/- and PDE4A+/+ 
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mice on HFD gain the same body weight as well as ob/ob and ob/ob:PDE4A-/- on 
ND (Fig.4.17&4.18). Previously, I have described that HFD increases the activity 
of PDE4 in the hypothalamus (Fig.4.7). Moreover, through separation of the 
cytosol from the membrane fraction I was able to identify that the specific 
increase in PDE4 activity was associated with the membrane fraction (Fig.4.19). 
This increase of the PDE4 activity correlates with the increased level of PDE4A5 
phosphorylation (Fig.4.21) and is in agreement with previous studies showing a 
positive correlation between increased phosphorylation of PDE4A5 and its 
enzymatic activity (Laliberte et al., 2002). This is in accordance with previous 
studies that PDE4 isoforms are targeted and interact with specific proteins/lipids 
in cells (Houslay and Adams, 2003) and in so doing they play a pivotal role in 
underpinning the compartmentalization of cAMP signalling (Mongillo et al., 
2004). That increased PDE4 activity at the membrane fraction was abolished for 
the PDE4A-/- mice compared to the PDE4A+/+ mice, which suggests no 
compensatory mechanisms from the other isoforms and further suggests a 
specific role of PDE4A in this locality (Fig.4.19). However, the ob/ob and the 
ob/ob:PDE4A-/- mice showed a different pattern of PDE4 activity as there was an 
increased PDE4 activity at the cytosol fraction of hypothalamic samples as well 
as the membrane fraction of ob/ob:PDE4A-/- compared to ob/ob (Fig.4.22&4.23) 
suggesting another mechanism involved for the genetic obesity induced 
depression phenotype. These PDE4 activity measurements for the ob/ob and 
ob/ob:PDE4A-/- are opposite observations from the dietary obesity induce 
depression phenotype and suggest that in this genetic mouse model of obesity 
there might be a compensatory mechanism for the loss of PDE4A in the PDE4A-/- 
knockout mice on an ob/ob background. Further investigation into the exact role 
of PDE4 in the leptin deficient ob/ob mice is needed. Nonetheless, the data 
presented regarding PDE4 activity shows for the first time the role of PDE4 
activity in models of dietary and genetic obesity. 
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6.5. Dietary or genetic obesity induced depression was 
not caused due to cytokine expression  
A “cytokine hypothesis” of depression is supported by the observation that 
depressed individuals have elevated plasma levels of certain cytokines compared 
to healthy controls (Schiepers et al., 2005). Systemic low grade inflammation is 
a consistent finding in metabolic disorders (Hotamisligil, 2006) and the resulting 
elevated level of circulating cytokines is suggested to promote depression 
(Raison et al., 2006). Depression has been linked with peripheral and central 
inflammation and increase of cytokines such as TNF-α, IL-1 and IL-6 in peripheral 
blood and cerebrospinal fluid (Watkins et al., 2014; Logan, 2003). All these 
molecules have been implicated in obesity as well (Park et al., 2010a). An 
altered HPA-axis is often seen in depressed individuals and may be involved in 
the development of metabolic syndrome (Turnbull and Rivier, 1995). In the light 
of this, I set out to evaluate transcript levels of different cytokines in the 
hypothalamus of our model of depression. Interestingly, there was no increase in 
cytokine expression in the hypothalamus of mice fed HFD and for the genetically 
obese mice, suggesting the exclusion of the involvement of these molecules in 
this model of depression (Fig.4.26&4.27&4.28). The real time PCR data are in 
accordance to the mRNA array analysis data done in this study as the 
inflammatory pathways were not affected after the consumption of the HFD 
shown by the array analysis by ingenuity. 
 
6.6. PDE4A5 overexpression in the hypothalamus induces 
hyperphagia and obesity at the PDE4A-/- mouse 
Depression has been linked with appetite disorders as people with depression are 
characterized by irregular eating habits. Despite the significant advances in the 
understanding of the molecular mechanism of appetite and satiety (Wilding, 
2002; Schwartz et al., 2000; Woods and D'Alessio, 2008) practical therapies for 
weight loss or appetite disorders remain elusive. Central control of food intake is 
highly involved in emerging metabolism and body weight regulation (Lee and 
Wardlaw, 2007; Cota et al., 2007; Moran, 2010). Given the rising rates of 
obesity, this has inspired efforts to understand the brain regulation of food 
intake and energy expenditure. The main regulators of appetite are insulin and 
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leptin. Leptin is secreted from white adipose tissue (WAT) and insulin is secreted 
from pancreatic β celss. These hormones, can cross the BBB, and get access in 
the brain to signal directly at their receptors in the ARC, ventromedial 
hypothalamic nucleus (VMN), NTS and elsewhere (Grill and Hayes, 2012; 
Schwartz et al., 2000) in order to regulate different pathways. Both leptin and 
insulin exert their effects on energy balance in part by activating the 
hypothalamic melanocortin system (Benoit et al., 2002; Seeley et al., 1997). The 
hypothalamic melanocortin system has a predominant role in food intake 
regulation and energy homeostasis (Adan et al., 2006; Seeley et al., 2004; 
Vergoni and Bertolini, 2000). This system consists of first order pro-
opiomelanocortin (POMC) and agouti-related peptide (AgRP) expressing neurons 
in the ARC that project to melanocortin-4 receptor (MC4R)-positive neurons that 
exist in the paraventricular nucleus of the hypothalamus (PVN), the lateral 
hypothalamic area (LHA) and other brain regions (Cone, 2005). This system 
consists of heterogeneous sets of neurons primarily in the arcuate nucleus 
expressing various orexigenic and anorexigenic neuropeptides  (Lee and 
Wardlaw, 2007). Orexigenic neuropeptides such as neuropeptide Y (NPY) and 
agouti related protein as well as anorexigenic neuropeptides such as those 
derived from pro-opiomelanocortin (POMC) act through multiple mechanism to 
control energy homeostasis (Chee and Colmers, 2008; Coll et al., 2005; Ilnytska 
and Argyropoulos, 2008).  Interestingly it has been shown that adeno-associated 
virus-mediated knockdown of melanocortin-4 receptor in the paraventricular 
nucleus of the hypothalamus promotes high-fat diet-induced hyperphagia and 
obesity (Garza et al., 2008). The role of the cAMP pathway in the melanocortin, 
as well as the leptin system, and whether cAMP regulates orexigenic and 
anorexigenic peptide production, is unknown. However, brain leptin and insulin 
signalling activate POMC and inhibit AgRP neurons (Cowley et al., 2001; van den 
Top et al., 2004). The net effect of this is to increase MC4R signalling and, 
thereby, to reduce food intake and increase energy expenditure. 
 
Here we show, for the first time, that the introduction of PDE4A5, via viral 
overexpression in the hypothalamic area, in vivo can promote hyperphagia and 
obesity in mice (Fig.4.37). These data involve the role of the cAMP signalling 
pathway as increased PDE activity in the hypothalamus results in the reduction 
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of cAMP signalling. The extreme increase in body weight of these animals 
injected with the PDE4A5-wt virus and subjected to three weeks on HFD is of 
particular significance. Interestingly, another study recently showed that the 
leptin effect on feeding depends on a pathway regulated by 
phosphatidylinositol-3 kinase and PDE3B in the hypothalamus (Zhao et al., 2002). 
The identification of the hypothalamic nuclei involved in this phenomenon as 
well as the molecular mechanism remains to be found. 
 
Therefore, further studies on the role of PDE4A5 as a potential regulator of the 
appetite in the hypothalamus and its role on the neuropeptide expression 
affecting food intake and body weight should be performed. Based on our 
observations, targeting components of the cAMP signalling such as PDE4s might 
represent a good target for the treatment of eating disorders. Food intake 
targeting would be of particular interest, considering the recent rejection of 
rimonabant for the treatment of obesity.  
 
6.7. Specific PDE4A5 down-regulation in the 
hypothalamus might lead to the rescue of dietary or 
genetic obesity induced depression phenotype as 
well as treat appetite disorders 
Further investigation of the specific role of PDE4A5 on the link between obesity 
and depression as well as its role in appetite is needed. The creation of a 
specific PDE4A5 inhibitor will shed light on the exact role of this isoform in the 
brain and will dissociate its action and side effects from the other PDE4 
isoforms. The creation of a specific inhibitor from the PDE4 family to be used as 
antidepressant is very important as it might be used in combination with current 
antidepressant treatment for faster antidepressant results as repeated co-
administration of rolipram with antidepressants has been shown to show faster 
antidepressant effects than antidepressants alone (Fujimaki et al., 2000). 
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Recently, antisense oligonucleotide therapy has been used in order to down-
regulate the mRNA expression of specific genes (Kordasiewicz et al., 2012). The 
Food and Drug Administration (FDA) has already approved the antisense 
oligonucleotide therapy for homozygous familiar hypercholesterolaemia. 
Sequence alignment between the different PDE4A isoforms revealed a specific 
area on the PDE4A5 for effective and specific targeting. Using this area 7 
candidate 21 base antisense oligonucleotide sequences were designed. Homology 
analyses were conducted for each oligonucleotide using the rat genome database 
to ensure that the sequence is unique to the mouse PDE4A5 gene. Further 
testing of these sequences which one can specifically down-regulate the PDE4A5 
is needed. Table 6.1 shows the proposed sequences of the antisense 
oligonucleotides that should be further tested. Figure 6.1 shows a sequence 
alignment of the mouse PDE4A5 with the antisense oligonucleotides. Specific 
down-regulation of PDE4A5 might be an interesting means for treating obesity 
induced depression as well as for targeting eating disorders. 
Table 6.1. Proposed sequences for the downregulation of 
PDE4A5. Sequences of the 7 proposed antisense 
oligonucleotides that might downregulate the expression of 
PDE4A5 specifically. 
 
 
 
 
 
 
 
 
Name Sequence 
AOs1 GAGACAGGCTCCTCTCCGAG 
AOs2 AAGAGAGAGAGACAGGCTCC 
AOs3 GTAGCCGCGCTGCTGGATGC 
AOs4 CTGTCCGAGTAGCCGCGCTG 
AOs5 TGAGCGCTCGGCACTGTCCG 
AOs6 CAGGACATGCGGGTAGTCCG 
AOs7 ACCGGTGCCGTGGAAGGACG 
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Figure 6.1. Sequence alignment between the proposed antisense 
oligonucleotides and the mouse PDE4A5. The sequences of the 7 proposed 
antisense oligonucleotides that might downregulate the expression of PDE4A5 
specifically alignment with mouse PDE4A5 is shown. 
 
 
6.8. The effect of the influx of dietary fatty acids in the 
hypothalamus 
The effect of consumption of a HFD has been studied in relation to metabolic 
syndrome and inflammation (Hwang et al., 2010). However, what is the exact 
nature of the pathway that the fatty acids follow when they enter our body via 
the diet is unknown. Further studies using labelled fatty acids in the diet and 
studying their accumulation in the body are needed. Obesity is a condition 
characterized by high levels of circulating fatty acids suggesting a detrimental 
role of these fatty acids in the human physiology of overweight or obese 
individuals (Carpentier et al., 2000; Sako and Grill, 1990). Chronic physiological 
excess of FFAs can induce the dysregulation of physiological processes as it has 
been shown to pancreatic function (Steneberg et al., 2005). In this study, fatty 
acid profile analysis in the hypothalamic area of mice fed HFD revealed an 
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increase influx of saturated and unsaturated fatty acids in the hypothalamus 
(Fig.5.5). The hypothalamus is a highly vascularized brain region with a lot of 
communication with the periphery as it orchestrates the energy balance 
centrally with the periphery. Nutrient sensing within the hypothalamus has a 
critical role in the complex network of signals controlling energy metabolism 
(Cota et al., 2007; (Le Foll et al., 2009; Moran, 2010). Recently, lipid signalling 
in the brain has been shown to play an important role in regulating energy 
balance (Lam et al., 2005b; Lopez et al., 2005). The accumulation of the 
different fatty acids in the hypothalamus shown in this study and the molecular 
pathways they regulate in energy balance as well as mood disorders in the brain 
regions should be further studied. Saturated fatty acids alter the membrane 
distribution of proteins such as Src that are responsible for the activation of 
inflammatory signals and cause their partitioning into intracellular membrane 
subdomains in order to be activated whereas unsaturated fatty acids prevent 
that effect (Holzer et al., 2011). Even though the incorporation of fatty acids 
can alter the fatty acid composition at the plasma membrane resulting in 
altering the structure and function by changing membrane fluidity and signal 
capacity (Clamp et al., 1997; Karnovsky et al., 1982; Luo et al., 1996) the 
mechanism responsible for discriminating between saturated and unsaturated 
fatty acids and how this effect is responsible for the induction of mood disorders 
such as depression is unknown. 
 
6.9. The potential role of palmitic acid for the 
development of depression 
Consumption of western diet that is high in saturated and trans fat has been 
linked with depression. However, diets rich in specific fatty acids have only been 
studied in relation to obesity and energy balance. Diets rich in saturated fatty 
acids, such as palmitic acid, are considered obesogenic and promote systemic 
resistance to catabolic hormones such as insulin and leptin (Riccardi et al., 2004; 
van Dijk et al., 2009). On the contrary, diets rich in monounsaturated fatty 
acids, such as oleic acid, attenuate weight gain through increased fat oxidation 
and diet-induced thermogenesis (Bergouignan et al., 2009) have a protective 
role and can reverse the obesity induced insulin resistance (Robinson et al., 
2007). However, diets rich in specific fatty acids and the specific dietary 
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components that lead to the induction of depression, as well as the molecular 
mechanisms of this phenomenon have never been studied. In this study it was 
shown for the first time that ghee, which is high in palmitic acid, was able to 
partially induce a depression phenotype in vivo compare to a diet with olive oil 
that is high in oleic acid, an unsaturated fatty acid (Fig.5.12&5.13). To be able 
to demonstrate a depressant effect mice had to be fed with either ghee or olive 
oil by oral gavage for long period of time (7 weeks) as the 3 week time point 
that was tested did not show any difference (Fig.5.10&5.11). These data are in 
agreement with the preliminary data of the bilateral single stereotactic 
injections of palmitic acid in the hypothalamus that the mice developed a 
depression phenotype (Fig.5.15).  Future studies will establish whether palmitic 
acid plays a role as a causal factor in depression in vivo. It is possible that 
palmitic acid derived from food can cross the BBB and act directly in the 
hypothalamus to suppress the cAMP pathway through central hypothalamic 
mechanisms in order to induce a depression phenotype.  
 
Interestingly, two recent human studies suggest that a reduced caloric intake 
from fat and processed food is associated with improvements in mood and 
reduced risk of developing depression (Akbaraly et al., 2009; Brinkworth et al., 
2009), which agrees with our findings. The nutritional epidemiology of 
depression probable deserves a higher attention because it is one of the most 
relevant single contributors to the global burden of disease, being the world 
leading cause of years of life lived with disability for both men and women 
(Lopez et al., 2006). 
 
6.10. Upregulation of the RNA levels for the different free 
fatty acid receptors in the hypothalamus of mice fed 
HFD 
Even though epidemiological and clinical studies have shown a link between 
western diet and depression the mechanism/s of this phenomenon is totally 
unknown. Free fatty acid receptors have been studied extensively for their role 
in the gut and in pancreas (Itoh et al., 2003; Thorburn et al., 2014). However, 
their role in the brain remains unknown. The free fatty acid receptors are in the 
unique position to explain how dietary fatty acids can link food with mood 
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disorders such as depression. The finding of the RNA upregulation of the 
different free fatty acid receptors in the hypothalamus after dietary and genetic 
obesity is a very interesting result (Fig.5.17&5.18&5.19). More strikingly, the 4-
5 fold increase at the RNA levels of GPR40 even after 1 week on HFD involves 
GPR40 in the regulation of different signalling in the hypothalamus and more 
specifically in depression (Fig.5.19). Therefore, for the first time, a free fatty 
acid receptor has been implicated as playing a role in depression. 
 
6.11. Palmitic but not oleic acid alters the activation of 
the PKA signalling cascade 
The role of macronutrients such as lipids in the control of metabolism and food 
intake in the hypothalamic nuclei have been studied extensively and how they 
regulate the circulating levels of leptin and insulin (Woods et al., 1998) which in 
turn modulate appetite, energy expenditure, and intermediary metabolism 
mainly via their hypothalamic receptors  nuclei (Woods et al., 1998) (Schwartz 
et al., 2000). Different lipids differentially regulate orectic and anorectic effects 
as well as apoptosis (Welters et al., 2006) (Newsholme et al., 2007) as saturated 
fatty acids have been shown to produce an orectic effect whereas unsaturated 
fatty acids such as oleic an anorectic (Obici et al., 2002) (Milanski et al., 2009). 
Palmitate has been shown to have a strong apoptotic effect whereas 
monounsaturated fatty acids have a protective effect in the induction of 
apoptosis (Newsholme et al., 2007) (Maedler et al., 2003). Moreover, saturated 
but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat 
ventricular myocyte (de Vries et al., 1997). Saturated fatty acids, but not 
unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated 
through Toll-like receptor 4 (Lee et al., 2001). Saturated and unsaturated fatty 
acids have been shown to have a different effect on beta-cell apoptosis (Eitel et 
al., 2002). 
 
However, how lipids regulate intracellular signalling pathways to have this effect 
and whether they can influence the PKA signalling cascade that has been 
involved in our model of depression has never been studied. A mouse neuronal 
cell line was used in this study has been shown to express high levels of the 
GPR40 receptor. GPR40 has been shown to bind a wide range of fatty acids such 
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as oleic, palmitic and myristic (Briscoe et al., 2003). Neuronal cells transfected 
with a PKA sensor and treated with forskolin and IBMX demonstrated an increase 
at the FRET signal (Fig.5.7). However, neuronal cells pretreated with palmitic 
acid were unable to show the forskolin induced activation of the PKA sensor 
(Fig.5.7). On the contrary to this, neither myristic nor oleic acid pretreatment 
of cells transfected with the same PKA sensor inhibited the activation of PKA by 
foskolin (Fig.5.7). The differential effect of these different fatty acids suggests 
their differential role on the PKA signalling cascade. Thus binding of palmitic 
acid to GPR40 can provide a signal for reduction of cAMP signalling that in turn 
activates a chain of neuronal events designed to promote depression. Even 
though in our study we focused on the role of oleic, palmitic and myristic acids, 
it still remains to be determined whether other fatty acids have a similar effect. 
 
6.12. Targeting the GPR40 receptor as a new molecule for 
the treatment of depression caused by diet 
Considerable focus has been placed on developing agents targeting the serotonin 
or noradrenoreceptor pathway and more specifically the monoamines and their 
metabolism in the brain (Shelton, 2007). However 50% of individuals do not 
respond to the current antidepressants (Berton and Nestler, 2006). Moreover, 
overweight and obese individuals do not respond to current antidepressant 
treatments suggesting other molecular pathway being involved in the 
development of depression for this subpopulation (Papakostas et al., 2005). As 
an aside we wanted to determine whether we could identify novel targets for 
the development of antidepressant treatment for depression that is caused by 
dietary factors. 
 
Given the increase RNA expression of GPR40 (Fig.5.19), I wanted to ascertain 
whether GPR40 is located upstream of the cAMP/PKA/PDE4A5 signalling pathway 
that I identified to be involved in the obesity induced depression phenotype. 
Previously it has been shown that PDEs interact with GPCRs either directly of via 
the help of scaffolding proteins such as the β-arrestins (Richter et al., 2008). 
GPR40 has not been shown previously to interact with phosphodiesterase. 
However, here, for the first time, I show that GPR40 interacts with PDE4A5 in 
vitro in neurons (Fig.5.24) and in vivo in the hypothalamus (Fig.5.28). I then 
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demonstrated that PDE4A5 translocation at the membrane fraction was time 
dependent subsequent to palmitic acid treatment of neuronal cells (Fig.5.30). 
However, it was not affected by oleic acid treatment (Fig.5.31), suggesting a 
differential effect of the fatty acids of different chain length and degree of 
saturation. In line with these data is the concept that PDEs contribute to the 
compartmentalization of signalling, many PDEs show unique subcellular 
distributions due to their ability to form complexes with different receptors 
(Conti et al., 2003; Houslay and Adams, 2003). Given the discovery of a free 
fatty acid receptor in the hypothalamus being involved in the regulation of mood 
disorders, the inhibition of this receptor and whether this could protect from the 
dietary obesity induced depression phenotype was investigated next. In vivo 
i.c.v. administration of GPR40 antagonist in the hypothalamus of mice that were 
on HFD tended to partially reverse the HFD induced depression phenotype 
usually observed (Fig.5.39). However, the difference was not statistical 
significant and more experiments should be performed with larger cohorts of 
animals per group.  
 
Despite the potential role of GPR40 signalling in the hypothalamus for lipid 
sensing that controls energy balance and food intake (Lam et al., 2005b; Obici et 
al., 2002; Pocai et al., 2006) in this study it is shown for the first time that it 
might also play an important role in mood disorders such as depression. The data 
presented in this study set GPR40 as a potential clinical candidate that play a 
major role in the neurobiology of depression due to diet. This result set the 
stage for the concept that centrally located mechanisms of fatty acid receptors 
in the brain can promote signalling that is related to mood disorders as opposed 
to the traditional view that they regulate physiological pathways in the 
periphery, such as insulin secretion (Itoh et al., 2003). Hence, in light of this, 
the development of an inhibitor for the GPR40 that could be used as an 
antidepressant should be considered. Drugs that selectively block the activation 
of the free fatty acid signalling in the brain could treat depression even faster 
than the usual antidepressant drugs and such drugs would be very beneficial for 
obese and overweight individuals that exhibit resistance to different 
antidepressant treatments.  The identification of the GPR40 as a potential target 
and the blockage of this target that can rescue the dietary obesity induced 
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depression may also have repositioning potential for the treatment of depressive 
disorders associated with pathophysiological changes in cAMP signalling pathway. 
 
What is the role and importance of the interaction between GPR40 and PDE4A5 
could be answered with the development of specific inhibitor that disrupts this 
interaction. Small-molecule inhibitor that selectively target the interaction of 
the PDEs with free fatty acid receptors could represent a new generation of 
antidepressants with greater specificity for the overweight or obese individuals 
or temporally protracted and severe forms of depression due to obesity.  
 
Even though in our study we focused on the role of GPR40 as it showed the most 
robust RNA increase, other free fatty acid receptors showed a similar increase 
and it still remains to be determined whether other free fatty acids have a 
similar effect on the dietary obesity induced depression phenotype. Further 
studies examining the underlying mechanisms of how activation of different free 
fatty acid receptors in the brain can activate pathways that can lead to 
depression should be characterized. 
 
6.13. A potential model for the differential effect of fatty 
acids on the depression phenotype via GPR40 
activation 
Various underlying pathophysiological mechanisms may explain our findings, and 
studies with a mechanistic focus are urgently needed to attain a better 
understanding of the pathophysiological link between obesity and depression. 
The adrenergic receptor signalling has long served as prototypes for 
understanding the function and regulation of GPCRs (Rockman et al., 2002). 
Many reports indicate that activation of the same GPCR can have distinct and 
often opposing effects. The specificity of the ligand binding for the signal 
compartmentalization, coupling and activation may account for the divergent 
biological effects. Ligand binding on GPCR leads to its activation and interaction 
with G proteins intracellularly. Different ligand binding induces the assembly of 
distinct macromolecular signalling complexes with transducer scaffold proteins 
on the receptor. Moreover, different ligands promote differential conformation 
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of β-arrestins that leads to distinct functional outcomes (Zimmerman et al., 
2012).  
 
Furthermore, the function of GPCRs is highly regulated by their agonist 
stimulated phosphorylation by both second messenger stimulated kinase PKA or 
PKC and the specialized G protein coupled kinases GRKS (Rockman et al., 2002). 
PKA phosphorylation of GPCRs which is activated by ensuing rise in cAMP levels 
has been shown to switch the coupling of the receptor from Gs to Gi (Daaka et 
al., 1997; Lefkowitz et al., 2002; Zamah et al., 2002; Baillie et al., 2003). 
Phosphorylation of GPCRs by GRKs promotes binding of arrestins to the 
phosphorylated receptors. β-arrestin desensitizes the receptor by sterically 
interdicting signalling to the G protein as well as serves an adaptor that links the 
receptor to a variety of signalling pathways (Freedman and Lefkowitz, 1996; 
Goodman et al., 1998; Miller and Lefkowitz, 2001; Krupnick and Benovic, 1998). 
The recruitment of the β-arrestin scaffold protein bound with PDE4 at the 
activated GPCRs regulates the PKA membrane activity that, in turn, regulates 
the switching from Gs to Gi (Baillie et al., 2003; Zamah et al., 2002). Moreover, 
the recruitment of β-arrestin bound to PDE4 target the degradation of the cAMP 
at the membrane fraction (Bolger et al., 2003a; Perry et al., 2002) as well as 
inhibiting further cAMP production by inhibiting the coupling of the receptor 
with Gs (Perry et al., 2002; Houslay, 2001; Houslay et al., 1998; Houslay and 
Adams, 2003). 
 
A similar hypothalamic mechanism may underly the development of depression 
following the consumption of a diet high in saturated fatty acids. GPR40 has 
been shown to activate different pathways by the binding of different ligands 
since unsaturated fatty acids stimulate, whereas saturated fatty acids inhibit, 
cell proliferation via GPR40 in a cultured human breast cancer cell line (Hardy et 
al., 2000) (Hardy et al., 2003) (Hardy et al., 2005). The lack of ligand 
discrimination of this receptor supports this hypothesis. The data presented in 
the study further support that as it was shown that different fatty acids have a 
different end result on the PKA activity. GPR40 has been shown to bind both 
palmitic and oleic acid (Briscoe et al., 2003). Ligand binding on the GPR40 might 
have a differential effect on the macromolecular complexes intracellularly on 
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the receptor with palmitic acid leading to the coupling with Gi protein and oleic 
acid with Gs.  
 
Abundance of palmitic acid in the hypothalamus after the consumption of a HFD 
might leads to quantitatively more binding of palmitic acid on GPR40. This might 
result to the intracellular macromolecular complex on GPR40 with Gi that 
inhibits cAMP generation. Moreover, GRK2 phosphorylation of GPR40 might signal 
the translocation of β-arrestin bound to PDE4A5. This effect will further lead to 
the switch to Gi signalling and simultaneously the PDE4A5 further degrades and 
downregulates the cAMP at the membrane. Therefore, the GRK/β-
arrestin/PDE4A5 system is not restricted to dampening the rate of cAMP 
generation but it also increases the local rates of cAMP degradation and this is 
accomplished by the β-arrestin mediated recruitment of a phosphodiesterase to 
the receptor that further regulates PKA activity (Perry et al., 2002). The PDE4A5 
is therefore playing a pivotal role in underpinning the compartmentalization of 
the cAMP signalling. This hypothesis is in agreement with our data where HFD 
leads to increase PDE4 activity at the membrane fraction. The reduction of the 
cAMP signalling leads to the downregulation of the PKA/CREB pathway that I also 
observed in the model. On the contrary under normal conditions, consumption of 
a diet rich in PUFAs might lead to the binding of oleic acid on GPR40 that leads 
to the coupling of the receptor with Gs that results in the production of cAMP. 
This model suggests a mechanism where some fatty acids have an antidepressant 
effect whereas other a depressant effect.  
 
Another possible explanation would be the existence of another receptor that 
interacts with GPR40 and its one is coupled with either Gi or Gs. Although 
considerable biochemical and biophysical data are consistent with monomeric 
GPCRs binding and activating G proteins (Ernst et al., 2007; Whorton et al., 
2007) several recent studies suggest that G protein coupling in cell membranes 
involve the formation of homomeric and heteromeric GPCR complexes (Han et 
al., 2009; Lopez-Gimenez et al., 2007; Carriba et al., 2008; Vilardaga et al., 
2008). Receptor dimerization is one of the most common themes in biology 
therefore we cannot exclude the interaction of GPR40 with another receptor and 
this imbalance might result to the development of depression. A possible 
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candidate might the GPR20 which is an orphan GPCR that is expressed in the 
brain and in various types of neuroblastoma and is constitutively active and 
activate Gi proteins leading to the downregulation of the cAMP signalling (Hase 
et al., 2008). Another possible candidate is GPR21 that has been shown to be 
highly expressed in the hypothalamus and play a central role in the regulation of 
energy balance as the GPR21 knock out mice are resistant to obesity induced 
depression and insulin resistance (Osborn et al., 2012). In support to this 
hypothesis it has been shown that serotonergic and glutamatergic receptor 
complexes regulate the balance between Gi and Gq signalling that when the 
balance between these two receptors is disrupted it can lead to psychosis 
(Fribourg et al., 2011). A similar phenomenon might happen in the hypothalamus 
with GPR120 that mainly binds unsaturated fatty acids and GPR40 that binds 
mainly saturated fatty acids. Both receptors and their downstream scaffold 
protein β-arrestin2 were shown to be involved in inflammasome inhibition 
induced by ω-3 FAs (Yan et al., 2013). A imbalance in the signalling cascade 
coming from the GPR40 and GPR120 receptor under HFD consumption might be 
responsible for the aberrant signalling that might lead to the development of 
depression. Further investigation whether GPR40 interacts with another GPCR to 
regulate depression should be studied. Figure 6.1 represents a schematic of the 
proposed model that the different fatty acids can lead to the development of 
depression. 
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Figure 6.2. Potential model for the dietary obesity induced depression 
phenotype. A schematic representation of the potential model via which the 
dietary fatty acids such as unsaturated (USFAs) or saturated (SFAs) bind to 
GPR40 and differentially regulate the PKA activity that results in gene expression 
that might affect mood disorders. Picture at the top was taken by
http://www.yourhormones.info/glands/hypothalamus.aspx 
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6.14. The evolutionary relationship of diet with mood 
disorders 
Obesity reached epidemic proportions worldwide, with incidence rates above 
20% in most of the western countries representing a major public health burden 
(Swinburn et al., 2011). The rise in obesity rates is fuelled by the mismatch 
between an inherited genetic predisposition for survival in environments where 
food supply is limited and the current obesogenic environment where reduced 
physical activity and excess energy intake caused by western diet consumption 
prevails (Prentice and Jebb, 1995). Modern food processing has resulted in the 
mass production of cheap, energy-dense foods that are generally high in refined 
sugars and fats but low in fibre and essential nutrients (Prentice and Jebb, 
2003). Putting the psychiatric disorders in the context of evolution I would like 
to mention “With regards to the intake of essential fatty acids, the modern diets 
of post industrialized societies appears to be discordant with our genetic pattern 
and may contribute to the increased prevalence rates of major depression” 
“Because changes in the dietary intake of essential fatty acids appear to be able 
to directly influence central nervous system function, these nutrition factors 
should be further investigated in connection with psychiatric disorders” (Perica 
and Delas, 2011). 
 
In this context, our study suggests that in the past the free fatty acid receptors 
in the hypothalamus might have been used for the regulation of appetite via the 
direct binding of different fatty acids. However over time and the development 
of a complex hormonal system that tightly regulates the energy balance the free 
fatty acid receptor pathways in the brain were degenerate to serve for other 
purposes in our case the development of mood disorders such as depression. 
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6.15. Final Conclusions 
The findings in this study revealed for the first time that obesity, either dietary 
or genetic is a causative factor for the development of depression and identified 
a novel molecular mechanism that this phenomenon occurs in mice. This effect 
is independent of inflammatory pathways and any increase in the body weight 
and it occurs at a very early stage of obesity. At the mechanistic level high fat 
diet down-regulates the PKA signalling in the hypothalamus of WT mice by 
increasing cAMP PDE activity the sole family of enzymes that degrade the cAMP. 
HFD up-regulates the RNA, protein and phosphorylation state specifically for the 
PDE4A5 isoform in the hypothalamus. The loss of PDE4A gene in vivo rescues the 
dietary and genetic obesity induced depression phenotype. The increase PDE4 
activity observed at the membrane fraction of hypothalamic samples fed HFD 
was abolished in PDE4A-/- mice suggesting the important role of the PDE4A gene 
and the lack of compensatory mechanisms from the other isoforms. Therefore, 
the biochemical impairment of the PDE4 activity had in vivo functional 
consequences reflected by the different behavioural paradigms. By exploring the 
role of PDE4A5 in the hypothalamus we were able to identify its importance in 
appetite disorders as overexpression of PDE4A5 with the consequence of the 
downregulation of the cAMP levels in vivo led to severe obesity and hyperphagia. 
  
I also present a novel finding where diet rich in palmitic acid was able to 
partially induce a depression phenotype whereas a diet rich in oleic acid did not. 
By exploring the role of the palmitic acid in depression we were able to see the 
direct effect of palmitic acid in depression after single stereotactic injections in 
the hypothalamus. The present study provides evidence for the first time of the 
role of a free fatty acid receptor (GPR40) regulating mood disorders in mice. The 
interaction of GPR40-PDE4A5 in the hypothalamus implies the important role of 
this interaction in depression behaviours. GPR40 RNA expression was upregulated 
in the hypothalamus of mice that consumed HFD. Strikingly, GPR40 antagonist 
administration specifically in the hypothalamus was able to partially block the 
development of depression phenotype observed after the consumption of a HFD.  
 
Taken together, these data demonstrate that both PDE4A5 and GPR40 may 
provide potential targets for the development of antidepressant treatment 
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specific for the obese or overweight population or population that consume 
western diet. The data in this study suggest that GPR40 may form a mechanistic 
link between diet, obesity, and depression. An attractive element of the dietary 
influence for depression is that it is relatively easy to change this factor 
compared to gene changes or reducing life stress that are also causative factors 
for the development of depression. This study provides new and important 
perspectives regarding underlying mechanisms that may relate to linkages 
between western dietary habits and mood disorders. In industrialized countries, 
it is recommended to change diets rich in saturated fat as well as increase 
exercise to prevent depression and there is a considerable interest in 
understanding the molecular pathways of how food participates to mental 
disorders and especially depression and the molecular mechanism presented in 
this study might be one explanation. The obesity epidemic illustrates how food, 
particularly low-cost food high in saturated and trans fat can shape our bodies 
and moreover affect our general mental health status.  
 
In conclusion, even though neuronal and behavioural responses to nutrients are 
complex and unclear here we provide novel insight into a mechanism through 
which a specific fatty acid is able to partially mediate the development of 
depression phenotype. This occurs via the down-regulation of the cAMP/PKA 
signalling cascade and the activation of a PDE4A5 and a free fatty acid receptor 
in the brain (GPR40). The PDE4A5-GPR40 interaction in this model of depression 
offers a novel pharmacological approach in the treatment of depression as 
targeting a free fatty acid receptor for the treatment of depression has never 
been investigated. Moreover, evidence in this study implicates that targeting the 
PDE4A5 in the hypothalamus might be a therapeutic target for eating disorders. 
How diet influences mood disorders is unknown but this study set the important 
role of phosphodiestersses and fatty acid receptors to link the gap. 
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6.16. Future directions 
6.16.1. The role of specific diets in memory impairment 
More studies directed towards the mechanistic basis of these findings should be 
performed.  It is suggested that mood disorders are associated with a distinct 
pattern of cognitive impairment, including memory deficits (Arendash et al., 
2001). Rolipram has been shown to facilitate the establishment of long-term 
potentiation which leads to improved learning and memory and act as a 
cognitive enhancer (Barad et al., 1998; Rose, Hopper et al. 2005; Rutten, 
Prickaerts et al. 2008). The important role of PDE4A isoforms in synaptic 
plasticity, memory processing and cognition has been described (Ye, Jackson et 
al. 2000; Ye, Conti et al. 1997; Takahashi, Terwilliger et al. 1999). HFD has been 
shown to impair learning and memory in rats (Winocur and Greenwood, 2005; 
Pathan et al., 2008). Whether diet rich in specific fatty acids might have a 
similar effect on memory should be further investigated. Furthermore 
investigation in our model of depression and whether memory impairment is 
needed and whether it is rescued after the loss of PDE4A gene in vivo. 
 
6.16.2. The role of exercise in depression 
Another interesting follow up of this study would be the role of exercise in 
depression phenotype after HFD. Several experimental studies have documented 
the preventive effect of exercise in animal model before the installation of 
obesity/metabolic syndrome (Arvola et al., 1999; Frisbee et al., 2006). Exercise 
is also able to reverse the metabolic syndrome that occurs in rats that were fed 
a HFD (Touati et al., 2011). Voluntary wheel running increased cell proliferation 
and survival in the hippocampal dentate gyrus in mice (van Praag et al., 1999) as 
well as cell proliferation in rats (Trejo et al., 2001) suggesting an antidepressant 
effect.  Little exercise has been shown to have a huge benefit reversing the 
aging and infection-induced memory deficits (Barrientos et al., 2011). It has 
already been shown that postnatal treadmill exercise rescues the depression 
phenotype of maternal-separated rat pups via the decrease of the apoptotic 
neuronal death and cell proliferation (Baek et al., 2012). That rescue was 
accompanied with an increase of serotonin synthesis and tryptophan 
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hydroxylase, both molecules playing very important role in depression (Baek et 
al., 2012). Whether exercise is adequate to reverse the HFD induced depression 
phenotype should be further studied. 
 
6.16.3. The role of microbiota in the development of 
depression 
“The concept that the gut and the brain are closely connected, and that this 
interaction plays an important part not only in gastrointestinal function but also 
in certain feeling states and in intuitive decision making, is deeply rooted in our 
language” (Mayer, 2011). From the revolutionary data that revealed that 9 out 
of the 10 cells in our human body are not human the emerging role of microbiota 
in different physiological pathways is arising. Gut, the home of most of them has 
a wide variety of different fatty acid receptors that can be stimulated and 
induce different molecular pathways. In addition to the obvious role of the gut 
in the digestion and absorption of nutrients it has an important sensing and 
signalling role in the regulation of energy homeostasis (Badman and Flier, 2005) 
which occurs via neuronal and endocrine pathways.  
 
The role of gut microbiota has been implicated in many disorders and spectrums 
as its composition relates to human disease (Clemente et al., 2012; Kau et al., 
2011; Round and Mazmanian, 2009). The diversity of the microbiota can be 
considered in terms of both richness (the number of species per sample) and 
evenness (the relative abundance of species). It has been shown that individuals 
with low bacterial richness are characterized by increased adiposity, insulin 
resistance and dyslipidemia and a more pronounced inflammatory phenotype in 
comparison to individuals with higher bacterial richness (Le Chatelier et al., 
2013). Microbiota in the gut can secrete different fatty acids that are inserted in 
the plasma and via the circulation can enter different organs to regulate 
different molecular pathways. Different diets have been shown to shape gut 
bacteria ecology and diversity (De Filippo et al., 2010; Le Chatelier et al., 2013; 
Ou et al., 2013b). HFD consumption has been linked with reversible alterations 
in the mouse distal gut microbiome (Turnbaugh et al., 2008). Different 
microbiome due to different diets might result in the expression of different 
fatty acids from the microbiota that can cross the BBB and might present 
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another pathway for the development of mood disorders that should be further 
investigated. Whether overweight and obese populations have different 
microbiota than the normal weight population an whether this difference might 
play a role for the development of depression should be further investigated. It 
has already been shown that the manipulation of specific bacteria in the gut can 
work as an anti-obesity drug. Manipulation of gut bacteria that express specific 
beneficial fatty acids and metabolize in a higher rate the saturated might 
represent a new therapeutic intervention to treat depression and mood 
disorders. Therefore the molecular mechanism that link diet, gut, microbiota, 
metabolites and mood disorders should be further investigated and whether it 
plays a role in this model of depression.  
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